{"PMC7492154": [], "PMC7199674": [["Nomenclature - COVID-19 and SARS-COV-2Currently, people all over the world have been affected by coronavirus disease 2019 (COVID-19), which is the fifth pandemic after the 1918 flu pandemic.", [["coronavirus disease", "DISEASE", 97, 116], ["people", "ORGANISM", 49, 55], ["people", "SPECIES", 49, 55], ["Nomenclature", "TEST", 0, 12], ["COVID", "TEST", 15, 20], ["coronavirus disease", "PROBLEM", 97, 116], ["COVID", "TEST", 123, 128], ["coronavirus disease", "OBSERVATION", 97, 116]]], ["As of now, we can trace the first report and subsequent outbreak from a cluster of novel human pneumonia cases in Wuhan City, China, since late December 2019.", [["pneumonia", "DISEASE", 95, 104], ["human", "ORGANISM", 89, 94], ["human", "SPECIES", 89, 94], ["human", "SPECIES", 89, 94], ["novel human pneumonia", "PROBLEM", 83, 104], ["pneumonia", "OBSERVATION", 95, 104]]], ["The symptomatology of these patients, including fever, malaise, dry cough, and dyspnea, was diagnosed as viral pneumonia [1, 2].", [["fever", "DISEASE", 48, 53], ["dry cough", "DISEASE", 64, 73], ["dyspnea", "DISEASE", 79, 86], ["viral pneumonia", "DISEASE", 105, 120], ["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["fever", "PROBLEM", 48, 53], ["malaise", "PROBLEM", 55, 62], ["dry cough", "PROBLEM", 64, 73], ["dyspnea", "PROBLEM", 79, 86], ["viral pneumonia", "PROBLEM", 105, 120], ["viral", "OBSERVATION_MODIFIER", 105, 110], ["pneumonia", "OBSERVATION", 111, 120]]], ["Initially, the disease was called Wuhan pneumonia by the press because of the area and pneumonia symptoms.", [["pneumonia", "DISEASE", 40, 49], ["pneumonia", "DISEASE", 87, 96], ["the disease", "PROBLEM", 11, 22], ["pneumonia", "PROBLEM", 40, 49], ["pneumonia symptoms", "PROBLEM", 87, 105], ["disease", "OBSERVATION", 15, 22], ["pneumonia", "OBSERVATION", 40, 49], ["pneumonia", "OBSERVATION", 87, 96]]], ["Whole-genome sequencing results showed that the causative agent is a novel coronavirus.", [["coronavirus", "DISEASE", 75, 86], ["coronavirus", "ORGANISM", 75, 86], ["coronavirus", "SPECIES", 75, 86], ["Whole-genome sequencing", "TEST", 0, 23], ["a novel coronavirus", "PROBLEM", 67, 86]]], ["Therefore, this virus is the seventh member of the coronavirus family to infect humans [3].", [["coronavirus", "ORGANISM", 51, 62], ["humans", "ORGANISM", 80, 86], ["coronavirus", "SPECIES", 51, 62], ["humans", "SPECIES", 80, 86], ["humans", "SPECIES", 80, 86]]], ["The World Health Organization (WHO) temporarily termed the new virus 2019 novel coronavirus (2019-nCoV) on 12 January 2020 and then officially named this infectious disease coronavirus disease 2019 (COVID-19) on 12 February 2020.", [["infectious disease coronavirus disease", "DISEASE", 154, 192], ["coronavirus", "ORGANISM", 80, 91], ["coronavirus", "SPECIES", 80, 91], ["the new virus", "PROBLEM", 55, 68], ["novel coronavirus", "PROBLEM", 74, 91], ["this infectious disease coronavirus disease", "PROBLEM", 149, 192], ["COVID", "TEST", 199, 204], ["infectious", "OBSERVATION_MODIFIER", 154, 164]]], ["Later, the International Committee on Taxonomy of Viruses (ICTV) officially designated the virus as SARS-CoV-2 based on phylogeny, taxonomy and established practice [4].", [["SARS", "DISEASE", 100, 104], ["ICTV", "SPECIES", 59, 63], ["SARS-CoV", "SPECIES", 100, 108], ["Viruses (ICTV)", "TREATMENT", 50, 64], ["the virus", "PROBLEM", 87, 96], ["CoV", "TEST", 105, 108]]], ["Subsequently, human-to-human transmission of COVID-19 occurring within Hong Kong has been shown in clinical data [5].", [["COVID-19", "CHEMICAL", 45, 53], ["human", "ORGANISM", 14, 19], ["human", "ORGANISM", 23, 28], ["COVID-19", "DNA", 45, 53], ["human", "SPECIES", 14, 19], ["human", "SPECIES", 23, 28], ["human", "SPECIES", 14, 19], ["human", "SPECIES", 23, 28], ["COVID", "TEST", 45, 50]]], ["Since COVID-19 initially emerged in China, the virus has evolved for four months and rapidly spread to other countries worldwide as a global threat.", [["COVID-19", "CHEMICAL", 6, 14], ["COVID-19", "DNA", 6, 14], ["COVID", "TEST", 6, 11], ["the virus", "PROBLEM", 43, 52], ["virus", "OBSERVATION", 47, 52]]], ["On 11 March 2020, the WHO finally made the assessment that COVID-19 can be characterized as a pandemic, following 1918 Spanish flu (H1N1), 1957 Asian flu (H2N2), 1968 Hong Kong flu (H3N2), and 2009 Pandemic flu (H1N1), which caused an estimated 50 million, 1.5 million, 1 million, and 300,000 human deaths, respectively [[6], [7], [8], [9]] [Fig. 1].Virology \u2013 Morphology, Gene structure and ReplicationSARS-CoV-2 is an enveloped and spherical particle approximately 120 nm in diameter containing a positive-sense single-stranded RNA genome.", [["COVID-19", "CHEMICAL", 59, 67], ["Asian flu", "DISEASE", 144, 153], ["Pandemic flu", "DISEASE", 198, 210], ["deaths", "DISEASE", 299, 305], ["Pandemic flu", "ORGANISM", 198, 210], ["human", "ORGANISM", 293, 298], ["[7], [8], [9]", "SIMPLE_CHEMICAL", 326, 339], ["ReplicationSARS-CoV-2", "DNA", 392, 413], ["positive-sense single-stranded RNA genome", "DNA", 499, 540], ["Asian flu", "SPECIES", 144, 153], ["Pandemic flu", "SPECIES", 198, 210], ["human", "SPECIES", 293, 298], ["Asian flu (H2N2)", "SPECIES", 144, 160], ["Hong Kong flu (H3N2)", "SPECIES", 167, 187], ["2009 Pandemic flu (H1N1)", "SPECIES", 193, 217], ["human", "SPECIES", 293, 298], ["the assessment", "TEST", 39, 53], ["COVID", "TEST", 59, 64], ["H3N2", "PROBLEM", 182, 186], ["Pandemic flu (H1N1", "PROBLEM", 198, 216], ["Gene structure", "TEST", 373, 387], ["ReplicationSARS", "TEST", 392, 407], ["CoV", "TEST", 408, 411], ["120 nm", "OBSERVATION_MODIFIER", 467, 473], ["positive", "OBSERVATION", 499, 507], ["RNA genome", "OBSERVATION", 530, 540]]], ["It belongs to the subfamily Coronavirinae, family Coronavirdiae, and order Nidovirales.", [["Coronavirinae", "GENE_OR_GENE_PRODUCT", 28, 41], ["Nidovirales", "TREATMENT", 75, 86]]], ["The RNA genome of SARS-CoV-2 contains a 5' methyl-guanosine cap, poly (A)-tail, and 29,903 nucleotides according to WH-Human 1 coronavirus (WHCV) [3, 10].", [["5' methyl-guanosine", "CHEMICAL", 40, 59], ["5' methyl-guanosine", "CHEMICAL", 40, 59], ["nucleotides", "CHEMICAL", 91, 102], ["SARS-CoV-2", "ORGANISM", 18, 28], ["methyl-guanosine cap", "SIMPLE_CHEMICAL", 43, 63], ["WH-Human 1 coronavirus", "ORGANISM", 116, 138], ["RNA genome", "DNA", 4, 14], ["SARS-CoV-2", "DNA", 18, 28], ["5' methyl-guanosine cap", "DNA", 40, 63], ["poly (A)-tail", "DNA", 65, 78], ["Human 1 coronavirus", "SPECIES", 119, 138], ["SARS-CoV", "SPECIES", 18, 26], ["Human 1 coronavirus", "SPECIES", 119, 138], ["WHCV", "SPECIES", 140, 144], ["SARS", "TEST", 18, 22], ["CoV", "TEST", 23, 26], ["a 5' methyl-guanosine cap", "TREATMENT", 38, 63], ["nucleotides", "TEST", 91, 102], ["WH", "TEST", 116, 118], ["RNA genome", "OBSERVATION", 4, 14], ["tail", "ANATOMY", 74, 78]]], ["It is classified as a beta-coronavirus (\u03b2CoV) [lineage B] and is the seventh coronavirus to infect humans, following 2 \u03b1CoV (HCoV-229E and HKU-NL63) and 4 \u03b2CoV (HCoV-OC43 [lineage A], HCoV-HKU1 [lineage A], severe acute respiratory syndrome SARS-CoV [lineage B] and Middle East respiratory syndrome MERS-CoV [lineage C]) [[11], [12], [13], [14]].", [["acute respiratory syndrome SARS-CoV [lineage B", "DISEASE", 214, 260], ["beta-coronavirus", "ORGANISM", 22, 38], ["\u03b2CoV", "ORGANISM", 40, 44], ["lineage B", "CELL", 47, 56], ["coronavirus", "ORGANISM", 77, 88], ["humans", "ORGANISM", 99, 105], ["\u03b1CoV", "ORGANISM", 119, 123], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 125, 134], ["HKU-NL63", "GENE_OR_GENE_PRODUCT", 139, 147], ["\u03b2CoV", "ORGANISM", 155, 159], ["HCoV-OC43 [lineage A", "GENE_OR_GENE_PRODUCT", 161, 181], ["[11], [12], [13], [14]]", "SIMPLE_CHEMICAL", 322, 345], ["OC43", "PROTEIN", 166, 170], ["humans", "SPECIES", 99, 105], ["\u03b2CoV", "SPECIES", 40, 44], ["humans", "SPECIES", 99, 105], ["\u03b2CoV", "SPECIES", 155, 159], ["severe acute respiratory syndrome SARS-CoV", "SPECIES", 207, 249], ["Middle East respiratory syndrome MERS-CoV", "SPECIES", 266, 307], ["a beta-coronavirus", "TEST", 20, 38], ["CoV", "TEST", 120, 123], ["HCoV", "TEST", 125, 129], ["HKU", "TEST", 139, 142], ["CoV", "TEST", 156, 159], ["HCoV", "TEST", 161, 165], ["OC43", "TEST", 166, 170], ["A", "TEST", 180, 181], ["HCoV", "TEST", 184, 188], ["severe acute respiratory syndrome SARS", "PROBLEM", 207, 245], ["Middle East respiratory syndrome", "PROBLEM", 266, 298], ["severe", "OBSERVATION_MODIFIER", 207, 213], ["acute", "OBSERVATION_MODIFIER", 214, 219], ["respiratory syndrome", "OBSERVATION", 220, 240], ["Middle", "ANATOMY_MODIFIER", 266, 272], ["respiratory syndrome", "OBSERVATION", 278, 298]]], ["It has been shown that bats and rodents are the gene sources of most \u03b1CoVs and \u03b2CoVs, however, avian species are the gene sources of most \u03b4CoVs and \u03b3CoVs by evolutionary analyses.", [["\u03b1CoVs", "GENE_OR_GENE_PRODUCT", 69, 74], ["\u03b2CoVs", "GENE_OR_GENE_PRODUCT", 79, 84], ["avian species", "ORGANISM", 95, 108], ["\u03b4CoVs", "GENE_OR_GENE_PRODUCT", 138, 143], ["\u03b3CoVs", "GENE_OR_GENE_PRODUCT", 148, 153], ["\u03b1CoVs", "DNA", 69, 74], ["\u03b2CoVs", "DNA", 79, 84], ["\u03b4CoVs", "DNA", 138, 143], ["\u03b3CoVs", "DNA", 148, 153], ["most \u03b1CoVs and \u03b2CoVs", "PROBLEM", 64, 84], ["avian species", "PROBLEM", 95, 108], ["most \u03b4CoVs", "PROBLEM", 133, 143]]], ["The human coronavirus (HCoV) strains HCoV-NL63, HCoV-229E, HCoV-HKU1, and HCoV-OC43 usually cause mild, self-limiting upper respiratory tract infections, such as the common cold [15, 16].", [["upper respiratory tract", "ANATOMY", 118, 141], ["respiratory tract infections", "DISEASE", 124, 152], ["human coronavirus", "ORGANISM", 4, 21], ["HCoV", "ORGANISM", 23, 27], ["HCoV-NL63", "ORGANISM", 37, 46], ["HCoV-229E", "ORGANISM", 48, 57], ["HCoV-HKU1", "ORGANISM", 59, 68], ["HCoV-OC43", "ORGANISM", 74, 83], ["upper", "ORGANISM_SUBDIVISION", 118, 123], ["respiratory tract", "ORGANISM_SUBDIVISION", 124, 141], ["human", "SPECIES", 4, 9], ["coronavirus", "SPECIES", 10, 21], ["human coronavirus", "SPECIES", 4, 21], ["HCoV", "SPECIES", 23, 27], ["HCoV", "SPECIES", 37, 41], ["HCoV-229E", "SPECIES", 48, 57], ["HCoV-OC43", "SPECIES", 74, 83], ["The human coronavirus", "TEST", 0, 21], ["HCoV", "TEST", 23, 27], ["HCoV", "TEST", 37, 41], ["HCoV", "TEST", 48, 52], ["HCoV", "TEST", 59, 63], ["HKU1", "TEST", 64, 68], ["HCoV", "TEST", 74, 78], ["self-limiting upper respiratory tract infections", "PROBLEM", 104, 152], ["human coronavirus", "ANATOMY", 4, 21], ["mild", "OBSERVATION_MODIFIER", 98, 102], ["upper", "ANATOMY_MODIFIER", 118, 123], ["respiratory tract", "ANATOMY", 124, 141], ["infections", "OBSERVATION", 142, 152]]], ["However, SARS-CoV, MERS-CoV, and SARS-CoV-2 can cause severe acute respiratory syndrome and result in life-threatening disease [[17], [18], [19]] [Table 1].Virology \u2013 Morphology, Gene structure and ReplicationSARS-CoV-2 transcribes nine subgenomic RNAs, and its genome comprises a 5' untranslated region including a 5' leader sequence; an open reading frame (ORF) 1a/ab encoding nonstructural proteins (nsp) for replication; four structural proteins including spike (S), envelope (E), membrane (M) and nucleocapsid (N); several accessory proteins such as ORF 3a, 6, 7a/b, and 8; and a 3' untranslated region.", [["membrane", "ANATOMY", 485, 493], ["SARS", "DISEASE", 9, 13], ["acute respiratory syndrome", "DISEASE", 61, 87], ["SARS-CoV", "ORGANISM", 9, 17], ["MERS-CoV", "ORGANISM", 19, 27], ["SARS-CoV-2", "ORGANISM", 33, 43], ["ReplicationSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 198, 219], ["nsp", "GENE_OR_GENE_PRODUCT", 403, 406], ["spike (S), envelope (E)", "GENE_OR_GENE_PRODUCT", 460, 483], ["membrane", "CELLULAR_COMPONENT", 485, 493], ["nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 502, 518], ["ORF 3a", "GENE_OR_GENE_PRODUCT", 555, 561], ["6", "GENE_OR_GENE_PRODUCT", 563, 564], ["7a", "GENE_OR_GENE_PRODUCT", 566, 568], ["b", "GENE_OR_GENE_PRODUCT", 569, 570], ["8", "GENE_OR_GENE_PRODUCT", 576, 577], ["Gene structure", "DNA", 179, 193], ["ReplicationSARS-CoV-2", "DNA", 198, 219], ["subgenomic RNAs", "RNA", 237, 252], ["5' untranslated region", "DNA", 281, 303], ["5' leader sequence", "DNA", 316, 334], ["open reading frame (ORF) 1a", "DNA", 339, 366], ["nonstructural proteins", "PROTEIN", 379, 401], ["nsp", "PROTEIN", 403, 406], ["structural proteins", "PROTEIN", 430, 449], ["spike (S), envelope (E), membrane (M)", "PROTEIN", 460, 497], ["nucleocapsid (N)", "PROTEIN", 502, 518], ["accessory proteins", "PROTEIN", 528, 546], ["ORF 3a, 6, 7a/b, and 8", "PROTEIN", 555, 577], ["3' untranslated region", "DNA", 585, 607], ["SARS-CoV", "SPECIES", 9, 17], ["MERS-CoV", "SPECIES", 19, 27], ["SARS-CoV", "SPECIES", 33, 41], ["SARS", "PROBLEM", 9, 13], ["CoV", "TEST", 14, 17], ["MERS", "TEST", 19, 23], ["CoV", "PROBLEM", 24, 27], ["SARS", "PROBLEM", 33, 37], ["severe acute respiratory syndrome", "PROBLEM", 54, 87], ["life-threatening disease", "PROBLEM", 102, 126], ["Gene structure", "TEST", 179, 193], ["ReplicationSARS", "TEST", 198, 213], ["CoV", "TEST", 214, 217], ["a 5' untranslated region", "PROBLEM", 279, 303], ["a 5' leader sequence", "TREATMENT", 314, 334], ["an open reading frame", "TEST", 336, 357], ["replication", "PROBLEM", 412, 423], ["four structural proteins", "PROBLEM", 425, 449], ["spike (S), envelope (E), membrane (M) and nucleocapsid (N)", "PROBLEM", 460, 518], ["several accessory proteins", "PROBLEM", 520, 546], ["a 3' untranslated region", "PROBLEM", 583, 607], ["severe", "OBSERVATION_MODIFIER", 54, 60], ["acute", "OBSERVATION_MODIFIER", 61, 66], ["respiratory syndrome", "OBSERVATION", 67, 87], ["subgenomic RNAs", "OBSERVATION", 237, 252]]], ["The replicase polyprotein pp1a/ab encodes and is proteolytically cleaved into 16 putative nsps, including nsp3 (papain-like protease), nsp5 (3C-like protease), nsp12 (RNA-dependent RNA polymerase [RdRp]), nsp13 (helicase), and other nsps [10, 13, 20].", [["pp1a", "GENE_OR_GENE_PRODUCT", 26, 30], ["nsps", "GENE_OR_GENE_PRODUCT", 90, 94], ["nsp3", "GENE_OR_GENE_PRODUCT", 106, 110], ["papain-like protease", "GENE_OR_GENE_PRODUCT", 112, 132], ["nsp5", "GENE_OR_GENE_PRODUCT", 135, 139], ["3C-like protease", "GENE_OR_GENE_PRODUCT", 141, 157], ["nsp12", "GENE_OR_GENE_PRODUCT", 160, 165], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 167, 195], ["RdRp", "GENE_OR_GENE_PRODUCT", 197, 201], ["nsp13", "GENE_OR_GENE_PRODUCT", 205, 210], ["nsps", "GENE_OR_GENE_PRODUCT", 233, 237], ["replicase polyprotein", "PROTEIN", 4, 25], ["pp1a", "PROTEIN", 26, 30], ["ab", "PROTEIN", 31, 33], ["16 putative nsps", "PROTEIN", 78, 94], ["nsp3", "PROTEIN", 106, 110], ["papain", "PROTEIN", 112, 118], ["protease", "PROTEIN", 124, 132], ["nsp5 (3C-like protease", "PROTEIN", 135, 157], ["nsp12", "PROTEIN", 160, 165], ["RNA-dependent RNA polymerase", "PROTEIN", 167, 195], ["RdRp", "PROTEIN", 197, 201], ["nsp13", "PROTEIN", 205, 210], ["helicase", "PROTEIN", 212, 220], ["nsps", "PROTEIN", 233, 237], ["The replicase polyprotein pp1a/ab encodes", "TREATMENT", 0, 41], ["nsp3 (papain-like protease", "TREATMENT", 106, 132], ["nsp5", "TEST", 135, 139], ["nsp12", "TEST", 160, 165], ["RNA", "TEST", 167, 170], ["other nsps", "TEST", 227, 237]]], ["The spike glycoprotein of SARS-CoV-2 binds to angiotensin-converting enzyme 2 (ACE2) in human and Chinese horseshoe bats, civet for cell entry, that is also dependent on S protein priming by the serine protease TMPRSS2.", [["cell", "ANATOMY", 132, 136], ["angiotensin", "CHEMICAL", 46, 57], ["serine", "CHEMICAL", 195, 201], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 26, 36], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 46, 77], ["ACE2", "GENE_OR_GENE_PRODUCT", 79, 83], ["human", "ORGANISM", 88, 93], ["horseshoe bats", "ORGANISM", 106, 120], ["cell", "CELL", 132, 136], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 211, 218], ["spike glycoprotein", "PROTEIN", 4, 22], ["angiotensin-converting enzyme 2", "PROTEIN", 46, 77], ["ACE2", "PROTEIN", 79, 83], ["S protein", "PROTEIN", 170, 179], ["serine protease", "PROTEIN", 195, 210], ["TMPRSS2", "PROTEIN", 211, 218], ["human", "SPECIES", 88, 93], ["SARS-CoV", "SPECIES", 26, 34], ["human", "SPECIES", 88, 93], ["Chinese horseshoe bats", "SPECIES", 98, 120], ["The spike glycoprotein of SARS", "PROBLEM", 0, 30], ["CoV", "TEST", 31, 34], ["angiotensin", "TEST", 46, 57], ["enzyme", "TEST", 69, 75], ["Chinese horseshoe bats", "TREATMENT", 98, 120], ["cell entry", "PROBLEM", 132, 142], ["the serine protease TMPRSS2", "TREATMENT", 191, 218]]], ["A similar panel of mammalian cell lines can be infected with SARS-CoV-2-S and SARS-CoV-S [[21], [22], [23], [24]].", [["cell lines", "ANATOMY", 29, 39], ["mammalian cell lines", "CELL", 19, 39], ["SARS-CoV", "ORGANISM", 61, 69], ["SARS-CoV", "ORGANISM", 78, 86], ["[21], [22], [23], [24]]", "SIMPLE_CHEMICAL", 90, 113], ["mammalian cell lines", "CELL_LINE", 19, 39], ["SARS-CoV", "SPECIES", 61, 69], ["SARS-CoV", "SPECIES", 78, 86], ["mammalian cell lines", "TREATMENT", 19, 39], ["SARS", "TEST", 61, 65], ["CoV", "TEST", 66, 69], ["SARS-CoV-S", "TEST", 78, 88], ["mammalian cell lines", "OBSERVATION", 19, 39]]], ["The spike protein could be cleaved by host proteases into the S1 and S2 subunits, which are responsible for receptor recognition and membrane fusion, respectively.", [["membrane", "ANATOMY", 133, 141], ["S1", "GENE_OR_GENE_PRODUCT", 62, 64], ["S2", "GENE_OR_GENE_PRODUCT", 69, 71], ["membrane", "CELLULAR_COMPONENT", 133, 141], ["spike protein", "PROTEIN", 4, 17], ["host proteases", "PROTEIN", 38, 52], ["S1 and S2 subunits", "PROTEIN", 62, 80], ["The spike protein", "PROBLEM", 0, 17], ["membrane fusion", "TREATMENT", 133, 148], ["membrane fusion", "OBSERVATION", 133, 148]]], ["S1 also can be divided into an N-terminal domain (NTD) and a C-terminal domain (CTD).", [["N", "CHEMICAL", 31, 32], ["C", "CHEMICAL", 61, 62], ["S1", "GENE_OR_GENE_PRODUCT", 0, 2], ["S1", "PROTEIN", 0, 2], ["N-terminal domain", "PROTEIN", 31, 48], ["NTD", "PROTEIN", 50, 53], ["C-terminal domain", "PROTEIN", 61, 78], ["CTD", "PROTEIN", 80, 83], ["an N-terminal domain (NTD", "PROBLEM", 28, 53], ["a C-terminal domain (CTD)", "TREATMENT", 59, 84]]], ["The S1 CTD of SARS-CoV-2, but not the NTD, showed strong affinity for human ACE2 (hACE2).", [["SARS", "DISEASE", 14, 18], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 14, 24], ["human", "ORGANISM", 70, 75], ["ACE2", "GENE_OR_GENE_PRODUCT", 76, 80], ["hACE2", "GENE_OR_GENE_PRODUCT", 82, 87], ["S1 CTD", "PROTEIN", 4, 10], ["NTD", "PROTEIN", 38, 41], ["human ACE2", "PROTEIN", 70, 80], ["hACE2", "PROTEIN", 82, 87], ["human", "SPECIES", 70, 75], ["SARS-CoV", "SPECIES", 14, 22], ["human", "SPECIES", 70, 75], ["The S1 CTD of SARS", "TEST", 0, 18], ["CoV", "TEST", 19, 22], ["the NTD", "PROBLEM", 34, 41], ["S1", "ANATOMY", 4, 6], ["CTD", "OBSERVATION", 7, 10], ["SARS", "OBSERVATION", 14, 18]]], ["The receptor-binding domain (RBD) within SARS-CoV-2 CTD is the key region that interacts with the hACE2 receptor with higher affinity than the RBD of SARS-CoV by 10- to 20-fold with kinetic quantification [23, 25].", [["SARS", "DISEASE", 150, 154], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 41, 51], ["hACE2 receptor", "GENE_OR_GENE_PRODUCT", 98, 112], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 150, 158], ["receptor-binding domain", "PROTEIN", 4, 27], ["RBD", "PROTEIN", 29, 32], ["SARS-CoV-2 CTD", "PROTEIN", 41, 55], ["hACE2 receptor", "PROTEIN", 98, 112], ["RBD", "PROTEIN", 143, 146], ["SARS-CoV", "SPECIES", 150, 158], ["The receptor-binding domain (RBD)", "PROBLEM", 0, 33], ["SARS", "PROBLEM", 41, 45], ["the hACE2 receptor", "TREATMENT", 94, 112], ["higher affinity", "PROBLEM", 118, 133], ["SARS", "PROBLEM", 150, 154], ["CoV", "TEST", 155, 158], ["kinetic quantification", "TEST", 182, 204]]], ["The putative life cycle of SARS-CoV-2 in host cells begins from spike protein and hACE2 receptor binding.", [["cells", "ANATOMY", 46, 51], ["SARS", "DISEASE", 27, 31], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 27, 37], ["host cells", "CELL", 41, 51], ["hACE2 receptor", "GENE_OR_GENE_PRODUCT", 82, 96], ["host cells", "CELL_TYPE", 41, 51], ["spike protein", "PROTEIN", 64, 77], ["hACE2 receptor", "PROTEIN", 82, 96], ["SARS-CoV", "SPECIES", 27, 35], ["SARS", "TEST", 27, 31], ["CoV", "TEST", 32, 35], ["host cells", "PROBLEM", 41, 51], ["spike protein", "PROBLEM", 64, 77], ["hACE2 receptor binding", "PROBLEM", 82, 104], ["host cells", "OBSERVATION", 41, 51]]], ["The conformational change in the S protein after receptor binding facilitates viral envelope fusion with the cell membrane through the endosomal pathway.", [["cell membrane", "ANATOMY", 109, 122], ["endosomal", "ANATOMY", 135, 144], ["cell membrane", "CELLULAR_COMPONENT", 109, 122], ["endosomal", "CELLULAR_COMPONENT", 135, 144], ["S protein", "PROTEIN", 33, 42], ["The conformational change", "PROBLEM", 0, 25], ["the S protein", "TREATMENT", 29, 42], ["receptor binding", "TREATMENT", 49, 65], ["viral envelope fusion", "TREATMENT", 78, 99], ["the cell membrane", "TREATMENT", 105, 122], ["conformational change", "OBSERVATION", 4, 25], ["envelope fusion", "OBSERVATION", 84, 99], ["cell membrane", "OBSERVATION", 109, 122]]], ["The viral RNA genome is then released into the cytoplasm and translated into viral replicase polyproteins pp1a and 1ab, which can be cleaved into small products by virus-encoded proteinases.", [["cytoplasm", "ANATOMY", 47, 56], ["cytoplasm", "ORGANISM_SUBSTANCE", 47, 56], ["pp1a", "GENE_OR_GENE_PRODUCT", 106, 110], ["1", "GENE_OR_GENE_PRODUCT", 115, 116], ["proteinases", "GENE_OR_GENE_PRODUCT", 178, 189], ["viral RNA genome", "DNA", 4, 20], ["viral replicase polyproteins", "PROTEIN", 77, 105], ["pp1a", "PROTEIN", 106, 110], ["1ab", "PROTEIN", 115, 118], ["virus-encoded proteinases", "PROTEIN", 164, 189], ["The viral RNA genome", "PROBLEM", 0, 20], ["viral replicase polyproteins pp1a", "TREATMENT", 77, 110], ["viral RNA genome", "OBSERVATION", 4, 20], ["viral replicase polyproteins", "OBSERVATION", 77, 105]]], ["The polymerase transcribes a series of subgenomic mRNAs by discontinuous transcription.", [["subgenomic mRNAs", "RNA", 39, 55], ["subgenomic mRNAs", "TREATMENT", 39, 55], ["subgenomic mRNAs", "OBSERVATION", 39, 55]]], ["The subgenomic mRNAs are finally translated into viral structural proteins.", [["subgenomic mRNAs", "RNA", 4, 20], ["viral structural proteins", "PROTEIN", 49, 74], ["subgenomic mRNAs", "OBSERVATION", 4, 20], ["viral structural proteins", "OBSERVATION", 49, 74]]], ["The S, E and M proteins enter the endoplasmic reticulum (ER) and Golgi apparatus, and the N protein is combined with the positive-stranded genomic RNA to form a nucleoprotein complex.", [["endoplasmic reticulum", "ANATOMY", 34, 55], ["ER", "ANATOMY", 57, 59], ["Golgi apparatus", "ANATOMY", 65, 80], ["M proteins", "GENE_OR_GENE_PRODUCT", 13, 23], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 34, 55], ["ER", "GENE_OR_GENE_PRODUCT", 57, 59], ["Golgi apparatus", "CELLULAR_COMPONENT", 65, 80], ["S, E and M proteins", "PROTEIN", 4, 23], ["ER", "PROTEIN", 57, 59], ["N protein", "PROTEIN", 90, 99], ["positive-stranded genomic RNA", "RNA", 121, 150], ["nucleoprotein complex", "PROTEIN", 161, 182], ["The S, E and M proteins", "TEST", 0, 23], ["Golgi apparatus", "TEST", 65, 80], ["the N protein", "TEST", 86, 99], ["the positive-stranded genomic RNA", "PROBLEM", 117, 150], ["a nucleoprotein complex", "PROBLEM", 159, 182], ["endoplasmic reticulum", "ANATOMY", 34, 55], ["stranded genomic RNA", "OBSERVATION", 130, 150], ["nucleoprotein complex", "OBSERVATION", 161, 182]]], ["The structural proteins and nucleoprotein complex are assembled with the viral envelope at the ER\u2013Golgi intermediate compartment.", [["ER\u2013Golgi intermediate compartment", "ANATOMY", 95, 128], ["ER", "GENE_OR_GENE_PRODUCT", 95, 97], ["structural proteins", "PROTEIN", 4, 23], ["nucleoprotein complex", "PROTEIN", 28, 49], ["ER", "PROTEIN", 95, 97], ["The structural proteins and nucleoprotein complex", "PROBLEM", 0, 49], ["the viral envelope", "PROBLEM", 69, 87], ["nucleoprotein complex", "OBSERVATION", 28, 49], ["viral envelope", "OBSERVATION", 73, 87], ["intermediate compartment", "OBSERVATION", 104, 128]]], ["The newly assembled viral particles are then released from the infected cell [Fig. 2].Ecology - the potential origin of the virusAll human coronaviruses have animal origins, namely, natural hosts.", [["cell", "ANATOMY", 72, 76], ["cell", "CELL", 72, 76], ["human", "ORGANISM", 133, 138], ["coronaviruses", "ORGANISM", 139, 152], ["human", "SPECIES", 133, 138], ["human coronaviruses", "SPECIES", 133, 152], ["The newly assembled viral particles", "PROBLEM", 0, 35], ["the virus", "PROBLEM", 120, 129], ["viral particles", "OBSERVATION", 20, 35], ["infected cell", "OBSERVATION", 63, 76], ["virus", "OBSERVATION", 124, 129]]], ["Bats may be the natural hosts of HCoV-229E, SARS-CoV, HCoV-NL63, and MERS-CoV.", [["Bats", "CELL", 0, 4], ["HCoV-229E", "ORGANISM", 33, 42], ["SARS-CoV", "ORGANISM", 44, 52], ["HCoV-NL63", "ORGANISM", 54, 63], ["MERS-CoV", "ORGANISM", 69, 77], ["HCoV-229E", "SPECIES", 33, 42], ["SARS-CoV", "SPECIES", 44, 52], ["HCoV", "SPECIES", 54, 58], ["MERS-CoV", "SPECIES", 69, 77], ["HCoV", "TEST", 33, 37], ["SARS", "TEST", 44, 48], ["CoV", "TEST", 49, 52], ["HCoV", "TEST", 54, 58]]], ["Furthermore, HCoV-OC43 and HKU1 probably originated from rodents [[26], [27], [28]].", [["HCoV-OC43", "GENE_OR_GENE_PRODUCT", 13, 22], ["HKU1", "GENE_OR_GENE_PRODUCT", 27, 31], ["[26], [27], [28]", "SIMPLE_CHEMICAL", 66, 82], ["HCoV", "PROTEIN", 13, 17], ["OC43", "DNA", 18, 22], ["HKU1", "DNA", 27, 31], ["HCoV", "TEST", 13, 17], ["HKU1", "TEST", 27, 31]]], ["Bats are undoubtedly important and the major natural reservoirs of alpha-coronaviruses and beta-coronaviruses [29].", [["Bats", "CELL", 0, 4], ["alpha-coronaviruses", "GENE_OR_GENE_PRODUCT", 67, 86]]], ["Domestic animals can suffer from disease as intermediate hosts that cause virus transmission from natural hosts to humans; for example, SARS-CoV and MERS-CoV crossed the species barriers into masked palm civets and camels, respectively [30, 31] [Table 1].", [["SARS", "DISEASE", 136, 140], ["humans", "ORGANISM", 115, 121], ["SARS-CoV", "ORGANISM", 136, 144], ["MERS-CoV", "ORGANISM", 149, 157], ["palm", "ORGANISM_SUBDIVISION", 199, 203], ["humans", "SPECIES", 115, 121], ["humans", "SPECIES", 115, 121], ["SARS-CoV", "SPECIES", 136, 144], ["MERS-CoV", "SPECIES", 149, 157], ["disease", "PROBLEM", 33, 40], ["virus transmission", "PROBLEM", 74, 92], ["SARS", "PROBLEM", 136, 140], ["MERS", "PROBLEM", 149, 153]]], ["SARS-CoV-2 sequenced at the early stage of the COVID-19 outbreak only shares 79.6% sequence identity with SARS-CoV through early full-length genomic comparisons.", [["SARS", "DISEASE", 0, 4], ["SARS", "DISEASE", 106, 110], ["SARS-CoV-2", "ORGANISM", 0, 10], ["SARS-CoV", "ORGANISM", 106, 114], ["SARS-CoV", "SPECIES", 0, 8], ["COVID-19", "SPECIES", 47, 55], ["SARS-CoV", "SPECIES", 106, 114], ["SARS-CoV", "TEST", 0, 8], ["the COVID", "TEST", 43, 52], ["SARS", "TEST", 106, 110]]], ["However, it is highly identical (96.2%) at the whole-genome level to Bat-CoV RaTG13, which was previously detected in Rhinolophus affinis from Yunnan Province, over 1,500 km from Wuhan [21].", [["Bat-CoV RaTG13", "ORGANISM", 69, 83], ["Rhinolophus affinis", "ORGANISM", 118, 137], ["Bat-CoV RaTG13", "DNA", 69, 83], ["Rhinolophus affinis", "SPECIES", 118, 137], ["Bat-CoV", "SPECIES", 69, 76], ["Rhinolophus affinis", "SPECIES", 118, 137], ["CoV RaTG13", "TEST", 73, 83]]], ["Bats are likely reservoir hosts for SARS-CoV-2; however, whether Bat-CoV RaTG13 directly jumped to humans or transmits to intermediate hosts to facilitate animal-to-human transmission remains inconclusive.", [["Bats", "CELL", 0, 4], ["SARS-CoV-2", "ORGANISM", 36, 46], ["Bat-CoV RaTG13", "ORGANISM", 65, 79], ["humans", "ORGANISM", 99, 105], ["human", "ORGANISM", 165, 170], ["Bat-CoV RaTG13", "PROTEIN", 65, 79], ["humans", "SPECIES", 99, 105], ["human", "SPECIES", 165, 170], ["SARS-CoV", "SPECIES", 36, 44], ["Bat-CoV", "SPECIES", 65, 72], ["humans", "SPECIES", 99, 105], ["human", "SPECIES", 165, 170], ["reservoir hosts", "TREATMENT", 16, 31], ["SARS", "PROBLEM", 36, 40], ["likely", "UNCERTAINTY", 9, 15], ["reservoir hosts", "OBSERVATION", 16, 31]]], ["No intermediate host sample was obtained by scientists in an initial cluster of infections of the Huanan Seafood and Wildlife Market in Wuhan, where the sale of wild animals may be the source of zoonotic infection.", [["infections", "DISEASE", 80, 90], ["zoonotic infection", "DISEASE", 195, 213], ["zoonotic infection", "PROBLEM", 195, 213], ["intermediate", "OBSERVATION_MODIFIER", 3, 15], ["host sample", "OBSERVATION", 16, 27], ["infections", "OBSERVATION", 80, 90], ["zoonotic", "OBSERVATION_MODIFIER", 195, 203], ["infection", "OBSERVATION", 204, 213]]], ["Furthermore, the earliest three patients with symptom onset had no known history of exposure to the Huanan market [1].", [["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40]]], ["Therefore, there may be multiple sources of COVID-19 in the beginning.", [["COVID", "TEST", 44, 49], ["may be", "UNCERTAINTY", 17, 23], ["multiple", "OBSERVATION_MODIFIER", 24, 32]]], ["According to previous studies by metagenomic sequencing for the samples from Malayan pangolins (Manis javanica) in Guangxi and Guangdong, China, it has been suggested that pangolins might be the intermediate hosts between bats and humans because of the similarity of the pangolin coronavirus to SARS-CoV-2 [32, 33].", [["samples", "ANATOMY", 64, 71], ["pangolins", "CHEMICAL", 172, 181], ["SARS", "DISEASE", 295, 299], ["Malayan pangolins", "ORGANISM", 77, 94], ["Manis javanica", "ORGANISM", 96, 110], ["pangolins", "GENE_OR_GENE_PRODUCT", 172, 181], ["humans", "ORGANISM", 231, 237], ["pangolin coronavirus", "ORGANISM", 271, 291], ["SARS-CoV-2", "ORGANISM", 295, 305], ["Manis javanica", "SPECIES", 96, 110], ["humans", "SPECIES", 231, 237], ["Malayan pangolins", "SPECIES", 77, 94], ["Manis javanica", "SPECIES", 96, 110], ["humans", "SPECIES", 231, 237], ["pangolin coronavirus", "SPECIES", 271, 291], ["SARS-CoV", "SPECIES", 295, 303], ["previous studies", "TEST", 13, 29], ["metagenomic sequencing", "TEST", 33, 55], ["the samples", "TEST", 60, 71], ["Malayan pangolins", "TREATMENT", 77, 94], ["the pangolin coronavirus", "PROBLEM", 267, 291], ["CoV", "TEST", 300, 303]]], ["The additional analysis of phylogenetic networks can be effective and useful to trace undocumented COVID-19 infection sources [34].", [["infection", "DISEASE", 108, 117], ["phylogenetic networks", "PROBLEM", 27, 48], ["trace undocumented COVID-19 infection sources", "PROBLEM", 80, 125]]], ["In addition to the zoonotic origins of SARS-CoV-2 by natural evolution, there are still some disputes about the origin of the virus because its spike protein seems to perfectly interact with the human receptor in contributing to human-to-human transmission after evolution in a short period.", [["SARS", "DISEASE", 39, 43], ["SARS-CoV-2", "ORGANISM", 39, 49], ["human", "ORGANISM", 195, 200], ["human", "ORGANISM", 229, 234], ["human", "ORGANISM", 238, 243], ["spike protein", "PROTEIN", 144, 157], ["human receptor", "PROTEIN", 195, 209], ["human", "SPECIES", 195, 200], ["human", "SPECIES", 229, 234], ["human", "SPECIES", 238, 243], ["SARS-CoV", "SPECIES", 39, 47], ["human", "SPECIES", 195, 200], ["human", "SPECIES", 229, 234], ["human", "SPECIES", 238, 243], ["SARS", "PROBLEM", 39, 43], ["the virus", "PROBLEM", 122, 131], ["its spike protein", "PROBLEM", 140, 157], ["the human receptor", "TREATMENT", 191, 209], ["zoonotic", "OBSERVATION_MODIFIER", 19, 27], ["origin", "ANATOMY_MODIFIER", 112, 118], ["virus", "OBSERVATION", 126, 131]]], ["Nevertheless, more direct evidence is required to clarify the arguments.Evolution of SARS-COV-2 during the past few monthsReplication of RNA viruses could generate mutations due to the low proofreading ability of their RdRP.", [["SARS", "DISEASE", 85, 89], ["RdRP", "PROTEIN", 219, 223], ["SARS", "PROBLEM", 85, 89], ["RNA viruses", "PROBLEM", 137, 148], ["mutations", "PROBLEM", 164, 173], ["the low proofreading ability of their RdRP", "PROBLEM", 181, 223], ["SARS", "OBSERVATION", 85, 89], ["COV", "OBSERVATION_MODIFIER", 90, 93], ["RNA viruses", "OBSERVATION", 137, 148]]], ["The genome variations generated by viral RdRP could be beneficial for an emerging virus to adapt to new hosts.", [["viral RdRP", "PROTEIN", 35, 45], ["The genome variations", "PROBLEM", 0, 21], ["viral RdRP", "PROBLEM", 35, 45], ["an emerging virus", "PROBLEM", 70, 87], ["viral RdRP", "OBSERVATION", 35, 45]]], ["However, previous studies have shown that the mutation rates could vary in RNA viruses [35].", [["previous studies", "TEST", 9, 25], ["the mutation rates", "PROBLEM", 42, 60], ["RNA viruses", "PROBLEM", 75, 86]]], ["The synonymous substitution rate for coronaviruses might be approximately 1 \u00d7 10-3/synonymous site/year, which is lower than some other RNA viruses.", [["The synonymous substitution rate", "TREATMENT", 0, 32], ["coronaviruses", "PROBLEM", 37, 50], ["synonymous substitution", "OBSERVATION", 4, 27], ["RNA viruses", "OBSERVATION", 136, 147]]], ["The mutation rate during coronavirus replication could be partially controlled by the viral exoribonuclease nsp14 [36, 37].", [["coronavirus", "ORGANISM", 25, 36], ["viral exoribonuclease nsp14", "PROTEIN", 86, 113], ["coronavirus", "SPECIES", 25, 36], ["The mutation rate", "PROBLEM", 0, 17], ["coronavirus replication", "TREATMENT", 25, 48]]], ["Nevertheless, SARS-CoV-2 has been continuously evolving to different groups worldwide during the pandemic.Evolution of SARS-COV-2 during the past few monthsAccording to the information of nCoV-19 (SARS-CoV-2) sequences submitted to the GISAID database in January 2020, the virus was first collected in late December 2019 from Wuhan, China.", [["SARS", "DISEASE", 14, 18], ["SARS", "DISEASE", 119, 123], ["SARS-CoV-2", "ORGANISM", 14, 24], ["nCoV-19", "GENE_OR_GENE_PRODUCT", 188, 195], ["SARS-CoV-2", "ORGANISM", 197, 207], ["nCoV-19 (SARS-CoV-2) sequences", "DNA", 188, 218], ["GISAID", "DNA", 236, 242], ["SARS-CoV", "SPECIES", 14, 22], ["SARS", "PROBLEM", 14, 18], ["SARS", "PROBLEM", 119, 123], ["nCoV", "TEST", 188, 192], ["the virus", "PROBLEM", 269, 278], ["SARS", "OBSERVATION", 119, 123], ["COV", "OBSERVATION_MODIFIER", 124, 127]]], ["However, those viral sequences varied from the latest submitted sequence collected in early April 2020 from North America.", [["viral sequences", "DNA", 15, 30], ["those viral sequences", "TEST", 9, 30]]], ["Since the viral sequences continuously change, the construction of a phylogenetic network is crucial to investigate the adaption of the virus in different human populations and environments.", [["human", "ORGANISM", 155, 160], ["viral sequences", "DNA", 10, 25], ["human", "SPECIES", 155, 160], ["human", "SPECIES", 155, 160], ["the viral sequences", "TEST", 6, 25], ["the virus", "TREATMENT", 132, 141]]], ["Although the virus keeps evolving within humans who could also be susceptible to other human coronaviruses, recombination between SARS-CoV-2 and old human coronaviruses, such as HCoV-229E, OC43, NL63, and HKU1, has not been found.", [["SARS", "DISEASE", 130, 134], ["humans", "ORGANISM", 41, 47], ["human", "ORGANISM", 87, 92], ["SARS-CoV-2", "ORGANISM", 130, 140], ["human", "ORGANISM", 149, 154], ["coronaviruses", "ORGANISM", 155, 168], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 178, 187], ["OC43", "GENE_OR_GENE_PRODUCT", 189, 193], ["NL63", "GENE_OR_GENE_PRODUCT", 195, 199], ["HKU1", "GENE_OR_GENE_PRODUCT", 205, 209], ["HCoV", "PROTEIN", 178, 182], ["HKU1", "PROTEIN", 205, 209], ["humans", "SPECIES", 41, 47], ["human", "SPECIES", 87, 92], ["human", "SPECIES", 149, 154], ["humans", "SPECIES", 41, 47], ["human coronaviruses", "SPECIES", 87, 106], ["SARS-CoV", "SPECIES", 130, 138], ["human coronaviruses", "SPECIES", 149, 168], ["HCoV-229E", "SPECIES", 178, 187], ["the virus", "PROBLEM", 9, 18], ["other human coronaviruses", "PROBLEM", 81, 106], ["SARS", "TEST", 130, 134], ["CoV", "TEST", 135, 138], ["old human coronaviruses", "PROBLEM", 145, 168], ["HCoV", "TEST", 178, 182], ["OC43", "TEST", 189, 193], ["NL63", "TEST", 195, 199], ["HKU1", "TEST", 205, 209], ["virus", "OBSERVATION", 13, 18], ["coronaviruses", "OBSERVATION", 93, 106]]], ["Nevertheless, a recent study revealed that three genetic types, A, B, and C, of the virus have been circulating globally [34].", [["B", "GENE_OR_GENE_PRODUCT", 67, 68], ["C", "GENE_OR_GENE_PRODUCT", 74, 75], ["a recent study", "TEST", 14, 28], ["the virus", "PROBLEM", 80, 89]]], ["The study demonstrated that the genotypes could also correlate to the geographic locations.", [["The study", "TEST", 0, 9], ["the genotypes", "PROBLEM", 28, 41]]], ["This indicates that the evolution of SARS-CoV-2 may be affected by replication environments, such as genetic and immunological restrictions in different human populations.", [["SARS", "DISEASE", 37, 41], ["SARS-CoV-2", "ORGANISM", 37, 47], ["human", "ORGANISM", 153, 158], ["human", "SPECIES", 153, 158], ["SARS-CoV", "SPECIES", 37, 45], ["human", "SPECIES", 153, 158], ["SARS", "PROBLEM", 37, 41]]], ["With evolutionary pressure, the selection of SARS-CoV-2 mutations will be ongoing.", [["SARS", "DISEASE", 45, 49], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 45, 55], ["SARS-CoV", "SPECIES", 45, 53], ["evolutionary pressure", "TEST", 5, 26], ["SARS", "PROBLEM", 45, 49], ["CoV-2 mutations", "TREATMENT", 50, 65], ["pressure", "OBSERVATION_MODIFIER", 18, 26]]], ["The investigation of the geographic patterns of SARS-CoV-2 variations will provide information on vaccine development for different populations.ConclusionsHuman coronaviruses usually cause mild upper respiratory diseases.", [["respiratory", "ANATOMY", 200, 211], ["SARS", "DISEASE", 48, 52], ["upper respiratory diseases", "DISEASE", 194, 220], ["Human", "ORGANISM", 155, 160], ["coronaviruses", "ORGANISM", 161, 174], ["Human", "SPECIES", 155, 160], ["SARS-CoV", "SPECIES", 48, 56], ["Human coronaviruses", "SPECIES", 155, 174], ["SARS", "PROBLEM", 48, 52], ["vaccine development", "TREATMENT", 98, 117], ["different populations", "PROBLEM", 122, 143], ["Human coronaviruses", "PROBLEM", 155, 174], ["mild upper respiratory diseases", "PROBLEM", 189, 220], ["mild", "OBSERVATION_MODIFIER", 189, 193], ["upper", "ANATOMY_MODIFIER", 194, 199], ["respiratory diseases", "OBSERVATION", 200, 220]]], ["However, in the past two decades, two coronaviruses transmitted from animals, SARS-CoV and MERS-CoV, have caused severe pneumonia and death in humans.", [["SARS", "DISEASE", 78, 82], ["pneumonia", "DISEASE", 120, 129], ["death", "DISEASE", 134, 139], ["coronaviruses", "ORGANISM", 38, 51], ["SARS-CoV", "ORGANISM", 78, 86], ["MERS-CoV", "ORGANISM", 91, 99], ["humans", "ORGANISM", 143, 149], ["humans", "SPECIES", 143, 149], ["SARS-CoV", "SPECIES", 78, 86], ["MERS-CoV", "SPECIES", 91, 99], ["humans", "SPECIES", 143, 149], ["two coronaviruses", "PROBLEM", 34, 51], ["SARS", "PROBLEM", 78, 82], ["severe pneumonia", "PROBLEM", 113, 129], ["death in humans", "PROBLEM", 134, 149], ["coronaviruses", "OBSERVATION", 38, 51], ["severe", "OBSERVATION_MODIFIER", 113, 119], ["pneumonia", "OBSERVATION", 120, 129]]], ["In addition, since late December 2019, the COVID-19 pandemic has spread globally and consequently resulted in at least 190,549 deaths worldwide as of April 24, 2020 [38].", [["deaths", "DISEASE", 127, 133], ["the COVID", "TEST", 39, 48], ["pandemic", "PROBLEM", 52, 60]]], ["Due to the high sequence homology with a coronavirus isolated from bats, SARS-CoV-2 is considered a zoonotic origin coronavirus.", [["zoonotic origin coronavirus", "DISEASE", 100, 127], ["coronavirus", "ORGANISM", 41, 52], ["SARS-CoV-2", "ORGANISM", 73, 83], ["coronavirus", "ORGANISM", 116, 127], ["coronavirus", "SPECIES", 41, 52], ["SARS-CoV-2", "SPECIES", 73, 83], ["the high sequence homology", "PROBLEM", 7, 33], ["a coronavirus", "PROBLEM", 39, 52], ["SARS", "PROBLEM", 73, 77], ["a zoonotic origin coronavirus", "PROBLEM", 98, 127]]], ["Undoubtedly, SARS-CoV-2 has become the fifth human coronavirus, and it is possible that this virus will continuously circulate in the human population in the future.", [["SARS", "DISEASE", 13, 17], ["SARS-CoV-2", "ORGANISM", 13, 23], ["human", "ORGANISM", 45, 50], ["human", "ORGANISM", 134, 139], ["human", "SPECIES", 45, 50], ["human", "SPECIES", 134, 139], ["SARS-CoV", "SPECIES", 13, 21], ["human coronavirus", "SPECIES", 45, 62], ["human", "SPECIES", 134, 139], ["SARS", "PROBLEM", 13, 17], ["CoV", "TEST", 18, 21], ["the fifth human coronavirus", "PROBLEM", 35, 62], ["this virus", "PROBLEM", 88, 98], ["coronavirus", "OBSERVATION", 51, 62]]], ["Because specific antiviral treatments and vaccines are still under development, testing, quarantine, and social distancing are encouraged to prevent virus spread.", [["specific antiviral treatments", "TREATMENT", 8, 37], ["vaccines", "TREATMENT", 42, 50], ["testing", "TEST", 80, 87], ["quarantine", "TREATMENT", 89, 99], ["virus spread", "PROBLEM", 149, 161], ["antiviral treatments", "OBSERVATION", 17, 37]]], ["Nonetheless, since the virus keeps mutating and evolving during the pandemic, studies on viral pathogenicity, treatments and prophylactic vaccines should closely consider the genetic characteristics of the virus.", [["the virus", "PROBLEM", 19, 28], ["viral pathogenicity", "PROBLEM", 89, 108], ["treatments", "TREATMENT", 110, 120], ["prophylactic vaccines", "TREATMENT", 125, 146], ["the virus", "PROBLEM", 202, 211]]]], "dc3a2c1ba073d49125016a0d61baa57eb8595bab": [["Infectious bronchitis virus (IBV), a member of the family be highly conserved differing by only 2 to 6% at the amino acid level (4, 5) .", [["Infectious bronchitis virus", "DISEASE", 0, 27], ["amino acid", "CHEMICAL", 111, 121], ["amino acid", "CHEMICAL", 111, 121], ["Infectious bronchitis virus", "ORGANISM", 0, 27], ["IBV", "ORGANISM", 29, 32], ["amino acid", "AMINO_ACID", 111, 121], ["Infectious bronchitis virus", "SPECIES", 0, 27], ["Infectious bronchitis virus", "SPECIES", 0, 27], ["IBV", "SPECIES", 29, 32], ["Infectious bronchitis virus", "PROBLEM", 0, 27]]], ["The high level of conservation in the N Coronaviridae, causes an acute highly contagious disprotein has resulted in the widely held view that the S1 ease of chickens resulting in significant economic losses glycoprotein, which may show up to 49% variation (6) , to poultry industries throughout the world.", [["disprotein", "CANCER", 89, 99], ["chickens", "ORGANISM", 157, 165], ["chickens", "SPECIES", 157, 165], ["chickens", "SPECIES", 157, 165], ["the N Coronaviridae", "TREATMENT", 34, 53], ["an acute highly contagious disprotein", "PROBLEM", 62, 99], ["significant economic losses glycoprotein", "PROBLEM", 179, 219], ["high", "OBSERVATION_MODIFIER", 4, 8], ["acute", "OBSERVATION_MODIFIER", 65, 70], ["highly", "OBSERVATION_MODIFIER", 71, 77], ["contagious", "OBSERVATION", 78, 88], ["significant", "OBSERVATION_MODIFIER", 179, 190], ["economic", "OBSERVATION_MODIFIER", 191, 199], ["losses glycoprotein", "OBSERVATION", 200, 219]]], ["The IBV geis the only relevant structural element in assessing the nome consists of a single strand of positive sense RNA genetic diversity and evolutionary direction of IBV. measuring 27.6 kb in length excluding the poly(A) tail (1) .", [["IBV", "ORGANISM", 4, 7], ["IBV", "ORGANISM", 170, 173], ["poly(A) tail", "GENE_OR_GENE_PRODUCT", 217, 229], ["nome", "DNA", 67, 71], ["poly(A) tail", "PROTEIN", 217, 229], ["IBV geis", "SPECIES", 4, 12], ["IBV", "SPECIES", 170, 173], ["IBV", "PROBLEM", 170, 173], ["structural element", "OBSERVATION", 31, 49], ["27.6 kb", "OBSERVATION_MODIFIER", 185, 192]]]], "PMC7448267": [["They are the result of long processes of inculcation, exposure, and training that fall under the broad concept of \u201csocialization\u201d or \u201csocial learning.\u201d", [["inculcation", "PROBLEM", 41, 52]]], ["Historically, the concept is perhaps most strongly associated with theories of how individuals, and specifically children, learn to feel, act, think, and relate to the world and to each other.", [["children", "ORGANISM", 113, 121], ["children", "SPECIES", 113, 121]]], ["Theories of social learning and socialization have explained how people come to assume behaviors and attitudes in ways not well captured by a focus on internal motivation or conscious deliberation (Miller and Dollard 1941; Bandura 1962; Mauss 1979; Elias 2000).", [["people", "ORGANISM", 65, 71], ["people", "SPECIES", 65, 71]]], ["Empirical studies have explored, for instance, how children learn speech and social grammar through a combination of direct experience (trying things out and experiencing rewarding or punishing consequences) and modeling (observing and imitating others, especially primary associates) (Gopnik 2009).", [["children", "ORGANISM", 51, 59], ["children", "SPECIES", 51, 59], ["Empirical studies", "TEST", 0, 17]]], ["Berger and Luckmann (1966), relying on the work of George Herbert Mead, discuss the learning process of socialization as one involving two stages: in the primary stage, children form a self by internalizing the attitudes of those others with whom they entertain an emotional relationship (typically their parents); in the secondary stage, persons-in-becoming learn to play appropriate roles in institutionalized subworlds, such as work or school.", [["children", "ORGANISM", 169, 177], ["persons", "ORGANISM", 339, 346], ["children", "SPECIES", 169, 177], ["persons", "SPECIES", 339, 346]]], ["Pierre Bourdieu offers a similar approach to the formation of habitus.", [["Pierre Bourdieu", "TREATMENT", 0, 15], ["a similar approach", "TREATMENT", 23, 41], ["habitus", "OBSERVATION", 62, 69]]], ["Collective socialization into policy paradigms is one of the main drivers of institutional path dependency, as it makes it difficult for people to imagine alternatives.Social learning and machine learningFor our purposes, social learning encapsulates all those social processes\u2014material, institutional, embodied, and symbolic\u2014through which particular ways of knowing, acting, and relating to one another as aggregate and individuated actants are encoded and reproduced, or by which \u201c[e]ach society [gains and sustains] its own special habits\u201d (Mauss 1979, p.", [["people", "ORGANISM", 137, 143], ["people", "SPECIES", 137, 143]]], ["Understood in this way, \u201clearning\u201d does not hinge decisively upon the embodied capacities and needs of human individuals because those capacities and needs are only ever realized relationally or through \u201cecological interaction,\u201d including through interaction with machines (Foster 2018).", [["human", "ORGANISM", 103, 108], ["human", "SPECIES", 103, 108], ["human", "SPECIES", 103, 108]]], ["Instead, machine learning is aimed at having computers learn (more or less autonomously) from preexisting data, including the data output from prior attempts to undertake the tasks in question, and devise their own ways of both tackling those tasks and iteratively improving at them (Alpaydin 2014).", [["the data output", "TEST", 122, 137]]], ["We do so recognizing that not all data analysis in which social media platforms engage is automated, and that those aspects that are automated do not necessarily involve machine learning.", [["all data analysis", "TEST", 30, 47]]], ["Two points are important for our purposes: most \u201cmachines\u201d must be trained, cleaned, and tested by humans in order to \u201clearn.\u201d", [["humans", "ORGANISM", 99, 105], ["humans", "SPECIES", 99, 105], ["humans", "SPECIES", 99, 105]]], ["In implementations of machine learning on social media platforms, for instance, humans are everywhere \u201cin the loop\u201d\u2014an immense, poorly paid, and crowdsourced workforce that relentlessly labels, rates, and expunges the \u201ccontent\u201d to be consumed (Gillespie 2018; Gray and Suri 2019).", [["humans", "ORGANISM", 80, 86], ["humans", "SPECIES", 80, 86], ["humans", "SPECIES", 80, 86]]], ["Any reference to machine learning throughout this article should be taken to encapsulate these \u201cmore-than-human\u201d and \u201cmore-than-machine\u201d qualities of machine learning.Data hunger: searching as a natural attitude ::: Cybernetic feedback, data hunger, and meaning accretionAs suggested earlier, the human person is the product of a long, dynamic, and never settled process of socialization.", [["human", "ORGANISM", 106, 111], ["human", "ORGANISM", 297, 302], ["human", "SPECIES", 106, 111], ["human", "SPECIES", 297, 302], ["person", "SPECIES", 303, 309], ["human", "SPECIES", 106, 111], ["human", "SPECIES", 297, 302], ["data hunger", "PROBLEM", 237, 248], ["meaning accretion", "PROBLEM", 254, 271]]], ["It is through this process of sustained exposure that the self (or the habitus, in Pierre Bourdieu\u2019s vocabulary) becomes adjusted to its specific social world.", [["sustained", "OBSERVATION_MODIFIER", 30, 39], ["exposure", "OBSERVATION", 40, 48]]], ["The richer the process\u2014the more varied and intense the interactions\u2014the more \u201cinformation\u201d about different parts of the social world will be internalized and the more socially versatile\u2014and socially effective, possibly\u2014the outcome.", [["more varied", "OBSERVATION_MODIFIER", 27, 38]]], ["(This is why, for instance, parents with means often seek to offer \u201call-round\u201d training to their offspring [Lareau 2011]).Data hunger: searching as a natural attitude ::: Cybernetic feedback, data hunger, and meaning accretionMachine learning, like social learning, is data hungry.", [["data hunger", "PROBLEM", 192, 203]]], ["At the outset, access to data in enough volume and variety must be ensured to enable a particular learner-model combination to attain desired accuracy and confidence levels.", [["confidence levels", "TEST", 155, 172]]], ["Thereafter, data of even greater volume and variety is typically (though not universally) required if machine learning is to deliver continuous improvement, or at least maintain performance, on assigned tasks.Data hunger: searching as a natural attitude ::: Cybernetic feedback, data hunger, and meaning accretionThe data hunger of machine learning interacts with that of social learning in important ways.", [["data hunger", "PROBLEM", 279, 290], ["meaning accretion", "PROBLEM", 296, 313]]], ["Engineers, particularly in the social media sector, have structured machine learning technologies not only to take advantage of vast quantities of behavioral traces that people leave behind when they interact with digital artefacts, but also to solicit more through playful or addictive designs and cybernetic feedback loops.", [["people", "ORGANISM", 170, 176], ["people", "SPECIES", 170, 176], ["cybernetic feedback loops", "PROBLEM", 299, 324]]], ["With the world\u2019s knowledge at her fingertips, she understands that she must \u201cdo her own research\u201d about everything\u2014be it religion, politics, vaccines, or cooking.", [["fingertips", "ORGANISM_SUBDIVISION", 34, 44]]], ["The development of searching as a \u201cnatural attitude\u201d (Schutz 1970) is an eminently social process of course: it often means finding the right people to follow or emulate (Pariser 2011), using the right keywords so that the search process yields results consistent with expectations (Tripodi 2018), or implicitly soliciting feedback from others in the form of likes and comments.Data hunger: searching as a natural attitude ::: Cybernetic feedback, data hunger, and meaning accretionThe social media user also must extend this searching disposition to her own person: through cybernetic feedback, algorithms habituate her to search for herself in the data.", [["people", "ORGANISM", 142, 148], ["people", "SPECIES", 142, 148], ["person", "SPECIES", 559, 565], ["data hunger", "PROBLEM", 448, 459], ["meaning accretion", "PROBLEM", 465, 482]]], ["Surrounded by digital devices, some of which she owns, she internalizes the all-seeing eye and learns to watch herself and respond to algorithmic demands (Brubaker 2020).", [["eye", "ANATOMY", 87, 90], ["eye", "ORGAN", 87, 90], ["digital devices", "OBSERVATION", 14, 29], ["eye", "ANATOMY", 87, 90]]], ["Data hunger transmutes into self-hunger: an imperative to be digitally discernible in order to be present as a subject.", [["Data hunger", "PROBLEM", 0, 11]]], ["It may also be increasingly familiar to users of health or car insurance, people living in a smart home, or anyone being \u201ctracked\u201d by their employer or school by virtue of simply using institutionally licensed IT infrastructure.Data hunger: searching as a natural attitude ::: Cybernetic feedback, data hunger, and meaning accretionBut the productive nature of the process is not a simple extension of what Michel Foucault called \u201cdisciplinary power\u201d nor of the self-governance characteristic of \u201cgovernmentality.\u201d", [["people", "ORGANISM", 74, 80], ["people", "SPECIES", 74, 80], ["data hunger", "PROBLEM", 298, 309], ["meaning accretion", "PROBLEM", 315, 332]]], ["As such, it is generative of a new sense of selfhood\u2014a sense of discovering and crafting oneself through digital means that is quite different from the \u201canalog\u201d means of self-cultivation through training and introspection.Data hunger: searching as a natural attitude ::: Cybernetic feedback, data hunger, and meaning accretionWhen one is learning from a machine, and in the process making oneself learnable by it, mundane activities undergo a subtle redefinition.", [["self-cultivation through training", "TREATMENT", 170, 203], ["data hunger", "PROBLEM", 292, 303]]], ["Hydrating regularly or taking a stroll are not only imperatives to be followed or coerced into.", [["Hydrating", "TREATMENT", 0, 9]]], ["For instance, Snapchat has perfected the art of classifying\u2014and ranking\u2014relationships that way, so people are constantly presented with an ever-changing picture of their own dyadic connections, ranked from most to least important.", [["Snapchat", "CHEMICAL", 14, 22], ["people", "ORGANISM", 99, 105], ["people", "SPECIES", 99, 105], ["Snapchat", "TREATMENT", 14, 22]]], ["No longer, contra Foucault (1988), is \u201cpermanent self-examination\u201d crucial to self-crafting so much as attention to data-productive practices capable of making the self learnable and sustaining its searching process.", [["permanent self-examination", "TEST", 39, 65]]], ["To ensure one\u2019s learnability\u2014and thereby one\u2019s selfhood\u2014one must both feed and reproduce a hunger for data on and around the self.Meaning accretion: from value to volume ::: Cybernetic feedback, data hunger, and meaning accretionHuman learning is not only about constant, dynamic social exposure and world hunger, it is also about what we might call world or meaning accretion.2 The self is constantly both unsettled (by new experiences) and settling (as a result of past experiences).", [["Human", "ORGANISM", 229, 234], ["Human", "SPECIES", 229, 234], ["data hunger", "PROBLEM", 195, 206]]], ["People take on well institutionalized social roles (Berger and Luckmann 1966).", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6]]], ["Accretion here refers to a process, like the incremental build-up of sediment on a riverbank, involving the gradual accumulation of additional layers or matter.", [["a riverbank", "TREATMENT", 81, 92], ["gradual", "OBSERVATION_MODIFIER", 108, 115], ["accumulation", "OBSERVATION_MODIFIER", 116, 128], ["layers", "OBSERVATION_MODIFIER", 143, 149]]], ["The habitus, Bourdieu would say, is both structured and structuring, historical and generative.Meaning accretion: from value to volume ::: Cybernetic feedback, data hunger, and meaning accretionSocial processes of impression formation offer a good illustration of how social learning depends upon accreting data at volume, irrespective of the value of any particular datum.", [["data hunger", "PROBLEM", 160, 171], ["habitus", "OBSERVATION", 4, 11]]], ["It is clear that impressions are formed cumulatively and that early-acquired information tends to structure and inform the interpretation of information later acquired about persons and groups encountered in social life (Hamilton and Sherman 1996).", [["persons", "ORGANISM", 174, 181], ["persons", "SPECIES", 174, 181], ["clear", "OBSERVATION", 6, 11]]], ["In other words, social impressions are constituted by the incremental build-up of a variegated mass of data.Meaning accretion: from value to volume ::: Cybernetic feedback, data hunger, and meaning accretionMachine learning produces insight in a somewhat comparable way\u2014that is, accretively.", [["a variegated mass of data", "PROBLEM", 82, 107], ["data hunger", "PROBLEM", 173, 184], ["mass", "OBSERVATION", 95, 99]]], ["Insofar as machine learning yields outputs that may be regarded as meaningful (which is often taken to mean \u201cuseful\u201d for the task assigned), then that \u201cmeaning\u201d is assembled through the accumulation of \u201cexperience\u201d or from iterative exposure to available data in sufficient volume, whether in the form of a stream or in a succession of batches.", [["a succession of batches", "TREATMENT", 320, 343]]], ["Machine learning, like social learning, never produces insight entirely ab initio or independently of preexisting data.Meaning accretion: from value to volume ::: Cybernetic feedback, data hunger, and meaning accretionTo say that meaning is made accretively in machine learning is not to say that machine learning programs are inflexible or inattentive to the unpredictable; far from it.", [["data hunger", "PROBLEM", 184, 195], ["meaning accretion", "PROBLEM", 201, 218], ["inattentive", "PROBLEM", 341, 352]]], ["If, paraphrasing Marx, one considers that people make their own history, but not in circumstances they choose for themselves, but rather in present circumstances given and inherited, then the social-machine learning interface emphasizes the preponderance of the \u201cgiven and inherited\u201d in present circumstances, far more than the potentiality for \u201cmak[ing]\u201d that may lie within them (Marx 1996 [1852]).Meaning accretion: from value to volume ::: Cybernetic feedback, data hunger, and meaning accretionOne example of the compound effect of social and automated meaning accretion in the exemplary setting to which we return throughout this article\u2014social media\u2014is the durability of negative reputation across interlocking platforms.", [["people", "ORGANISM", 42, 48], ["people", "SPECIES", 42, 48], ["data hunger", "PROBLEM", 465, 476], ["meaning accretion", "PROBLEM", 482, 499], ["compound", "OBSERVATION_MODIFIER", 518, 526], ["effect", "OBSERVATION_MODIFIER", 527, 533], ["interlocking platforms", "OBSERVATION", 705, 727]]], ["For instance, people experience considerable difficulty in countering the effects of \u201crevenge porn\u201d online, reversing the harms of identity theft, or managing spoiled identities once they are digitally archived (Lageson and Maruna 2018).", [["people", "ORGANISM", 14, 20], ["people", "SPECIES", 14, 20]]], ["In such settings, the data accretion upon which machine learning depends for the development of granular insights\u2014and, on social media platforms, associated auctioning and targeting of advertising\u2014compounds the cumulative, sedimentary effect of social data, making negative impressions generated by \u201crevenge porn,\u201d or by one\u2019s online identity having been fraudulently coopted, hard to displace or renew.", [["the data accretion", "PROBLEM", 18, 36]]], ["The truth value of later, positive data may be irrelevant if enough negative data has accumulated in the meantime.Meaning accretion: from value to volume ::: Cybernetic feedback, data hunger, and meaning accretionData hunger and the accretive making of meaning are two aspects of the embedded sociality of machine learning and of the \u201cmechanical\u201d dimensions of social learning.", [["The truth value", "TEST", 0, 15], ["data hunger", "PROBLEM", 179, 190], ["meaning accretionData hunger", "PROBLEM", 196, 224]]], ["Together, they suggest modes of social relation, conflict, and action that machine learning systems may nourish among people on whom those systems bear, knowingly or unknowingly.", [["people", "ORGANISM", 118, 124], ["people", "SPECIES", 118, 124]]], ["This has significant implications for social and economic inequality, as we explore below.Terms of inclusion ::: Ordering, social and automatedMachine learning\u2019s data appetite and the \u201cdigestive\u201d or computational abilities that attend it are often sold as tools for the increased organizational efficiency, responsiveness, and inclusiveness of societies and social institutions.", [["the increased organizational efficiency", "PROBLEM", 266, 305], ["significant", "OBSERVATION_MODIFIER", 9, 20]]], ["Among international organizations, too, there is much hope that enhanced learning along these lines might result from the further utilization of machine learning capacities (Johns 2019).", [["lines", "CELL", 94, 99], ["these lines", "TREATMENT", 88, 99]]], ["For instance, machine learning, deployed in fingerprint, iris, or facial recognition, or to nourish sophisticated forms of online identification, is increasingly replacing older, document-based ones (Torpey 2018)\u2014and transforming the very concept of citizenship in the process (Cheney-Lippold 2016).Terms of inclusion ::: Ordering, social and automatedWhatever the pluses and minuses of \u201cinclusiveness\u201d in this mode, it entails a major infrastructural shift in the way that social learning takes place at the state and inter-state level, or how governments come to \u201cknow\u201d their polities.", [["iris", "ANATOMY", 57, 61], ["facial", "ANATOMY", 66, 72], ["iris", "ANATOMY", 57, 61], ["facial", "ANATOMY", 66, 72], ["infrastructural shift", "OBSERVATION", 436, 457]]], ["This devolves the process of assembling and representing a polity, and understanding its social and economic condition, down to agents outside the scope of public administration: commercial satellite operators (capturing satellite image data being used to assess a range of conditions, including agricultural yield and poverty), supermarkets (gathering scanner data, now widely used in CPI generation), and social media platforms.", [["gathering scanner data", "TEST", 343, 365]]], ["If official statistics (and associated data gathering infrastructures and labor forces) have been key to producing the modern polity, governmental embrace of machine learning capacities signals a change in ownership of that means of production.", [["learning capacities signals", "PROBLEM", 166, 193]]], ["This is notwithstanding the fact that automated systems\u2019 effects may be tempered by manual work-arounds and other modes of resistance within bureaucracies, such as the practices of frontline welfare workers intervening in automated systems in the interests of their clients, and strategies of foot-dragging and data obfuscation by legal professionals confronting predictive technologies in criminal justice (Raso 2017; Brayne and Christin 2020).Terms of inclusion ::: Ordering, social and automatedThe deployment of machine learning to the ends outlined in the foregoing paragraph furthers the centrality of data hungry social media platforms to the distribution of all sorts of economic and social opportunities and scarce public resources.", [["foot", "ORGANISM_SUBDIVISION", 293, 297], ["resistance within bureaucracies", "PROBLEM", 123, 154], ["The deployment of machine", "TREATMENT", 498, 523], ["foot", "ANATOMY", 293, 297]]], ["The \u201cpowerful network\u201d in question is society, but it is heterogeneous, comprising living and non-living, automated and organic elements: a composite to which we can give the name \u201csociety\u201d only with impropriety (that is, without adherence to conventional, anthropocentric understandings of the term).", [["heterogeneous", "OBSERVATION_MODIFIER", 57, 70]]], ["For all practical purposes, much of social life already is digital.Terms of inclusion ::: Ordering, social and automatedThis insertion of new translators, or repositioning of old translators, within the circuits of society is an important socio-economic transformation in its own right.", [["new translators", "TREATMENT", 138, 153], ["repositioning of old translators", "TREATMENT", 158, 190], ["new", "OBSERVATION_MODIFIER", 138, 141], ["economic transformation", "OBSERVATION", 245, 268], ["right", "ANATOMY_MODIFIER", 280, 285]]], ["Consequently, satisfaction of data hunger and practices of automated meaning accretion may come at the cost of increased social distrust, fostering strategies of posturing, evasion, and resistance among those targeted by such practices.", [["posturing", "DISEASE", 162, 171], ["data hunger", "PROBLEM", 30, 41], ["automated meaning accretion", "PROBLEM", 59, 86], ["posturing", "PROBLEM", 162, 171]]], ["These reactions, in turn, may undermine the capacity of state agents to tap into social data-gathering practices, further compounding existing power and information asymmetries (Harkin 2015).", [["These reactions", "PROBLEM", 0, 15]]], ["Finally, people accustomed to being surveilled will not hesitate to instrumentalize social media to reverse monitor their relationships with surveilling institutions, for instance by taping public interactions with police officers or with social workers and sharing them online (Byrne et al. 2019).", [["people", "ORGANISM", 9, 15], ["people", "SPECIES", 9, 15]]], ["While this kind of resistance might further draw a wedge between vulnerable populations and those formally in charge of assisting and protecting them, it has also become a powerful aspect of grassroots mobilization in and around machine learning and techno-social approaches to institutional reform (Benjamin 2019).Stratification by optimization ::: Automated social orders ::: Ordering, social and automatedWhat does it mean, and what does it feel like, to live in a society that is regulated through machine learning systems\u2014or rather, where machine learning systems are interacting productively with social ordering systems of an ordinal and nominal kind?", [["a wedge between vulnerable populations", "TREATMENT", 49, 87], ["grassroots mobilization", "TREATMENT", 191, 214], ["grassroots mobilization", "OBSERVATION", 191, 214]]], ["In this section, we identify some new, or newly manifest, drivers of social structure that emerge in machine learning-dominated environments.", [["new", "OBSERVATION_MODIFIER", 34, 37]]], ["Let us begin with the ordinal effects of these technologies (remembering that machine learning systems comprise human as well as non-human elements).", [["human", "ORGANISM", 112, 117], ["non-human", "ORGANISM", 129, 138], ["human", "SPECIES", 112, 117], ["human", "SPECIES", 112, 117], ["these technologies", "TREATMENT", 41, 59]]], ["If one is not active on the dating app Tinder, one cannot expect one\u2019s profile to be shown to prospective suitors.", [["not", "UNCERTAINTY", 10, 13], ["active", "OBSERVATION_MODIFIER", 14, 20]]], ["Failure to respond to someone\u2019s tag, or to like their photo, or otherwise maintain data productivity, and one might be dropped from their network, consciously or unconsciously, a dangerous proposition in a world where self-worth has become closely associated with measures of network centrality or social influence.", [["network", "MULTI-TISSUE_STRUCTURE", 276, 283], ["Failure", "PROBLEM", 0, 7]]], ["As Bucher has observed, \u201cabstaining from using a digital device for one week does not result in disconnection, or less data production, but more digital data points \u2026 To an algorithm, \u2026 absence provides important pieces of information\u201d (Bucher 2020, p.", [["a digital device", "TREATMENT", 47, 63], ["disconnection", "PROBLEM", 96, 109], ["disconnection", "OBSERVATION", 96, 109]]], ["But any ordering system that acts on people will generate social learning, including action directed at itself in return.Stratification by optimization ::: Automated social orders ::: Ordering, social and automatedEngagement, to feed data hunger and enable the accretion of \u201cmeaningful\u201d data from noise, is not neutral, socially or psychologically.", [["people", "ORGANISM", 37, 43], ["people", "SPECIES", 37, 43]]], ["The constant monitoring and management of one\u2019s social connections, interactions, and interpellations places a non-trivial burden on one\u2019s life.", [["The constant monitoring", "TEST", 0, 23], ["constant", "OBSERVATION_MODIFIER", 4, 12]]], ["Otherwise, how can we explain the fact that a whole industry of social media derivatives has popped up, to help people optimize their behavior vis-a-vis the algorithm, manage their following, and gain an edge so that they can climb the priority order over other, less savvy users?", [["people", "ORGANISM", 112, 118], ["people", "SPECIES", 112, 118], ["social media derivatives", "TREATMENT", 64, 88]]], ["Now users need to manage two systems (if not more): the primary one and the (often multiple) analytics apps that help improve and adjust their conduct in it.", [["analytics apps", "TREATMENT", 93, 107]]], ["In these ways, interaction with machine learning systems tends to encourage continuous effort towards ordinal self-optimization.Stratification by optimization ::: Automated social orders ::: Ordering, social and automatedHowever, efforts of ordinal optimization, too, may soon become useless: as Marilyn Strathern (citing British economist Charles Goodhardt) put it, \u201cwhen a measure becomes a target, it ceases to be a good measure\u201d (Strathern 1997, p.", [["ordinal self-optimization", "TREATMENT", 102, 127]]], ["The same is true of Tinder.", [["Tinder", "OBSERVATION", 20, 26]]], ["Finally, wealthier users can completely outsource the process of online profile management to someone else (perhaps recruiting a freelance social media manager through an online platform like Upwork, the interface of which exhibits ordinal features like client ratings and job success scores).Stratification by optimization ::: Automated social orders ::: Ordering, social and automatedIn all the foregoing ways, the inclusionary promise of machine learning has shifted toward more familiar sociological terrain, where money and other vectors of domination determine outcomes.", [["online profile management", "TREATMENT", 65, 90]]], ["In addition to economic capital, distributions of social and cultural capital, as well as traditional ascriptive characteristics, such as race or gender, play an outsized role in determining likeability and other outcomes of socially learned modes of engagement with machine learning systems.", [["economic", "OBSERVATION_MODIFIER", 15, 23], ["capital", "OBSERVATION", 24, 31]]], ["For instance, experiments with Mechanical Turkers have shown that being attractive increases the likelihood of appearing trustworthy on Twitter, but being Black creates a contrarian negative effect (Groggel et al. 2019).", [["Mechanical Turkers", "TREATMENT", 31, 49]]], ["In another example, empirical studies of social media use among those bilingual in Hindi and English have observed that positive modes of social media engagement tend to be expressed in English, with negative emotions and profanity more commonly voiced in Hindi.", [["empirical studies", "TEST", 20, 37]]], ["In short, well-established off-platform distinctions and social hierarchies shape the extent to which on-platform identities and forms of materialized labor will be defined as valuable and value-generating in the field of social media.Stratification by optimization ::: Automated social orders ::: Ordering, social and automatedIn summary, ordinality is a necessary feature of all online socio-technical systems and it demands a relentless catering to one\u2019s digital doppelg\u00e4ngers\u2019 interactions with others and with algorithms.", [["materialized labor", "PROBLEM", 138, 156], ["social hierarchies", "OBSERVATION", 57, 75]]], ["In the social world, any type of scoring, whether implicit or explicit, produces tremendous amounts of status anxiety and often leads to productive resources (time and money) being diverted in an effort to better one\u2019s odds (Espeland and Sauder 2016; Mau 2019).4 Those who are short on both presumably fare worse, not only because that makes them less desirable in the real world, but also because they cannot afford the effort and expense needed to overcome their disadvantage in the online world.", [["anxiety", "DISEASE", 110, 117], ["status anxiety", "PROBLEM", 103, 117]]], ["The very act of ranking thus both recycles old forms of social inequality and also creates new categories of undesirables.", [["new", "OBSERVATION_MODIFIER", 91, 94]]], ["In this light, Jeff Bezos may be the perfect illustration of intertwining between asymmetries of real world and virtual world power: the founder and CEO of Amazon and currently the richest man in the world has 1.4 million followers on Twitter, but follows only one person: his ex-wife.Association by pattern recognition ::: Automated social orders ::: Ordering, social and automatedOrdinalization has implications not just for hierarchical positioning, but also for belonging\u2014an important dimension of all social systems (Simmel 1910).", [["man", "ORGANISM", 189, 192], ["man", "SPECIES", 189, 192], ["person", "SPECIES", 265, 271]]], ["Ordinal stigma (the shame of being perceived as inferior) often translates into nominal stigma, or the shame of non-belonging.", [["non-belonging", "DISEASE", 112, 125], ["Ordinal stigma", "PROBLEM", 0, 14], ["stigma", "OBSERVATION", 8, 14]]], ["Not obtaining recognition (in the form of \u201clikes\u201d or \u201cfollowers\u201d), in return for one\u2019s appreciation of other people, can be a painful experience, all the more since it is public.", [["people", "ORGANISM", 109, 115], ["people", "SPECIES", 109, 115]]], ["Concern to lessen the sting of this kind of algorithmic cruelty is indeed why, presumably, Tinder has moved from a simple elo or desirability score (which depends on who has swiped to indicate liking for the person in question, and their own scores, an ordinal measure) to a system that relies more heavily on type matching (a nominal logic), where people are connected based on taste similarity as expressed through swiping, sound, and image features (Carman 2019).Association by pattern recognition ::: Automated social orders ::: Ordering, social and automatedIn addition to employing machine learning to rank users, most social media platforms also use forms of clustering and type matching, which allow them to group users according to some underlying similarity (analogical machine learning in Domingos\u2019s terms).", [["people", "ORGANISM", 349, 355], ["person", "SPECIES", 208, 214], ["people", "SPECIES", 349, 355], ["type matching", "PROBLEM", 681, 694], ["cruelty", "OBSERVATION", 56, 63]]], ["Now the aim is trying to figure a person out or at least to amplify and reinforce a version of that person that appears in some confluence of data exhaust within the system in question.", [["person", "SPECIES", 34, 40], ["person", "SPECIES", 100, 106]]], ["The more predictable one is, the better the chances that one will be seen\u2014and engaged\u2014by relevant audiences.", [["more", "OBSERVATION_MODIFIER", 4, 8], ["predictable", "OBSERVATION_MODIFIER", 9, 20]]], ["Being inconsistent or too frequently turning against type in data-generative behaviors can make it harder for a machine learning system to place and connect a person associatively.Association by pattern recognition ::: Automated social orders ::: Ordering, social and automatedIn both offline and online social worlds (not that the two can easily be disentangled), deviations from those expectations that data correlations tend to yield are often harshly punished by verbal abuse, dis-association, or both.", [["verbal abuse", "DISEASE", 467, 479], ["person", "SPECIES", 159, 165]]], ["Experiences of being so punished, alongside experiences of being rewarded by a machine learning interface for having found a comfortable group (or a group within which one has strong correlations), can lead to some form of social closure, a desire to \u201cplay to type.\u201d", [["social closure", "TREATMENT", 223, 237], ["closure", "OBSERVATION", 230, 237]]], ["As one heavy social media user told us, \u201cyou want to mimic the behavior [and the style] of the people who are worthy of your likes\u201d in the hope that they will like you in return.", [["people", "ORGANISM", 95, 101], ["people", "SPECIES", 95, 101]]], ["That\u2019s why social media have been variously accused of generating \u201conline echo chambers\u201d and \u201cfilter bubbles,\u201d and of fueling polarization (e.g., Pariser 2011).", [["filter bubbles", "OBSERVATION", 94, 108]]], ["On the other hand, being visible to the wrong group is often a recipe for being ostracized, \u201cwoke-shamed,\u201d \u201ccalled-out,\u201d or even \u201ccanceled\u201d (Yar and Bromwich 2019).Association by pattern recognition ::: Automated social orders ::: Ordering, social and automatedIn these and other ways, implementations of machine learning in social media complement and reinforce certain predilections widely learned socially.", [["social media complement", "TREATMENT", 325, 348]]], ["In many physical, familial, political, legal, cultural, and institutional environments, people learn socially to feel suspicious of those they experience as unfamiliar or fundamentally different from themselves.", [["people", "ORGANISM", 88, 94], ["people", "SPECIES", 88, 94]]], ["There is an extensive body of scholarly work investigating social rules and procedures through which people learn to recognize, deal with, and distance themselves from bodies that they read as strange and ultimately align themselves with and against pre-existing nominal social groupings and identities (Ahmed 2013; Goffman 1963).", [["people", "ORGANISM", 101, 107], ["people", "SPECIES", 101, 107], ["extensive", "OBSERVATION_MODIFIER", 12, 21], ["body", "OBSERVATION_MODIFIER", 22, 26], ["scholarly work", "OBSERVATION", 30, 44]]], ["On Facebook, such an algorithm generates a list of \u201cPeople You May Know\u201d and on Twitter, a \u201cWho to follow\u201d list.Association by pattern recognition ::: Automated social orders ::: Ordering, social and automatedRecommendation algorithms derive value from this social learning of homophily (McPherson et al. 2001).", [["People", "SPECIES", 52, 58]]], ["First, growing awareness that extreme type consistency may lead to online boredom, claustrophobia, and insularity (Crawford 2009) has led platforms to experiment with and implement various kinds of exploratory features.", [["boredom", "DISEASE", 74, 81], ["claustrophobia", "DISEASE", 83, 97], ["insularity", "DISEASE", 103, 113], ["extreme type consistency", "PROBLEM", 30, 54], ["claustrophobia", "PROBLEM", 83, 97], ["exploratory features", "PROBLEM", 198, 218]]], ["Second, people willfully sort themselves online in all sorts of non-overlapping ways: through Twitter hashtags, group signups, click and purchasing behavior, social networks, and much more.", [["people", "ORGANISM", 8, 14], ["people", "SPECIES", 8, 14]]], ["The abundance of data, which is a product of the sheer compulsion that people feel to self-index and classify others (Harcourt 2015; Brubaker 2020), might be repurposed to revisit common off-line classifications.", [["people", "ORGANISM", 71, 77], ["people", "SPECIES", 71, 77]]], ["Categories like marriage or citizenship can now be algorithmically parsed and tested in ways that wield power over people.", [["people", "ORGANISM", 115, 121], ["people", "SPECIES", 115, 121]]], ["Similarly, the US National Security Agency measures people\u2019s national allegiance from how they search on the internet, redefining rights in the process (Cheney-Lippold 2016).", [["people", "ORGANISM", 52, 58], ["people", "SPECIES", 52, 58]]], ["Changes in market research from the 1970s to the 1990s, aimed at tracking consumer mobility and aspiration through attention to \u201cpsychographic variables,\u201d constitute a pre-history, of sorts, for contemporary machine learning practices in commercial settings (Arvidsson 2004; Gandy 1993; Fourcade and Healy 2017; Lauer 2017).", [["aspiration", "PROBLEM", 96, 106]]], ["However, the volume and variety of variables now digitally discernible mean that the latter have outstripped the former exponentially.", [["the volume", "TEST", 9, 19], ["volume", "OBSERVATION_MODIFIER", 13, 19], ["variety", "OBSERVATION_MODIFIER", 24, 31], ["former", "OBSERVATION_MODIFIER", 113, 119], ["exponentially", "OBSERVATION_MODIFIER", 120, 133]]], ["Machine learning techniques have the potential to reveal unlikely associations, no matter how small, that may have been invisible, or muted, in the physically constraining geography of the offline world.", [["Machine learning techniques", "TREATMENT", 0, 27], ["small", "OBSERVATION_MODIFIER", 94, 99]]], ["Repurposed for intervention, disparate data can be assembled to form new, meaningful types and social entities.", [["intervention", "TREATMENT", 15, 27], ["social entities", "OBSERVATION", 95, 110]]], ["Christopher Wylie, a former lead scientist at the defunct firm Cambridge Analytica\u2014which famously matched fraudulently obtained Facebook data with consumer data bought from US data brokers and weaponized them in the context of the 2016 US Presidential election\u2014recalls the experience of searching for\u2014and discovering\u2014incongruous social universes: \u201c[we] spent hours exploring random and weird combinations of attributes.\u2026 One day we found ourselves wondering whether there were donors to anti-gay churches who also shopped at organic food stores.", [["donors", "ORGANISM", 477, 483]]], ["We did a search of the consumer data sets we had acquired for the pilot and I found a handful of people whose data showed that they did both.", [["people", "ORGANISM", 97, 103], ["people", "SPECIES", 97, 103]]], ["After identifying a potential target in Fairfax County, he discovered a real person who wore yoga pants, drank Kombucha, and held fire-and-brimstone views on religion and sexuality.", [["person", "SPECIES", 77, 83]]], ["\u201cHow the hell would a pollster classify this woman?\u201d", [["woman", "SPECIES", 45, 50]]], ["This is why people strive to raise their digital profiles and to belong to those categories that are most valued there (for instance \u201cverified\u201d badges or recognition as a social media \u201cinfluencer\u201d).", [["people", "ORGANISM", 12, 18], ["people", "SPECIES", 12, 18]]], ["Conversely, pattern-matching can be a strategy of optimization, too: people will carefully manage their affiliations, for instance, so as to raise their score\u2014aligning themselves with the visible and disassociating themselves from the underperforming.", [["people", "ORGANISM", 69, 75], ["people", "SPECIES", 69, 75]]], ["We examine these complex interconnections below and discuss the dispositions and sentiments that they foster and nourish.Social struggles, platformized ::: Sociality and change in\u00a0the age of machine learningSocial scientists\u2019 accounts of modes of sociality online are often rendered in terms of the antagonism between competition and cooperation immanent in capitalism (e.g., Fuchs 2007).", [["Sociality", "DISEASE", 156, 165]]], ["This is not without justification.", [["not without", "UNCERTAINTY", 8, 19]]], ["After all, social media platforms are sites of social struggle, where people seek recognition: to be seen, first and foremost, but also to see\u2014to be a voyeur of themselves and of others (Harcourt 2015; Brubaker 2020).", [["people", "ORGANISM", 70, 76], ["people", "SPECIES", 70, 76]]], ["In that sense, platforms may be likened to fields in the Bourdieusian sense, where people who invest in platform-specific stakes and rules of the game6 are best positioned to accumulate platform-specific forms of capital (e.g., likes, followers, views, retweets, etc.)", [["people", "ORGANISM", 83, 89], ["game6", "GENE_OR_GENE_PRODUCT", 146, 151], ["people", "SPECIES", 83, 89], ["capital", "OBSERVATION", 213, 220]]], ["According to a recent and well-publicized survey, \u201cVlogger/YouTuber\u201d has replaced \u201castronaut\u201d as the most enviable job for American and British children (Berger 2019).", [["children", "ORGANISM", 144, 152], ["children", "SPECIES", 144, 152]]], ["In this real-life competition, digitally produced ordinal positions (e.g., popularity, visibility, influence, social network location) and nominal associations (e.g., matches to advertised products, educational institutions, jobs) may be relevant.Social struggles, platformized ::: Sociality and change in\u00a0the age of machine learningMachine learning algorithms within social media both depend on and reinforce competitive striving within ordinal registers of the kind highlighted above\u2014or in Bourdieu\u2019s terms, competitive struggles over field-specific forms of capital.", [["Sociality", "DISEASE", 282, 291]]], ["As Georg Simmel observed, the practice of competing socializes people to compete; it \u201ccompels the competitor\u201d (Simmel 2008 [1903]).", [["people", "ORGANISM", 63, 69], ["people", "SPECIES", 63, 69]]], ["For instance, empirical studies suggest that motives for \u201cfriending\u201d and following others on social media include upward and downward social comparison (Ouwerkerk and Johnson 2016; Vogel et al. 2014).", [["empirical studies", "TEST", 14, 31]]], ["1349)\u2014engagement from which algorithms can continuously learn in order to enhance their own predictive capacity and its monetization through sales of advertising.Social struggles, platformized ::: Sociality and change in\u00a0the age of machine learningAt the same time, the distributed structure of social media (that is, its multi-nodal and cumulative composition) also fosters forms of cooperation, gift exchange, redistribution, and reciprocity.", [["Sociality", "DISEASE", 197, 206], ["\u2014engagement", "TREATMENT", 5, 16], ["distributed", "OBSERVATION_MODIFIER", 270, 281], ["structure", "OBSERVATION_MODIFIER", 282, 291], ["social media", "OBSERVATION", 295, 307], ["redistribution", "OBSERVATION_MODIFIER", 412, 426]]], ["Redistributive behavior on social media platforms manifests primarily in a philanthropic mode rather than in the equity-promoting mode characteristic of, for instance, progressive taxation.7 Examples include practices like the #followfriday or #ff hashtag on Twitter, a spontaneous form of redistributive behavior that emerged in 2009 whereby \u201cmicro-influencers\u201d started actively encouraging their own followers to follow others.8 Insofar as those so recommended are themselves able to monetize their growing follower base through product endorsement and content creation for advertisers, this redistribution of social capital serves, at least potentially, as a redistribution of economic capital.", [["Redistributive behavior", "PROBLEM", 0, 23], ["social media platforms", "TREATMENT", 27, 49], ["redistributive behavior", "PROBLEM", 290, 313], ["advertisers", "TREATMENT", 576, 587], ["redistribution", "OBSERVATION_MODIFIER", 594, 608], ["social capital", "OBSERVATION", 612, 626], ["redistribution", "OBSERVATION_MODIFIER", 662, 676], ["economic capital", "OBSERVATION", 680, 696]]], ["In these and other ways, digitized sociality is often at once competitive and cooperative, connective and divisive (Zukin and Papadantonakis 2017).Dependency by design ::: Sociality and change in\u00a0the age of machine learningWhether it is enacted in competitive, redistributive or other modes, sociality on social media is nonetheless emergent and dynamic.", [["Sociality", "DISEASE", 172, 181], ["connective", "TISSUE", 91, 101]]], ["No wonder that Bruno Latour was the social theorist of choice when we started this investigation.", [["this investigation", "TEST", 78, 96]]], ["The properties of machine learning highlighted above\u2014cybernetic feedback; data hunger; accretive meaning-making; ordinal and nominal ordering\u2014lend social media platforms and interfaces a distinctive, compulsive, and calculating quality\u2014engineering a relentlessly \u201cparticipatory subjectivity\u201d (Bucher 2020, p.88; boyd 2015).", [["compulsive", "DISEASE", 200, 210], ["data hunger", "PROBLEM", 74, 85]]], ["It is also an effect of the software and hardware that mediate the imitative (or counter-imitative) process itself\u2014and of the economic rationale behind their implementation.Dependency by design ::: Sociality and change in\u00a0the age of machine learningWe cannot understand the structural features and phenomenological nature of digital technologies in general, and of social media in particular, if we do not understand the purposes for which they were designed.", [["Sociality", "DISEASE", 198, 207], ["hardware", "TREATMENT", 41, 49], ["hardware", "OBSERVATION", 41, 49]]], ["The simple answer, of course, is that data hunger and meaning accretion are essential to the generation of profit (Zuboff 2019), whether profit accrues from a saleable power to target advertising, commercializable developments in artificial intelligence, or by other comparable means.", [["data hunger", "PROBLEM", 38, 49], ["meaning accretion", "PROBLEM", 54, 71]]], ["Social media interfaces tend to exhibit design features at both the back- and front-end that support user dependency and enable its monetization.", [["design features", "PROBLEM", 40, 55], ["back", "ANATOMY", 68, 72]]], ["For example, the \u201cinfinite scroll,\u201d which allows users to swipe down a page endlessly (without clicking or refreshing) rapidly became a staple of social media apps after its invention in 2006, giving them an almost hypnotic feel and maximizing the \u201ctime on device\u201d and hence users\u2019 availability to advertisers (Andersson 2018).", [["clicking", "PROBLEM", 95, 103], ["social media apps", "TREATMENT", 146, 163], ["staple", "OBSERVATION", 136, 142]]], ["Social media platforms also employ psycho-social strategies to this end, including campaigns to draw people in by drumming up reciprocity and participation\u2014the notifications, the singling out of trends, the introduction of \u201cchallenges\u201d\u2014and more generally the formation of habits through gamification.", [["people", "ORGANISM", 101, 107], ["people", "SPECIES", 101, 107]]], ["Prominent critics of social media, such as Tristan Harris (originally from Google) and Sandy Parakilas (originally from Facebook), have denounced apps that look like \u201cslot machines\u201d and use a wide range of intermittent rewards to keep users hooked and in the (Instagram, TikTok, Facebook, \u2026) zone, addicted \u201cby design\u201d (Sch\u00fcll 2012; Fourcade 2017).Dependency by design ::: Sociality and change in\u00a0the age of machine learningImportantly, this dependency has broader social ramifications than may be captured by a focus on individual unfreedom.", [["Sociality", "DISEASE", 373, 382], ["critics", "OBSERVATION", 10, 17], ["social media", "OBSERVATION_MODIFIER", 21, 33]]], ["Dependencies engineered into social media interfaces help, in combination with a range of other structural factors, to sustain broader economic dependencies, the burdens and benefits of which land very differently across the globe (see, e.g., Taylor and Broeders 2015).", [["broader economic dependencies", "PROBLEM", 127, 156], ["globe", "ANATOMY", 225, 230]]], ["In this light, the question of how amenable these dynamics may be to social change becomes salient for many.Dynamics of machine-learned sociality ::: Sociality and change in\u00a0the age of machine learningRecent advances in digital technology are often characterized as revolutionary.", [["Sociality", "DISEASE", 150, 159], ["change", "OBSERVATION_MODIFIER", 164, 170]]], ["Data hunger on the part of mechanisms of both social learning and machine learning, together with their dependence on data accretion to make meaning, encourage replication of interface features and usage practices known to foster continuous, data-productive engagement.", [["Data hunger", "PROBLEM", 0, 11], ["usage practices", "TREATMENT", 198, 213]]], ["Significant shifts in interface design\u2014and in the social learning that has accreted around use of a particular interface\u2014risk negatively impacting data-productive engagement.", [["Significant shifts in interface design\u2014and", "PROBLEM", 0, 42], ["shifts", "OBSERVATION_MODIFIER", 12, 18], ["interface design\u2014and", "OBSERVATION", 22, 42]]], ["One study of users\u2019 reactions to changes in the Facebook timeline suggested that \u201cmajor interface changes induce psychological stress as well as technology-related stress\u201d (Wisniewski et al. 2014).", [["One study", "TEST", 0, 9], ["psychological stress", "PROBLEM", 113, 133]]], ["In recognition of these sensitivities, those responsible for social media platforms\u2019 interfaces tend to approach their redesign incrementally, so as to promote continuity rather than discontinuity in user behaviour.", [["these sensitivities", "TEST", 18, 37]]], ["The emphasis placed on continuity in social media platform design may foster tentativeness in other respects as well, as we discuss in the next section.Dynamics of machine-learned sociality ::: Sociality and change in\u00a0the age of machine learningAt the same time, social learning and machine learning, in combination, are not necessarily inimical to social change.", [["Sociality", "DISEASE", 194, 203]]], ["For example, the popular Chinese social media platform WeChat has three features, enabled by machine learning, that encourage open-ended, opportunistic interactions between random users\u2014Shake, Drift Bottle, and People Nearby\u2014albeit, in the case of People Nearby, random users within one\u2019s immediate geographic vicinity.", [["People", "SPECIES", 211, 217], ["People", "SPECIES", 248, 254]]], ["(These are distinct from the more narrow, instrumental range of encounters among strangers occasioned by platforms like Tinder, the sexual tenor of which are clearly established in advance, with machine learning parameters set accordingly.)", [["distinct", "OBSERVATION_MODIFIER", 11, 19], ["more narrow", "OBSERVATION_MODIFIER", 29, 40]]], ["Qualitative investigation of WeChat use and its impact on Chinese social practices has suggested that WeChat challenges some existing social practices, while reinforcing others.", [["WeChat", "CHEMICAL", 29, 35]]], ["It may also foster the establishment of new social practices, some defiant of prevailing social order.", [["new", "OBSERVATION_MODIFIER", 40, 43]]], ["For instance, people report interacting with strangers via WeChat in ways they normally would not, including shifting to horizontally-structured interactions atypical of Chinese social structures offline (Wang et al. 2016).", [["people", "ORGANISM", 14, 20], ["people", "SPECIES", 14, 20]]], ["This is not necessarily unique to WeChat.Dynamics of machine-learned sociality ::: Sociality and change in\u00a0the age of machine learningThe kinds of ruptures and reorderings engineered through machine learning do not, however, create equal opportunities for value creation and accumulation, any more than they are inherently liberating or democratizing.", [["Sociality", "DISEASE", 83, 92], ["ruptures", "DISEASE", 147, 155], ["WeChat", "PROTEIN", 34, 40], ["ruptures", "PROBLEM", 147, 155], ["accumulation", "PROBLEM", 275, 287], ["not necessarily", "UNCERTAINTY", 8, 23], ["ruptures", "OBSERVATION", 147, 155]]], ["It favors certain companies, their shareholders and executives, while compounding conditions of social dependency and economic precarity for most other people.", [["people", "ORGANISM", 152, 158], ["people", "SPECIES", 152, 158], ["social dependency", "PROBLEM", 96, 113]]], ["Although resistance to algorithms is growing, those who are classified in ways they find detrimental (on either dimension) may be more likely to try to work on themselves or navigate algorithmic workarounds than to contest the classificatory instrument itself (Ziewitz 2019).", [["growing", "OBSERVATION_MODIFIER", 37, 44]]], ["Furthermore, we know that people who work under distributed, algorithmically managed conditions (e.g., Mechanical Turk workers, Uber drivers) find it difficult to communicate amongst themselves and organize (Irani and Silberman 2013; Lehdonvirta 2016; Dubal 2017).", [["people", "ORGANISM", 26, 32], ["people", "SPECIES", 26, 32]]], ["These features of the growing entanglement of social and machine learning may imply dire prospects for collective action\u2014and beyond it, for the achievement of any sort of broad-based, solidaristic project.", [["growing", "OBSERVATION_MODIFIER", 22, 29], ["entanglement", "OBSERVATION", 30, 42]]], ["In this section, we tentatively review possibilities for solidarity and mobilization as they present themselves in the field of social media.Solidaristic propectsMachine learning systems\u2019 capacity to ingest and represent immense quantities of data does increase the chances that those with common experiences will find one another, at least insofar as those experiences are shared online.", [["solidarity and mobilization", "TREATMENT", 57, 84], ["Solidaristic propects", "TREATMENT", 141, 162]]], ["Machine-learned types thereby become potentially important determinants of solidarity, displacing or supplementing the traditional forces of geography, ascribed identities, and voluntary association.", [["solidarity", "OBSERVATION", 75, 85]]], ["Those dimensions of social life that social media algorithms have determined people really care about often help give rise to, or supercharge, amorphous but effective forms of offline action, if only because the broadcasting costs are close to zero.", [["people", "ORGANISM", 77, 83], ["people", "SPECIES", 77, 83]]], ["Nonetheless, the thinness, fleeting character, and relative randomness of the affiliations summoned in those ways (based on segmented versions of the self, which may or may not overlap) might make social recognition and commonality of purpose difficult to sustain in the long run.Solidaristic propectsMore significant, perhaps, is the emergence of modes of collective action that are specifically designed not only to fit the online medium, but also to capitalize on its technical features.", [["the thinness, fleeting character", "PROBLEM", 13, 45], ["Solidaristic propects", "TREATMENT", 280, 301], ["fleeting", "OBSERVATION_MODIFIER", 27, 35], ["character", "OBSERVATION_MODIFIER", 36, 45], ["significant", "OBSERVATION_MODIFIER", 306, 317]]], ["Many of these strategies were first implemented to stigmatize or sow division, although there is no fatality that this is their only possible use.", [["no", "UNCERTAINTY", 97, 99]]], ["Examples include the anti-semitic (((echo))) tagging on Twitter\u2014originally devised to facilitate trolling by online mobs (Weisman 2018) but later repurposed by non-Jews as an expression of solidarity; the in-the-wild training of a Microsoft chatter bot, literally \u201ctaught\u201d by well-organized users to tweet inflammatory comments; the artificial manipulation of conversations and trends through robotic accounts; or the effective delegation, by the Trump 2020 campaign, of the management of its ad-buying activities to Facebook\u2019s algorithms, optimized on the likelihood that users will take certain campaign-relevant actions\u2014\u201csigning up for a rally, buying a hat, giving up a phone number\u201d (Bogost and Madrigal 2020).11Solidaristic propectsThe exploitation of algorithms for divisive purposes often spurs its own reactions, from organized counter-mobilizations to institutional interventions by platforms themselves.", [["Solidaristic propects", "TREATMENT", 717, 738], ["algorithms", "TREATMENT", 758, 768], ["divisive purposes", "TREATMENT", 773, 790], ["spurs its own reactions", "PROBLEM", 797, 820], ["institutional interventions", "TREATMENT", 862, 889]]], ["Even so, often the work of \u201ccivilizing\u201d the social media public sphere is left to algorithms, supported by human decision-makers working through rules and protocols (and replacing them in especially sensitive cases).", [["human", "ORGANISM", 107, 112], ["human", "SPECIES", 107, 112], ["human", "SPECIES", 107, 112]]], ["Social media companies ban millions of accounts every month for inappropriate language or astroturfing (coordinated operations on social media that masquerade as a grassroot movement): algorithms have been trained to detect and exclude certain types of coalitions on the basis of a combination of social structure and content.", [["inappropriate language", "PROBLEM", 64, 86], ["social media", "TREATMENT", 130, 142], ["coalitions", "OBSERVATION", 253, 263], ["social structure", "OBSERVATION", 297, 313]]], ["In 2020, the British far right movement \u201cBritain first\u201d moved to TikTok after being expelled from Facebook, Twitter, Instagram, and YouTube\u2014and then over to VKontakte or VK, a Russian platform, after being banned from TikTok (USA News 2020).", [["right", "ANATOMY_MODIFIER", 25, 30]]], ["Chastised in the offline world for stirring discord and hate, the economic engines that gave the movement a megaphone have relegated it to their margins with embarrassment.", [["a megaphone", "TREATMENT", 106, 117]]], ["The episode goes to show that there is nothing inherently inclusive in the kind of group solidarity that machine learning enables, and thus it has to be constantly put to the (machine learning) test.Solidaristic propectsIn the end, platforms\u2019 ideal of collective action may resemble the Tardean, imitative but atomized crowd, nimble but lacking in endurance and capacity (Tufekci 2016).", [["The episode", "PROBLEM", 0, 11]]], ["Mimetic expressions of solidarity, such as photo filters (e.g., rainbow), the \u201cblacking out\u201d of one\u2019s newsfeed, or the much-bemoaned superficiality of \u201cclicktivism\u201d may be effective at raising consciousness or the profile of an issue, but they may be insufficient to support broader-based social and political transformations.", [["photo filters", "TREATMENT", 43, 56], ["political transformations", "OBSERVATION", 300, 325]]], ["In fact, social media might actually crowd out other solidaristic institutions by also serving as a (feeble, often) palliative for their failures.", [["their failures", "PROBLEM", 131, 145]]], ["For example, crowdsourced campaigns, now commonly used to finance healthcare costs, loss of employment, or educational expenses, perform a privatized solidarity that is a far cry from the universal logic of public welfare institutions.Conclusion: Reassembling the machineUp to this point, our emphasis has been on the kinds of sociality that machine learning implementations tend to engender on the social media field, in both vertical (ordinal) and horizontal (nominal) configurations.", [["both", "ANATOMY_MODIFIER", 422, 426], ["vertical", "ANATOMY_MODIFIER", 427, 435]]], ["We have, in a sense, been \u201creassembling the social\u201d afresh, with an eye, especially, to its computational components and chains of reference (Latour 2005).", [["eye", "ANATOMY", 68, 71], ["eye", "ORGAN", 68, 71], ["eye", "ANATOMY", 68, 71]]], ["Throughout, we have stressed, nonetheless, that machine learning and other applications of artificial intelligence must be understood as forces internal to social life\u2014both subject to and integral to its contingent properties\u2014not forces external to it or determinative of it.", [["artificial intelligence", "TREATMENT", 91, 114]]], ["233), \u201cit\u2019s necessary, aside from the circulation and formatting of traditionally conceived [socio-technical] ties, to detect other circulating entities.\u201dConclusion: Reassembling the machineSo what could be some \u201cother circulating entities\u201d within the socio-technical complex of machine learning, or how could we envisage its elements circulating, and associating, otherwise?", [["other circulating entities", "PROBLEM", 126, 152], ["circulation", "ANATOMY", 38, 49]]], ["On some level, our analysis suggests that the world has changed very little.", [["our analysis", "TEST", 15, 27]]], ["Like every society, machine-learned society is powered by two fundamental, sometimes contradictory forces: stratification and association, vertical and horizontal difference.", [["vertical and horizontal difference", "PROBLEM", 139, 173], ["vertical", "OBSERVATION_MODIFIER", 139, 147]]], ["To be sure, preexisting social divisions and inequalities are still very much part of its operations.", [["its operations", "TREATMENT", 86, 100]]], ["But the forces of ordinality and nominality have also been materialized and formatted in new ways, of which for-profit social media offer a particularly stark illustration.", [["forces", "OBSERVATION_MODIFIER", 8, 14]]], ["The machine-learnable manifestations of these forces in social media: these are among the \u201cother circulating entities\u201d now traceable.", [["The machine", "TREATMENT", 0, 11]]], ["Central to these dynamics in the social media field are the development of a searching disposition to match the searchability of the environment, the learnability of the self through quantified measurement, the role of scores in the processing of social positions and hierarchies, the decategorization and recategorization of associational identities, automated feedback that fosters compulsive habits and competitive social dispositions, and strategic interactions between users and platforms around the manipulation of algorithms.Conclusion: Reassembling the machineWhat, then, of prospects for reassembly of existing configurations?", [["dynamics", "OBSERVATION_MODIFIER", 17, 25]]], ["In fact, they may be as divisive and hierarchizing as they may be connective and flattening.", [["connective", "ANATOMY", 66, 76], ["connective", "TISSUE", 66, 76], ["may be", "UNCERTAINTY", 59, 65], ["connective", "OBSERVATION", 66, 76], ["flattening", "OBSERVATION_MODIFIER", 81, 91]]], ["Moreover, the conditions for entry into struggle in the social media field are set by a remarkably small number of corporate entities and \u201cgreat men of tech\u201d with global reach and influence (Grewal 2008).", [["men", "ORGANISM", 145, 148], ["men", "SPECIES", 145, 148], ["small", "OBSERVATION_MODIFIER", 99, 104]]], ["Rather, it has been carved up and crenellated by those who happen to have accumulated greatest access to the data processing and storage capacity that machine learning systems require, together with the real property, intellectual property, and personal property rights, and the network of political and regulatory lobbyists that ensure that exclusivity of access is maintained (Cohen 2019).", [["storage capacity", "PROBLEM", 129, 145], ["political and regulatory lobbyists", "TREATMENT", 290, 324]]], ["Power in this field is, accordingly, unlikely to be reconfigured or redistributed organically, or through generalized exhortation to commit to equity or ethics (many versions of which are self-serving on the part of major players).Conclusion: Reassembling the machineInstead, political action aimed at building or rebuilding social solidarities across such hierarchies and among such clusters must work with and through them, in ways attentive to the specifics of their instantiation in particular techno-social settings.", [["generalized exhortation", "PROBLEM", 106, 129], ["the machine", "TREATMENT", 256, 267], ["unlikely to be", "UNCERTAINTY", 37, 51], ["redistributed", "OBSERVATION_MODIFIER", 68, 81], ["organically", "OBSERVATION_MODIFIER", 82, 93]]], ["To open to meaningful political negotiation those allocations and configurations of power that machine learning systems help to inscribe in public and private life\u2014this demands more than encompassing a greater proportion of people within existing practices of ruling and being ruled, and more than tinkering around the edges of existing rules.", [["people", "ORGANISM", 224, 230], ["people", "SPECIES", 224, 230]]], ["The greater the change in sociality and social relations\u2014and machine learning is transforming both, as we have recounted\u2014the more arrant and urgent the need for social, political and regulatory action specifically attuned to that change and to the possibility of further changes.", [["greater", "OBSERVATION_MODIFIER", 4, 11], ["change", "OBSERVATION_MODIFIER", 16, 22]]], ["Social and political action must be organized around the inequalities and nominal embattlements axiomatic to the field of social media, and to all fields shaped in large part by machine learning.", [["large", "OBSERVATION_MODIFIER", 164, 169]]], ["This cannot, moreover, be left up to the few whose interests and investments have most shaped the field to date.", [["most shaped", "OBSERVATION_MODIFIER", 82, 93]]]], "1be39aa9b2bddb2674f871c646444817ab881be2": [["IntroductionOn January 24, 2020, a new virus named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has been identified, quickly gaining worldwide attention [21] .", [["Acute Respiratory Syndrome Coronavirus", "DISEASE", 58, 96], ["SARS-CoV-2", "ORGANISM", 100, 110], ["Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2", "SPECIES", 51, 110], ["a new virus", "PROBLEM", 33, 44], ["Severe Acute Respiratory Syndrome Coronavirus", "PROBLEM", 51, 96], ["Severe", "OBSERVATION_MODIFIER", 51, 57], ["Acute", "OBSERVATION_MODIFIER", 58, 63], ["Respiratory Syndrome", "OBSERVATION", 64, 84]]], ["More than one third of patients with SARS-CoV-2 develop neurological manifestations [10] .", [["neurological", "ANATOMY", 56, 68], ["SARS", "DISEASE", 37, 41], ["patients", "ORGANISM", 23, 31], ["SARS-CoV-2", "ORGANISM", 37, 47], ["patients", "SPECIES", 23, 31], ["SARS", "PROBLEM", 37, 41], ["neurological manifestations", "PROBLEM", 56, 83]]], ["Similarly to other Coronavirus, SARS-CoV-2 can attack the olfactory bulb and then affect the central nervous system (CNS) through the olfactory tract in the early stages of infection [5] .", [["olfactory bulb", "ANATOMY", 58, 72], ["central nervous system", "ANATOMY", 93, 115], ["CNS", "ANATOMY", 117, 120], ["olfactory tract", "ANATOMY", 134, 149], ["SARS", "DISEASE", 32, 36], ["infection", "DISEASE", 173, 182], ["SARS-CoV-2", "ORGANISM", 32, 42], ["olfactory bulb", "ORGAN", 58, 72], ["central nervous system", "ANATOMICAL_SYSTEM", 93, 115], ["CNS", "ANATOMICAL_SYSTEM", 117, 120], ["olfactory tract", "ORGAN", 134, 149], ["SARS-CoV", "SPECIES", 32, 40], ["other Coronavirus", "TEST", 13, 30], ["SARS", "TEST", 32, 36], ["CoV", "TEST", 37, 40], ["infection", "PROBLEM", 173, 182], ["Coronavirus", "OBSERVATION", 19, 30], ["olfactory bulb", "ANATOMY", 58, 72], ["central", "ANATOMY_MODIFIER", 93, 100], ["nervous system", "ANATOMY", 101, 115], ["olfactory tract", "ANATOMY", 134, 149], ["early stages", "OBSERVATION_MODIFIER", 157, 169], ["infection", "OBSERVATION", 173, 182]]], ["Neurological impairment and demyelinating reaction appear as complications in case of severe Coronavirus Disease 2019 (COVID-19) [10] .", [["Neurological", "ANATOMY", 0, 12], ["Neurological impairment", "DISEASE", 0, 23], ["demyelinating reaction", "DISEASE", 28, 50], ["Coronavirus Disease", "DISEASE", 93, 112], ["Neurological impairment", "PROBLEM", 0, 23], ["demyelinating reaction", "PROBLEM", 28, 50], ["severe Coronavirus Disease", "PROBLEM", 86, 112], ["COVID", "TEST", 119, 124], ["demyelinating", "OBSERVATION", 28, 41], ["severe", "OBSERVATION_MODIFIER", 86, 92], ["Coronavirus", "OBSERVATION", 93, 104]]], ["We described the case of a COVID-19 patient with newly diagnosed demyelinating lesions.Case reportA 54 years old women, with a past medical history of anterior communicating artery (AComA) aneurysm treated surgically 20 years before, was found unconscious at home.", [["lesions", "ANATOMY", 79, 86], ["anterior communicating artery", "ANATOMY", 151, 180], ["demyelinating lesions", "DISEASE", 65, 86], ["anterior communicating artery (AComA) aneurysm", "DISEASE", 151, 197], ["patient", "ORGANISM", 36, 43], ["demyelinating lesions", "CANCER", 65, 86], ["women", "ORGANISM", 113, 118], ["anterior communicating artery", "MULTI-TISSUE_STRUCTURE", 151, 180], ["patient", "SPECIES", 36, 43], ["women", "SPECIES", 113, 118], ["newly diagnosed demyelinating lesions", "PROBLEM", 49, 86], ["anterior communicating artery (AComA) aneurysm", "PROBLEM", 151, 197], ["demyelinating", "OBSERVATION_MODIFIER", 65, 78], ["lesions", "OBSERVATION", 79, 86], ["anterior", "ANATOMY_MODIFIER", 151, 159], ["communicating artery", "ANATOMY", 160, 180], ["aneurysm", "OBSERVATION", 189, 197]]], ["When the rescue arrived, she regained consciousness and became unrest.", [["consciousness", "PROBLEM", 38, 51], ["unrest", "PROBLEM", 63, 69]]], ["At the emergency department, a brief neurological examination revealed a GCS of 12 (E3 M6 V3), without focal sensorimotor deficits.", [["neurological", "ANATOMY", 37, 49], ["focal sensorimotor", "ANATOMY", 103, 121], ["GCS", "DISEASE", 73, 76], ["focal sensorimotor deficits", "DISEASE", 103, 130], ["E3", "PROTEIN", 84, 86], ["a brief neurological examination", "TEST", 29, 61], ["a GCS", "TEST", 71, 76], ["focal sensorimotor deficits", "PROBLEM", 103, 130], ["without", "UNCERTAINTY", 95, 102], ["focal", "OBSERVATION_MODIFIER", 103, 108], ["sensorimotor deficits", "OBSERVATION", 109, 130]]], ["No signs of both tongue biting and incontinence were reported by the familiars.", [["tongue", "ANATOMY", 17, 23], ["tongue biting", "DISEASE", 17, 30], ["incontinence", "DISEASE", 35, 47], ["tongue", "ORGANISM_SUBDIVISION", 17, 23], ["both tongue biting", "PROBLEM", 12, 30], ["incontinence", "PROBLEM", 35, 47], ["signs of", "UNCERTAINTY", 3, 11], ["both", "ANATOMY_MODIFIER", 12, 16], ["tongue", "ANATOMY", 17, 23], ["biting", "OBSERVATION", 24, 30], ["incontinence", "OBSERVATION", 35, 47]]], ["Anosmia and ageusia were referred by several days.", [["Anosmia", "DISEASE", 0, 7], ["ageusia", "DISEASE", 12, 19], ["Anosmia", "PROBLEM", 0, 7], ["ageusia", "PROBLEM", 12, 19]]], ["Head CT scan was normal Fig. 1) .", [["Head CT scan", "TEST", 0, 12], ["normal", "OBSERVATION", 17, 23]]], ["Chest X-ray ( Fig. 2 ) revealed an interstitial pneumonia (IP), and real-time polymerase chain reaction (RT-PCR) for SARS-CoV-2 was positive.", [["interstitial", "ANATOMY", 35, 47], ["interstitial pneumonia", "DISEASE", 35, 57], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 117, 127], ["SARS-CoV", "SPECIES", 117, 125], ["Chest X-ray", "TEST", 0, 11], ["an interstitial pneumonia", "PROBLEM", 32, 57], ["real-time polymerase chain reaction", "PROBLEM", 68, 103], ["RT-PCR", "TEST", 105, 111], ["SARS", "PROBLEM", 117, 121], ["CoV", "TEST", 122, 125], ["positive", "PROBLEM", 132, 140], ["interstitial", "ANATOMY_MODIFIER", 35, 47], ["pneumonia", "OBSERVATION", 48, 57]]], ["The patient was admitted to our Neurosurgical Unit and complete blood tests showed moderate lymphocytopenia with mild elevation of inflammatory indices (WBC 8.81/mm 3 , Ly 0.3/mm 3 , CRP 41.3 mg/L, Fibrinogen 520 mg/dL).", [["blood", "ANATOMY", 64, 69], ["lymphocytopenia", "DISEASE", 92, 107], ["patient", "ORGANISM", 4, 11], ["blood", "ORGANISM_SUBSTANCE", 64, 69], ["CRP", "PROTEIN", 183, 186], ["Fibrinogen", "PROTEIN", 198, 208], ["patient", "SPECIES", 4, 11], ["complete blood tests", "TEST", 55, 75], ["moderate lymphocytopenia", "PROBLEM", 83, 107], ["mild elevation of inflammatory indices", "PROBLEM", 113, 151], ["WBC", "TEST", 153, 156], ["mm", "TEST", 162, 164], ["Ly", "TEST", 169, 171], ["CRP", "TEST", 183, 186], ["Fibrinogen", "TEST", 198, 208], ["moderate", "OBSERVATION_MODIFIER", 83, 91], ["lymphocytopenia", "OBSERVATION", 92, 107], ["mild", "OBSERVATION_MODIFIER", 113, 117], ["elevation", "OBSERVATION_MODIFIER", 118, 127], ["inflammatory", "OBSERVATION_MODIFIER", 131, 143]]], ["Both blood and urinary cultures were negative.", [["blood", "ANATOMY", 5, 10], ["urinary cultures", "ANATOMY", 15, 31], ["blood", "ORGANISM_SUBSTANCE", 5, 10], ["urinary cultures", "ORGANISM_SUBSTANCE", 15, 31], ["Both blood and urinary cultures", "TEST", 0, 31], ["blood", "ANATOMY", 5, 10], ["urinary", "ANATOMY", 15, 22]]], ["Antiretroviral and hydroxychloroquine were started.", [["hydroxychloroquine", "CHEMICAL", 19, 37], ["hydroxychloroquine", "CHEMICAL", 19, 37], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 19, 37], ["Antiretroviral", "TREATMENT", 0, 14], ["hydroxychloroquine", "TREATMENT", 19, 37]]], ["No abnormalities at arterial blood gas (ABG) analysis were detected (pO2 89, pCO2 41, pH 7.43).Case reportAfter few hours, the patient clinically deteriorated.", [["arterial blood", "ANATOMY", 20, 34], ["arterial", "MULTI-TISSUE_STRUCTURE", 20, 28], ["blood", "ORGANISM_SUBSTANCE", 29, 34], ["patient", "ORGANISM", 127, 134], ["patient", "SPECIES", 127, 134], ["abnormalities", "PROBLEM", 3, 16], ["arterial blood gas", "TEST", 20, 38], ["ABG) analysis", "TEST", 40, 53], ["pO2", "TEST", 69, 72], ["pCO2", "TEST", 77, 81], ["pH", "TEST", 86, 88], ["abnormalities", "OBSERVATION", 3, 16], ["arterial", "ANATOMY_MODIFIER", 20, 28]]], ["Body temperature was normal, and no electrolyte disorders were found.", [["Body", "ANATOMY", 0, 4], ["Body", "ORGANISM_SUBDIVISION", 0, 4], ["Body temperature", "TEST", 0, 16], ["electrolyte disorders", "PROBLEM", 36, 57], ["normal", "OBSERVATION", 21, 27], ["no", "UNCERTAINTY", 33, 35], ["electrolyte disorders", "OBSERVATION", 36, 57]]], ["ABG revealed a severe normocapnic hypoxia.", [["hypoxia", "DISEASE", 34, 41], ["ABG", "CHEMICAL", 0, 3], ["ABG", "TEST", 0, 3], ["a severe normocapnic hypoxia", "PROBLEM", 13, 41], ["severe", "OBSERVATION_MODIFIER", 15, 21], ["normocapnic hypoxia", "OBSERVATION", 22, 41]]], ["Therefore, she was intubated.", [["intubated", "TREATMENT", 19, 28]]], ["Subsequent head CT scan was unchanged.", [["head", "ANATOMY", 11, 15], ["head", "ORGAN", 11, 15], ["Subsequent head CT scan", "TEST", 0, 23], ["head", "ANATOMY", 11, 15], ["unchanged", "OBSERVATION_MODIFIER", 28, 37]]], ["Electroencephalography showed two seizures starting from right frontotemporal region and diffusing in homologous contralateral hemisphere.", [["right frontotemporal region", "ANATOMY", 57, 84], ["contralateral hemisphere", "ANATOMY", 113, 137], ["seizures", "DISEASE", 34, 42], ["Electroencephalography", "TEST", 0, 22], ["two seizures", "PROBLEM", 30, 42], ["seizures", "OBSERVATION", 34, 42], ["right", "ANATOMY_MODIFIER", 57, 62], ["frontotemporal", "ANATOMY_MODIFIER", 63, 77], ["region", "ANATOMY_MODIFIER", 78, 84], ["diffusing", "OBSERVATION_MODIFIER", 89, 98], ["homologous", "ANATOMY_MODIFIER", 102, 112], ["contralateral", "ANATOMY_MODIFIER", 113, 126], ["hemisphere", "ANATOMY_MODIFIER", 127, 137]]], ["Antiepileptic therapy with lacosamide, levetiracetam, and phenytoin was started with seizures control.Case reportBrain MRI revealed alterations of the periventricular white matter, hyperintense in T2WI, without restriction of diffusion nor contrast enhancement ( Fig. 3a-f ).", [["periventricular white matter", "ANATOMY", 151, 179], ["lacosamide", "CHEMICAL", 27, 37], ["levetiracetam", "CHEMICAL", 39, 52], ["phenytoin", "CHEMICAL", 58, 67], ["seizures", "DISEASE", 85, 93], ["lacosamide", "CHEMICAL", 27, 37], ["levetiracetam", "CHEMICAL", 39, 52], ["phenytoin", "CHEMICAL", 58, 67], ["lacosamide", "SIMPLE_CHEMICAL", 27, 37], ["levetiracetam", "SIMPLE_CHEMICAL", 39, 52], ["phenytoin", "SIMPLE_CHEMICAL", 58, 67], ["Antiepileptic therapy", "TREATMENT", 0, 21], ["lacosamide", "TREATMENT", 27, 37], ["levetiracetam", "TREATMENT", 39, 52], ["phenytoin", "TREATMENT", 58, 67], ["seizures control", "TREATMENT", 85, 101], ["Case reportBrain MRI", "TEST", 102, 122], ["alterations of the periventricular white matter, hyperintense in T2WI", "PROBLEM", 132, 201], ["restriction of diffusion nor contrast enhancement", "PROBLEM", 211, 260], ["alterations", "OBSERVATION", 132, 143], ["periventricular", "ANATOMY_MODIFIER", 151, 166], ["white matter", "ANATOMY", 167, 179], ["hyperintense", "OBSERVATION_MODIFIER", 181, 193], ["without", "UNCERTAINTY", 203, 210]]], ["Similar lesions were found at the bulbo-medullary junction and in both the cervical and dorsal spinal cord (Fig. 3g) .", [["lesions", "ANATOMY", 8, 15], ["bulbo-medullary junction", "ANATOMY", 34, 58], ["cervical", "ANATOMY", 75, 83], ["dorsal spinal cord", "ANATOMY", 88, 106], ["lesions", "CANCER", 8, 15], ["medullary junction", "MULTI-TISSUE_STRUCTURE", 40, 58], ["cervical", "ORGAN", 75, 83], ["dorsal spinal cord", "TISSUE", 88, 106], ["Similar lesions", "PROBLEM", 0, 15], ["lesions", "OBSERVATION", 8, 15], ["bulbo", "ANATOMY_MODIFIER", 34, 39], ["medullary", "ANATOMY_MODIFIER", 40, 49], ["junction", "ANATOMY_MODIFIER", 50, 58], ["both", "ANATOMY_MODIFIER", 66, 70], ["cervical", "ANATOMY", 75, 83], ["dorsal", "ANATOMY_MODIFIER", 88, 94], ["spinal cord", "ANATOMY", 95, 106]]], ["Chemical-physical cerebrospinal fluid (CSF) examination was normal, and further analysis ruled out multiple sclerosis.", [["cerebrospinal fluid", "ANATOMY", 18, 37], ["multiple sclerosis", "DISEASE", 99, 117], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 18, 37], ["CSF", "ORGANISM_SUBSTANCE", 39, 42], ["Chemical-physical cerebrospinal fluid (CSF) examination", "TEST", 0, 55], ["further analysis", "TEST", 72, 88], ["multiple sclerosis", "PROBLEM", 99, 117], ["cerebrospinal", "ANATOMY", 18, 31], ["fluid", "OBSERVATION", 32, 37], ["multiple", "OBSERVATION_MODIFIER", 99, 107], ["sclerosis", "OBSERVATION", 108, 117]]], ["The CSF RT-PCR for neurotropic viruses, including SARS-CoV-2, was negative.Case reportHigh-dose steroid treatment (dexamethasone 20 mg/die for 10 days and 10 mg/die for 10 days) allowed a progressive recovery of the pulmonary impairment.", [["pulmonary", "ANATOMY", 216, 225], ["steroid", "CHEMICAL", 96, 103], ["dexamethasone", "CHEMICAL", 115, 128], ["pulmonary impairment", "DISEASE", 216, 236], ["steroid", "CHEMICAL", 96, 103], ["dexamethasone", "CHEMICAL", 115, 128], ["CSF", "GENE_OR_GENE_PRODUCT", 4, 7], ["SARS-CoV-2", "ORGANISM", 50, 60], ["steroid", "SIMPLE_CHEMICAL", 96, 103], ["dexamethasone", "SIMPLE_CHEMICAL", 115, 128], ["pulmonary", "ORGAN", 216, 225], ["SARS-CoV", "SPECIES", 50, 58], ["The CSF RT-PCR", "TEST", 0, 14], ["neurotropic viruses", "PROBLEM", 19, 38], ["SARS-CoV", "TEST", 50, 58], ["Case reportHigh-dose steroid treatment", "TREATMENT", 75, 113], ["dexamethasone", "TREATMENT", 115, 128], ["the pulmonary impairment", "PROBLEM", 212, 236], ["negative", "OBSERVATION", 66, 74], ["pulmonary", "ANATOMY", 216, 225], ["impairment", "OBSERVATION", 226, 236]]], ["The patient was tracheostomized on the 7th day.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["tracheostomized", "OBSERVATION", 16, 31]]], ["After 15 days, ventilator weaning was performed, and the patient was discharged from the intensive care unit (ICU) and addressed to our Neurosurgical Unit.", [["patient", "ORGANISM", 57, 64], ["patient", "SPECIES", 57, 64], ["ventilator weaning", "TREATMENT", 15, 33]]], ["The patient was transferred to rehabilitation without sensorimotor deficits after 12 days.DiscussionThe family of Coronaviruses shows a potential neurotropism that can induce neurological disorders like polyneuropathy, encephalopathy, demyelinating lesions, and ischemic stroke [8, 15] .", [["neurological", "ANATOMY", 175, 187], ["lesions", "ANATOMY", 249, 256], ["sensorimotor deficits", "DISEASE", 54, 75], ["neurological disorders", "DISEASE", 175, 197], ["polyneuropathy", "DISEASE", 203, 217], ["encephalopathy", "DISEASE", 219, 233], ["demyelinating lesions", "DISEASE", 235, 256], ["ischemic stroke", "DISEASE", 262, 277], ["patient", "ORGANISM", 4, 11], ["Coronaviruses", "CANCER", 114, 127], ["lesions", "PATHOLOGICAL_FORMATION", 249, 256], ["patient", "SPECIES", 4, 11], ["sensorimotor deficits", "PROBLEM", 54, 75], ["Coronaviruses", "PROBLEM", 114, 127], ["a potential neurotropism", "PROBLEM", 134, 158], ["neurological disorders", "PROBLEM", 175, 197], ["polyneuropathy", "PROBLEM", 203, 217], ["encephalopathy", "PROBLEM", 219, 233], ["demyelinating lesions", "PROBLEM", 235, 256], ["ischemic stroke", "PROBLEM", 262, 277], ["polyneuropathy", "OBSERVATION", 203, 217], ["encephalopathy", "OBSERVATION", 219, 233], ["demyelinating", "OBSERVATION_MODIFIER", 235, 248], ["lesions", "OBSERVATION", 249, 256], ["ischemic", "OBSERVATION_MODIFIER", 262, 270], ["stroke", "OBSERVATION", 271, 277]]], ["The main clinical manifestations are headache, disturbance of consciousness, paralysis, paraesthesia, and seizures [14] .", [["headache", "DISEASE", 37, 45], ["disturbance of consciousness", "DISEASE", 47, 75], ["paralysis", "DISEASE", 77, 86], ["paraesthesia", "DISEASE", 88, 100], ["seizures", "DISEASE", 106, 114], ["headache", "PROBLEM", 37, 45], ["disturbance of consciousness", "PROBLEM", 47, 75], ["paralysis", "PROBLEM", 77, 86], ["paraesthesia", "PROBLEM", 88, 100], ["seizures", "PROBLEM", 106, 114], ["main", "OBSERVATION_MODIFIER", 4, 8], ["paralysis", "OBSERVATION", 77, 86]]], ["The neurological complications could appear delayed to respiratory symptoms [8] .DiscussionSARS-CoV-2 shows a genetic similarity to SARS-CoVand MERS-CoV [4, 17] and presents an analogous neurotropism.", [["neurological", "ANATOMY", 4, 16], ["respiratory", "ANATOMY", 55, 66], ["neurological complications", "DISEASE", 4, 30], ["SARS", "DISEASE", 132, 136], ["DiscussionSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 81, 101], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 144, 152], ["SARS-CoVand MERS-CoV", "SPECIES", 132, 152], ["The neurological complications", "PROBLEM", 0, 30], ["respiratory symptoms", "PROBLEM", 55, 75], ["DiscussionSARS", "TEST", 81, 95], ["CoV", "TEST", 96, 99], ["SARS", "PROBLEM", 132, 136], ["neurotropism", "OBSERVATION", 187, 199]]], ["Previous articles showed that a large number of patients report anosmia and dysgeusia.", [["anosmia", "DISEASE", 64, 71], ["dysgeusia", "DISEASE", 76, 85], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["anosmia", "PROBLEM", 64, 71], ["dysgeusia", "PROBLEM", 76, 85], ["large", "OBSERVATION_MODIFIER", 32, 37], ["number", "OBSERVATION_MODIFIER", 38, 44], ["dysgeusia", "OBSERVATION", 76, 85]]], ["Moreover COVID-19 may lead to symptoms similar to intracranial infections [2] .DiscussionOur patient showed symptoms consistent with a neurological involvement consequent to SARS-CoV-2 infection.", [["intracranial", "ANATOMY", 50, 62], ["neurological", "ANATOMY", 135, 147], ["COVID-19", "CHEMICAL", 9, 17], ["intracranial infections", "DISEASE", 50, 73], ["SARS-CoV-2 infection", "DISEASE", 174, 194], ["COVID-19", "CHEMICAL", 9, 17], ["patient", "ORGANISM", 93, 100], ["CoV-2", "ORGANISM", 179, 184], ["COVID-19", "DNA", 9, 17], ["patient", "SPECIES", 93, 100], ["COVID", "TEST", 9, 14], ["symptoms", "PROBLEM", 30, 38], ["intracranial infections", "PROBLEM", 50, 73], ["symptoms", "PROBLEM", 108, 116], ["a neurological involvement", "PROBLEM", 133, 159], ["SARS", "PROBLEM", 174, 178], ["CoV-2 infection", "PROBLEM", 179, 194], ["intracranial", "ANATOMY", 50, 62], ["infections", "OBSERVATION", 63, 73], ["consistent with", "UNCERTAINTY", 117, 132], ["infection", "OBSERVATION", 185, 194]]], ["Anosmia and dysgeusia appeared early, while seizures occurred as COVID-19 complication.", [["Anosmia", "DISEASE", 0, 7], ["dysgeusia", "DISEASE", 12, 21], ["seizures", "DISEASE", 44, 52], ["Anosmia", "PROBLEM", 0, 7], ["dysgeusia", "PROBLEM", 12, 21], ["seizures", "PROBLEM", 44, 52], ["complication", "PROBLEM", 74, 86], ["dysgeusia", "OBSERVATION", 12, 21]]], ["Moriguchi explains seizures as results of SARS-CoV-2 encephalitis [12] .", [["seizures", "DISEASE", 19, 27], ["SARS-CoV-2 encephalitis", "DISEASE", 42, 65], ["SARS-CoV-2 encephalitis", "ORGANISM", 42, 65], ["CoV-2 encephalitis", "SPECIES", 47, 65], ["seizures", "PROBLEM", 19, 27], ["SARS", "PROBLEM", 42, 46], ["CoV-2 encephalitis", "PROBLEM", 47, 65]]], ["Otherwise, we observed demyelinating lesions related to the neurological impairment.DiscussionThe presence of demyelination, as well as SARS-CoV virus particles and genome sequences, in the brain has been detected in autopsy studies [6, 19] .", [["lesions", "ANATOMY", 37, 44], ["neurological", "ANATOMY", 60, 72], ["brain", "ANATOMY", 190, 195], ["demyelinating lesions", "DISEASE", 23, 44], ["neurological impairment", "DISEASE", 60, 83], ["demyelination", "DISEASE", 110, 123], ["lesions", "PATHOLOGICAL_FORMATION", 37, 44], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 136, 144], ["brain", "ORGAN", 190, 195], ["genome sequences", "DNA", 165, 181], ["CoV virus", "SPECIES", 141, 150], ["SARS-CoV virus", "SPECIES", 136, 150], ["demyelinating lesions", "PROBLEM", 23, 44], ["the neurological impairment", "PROBLEM", 56, 83], ["demyelination", "PROBLEM", 110, 123], ["SARS-CoV virus particles", "PROBLEM", 136, 160], ["genome sequences", "TEST", 165, 181], ["autopsy studies", "TEST", 217, 232], ["demyelinating", "OBSERVATION_MODIFIER", 23, 36], ["lesions", "OBSERVATION", 37, 44], ["neurological", "OBSERVATION_MODIFIER", 60, 72], ["impairment", "OBSERVATION", 73, 83], ["demyelination", "OBSERVATION", 110, 123], ["brain", "ANATOMY", 190, 195]]], ["Our patient's brain and spine MRI showed new onset of multiple, non-enhancing demyelinating lesions.", [["brain", "ANATOMY", 14, 19], ["spine", "ANATOMY", 24, 29], ["lesions", "ANATOMY", 92, 99], ["patient", "ORGANISM", 4, 11], ["brain", "ORGAN", 14, 19], ["spine", "ORGAN", 24, 29], ["demyelinating lesions", "CANCER", 78, 99], ["patient", "SPECIES", 4, 11], ["Our patient's brain and spine MRI", "TEST", 0, 33], ["multiple, non-enhancing demyelinating lesions", "PROBLEM", 54, 99], ["brain", "ANATOMY", 14, 19], ["spine", "ANATOMY", 24, 29], ["new", "OBSERVATION_MODIFIER", 41, 44], ["multiple", "OBSERVATION_MODIFIER", 54, 62], ["non-enhancing", "OBSERVATION_MODIFIER", 64, 77], ["demyelinating", "OBSERVATION_MODIFIER", 78, 91], ["lesions", "OBSERVATION", 92, 99]]], ["Previous cerebral MRI controls performed as follow-up after the AComA aneurysm surgery were normal.", [["cerebral", "ANATOMY", 9, 17], ["AComA aneurysm", "ANATOMY", 64, 78], ["aneurysm", "DISEASE", 70, 78], ["cerebral", "ORGAN", 9, 17], ["Previous cerebral MRI controls", "TEST", 0, 30], ["the AComA aneurysm surgery", "TREATMENT", 60, 86], ["cerebral", "ANATOMY", 9, 17], ["aneurysm", "OBSERVATION", 70, 78], ["normal", "OBSERVATION", 92, 98]]], ["Multiple sclerosis (MS), viral encephalitis, and bacterial infections were excluded.", [["Multiple sclerosis", "DISEASE", 0, 18], ["MS", "DISEASE", 20, 22], ["viral encephalitis", "DISEASE", 25, 43], ["bacterial infections", "DISEASE", 49, 69], ["Multiple sclerosis (MS)", "PROBLEM", 0, 23], ["viral encephalitis", "PROBLEM", 25, 43], ["bacterial infections", "PROBLEM", 49, 69], ["sclerosis", "OBSERVATION", 9, 18], ["viral", "OBSERVATION_MODIFIER", 25, 30], ["encephalitis", "OBSERVATION", 31, 43], ["bacterial", "OBSERVATION_MODIFIER", 49, 58], ["infections", "OBSERVATION", 59, 69]]], ["Therefore, we speculated a pathogenesis SARS-CoV-2 related.DiscussionNeurotropism may occur via trans-lamina cribrosa that enables SARS-CoV-2 to reach the brain through the olfactory tract [1] .", [["lamina cribrosa", "ANATOMY", 102, 117], ["brain", "ANATOMY", 155, 160], ["olfactory tract", "ANATOMY", 173, 188], ["CoV-2", "ORGANISM", 45, 50], ["lamina cribrosa", "TISSUE", 102, 117], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 131, 141], ["brain", "ORGAN", 155, 160], ["olfactory tract", "ORGAN", 173, 188], ["a pathogenesis SARS", "PROBLEM", 25, 44], ["SARS", "TEST", 131, 135], ["CoV", "TEST", 136, 139], ["lamina cribrosa", "ANATOMY", 102, 117], ["brain", "ANATOMY", 155, 160], ["olfactory tract", "ANATOMY", 173, 188]]], ["The interaction between the spike protein S1 and the host ACE-2 receptor, expressed in the capillary endothelium, allows the virus to penetrate into the neuronal cells [16] .", [["capillary endothelium", "ANATOMY", 91, 112], ["neuronal cells", "ANATOMY", 153, 167], ["S1", "GENE_OR_GENE_PRODUCT", 42, 44], ["ACE-2 receptor", "GENE_OR_GENE_PRODUCT", 58, 72], ["capillary endothelium", "TISSUE", 91, 112], ["neuronal cells", "CELL", 153, 167], ["spike protein S1", "PROTEIN", 28, 44], ["host ACE-2 receptor", "PROTEIN", 53, 72], ["neuronal cells", "CELL_TYPE", 153, 167], ["the host ACE-2 receptor", "TREATMENT", 49, 72], ["the virus", "PROBLEM", 121, 130], ["capillary endothelium", "ANATOMY", 91, 112], ["neuronal cells", "OBSERVATION", 153, 167]]], ["The viral particles budding lead to the onset of symptoms such as anosmia and dysgeusia in the early phase of infection [10] .DiscussionThe delayed CNS damage appears mediated by the immune system [9] .", [["CNS", "ANATOMY", 148, 151], ["anosmia", "DISEASE", 66, 73], ["dysgeusia", "DISEASE", 78, 87], ["infection", "DISEASE", 110, 119], ["CNS", "ANATOMICAL_SYSTEM", 148, 151], ["The viral particles budding", "PROBLEM", 0, 27], ["symptoms", "PROBLEM", 49, 57], ["anosmia", "PROBLEM", 66, 73], ["dysgeusia", "PROBLEM", 78, 87], ["infection", "PROBLEM", 110, 119], ["The delayed CNS damage", "PROBLEM", 136, 158], ["viral particles", "OBSERVATION", 4, 19], ["early phase", "OBSERVATION_MODIFIER", 95, 106], ["infection", "OBSERVATION", 110, 119]]], ["As previously demonstrated, the pathogenesis of severe viral infections is closely linked to the development of virus induced systemic inflammatory response syndrome (SIRS) or SIRS-like immune disorders [3] .", [["viral infections", "DISEASE", 55, 71], ["systemic inflammatory response syndrome", "DISEASE", 126, 165], ["SIRS", "DISEASE", 167, 171], ["SIRS", "DISEASE", 176, 180], ["immune disorders", "DISEASE", 186, 202], ["severe viral infections", "PROBLEM", 48, 71], ["virus induced systemic inflammatory response syndrome", "PROBLEM", 112, 165], ["SIRS", "PROBLEM", 167, 171], ["SIRS", "PROBLEM", 176, 180], ["immune disorders", "PROBLEM", 186, 202], ["severe", "OBSERVATION_MODIFIER", 48, 54], ["viral", "OBSERVATION_MODIFIER", 55, 60], ["infections", "OBSERVATION", 61, 71], ["virus", "OBSERVATION", 112, 117], ["systemic", "OBSERVATION_MODIFIER", 126, 134], ["inflammatory response syndrome", "OBSERVATION", 135, 165]]], ["For SARS-CoV-2 infection, the pro-inflammatory state induced by the cytokine storm, mainly sustained by IL1, IL-6, and TNF \u03b1, may be responsible of the activation of glial cells with subsequent demyelination [11] .", [["glial cells", "ANATOMY", 166, 177], ["infection", "DISEASE", 15, 24], ["demyelination", "DISEASE", 194, 207], ["SARS-CoV-2", "ORGANISM", 4, 14], ["IL1", "GENE_OR_GENE_PRODUCT", 104, 107], ["IL-6", "GENE_OR_GENE_PRODUCT", 109, 113], ["TNF \u03b1", "GENE_OR_GENE_PRODUCT", 119, 124], ["glial cells", "CELL", 166, 177], ["cytokine", "PROTEIN", 68, 76], ["IL1", "PROTEIN", 104, 107], ["IL-6", "PROTEIN", 109, 113], ["TNF \u03b1", "PROTEIN", 119, 124], ["glial cells", "CELL_TYPE", 166, 177], ["SARS-CoV-2", "SPECIES", 4, 14], ["SARS", "PROBLEM", 4, 8], ["CoV-2 infection", "PROBLEM", 9, 24], ["the pro-inflammatory state", "PROBLEM", 26, 52], ["the cytokine storm", "PROBLEM", 64, 82], ["IL", "TEST", 109, 111], ["the activation of glial cells", "PROBLEM", 148, 177], ["subsequent demyelination", "PROBLEM", 183, 207], ["infection", "OBSERVATION", 15, 24], ["cytokine storm", "OBSERVATION", 68, 82], ["may be responsible", "UNCERTAINTY", 126, 144], ["glial cells", "OBSERVATION", 166, 177]]], ["A possible alternative could be the production of antibodies against glial cells triggered by the virus, as a para-infective or post-infective phenomenon.", [["glial cells", "ANATOMY", 69, 80], ["glial cells", "CELL", 69, 80], ["antibodies", "PROTEIN", 50, 60], ["glial cells", "CELL_TYPE", 69, 80], ["antibodies", "PROBLEM", 50, 60], ["glial cells", "PROBLEM", 69, 80], ["the virus", "PROBLEM", 94, 103], ["a para-infective or post-infective phenomenon", "PROBLEM", 108, 153], ["virus", "OBSERVATION", 98, 103], ["post-infective phenomenon", "OBSERVATION", 128, 153]]], ["Zhao described a case report of Guillan-Barr\u00e8 syndrome during SARS-CoV-2 infection [20] .", [["Guillan-Barr\u00e8 syndrome", "DISEASE", 32, 54], ["SARS-CoV-2 infection", "DISEASE", 62, 82], ["Guillan-Barr\u00e8", "ORGANISM", 32, 45], ["SARS-CoV-2", "ORGANISM", 62, 72], ["Barr\u00e8 syndrome", "PROBLEM", 40, 54], ["SARS", "PROBLEM", 62, 66], ["CoV-2 infection", "PROBLEM", 67, 82]]], ["Moreover, SARS-CoV-2 may play a role of infective trigger, similar to the one of Epstein Barr virus in MS. In SARS-CoV-2 infection, neurological impairment was observed only in case of severe COVID-19 [10] .", [["neurological", "ANATOMY", 132, 144], ["MS", "DISEASE", 103, 105], ["SARS-CoV-2 infection", "DISEASE", 110, 130], ["neurological impairment", "DISEASE", 132, 155], ["COVID", "DISEASE", 192, 197], ["COVID-19", "CHEMICAL", 192, 200], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 10, 20], ["Epstein Barr virus", "ORGANISM", 81, 99], ["SARS-CoV-2", "ORGANISM", 110, 120], ["SARS-CoV", "SPECIES", 10, 18], ["Epstein Barr virus", "SPECIES", 81, 99], ["SARS-CoV", "SPECIES", 110, 118], ["SARS", "PROBLEM", 10, 14], ["infective trigger", "PROBLEM", 40, 57], ["Epstein Barr virus in MS", "PROBLEM", 81, 105], ["SARS", "PROBLEM", 110, 114], ["CoV", "PROBLEM", 115, 118], ["2 infection", "PROBLEM", 119, 130], ["neurological impairment", "PROBLEM", 132, 155], ["severe COVID", "PROBLEM", 185, 197], ["Epstein Barr virus", "OBSERVATION", 81, 99], ["SARS", "OBSERVATION", 110, 114], ["CoV", "OBSERVATION_MODIFIER", 115, 118], ["infection", "OBSERVATION", 121, 130]]], ["As a matter of fact, our patient showed an IP that required ICU.", [["patient", "ORGANISM", 25, 32], ["patient", "SPECIES", 25, 32]]], ["Therefore, we supposed that a severe pneumonia with subsequent CNS hypoxia that leads to an increased anaerobic metabolism is required to trigger a neurological damage.DiscussionSARS-CoV-2 was not detected in the CSF probably because the neurological damage was sustained by a delayed immune response that occurred after the viremia.", [["CNS", "ANATOMY", 63, 66], ["neurological", "ANATOMY", 148, 160], ["neurological", "ANATOMY", 238, 250], ["pneumonia", "DISEASE", 37, 46], ["hypoxia", "DISEASE", 67, 74], ["neurological damage", "DISEASE", 148, 167], ["neurological damage", "DISEASE", 238, 257], ["viremia", "DISEASE", 325, 332], ["CNS", "ANATOMICAL_SYSTEM", 63, 66], ["DiscussionSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 168, 188], ["CSF", "GENE_OR_GENE_PRODUCT", 213, 216], ["a severe pneumonia", "PROBLEM", 28, 46], ["subsequent CNS hypoxia", "PROBLEM", 52, 74], ["an increased anaerobic metabolism", "PROBLEM", 89, 122], ["a neurological damage", "PROBLEM", 146, 167], ["DiscussionSARS", "TEST", 168, 182], ["CoV", "TEST", 183, 186], ["the CSF", "TEST", 209, 216], ["the neurological damage", "PROBLEM", 234, 257], ["a delayed immune response", "PROBLEM", 275, 300], ["the viremia", "PROBLEM", 321, 332], ["severe", "OBSERVATION_MODIFIER", 30, 36], ["pneumonia", "OBSERVATION", 37, 46], ["CNS", "ANATOMY", 63, 66], ["hypoxia", "OBSERVATION", 67, 74], ["increased", "OBSERVATION_MODIFIER", 92, 101], ["anaerobic metabolism", "OBSERVATION", 102, 122], ["viremia", "OBSERVATION", 325, 332]]], ["Moreover, as reported by different authors, CSF clearance, low sensibility of the method, and delayed sampling could explain this occurrence [7, 13, 18] .ConclusionSudden neurological impairment with seizures in COVID-19 patients may be sustained by CNS involvement and demyelinating lesions.", [["neurological", "ANATOMY", 171, 183], ["CNS", "ANATOMY", 250, 253], ["demyelinating lesions", "ANATOMY", 270, 291], ["neurological impairment", "DISEASE", 171, 194], ["seizures", "DISEASE", 200, 208], ["demyelinating lesions", "DISEASE", 270, 291], ["CSF", "GENE_OR_GENE_PRODUCT", 44, 47], ["patients", "ORGANISM", 221, 229], ["CNS", "ANATOMICAL_SYSTEM", 250, 253], ["demyelinating lesions", "CANCER", 270, 291], ["patients", "SPECIES", 221, 229], ["CSF clearance", "TEST", 44, 57], ["the method", "TEST", 78, 88], ["delayed sampling", "PROBLEM", 94, 110], ["ConclusionSudden neurological impairment", "PROBLEM", 154, 194], ["seizures", "PROBLEM", 200, 208], ["CNS involvement", "PROBLEM", 250, 265], ["demyelinating lesions", "PROBLEM", 270, 291], ["low sensibility", "OBSERVATION_MODIFIER", 59, 74], ["CNS", "ANATOMY", 250, 253], ["demyelinating", "OBSERVATION_MODIFIER", 270, 283], ["lesions", "OBSERVATION", 284, 291]]], ["Early CSF collection is suggested.", [["CSF", "ORGANISM_SUBSTANCE", 6, 9], ["Early CSF collection", "PROBLEM", 0, 20], ["CSF collection", "OBSERVATION", 6, 20]]], ["Prompt invasive treatment should be adopted to avoid hypoxic neurotoxicity and prevent CNS injuries.Compliance with ethical standardsConflict of interest The authors declare that they have no conflict of interest.Compliance with ethical standardsInformed consent The patient's consent has been obtained for this publication. cervical and dorsal MRI T2WI sagittal view (g): numerous focal hyperintense intramedullary signal alterations in T2 and without contrast enhancement, located at the bulb-medullary junction, at C2 and from C3 to Th 6", [["CNS", "ANATOMY", 87, 90], ["cervical", "ANATOMY", 325, 333], ["bulb-medullary junction", "ANATOMY", 490, 513], ["neurotoxicity", "DISEASE", 61, 74], ["CNS injuries", "DISEASE", 87, 99], ["CNS injuries", "PATHOLOGICAL_FORMATION", 87, 99], ["patient", "ORGANISM", 267, 274], ["cervical", "ORGAN", 325, 333], ["bulb", "MULTI-TISSUE_STRUCTURE", 490, 494], ["medullary junction", "MULTI-TISSUE_STRUCTURE", 495, 513], ["C3", "PROTEIN", 530, 532], ["patient", "SPECIES", 267, 274], ["Prompt invasive treatment", "TREATMENT", 0, 25], ["hypoxic neurotoxicity", "PROBLEM", 53, 74], ["CNS injuries", "PROBLEM", 87, 99], ["ethical standards", "TREATMENT", 116, 133], ["ethical standards", "TREATMENT", 229, 246], ["cervical and dorsal MRI T2WI sagittal view", "TEST", 325, 367], ["numerous focal hyperintense intramedullary signal alterations in T2", "PROBLEM", 373, 440], ["contrast enhancement", "PROBLEM", 453, 473], ["CNS", "ANATOMY", 87, 90], ["injuries", "OBSERVATION", 91, 99], ["dorsal", "ANATOMY_MODIFIER", 338, 344], ["numerous", "OBSERVATION_MODIFIER", 373, 381], ["focal", "OBSERVATION_MODIFIER", 382, 387], ["hyperintense", "OBSERVATION_MODIFIER", 388, 400], ["intramedullary signal alterations", "OBSERVATION", 401, 434], ["without", "UNCERTAINTY", 445, 452], ["contrast enhancement", "OBSERVATION", 453, 473], ["bulb", "ANATOMY_MODIFIER", 490, 494], ["medullary junction", "ANATOMY", 495, 513], ["C2", "ANATOMY_MODIFIER", 518, 520], ["C3", "ANATOMY_MODIFIER", 530, 532]]]], "aa31ce304d7a2abc6a46afed6974ccf792deaafc": [["particles in the stools of patients in this setting, (2) the incidence of virus-like particles in the NICU over a 40-week period, and (3) the characteristics of gastrointestinal symptoms in infants positive for virus-like particles in comparison to infants negative for virus-like particles.Patients and MethodsPatients.", [["stools", "ANATOMY", 17, 23], ["gastrointestinal", "ANATOMY", 161, 177], ["gastrointestinal symptoms", "DISEASE", 161, 186], ["stools", "ORGANISM_SUBDIVISION", 17, 23], ["patients", "ORGANISM", 27, 35], ["gastrointestinal", "ORGAN", 161, 177], ["infants", "ORGANISM", 190, 197], ["infants", "ORGANISM", 249, 256], ["Patients", "ORGANISM", 291, 299], ["patients", "SPECIES", 27, 35], ["infants", "SPECIES", 190, 197], ["infants", "SPECIES", 249, 256], ["Patients", "SPECIES", 291, 299], ["virus", "PROBLEM", 74, 79], ["gastrointestinal symptoms", "PROBLEM", 161, 186], ["virus", "PROBLEM", 211, 216], ["virus", "PROBLEM", 270, 275], ["stools", "OBSERVATION", 17, 23], ["virus", "OBSERVATION", 74, 79], ["gastrointestinal", "ANATOMY", 161, 177]]], ["To determine the frequency of viruslike particles in the patients in the NICU, eight .surveys of stools for the particles involving 88 infants from the NICU were conducted over a 40week period (September 1979 -June 1980 .", [["patients", "ORGANISM", 57, 65], ["stools", "ORGANISM_SUBSTANCE", 97, 103], ["infants", "ORGANISM", 135, 142], ["patients", "SPECIES", 57, 65], ["infants", "SPECIES", 135, 142], ["viruslike particles", "PROBLEM", 30, 49], ["stools", "OBSERVATION", 97, 103]]], ["Twelve infants were screened more than once.", [["infants", "ORGANISM", 7, 14], ["infants", "SPECIES", 7, 14]]], ["Thirteen additional infants positive for virus-like particles whose mothers had gastrointestinal or \"flu-like\" symptoms before or shortly after delivery were identified in the community (not part of the survey study) between September 1979 and May 1981.Patients and MethodsElectron microscopy ofstool specimens.", [["gastrointestinal", "ANATOMY", 80, 96], ["specimens", "ANATOMY", 301, 310], ["infants", "ORGANISM", 20, 27], ["mothers", "ORGANISM", 68, 75], ["gastrointestinal", "ORGANISM_SUBDIVISION", 80, 96], ["Patients", "ORGANISM", 253, 261], ["infants", "SPECIES", 20, 27], ["Patients", "SPECIES", 253, 261], ["virus", "PROBLEM", 41, 46], ["gastrointestinal or \"flu-like\" symptoms", "PROBLEM", 80, 119], ["delivery", "TREATMENT", 144, 152], ["the survey study", "TEST", 199, 215], ["Patients and MethodsElectron microscopy ofstool specimens", "TEST", 253, 310], ["gastrointestinal", "ANATOMY", 80, 96]]], ["Stool specimens were diluted with 1-2 ml of distilled water; the amount of water used was dependent upon the consistency of the stool specimens.", [["Stool specimens", "ANATOMY", 0, 15], ["stool specimens", "ANATOMY", 128, 143], ["Stool specimens", "ORGANISM_SUBSTANCE", 0, 15], ["Stool specimens", "TEST", 0, 15], ["distilled water", "TREATMENT", 44, 59], ["the stool specimens", "TEST", 124, 143]]], ["Rectal swab specimens were immersed and then shaken in 2 ml of distilled water.", [["Rectal swab specimens", "ANATOMY", 0, 21], ["Rectal swab specimens", "ORGANISM_SUBSTANCE", 0, 21], ["Rectal swab specimens", "TEST", 0, 21]]], ["All of the specimens were vortexed and then centrifuged at 2,000 g for 30 min in a swinging-bucket clinical centrifuge (model no. J-6B; Beckman Instruments, Palo Alto, Calif.) to remove bacteria and debris.", [["specimens", "ANATOMY", 11, 20], ["specimens", "CANCER", 11, 20], ["bacteria", "PROBLEM", 186, 194], ["debris", "PROBLEM", 199, 205], ["bacteria", "OBSERVATION", 186, 194], ["debris", "OBSERVATION", 199, 205]]], ["One drop of the supernatant was placed on the surface of each of two Fortnvarv-coated, 300-mesh copper grids (Ernest Fullam, Schenectady, N.Y.) that were placed in microtiter wells containing 1% agar.", [["supernatant", "ANATOMY", 16, 27], ["surface", "ANATOMY", 46, 53], ["copper", "CHEMICAL", 96, 102], ["copper", "CHEMICAL", 96, 102], ["the supernatant", "TREATMENT", 12, 27], ["drop", "OBSERVATION_MODIFIER", 4, 8]]], ["Grid no. 1 was immediately removed from the well and allowed to air-dry without blotting.", [["blotting", "PROBLEM", 80, 88], ["dry", "OBSERVATION", 68, 71]]], ["Grid no. 2 was left in the well, and the drop was allowed to dry completely (~1 hr) onto the grid surface.", [["surface", "ANATOMY", 98, 105], ["surface", "CELLULAR_COMPONENT", 98, 105], ["left", "ANATOMY_MODIFIER", 15, 19]]], ["Grid no. 1 was returned to the well, and both grids were negatively stained by adding several drops of 2% phosphotungstic acid (adjusted to pH 6.5 with 1 N KOH) directly to the well.", [["phosphotungstic acid", "CHEMICAL", 106, 126], ["phosphotungstic acid", "CHEMICAL", 106, 126], ["KOH", "CHEMICAL", 156, 159], ["phosphotungstic acid", "SIMPLE_CHEMICAL", 106, 126], ["2% phosphotungstic acid", "TREATMENT", 103, 126], ["pH", "TEST", 140, 142]]], ["The grids were removed after 3 min, blotted on filter paper, and examined under an electron microscope (model no. HU-12; Hitachi Scientific Instruments, Mountain View, Calif.).", [["an electron microscope", "TEST", 80, 102], ["HU", "TEST", 114, 116]]], ["All of the stool specimens were photographed at a magnification of 60,000.", [["stool specimens", "ANATOMY", 11, 26], ["stool specimens", "CANCER", 11, 26], ["the stool specimens", "TEST", 7, 26], ["a magnification", "TEST", 48, 63]]], ["Periodic calibration of the electron microscope with a carbon grating revealed a stable lens system during the entire period of observation.Patients and MethodsImmune electron microscopy.", [["carbon", "CHEMICAL", 55, 61], ["Patients", "ORGANISM", 140, 148], ["Patients", "SPECIES", 140, 148], ["the electron microscope", "TEST", 24, 47], ["a carbon grating", "TEST", 53, 69], ["MethodsImmune electron microscopy", "TEST", 153, 186], ["stable", "OBSERVATION", 81, 87], ["lens system", "OBSERVATION", 88, 99]]], ["A stool specimen that showed minimal spontaneous aggregation of the virus-like particles was chosen.", [["stool specimen", "ANATOMY", 2, 16], ["A stool specimen", "TEST", 0, 16], ["minimal spontaneous aggregation of the virus", "PROBLEM", 29, 73], ["stool", "OBSERVATION", 2, 7], ["minimal", "OBSERVATION_MODIFIER", 29, 36], ["spontaneous aggregation", "OBSERVATION", 37, 60], ["virus", "OBSERVATION", 68, 73], ["particles", "OBSERVATION_MODIFIER", 79, 88]]], ["Several grids were prepared by mixing 0.05 ml of this stool suspension with 0.05 ml of an infant's serum that was undiluted or diluted 1:2, 1:4, or 1:8 in 0.22070 bovine serum albumin.", [["serum", "ANATOMY", 99, 104], ["serum", "ANATOMY", 170, 175], ["serum", "ORGANISM_SUBSTANCE", 99, 104], ["bovine", "ORGANISM", 163, 169], ["serum", "ORGANISM_SUBSTANCE", 170, 175], ["albumin", "GENE_OR_GENE_PRODUCT", 176, 183], ["infant", "SPECIES", 90, 96], ["bovine", "SPECIES", 163, 169], ["bovine", "SPECIES", 163, 169], ["Several grids", "TREATMENT", 0, 13], ["this stool suspension", "TREATMENT", 49, 70], ["an infant's serum", "TEST", 87, 104], ["bovine serum albumin", "TEST", 163, 183]]], ["A drop of this mixture was then placed on a grid in a microtiter well and processed as described above.", [["A drop of this mixture", "PROBLEM", 0, 22], ["a grid in a microtiter", "TREATMENT", 42, 64], ["drop", "OBSERVATION_MODIFIER", 2, 6]]], ["Five random low-power fields (magnification, 10,000) were photographed from each grid.", [["low", "OBSERVATION_MODIFIER", 12, 15]]], ["The specimens were examined without knowledge of the serum source.Patients and MethodsCultures.", [["specimens", "ANATOMY", 4, 13], ["serum", "ANATOMY", 53, 58], ["specimens", "CANCER", 4, 13], ["serum", "ORGANISM_SUBSTANCE", 53, 58], ["Patients", "ORGANISM", 66, 74], ["Patients", "SPECIES", 66, 74], ["The specimens", "TEST", 0, 13], ["the serum source", "PROBLEM", 49, 65], ["MethodsCultures", "TEST", 79, 94]]], ["Combined nasopharyngeal-throat swabs, rectal swabs, and urine specimens were processed according to standard methods for isolating viruses [13] .", [["nasopharyngeal-throat swabs", "ANATOMY", 9, 36], ["rectal swabs", "ANATOMY", 38, 50], ["urine specimens", "ANATOMY", 56, 71], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 38, 50], ["urine specimens", "ORGANISM_SUBSTANCE", 56, 71], ["Combined nasopharyngeal-throat swabs", "TEST", 0, 36], ["rectal swabs", "TEST", 38, 50], ["urine specimens", "TEST", 56, 71], ["isolating viruses", "PROBLEM", 121, 138], ["nasopharyngeal", "ANATOMY", 9, 23], ["throat", "ANATOMY", 24, 30], ["rectal", "ANATOMY", 38, 44]]], ["Nasopharyngeal-throat and rectal specimens were inoculated onto cultures of primary cynomolgus monkey kidney cells, human lung cells (a continuous heteroploid cell line), and human embryonic tonsil cells (a diploid fibroblast cell strain).", [["Nasopharyngeal-throat", "ANATOMY", 0, 21], ["rectal specimens", "ANATOMY", 26, 42], ["cultures", "ANATOMY", 64, 72], ["kidney cells", "ANATOMY", 102, 114], ["lung cells", "ANATOMY", 122, 132], ["heteroploid cell line", "ANATOMY", 147, 168], ["embryonic tonsil cells", "ANATOMY", 181, 203], ["fibroblast cell strain", "ANATOMY", 215, 237], ["rectal specimens", "CANCER", 26, 42], ["cynomolgus", "ORGANISM", 84, 94], ["monkey", "ORGANISM", 95, 101], ["kidney cells", "CELL", 102, 114], ["human", "ORGANISM", 116, 121], ["lung cells", "CELL", 122, 132], ["heteroploid cell line", "CELL", 147, 168], ["human", "ORGANISM", 175, 180], ["embryonic tonsil cells", "CELL", 181, 203], ["fibroblast cell", "CELL", 215, 230], ["primary cynomolgus monkey kidney cells", "CELL_TYPE", 76, 114], ["human lung cells", "CELL_TYPE", 116, 132], ["continuous heteroploid cell line", "CELL_LINE", 136, 168], ["human embryonic tonsil cells", "CELL_TYPE", 175, 203], ["diploid fibroblast cell strain", "CELL_LINE", 207, 237], ["cynomolgus monkey", "SPECIES", 84, 101], ["human", "SPECIES", 116, 121], ["human", "SPECIES", 175, 180], ["cynomolgus monkey", "SPECIES", 84, 101], ["human", "SPECIES", 116, 121], ["human", "SPECIES", 175, 180], ["Nasopharyngeal-throat and rectal specimens", "TEST", 0, 42], ["cultures", "TEST", 64, 72], ["primary cynomolgus monkey kidney cells", "PROBLEM", 76, 114], ["human lung cells", "PROBLEM", 116, 132], ["a continuous heteroploid cell line", "TREATMENT", 134, 168], ["human embryonic tonsil cells", "PROBLEM", 175, 203], ["a diploid fibroblast cell strain", "TREATMENT", 205, 237], ["throat", "ANATOMY", 15, 21], ["rectal", "ANATOMY", 26, 32], ["primary cynomolgus monkey kidney cells", "OBSERVATION", 76, 114], ["lung", "ANATOMY", 122, 126], ["cells", "OBSERVATION", 127, 132], ["embryonic tonsil cells", "OBSERVATION", 181, 203], ["fibroblast cell strain", "OBSERVATION", 215, 237]]], ["Urine specimens were inoculated onto human embryonic tonsil cells.", [["Urine specimens", "ANATOMY", 0, 15], ["embryonic tonsil cells", "ANATOMY", 43, 65], ["Urine specimens", "ORGANISM_SUBSTANCE", 0, 15], ["human", "ORGANISM", 37, 42], ["embryonic tonsil cells", "CELL", 43, 65], ["human embryonic tonsil cells", "CELL_TYPE", 37, 65], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 37, 42], ["Urine specimens", "TEST", 0, 15], ["embryonic tonsil cells", "OBSERVATION", 43, 65]]], ["Stools from ill patients were also cultured for Salmonella, Shigella, and Campylobaeter species when it was considered appropriate by the attending staff.", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["Salmonella", "SPECIES", 48, 58], ["Salmonella", "PROBLEM", 48, 58], ["Shigella", "PROBLEM", 60, 68], ["Campylobaeter species", "PROBLEM", 74, 95]]], ["In addition, selected samples were tested for the presence of Clostridium difflcile toxin by a tissue-culture assay [14] and for human rotavirus antigen by an enzyme-linked immunosorbert assay [15] .Statistical analysis.", [["samples", "ANATOMY", 22, 29], ["tissue", "ANATOMY", 95, 101], ["Clostridium difflcile toxin", "GENE_OR_GENE_PRODUCT", 62, 89], ["tissue", "TISSUE", 95, 101], ["human", "ORGANISM", 129, 134], ["rotavirus antigen", "GENE_OR_GENE_PRODUCT", 135, 152], ["Clostridium difflcile toxin", "PROTEIN", 62, 89], ["human rotavirus antigen", "PROTEIN", 129, 152], ["Clostridium difflcile toxin", "SPECIES", 62, 89], ["human", "SPECIES", 129, 134], ["Clostridium difflcile", "SPECIES", 62, 83], ["human", "SPECIES", 129, 134], ["rotavirus", "SPECIES", 135, 144], ["selected samples", "TEST", 13, 29], ["Clostridium difflcile toxin", "PROBLEM", 62, 89], ["a tissue-culture assay", "TEST", 93, 115], ["human rotavirus antigen", "TEST", 129, 152], ["an enzyme", "TEST", 156, 165], ["immunosorbert assay", "TEST", 173, 192], ["Statistical analysis", "TEST", 199, 219]]], ["Statistical significance wasVaucher et al.Statistical analysis.", [["Statistical analysis", "TEST", 42, 62]]], ["Statistical significance wasdetermined by Student's t-test, X 2 analysis, or by exact binomial confidence limits.ResultsInitial episode and survey.", [["Student's t-test", "TEST", 42, 58]]], ["During an eightday period in September 1979, eight (50%) of all 16 infants in the NICU developed acute gastrointestinal symptoms, including persistent abdominal distention and bilious gastric aspirates (three patients) or green, water-loss stools that contained blood and mucus (five patients).", [["gastrointestinal", "ANATOMY", 103, 119], ["abdominal", "ANATOMY", 151, 160], ["bilious gastric aspirates", "ANATOMY", 176, 201], ["blood", "ANATOMY", 262, 267], ["mucus", "ANATOMY", 272, 277], ["acute gastrointestinal symptoms", "DISEASE", 97, 128], ["abdominal distention", "DISEASE", 151, 171], ["infants", "ORGANISM", 67, 74], ["gastrointestinal", "ORGANISM_SUBDIVISION", 103, 119], ["abdominal", "ORGANISM_SUBDIVISION", 151, 160], ["gastric aspirates", "MULTI-TISSUE_STRUCTURE", 184, 201], ["patients", "ORGANISM", 209, 217], ["blood", "ORGANISM_SUBSTANCE", 262, 267], ["mucus", "ORGANISM_SUBSTANCE", 272, 277], ["patients", "ORGANISM", 284, 292], ["infants", "SPECIES", 67, 74], ["patients", "SPECIES", 209, 217], ["patients", "SPECIES", 284, 292], ["acute gastrointestinal symptoms", "PROBLEM", 97, 128], ["persistent abdominal distention", "PROBLEM", 140, 171], ["bilious gastric aspirates", "PROBLEM", 176, 201], ["green, water-loss stools", "PROBLEM", 222, 246], ["acute", "OBSERVATION_MODIFIER", 97, 102], ["gastrointestinal", "ANATOMY", 103, 119], ["symptoms", "OBSERVATION", 120, 128], ["persistent", "OBSERVATION_MODIFIER", 140, 150], ["abdominal", "ANATOMY", 151, 160], ["distention", "OBSERVATION", 161, 171], ["bilious", "OBSERVATION", 176, 183], ["gastric", "ANATOMY", 184, 191], ["aspirates", "OBSERVATION", 192, 201]]], ["The illness was severe enough in five of the eight infants to warrant the discontinuation of oral feeding for at least five days.", [["oral", "ANATOMY", 93, 97], ["illness", "DISEASE", 4, 11], ["infants", "ORGANISM", 51, 58], ["oral", "ORGANISM_SUBDIVISION", 93, 97], ["infants", "SPECIES", 51, 58], ["The illness", "PROBLEM", 0, 11], ["oral feeding", "TREATMENT", 93, 105], ["illness", "OBSERVATION", 4, 11], ["severe", "OBSERVATION_MODIFIER", 16, 22]]], ["An infectious agent was suspected as the cause of gastrointestinal illness.", [["gastrointestinal", "ANATOMY", 50, 66], ["gastrointestinal illness", "DISEASE", 50, 74], ["gastrointestinal", "ORGAN", 50, 66], ["An infectious agent", "PROBLEM", 0, 19], ["gastrointestinal illness", "PROBLEM", 50, 74], ["infectious", "OBSERVATION", 3, 13], ["gastrointestinal", "ANATOMY", 50, 66], ["illness", "OBSERVATION", 67, 74]]], ["Viral cultures and examination of stools by electron microscopy were performed.", [["stools", "ORGANISM_SUBSTANCE", 34, 40], ["Viral cultures", "TEST", 0, 14], ["examination of stools", "TEST", 19, 40], ["electron microscopy", "TEST", 44, 63]]], ["Five of the eight symptomatic infants had virus-like particles in the stool that were identified by electron microscopy.", [["stool", "ANATOMY", 70, 75], ["infants", "ORGANISM", 30, 37], ["stool", "ORGANISM_SUBSTANCE", 70, 75], ["infants", "SPECIES", 30, 37], ["virus", "PROBLEM", 42, 47], ["electron microscopy", "TEST", 100, 119], ["symptomatic", "OBSERVATION_MODIFIER", 18, 29], ["virus", "OBSERVATION", 42, 47], ["stool", "ANATOMY", 70, 75]]], ["Echovirus type 30 was cultured from the rectal swab of another symptomatic infant whose stool was negative for virus-like particles (table 1) .ResultsTo determine the incidence of virus-like particles in the NICU, the eight infants without gastrointestinal symptoms were also surveyed.", [["rectal swab", "ANATOMY", 40, 51], ["stool", "ANATOMY", 88, 93], ["gastrointestinal", "ANATOMY", 240, 256], ["gastrointestinal symptoms", "DISEASE", 240, 265], ["Echovirus type 30", "ORGANISM", 0, 17], ["rectal swab", "MULTI-TISSUE_STRUCTURE", 40, 51], ["infant", "ORGANISM", 75, 81], ["stool", "ORGANISM_SUBSTANCE", 88, 93], ["infants", "ORGANISM", 224, 231], ["gastrointestinal", "ORGAN", 240, 256], ["infant", "SPECIES", 75, 81], ["infants", "SPECIES", 224, 231], ["Echovirus type 30", "SPECIES", 0, 17], ["Echovirus type", "TEST", 0, 14], ["the rectal swab", "TEST", 36, 51], ["stool", "TEST", 88, 93], ["virus", "PROBLEM", 111, 116], ["virus", "PROBLEM", 180, 185], ["gastrointestinal symptoms", "PROBLEM", 240, 265], ["rectal", "ANATOMY", 40, 46], ["virus", "OBSERVATION", 180, 185]]], ["Five of these infants had not yet received oral feedings, and six were positive for virus-like particles.", [["oral", "ANATOMY", 43, 47], ["infants", "ORGANISM", 14, 21], ["oral", "ORGANISM_SUBDIVISION", 43, 47], ["infants", "SPECIES", 14, 21], ["oral feedings", "TREATMENT", 43, 56], ["virus", "PROBLEM", 84, 89]]], ["Two of the six infants with virus-like particles had gastrointestinal symptoms either before or after the initial survey, and two others had signs of sepsis, including hepatosplenomegaly and abnormal white blood cell counts (neutropenia or neutro- , and 5 were also tested for bacterial pathogens and were found to be negative.", [["gastrointestinal", "ANATOMY", 53, 69], ["white blood cell", "ANATOMY", 200, 216], ["gastrointestinal symptoms", "DISEASE", 53, 78], ["sepsis", "DISEASE", 150, 156], ["hepatosplenomegaly", "DISEASE", 168, 186], ["abnormal white blood cell counts", "DISEASE", 191, 223], ["neutropenia", "DISEASE", 225, 236], ["infants", "ORGANISM", 15, 22], ["gastrointestinal", "ORGAN", 53, 69], ["blood cell", "CELL", 206, 216], ["infants", "SPECIES", 15, 22], ["virus", "PROBLEM", 28, 33], ["gastrointestinal symptoms", "PROBLEM", 53, 78], ["sepsis", "PROBLEM", 150, 156], ["hepatosplenomegaly", "PROBLEM", 168, 186], ["abnormal white blood cell counts", "PROBLEM", 191, 223], ["neutropenia", "PROBLEM", 225, 236], ["neutro", "TEST", 240, 246], ["bacterial pathogens", "PROBLEM", 277, 296], ["virus", "OBSERVATION", 28, 33], ["sepsis", "OBSERVATION", 150, 156], ["hepatosplenomegaly", "OBSERVATION", 168, 186], ["abnormal", "OBSERVATION_MODIFIER", 191, 199], ["negative", "OBSERVATION", 318, 326]]], ["Stool specimens were examined for pleomorphic, enveloped, viruslike particles by electron microscopy.", [["Stool specimens", "ANATOMY", 0, 15], ["Stool specimens", "CANCER", 0, 15], ["Stool specimens", "TEST", 0, 15], ["pleomorphic, enveloped, viruslike particles", "PROBLEM", 34, 77], ["electron microscopy", "TEST", 81, 100]]], ["NO ::::: not done. philia), despite negative bacterial and viral cultures.", [["NO", "CHEMICAL", 0, 2], ["NO", "CHEMICAL", 0, 2], ["NO", "SIMPLE_CHEMICAL", 0, 2], ["philia", "TEST", 19, 25], ["negative bacterial and viral cultures", "PROBLEM", 36, 73], ["negative bacterial", "OBSERVATION_MODIFIER", 36, 54], ["viral cultures", "OBSERVATION", 59, 73]]], ["One of these latter infants had large quantities of virus-like particles in the stool.ResultsSubsequent surveys.", [["stool", "ANATOMY", 80, 85], ["infants", "ORGANISM", 20, 27], ["stool", "ORGANISM_SUBSTANCE", 80, 85], ["infants", "SPECIES", 20, 27], ["large quantities of virus", "PROBLEM", 32, 57], ["large", "OBSERVATION_MODIFIER", 32, 37], ["quantities", "OBSERVATION_MODIFIER", 38, 48], ["virus", "OBSERVATION", 52, 57], ["particles", "OBSERVATION_MODIFIER", 63, 72], ["stool", "OBSERVATION", 80, 85]]], ["All of the infants in the NICU were surveyed for virus-like particles in the stool at one, three, six, 11, 19, 25, and 40 weeks after the initial survey (figure 1).", [["infants", "ORGANISM", 11, 18], ["stool", "ORGANISM_SUBSTANCE", 77, 82], ["infants", "SPECIES", 11, 18], ["virus", "PROBLEM", 49, 54], ["stool", "OBSERVATION", 77, 82]]], ["Although infants positive for virus-like particles were found at all times, the incidence decreased from 690/0 to <10% over the observation period.", [["infants", "ORGANISM", 9, 16], ["infants", "SPECIES", 9, 16], ["virus", "PROBLEM", 30, 35], ["like particles", "PROBLEM", 36, 50], ["virus", "OBSERVATION", 30, 35]]], ["Overall, 32 (36%) of all 88 infants screened in the NICU over the study period were positive for virus-like particles.ResultsElectron microscopy.", [["infants", "ORGANISM", 28, 35], ["infants", "SPECIES", 28, 35], ["Overall", "TEST", 0, 7], ["the study", "TEST", 62, 71], ["virus", "PROBLEM", 97, 102], ["ResultsElectron microscopy", "TEST", 118, 144]]], ["In all of the positive stool specimens, virus-like particles were present in large numbers and were easy to find by electron microscopy.", [["stool specimens", "ANATOMY", 23, 38], ["the positive stool specimens", "TEST", 10, 38], ["virus", "PROBLEM", 40, 45], ["electron microscopy", "TEST", 116, 135], ["positive", "OBSERVATION_MODIFIER", 14, 22], ["stool", "OBSERVATION", 23, 28], ["large", "OBSERVATION_MODIFIER", 77, 82]]], ["Rotaviruses, astroviruses, parvo-or picornaviruses, adenoviruses, and calicivirusesall of which have been previously identified in our laboratory -were absent during the entire 40-week observation period.", [["Rotaviruses", "DISEASE", 0, 11], ["parvo-or picornaviruses", "DISEASE", 27, 50], ["Rotaviruses", "GENE_OR_GENE_PRODUCT", 0, 11], ["parvo-or picornaviruses", "ORGANISM", 27, 50], ["adenoviruses", "ORGANISM", 52, 64], ["Rotaviruses", "PROBLEM", 0, 11], ["astroviruses", "PROBLEM", 13, 25], ["parvo", "TREATMENT", 27, 32], ["picornaviruses", "PROBLEM", 36, 50], ["adenoviruses", "TREATMENT", 52, 64], ["calicivirusesall", "TREATMENT", 70, 86], ["astroviruses", "OBSERVATION", 13, 25]]], ["The virus-like particles were surrounded by a fringe, 13-18 nm in length (figure 2, top).", [["The virus-like particles", "PROBLEM", 0, 24], ["virus", "OBSERVATION", 4, 9], ["particles", "OBSERVATION_MODIFIER", 15, 24], ["fringe", "OBSERVATION_MODIFIER", 46, 52]]], ["In most instances the individual filaments composing the fringe appeared somewhat flexible and had a bulbous shape at their distal end.", [["filaments", "ANATOMY", 33, 42], ["filaments", "CELLULAR_COMPONENT", 33, 42], ["somewhat flexible", "PROBLEM", 73, 90], ["a bulbous shape", "PROBLEM", 99, 114], ["most instances", "OBSERVATION_MODIFIER", 3, 17], ["flexible", "OBSERVATION_MODIFIER", 82, 90], ["bulbous", "OBSERVATION_MODIFIER", 101, 108], ["shape", "OBSERVATION_MODIFIER", 109, 114], ["distal", "ANATOMY_MODIFIER", 124, 130]]], ["Some of the virus-like particles occurred in aggregates (figure 2, bottom).ResultsSera obtained three to four weeks after initial screening from four neonates who had been positive for virus-like particles were compared with the sera obtained from three healthy neonates from the same NICU who were negative for virus-like particles for their ability to cause immune aggregation of the virus-like particles.", [["Sera", "ANATOMY", 82, 86], ["sera", "ANATOMY", 229, 233], ["Sera", "ORGANISM_SUBSTANCE", 82, 86], ["neonates", "ORGANISM", 150, 158], ["sera", "ORGANISM_SUBSTANCE", 229, 233], ["neonates", "ORGANISM", 262, 270], ["the virus-like particles", "PROBLEM", 8, 32], ["initial screening", "TEST", 122, 139], ["virus-like particles", "PROBLEM", 185, 205], ["the sera", "TEST", 225, 233], ["virus", "PROBLEM", 312, 317], ["immune aggregation", "PROBLEM", 360, 378], ["the virus", "PROBLEM", 382, 391], ["virus", "OBSERVATION", 12, 17], ["particles", "OBSERVATION_MODIFIER", 23, 32], ["aggregates", "OBSERVATION_MODIFIER", 45, 55]]], ["A striking aggregation of both envelopes and fringed particles was observed with the sera from the positive infants but not with the sera from the negative infants diluted than with the diluted sera.", [["sera", "ANATOMY", 85, 89], ["sera", "ANATOMY", 133, 137], ["sera", "ANATOMY", 194, 198], ["sera", "ORGANISM_SUBSTANCE", 85, 89], ["infants", "ORGANISM", 108, 115], ["sera", "ORGANISM_SUBSTANCE", 133, 137], ["infants", "ORGANISM", 156, 163], ["sera", "ORGANISM_SUBSTANCE", 194, 198], ["infants", "SPECIES", 108, 115], ["infants", "SPECIES", 156, 163], ["A striking aggregation of both envelopes and fringed particles", "PROBLEM", 0, 62], ["the sera", "TEST", 81, 89], ["the sera", "TEST", 129, 137], ["the diluted sera", "TREATMENT", 182, 198], ["striking", "OBSERVATION_MODIFIER", 2, 10], ["aggregation", "OBSERVATION", 11, 22]]], ["Although most of the immune aggregates contained a predominance of envelopes without characteristic fringes, definite virus-like particles could be identified at a high magnification (figure 4).", [["immune aggregates", "ANATOMY", 21, 38], ["immune aggregates", "CELL", 21, 38], ["the immune aggregates", "PROBLEM", 17, 38], ["characteristic fringes", "PROBLEM", 85, 107], ["definite virus-like particles", "PROBLEM", 109, 138], ["definite", "UNCERTAINTY", 109, 117], ["virus", "OBSERVATION", 118, 123]]], ["Apparent antibody bridges could also be observed between adjacent particles (figure 4).Symptoms related to the survey findings.To determine whether virus-like particles in the stool were associated with an increased incidence of gas- trointestinal symptoms, we compared the frequency of various findings in infants positive for viruslike particles with those in infants negative for virus-like particles.", [["stool", "ANATOMY", 176, 181], ["stool", "ORGANISM_SUBSTANCE", 176, 181], ["infants", "ORGANISM", 307, 314], ["infants", "ORGANISM", 362, 369], ["antibody bridges", "PROTEIN", 9, 25], ["infants", "SPECIES", 307, 314], ["infants", "SPECIES", 362, 369], ["Apparent antibody bridges", "PROBLEM", 0, 25], ["Symptoms", "PROBLEM", 87, 95], ["the survey findings", "TEST", 107, 126], ["virus-like particles in the stool", "PROBLEM", 148, 181], ["gas- trointestinal symptoms", "PROBLEM", 229, 256], ["viruslike particles", "PROBLEM", 328, 347], ["virus", "PROBLEM", 383, 388], ["antibody bridges", "OBSERVATION", 9, 25], ["could also be observed", "UNCERTAINTY", 26, 48], ["particles", "OBSERVATION_MODIFIER", 66, 75], ["virus", "OBSERVATION", 148, 153], ["particles", "OBSERVATION_MODIFIER", 159, 168], ["stool", "OBSERVATION", 176, 181], ["increased", "OBSERVATION_MODIFIER", 206, 215]]], ["Because the duration of viral shedding is unknown, we compared only the presence or absence of symptoms within seven days before or after each survey.", [["viral shedding", "PROBLEM", 24, 38], ["symptoms", "PROBLEM", 95, 103]]], ["These symptoms, routinely recorded in each infant's chart, were increases in stool frequency (more than eight per day), water loss or blood (occult or gross) in the stools, recurrent gastric aspirates (>2 ml) obtained>2 hr after feeding, bilious gastric aspirates, regurgitation, and abdominal distention.", [["stool", "ANATOMY", 77, 82], ["blood", "ANATOMY", 134, 139], ["gross", "ANATOMY", 151, 156], ["stools", "ANATOMY", 165, 171], ["gastric aspirates", "ANATOMY", 183, 200], ["bilious gastric aspirates", "ANATOMY", 238, 263], ["abdominal", "ANATOMY", 284, 293], ["abdominal distention", "DISEASE", 284, 304], ["stool", "ORGANISM_SUBSTANCE", 77, 82], ["blood", "ORGANISM_SUBSTANCE", 134, 139], ["gastric aspirates", "MULTI-TISSUE_STRUCTURE", 183, 200], ["gastric aspirates", "MULTI-TISSUE_STRUCTURE", 246, 263], ["abdominal", "ORGANISM_SUBDIVISION", 284, 293], ["infant", "SPECIES", 43, 49], ["These symptoms", "PROBLEM", 0, 14], ["stool frequency", "PROBLEM", 77, 92], ["water loss or blood (occult or gross) in the stools", "PROBLEM", 120, 171], ["recurrent gastric aspirates", "PROBLEM", 173, 200], ["bilious gastric aspirates", "PROBLEM", 238, 263], ["regurgitation", "PROBLEM", 265, 278], ["abdominal distention", "PROBLEM", 284, 304], ["increases", "OBSERVATION_MODIFIER", 64, 73], ["stool frequency", "OBSERVATION_MODIFIER", 77, 92], ["stools", "ANATOMY", 165, 171], ["gastric", "ANATOMY", 183, 190], ["aspirates", "OBSERVATION", 191, 200], ["gastric", "ANATOMY", 246, 253], ["aspirates", "OBSERVATION", 254, 263], ["regurgitation", "OBSERVATION", 265, 278], ["abdominal", "ANATOMY", 284, 293], ["distention", "OBSERVATION", 294, 304]]], ["The symptoms were collected by a retrospective chart review.Symptoms related to the survey findings.The symptoms that occurred more often in infants with stools positive for virus-like particles are shown in table 2.", [["infants", "ORGANISM", 141, 148], ["stools", "ORGANISM_SUBDIVISION", 154, 160], ["infants", "SPECIES", 141, 148], ["The symptoms", "PROBLEM", 0, 12], ["a retrospective chart review", "TEST", 31, 59], ["Symptoms", "PROBLEM", 60, 68], ["the survey findings", "TEST", 80, 99], ["The symptoms", "PROBLEM", 100, 112], ["stools positive", "PROBLEM", 154, 169], ["virus", "PROBLEM", 174, 179]]], ["Infants positive for virus-like particles were more likely to have multiple symptoms, including stools that contained both excessive water and blood (P< 0.002) and two or more additional symptoms in one of the following combinations: (1) gastric aspirates, regurgitation, and abdominal distention or (2) increased stool frequency, water-loss stools, and blood in the stool (P < 0.002).Symptoms related to the survey findings.Infants positive for virus-like particles were more likely to be symptomatic at any time during their hospitalization (P < 0.01) and within seven Figure 4 .", [["blood", "ANATOMY", 143, 148], ["gastric aspirates", "ANATOMY", 238, 255], ["abdominal", "ANATOMY", 276, 285], ["stool", "ANATOMY", 314, 319], ["blood", "ANATOMY", 354, 359], ["stool", "ANATOMY", 367, 372], ["abdominal distention", "DISEASE", 276, 296], ["blood", "ORGANISM_SUBSTANCE", 143, 148], ["gastric aspirates", "MULTI-TISSUE_STRUCTURE", 238, 255], ["abdominal", "ORGANISM_SUBDIVISION", 276, 285], ["stool", "ORGANISM_SUBSTANCE", 314, 319], ["blood", "ORGANISM_SUBSTANCE", 354, 359], ["stool", "ORGANISM_SUBSTANCE", 367, 372], ["Infants", "SPECIES", 0, 7], ["Infants", "SPECIES", 425, 432], ["virus", "PROBLEM", 21, 26], ["like particles", "PROBLEM", 27, 41], ["multiple symptoms", "PROBLEM", 67, 84], ["stools", "PROBLEM", 96, 102], ["more additional symptoms", "PROBLEM", 171, 195], ["gastric aspirates", "PROBLEM", 238, 255], ["regurgitation", "PROBLEM", 257, 270], ["abdominal distention", "PROBLEM", 276, 296], ["increased stool frequency", "PROBLEM", 304, 329], ["loss stools", "PROBLEM", 337, 348], ["blood in the stool", "PROBLEM", 354, 372], ["Symptoms", "PROBLEM", 385, 393], ["the survey findings", "TEST", 405, 424], ["virus", "PROBLEM", 446, 451], ["symptomatic", "PROBLEM", 490, 501], ["virus", "OBSERVATION", 21, 26], ["gastric", "ANATOMY", 238, 245], ["aspirates", "OBSERVATION", 246, 255], ["regurgitation", "OBSERVATION", 257, 270], ["abdominal", "ANATOMY", 276, 285], ["distention", "OBSERVATION", 286, 296], ["increased", "OBSERVATION_MODIFIER", 304, 313], ["stool", "OBSERVATION", 314, 319], ["stool", "ANATOMY", 367, 372], ["virus", "OBSERVATION", 446, 451]]], ["Immune electron micrograph of an infant's stool that was positive for virus-like particles combined with convalescent-phase serum from an infant with severe gastrointestinal illness whose stool was also positive for viruslike particles (negative contrast, phosphotungstic acid).", [["stool", "ANATOMY", 42, 47], ["serum", "ANATOMY", 124, 129], ["gastrointestinal", "ANATOMY", 157, 173], ["stool", "ANATOMY", 188, 193], ["gastrointestinal illness", "DISEASE", 157, 181], ["phosphotungstic acid", "CHEMICAL", 256, 276], ["phosphotungstic acid", "CHEMICAL", 256, 276], ["infant", "ORGANISM", 33, 39], ["stool", "ORGANISM_SUBSTANCE", 42, 47], ["serum", "ORGANISM_SUBSTANCE", 124, 129], ["gastrointestinal", "ORGANISM_SUBDIVISION", 157, 173], ["stool", "ORGANISM_SUBSTANCE", 188, 193], ["phosphotungstic acid", "SIMPLE_CHEMICAL", 256, 276], ["infant", "SPECIES", 33, 39], ["infant", "SPECIES", 138, 144], ["Immune electron micrograph", "TEST", 0, 26], ["an infant's stool", "TEST", 30, 47], ["virus", "PROBLEM", 70, 75], ["like particles", "PROBLEM", 76, 90], ["convalescent-phase serum", "TEST", 105, 129], ["severe gastrointestinal illness", "PROBLEM", 150, 181], ["viruslike particles", "PROBLEM", 216, 235], ["severe", "OBSERVATION_MODIFIER", 150, 156], ["gastrointestinal", "ANATOMY", 157, 173], ["illness", "OBSERVATION", 174, 181]]], ["The samples were obtained during an outbreak of gastrointestinal illness in a neonatal intensive-care unit.", [["samples", "ANATOMY", 4, 11], ["gastrointestinal", "ANATOMY", 48, 64], ["gastrointestinal illness", "DISEASE", 48, 72], ["gastrointestinal", "ORGAN", 48, 64], ["The samples", "TEST", 0, 11], ["gastrointestinal", "ANATOMY", 48, 64]]], ["Several pleomorphic, enveloped, virus-like particles can be seen at the periphery of this immune aggregate.", [["Several pleomorphic, enveloped, virus-like particles", "PROBLEM", 0, 52], ["pleomorphic", "OBSERVATION_MODIFIER", 8, 19], ["enveloped", "OBSERVATION_MODIFIER", 21, 30], ["virus", "OBSERVATION", 32, 37], ["periphery", "ANATOMY_MODIFIER", 72, 81], ["immune aggregate", "OBSERVATION", 90, 106]]], ["An apparent antibody bridge is evident between several of these particles (arrows).", [["An apparent antibody bridge", "TREATMENT", 0, 27], ["antibody bridge", "OBSERVATION", 12, 27], ["particles", "OBSERVATION_MODIFIER", 64, 73]]], ["In the interior of the aggregate, some of the fringes have been obscured, presumably by excessive antibody coating.Symptoms related to the survey findings.days before or after the survey (P < 0.005).", [["excessive antibody coating", "PROBLEM", 88, 114], ["Symptoms", "PROBLEM", 115, 123], ["the survey findings", "TEST", 135, 154], ["interior", "ANATOMY_MODIFIER", 7, 15], ["aggregate", "OBSERVATION_MODIFIER", 23, 32], ["some", "OBSERVATION_MODIFIER", 34, 38], ["fringes", "OBSERVATION_MODIFIER", 46, 53], ["presumably by", "UNCERTAINTY", 74, 87], ["excessive", "OBSERVATION_MODIFIER", 88, 97], ["antibody coating", "OBSERVATION", 98, 114]]], ["They were also more likely to be taken off oral feeding (P < 0.05), especially for more than three days (P < 0.005).", [["oral", "ANATOMY", 43, 47], ["oral", "ORGANISM_SUBDIVISION", 43, 47], ["oral feeding", "TREATMENT", 43, 55]]], ["Gastrointestinal symptoms lasted significantly longer (P < 0.05) in infants positive for virus-like particles than in infants negative for virus-like particles (mean \u00b1 SEM, 9.2 \u00b1 1.7 vs. 5.2 \u00b1 0.8 days).", [["Gastrointestinal", "ANATOMY", 0, 16], ["Gastrointestinal", "ORGAN", 0, 16], ["infants", "ORGANISM", 68, 75], ["infants", "ORGANISM", 118, 125], ["infants", "SPECIES", 68, 75], ["infants", "SPECIES", 118, 125], ["Gastrointestinal symptoms", "PROBLEM", 0, 25], ["virus", "PROBLEM", 89, 94], ["like particles", "PROBLEM", 95, 109], ["virus", "PROBLEM", 139, 144], ["mean", "TEST", 161, 165], ["SEM", "TEST", 168, 171]]], ["No significant differences were found between the infants positive for virus-like particles and those negative for virus-like particles with regard to birth weight, gestational age, day surveyed, or antibiotic usage.Symptoms related to the survey findings.Cultures and assays for toxin or antigen.", [["infants", "ORGANISM", 50, 57], ["toxin", "PROTEIN", 280, 285], ["infants", "SPECIES", 50, 57], ["significant differences", "PROBLEM", 3, 26], ["virus", "PROBLEM", 71, 76], ["like particles", "PROBLEM", 77, 91], ["virus", "PROBLEM", 115, 120], ["antibiotic usage", "TREATMENT", 199, 215], ["Symptoms", "PROBLEM", 216, 224], ["the survey findings", "TEST", 236, 255], ["Cultures", "TEST", 256, 264], ["assays", "TEST", 269, 275], ["toxin", "TEST", 280, 285], ["antigen", "PROBLEM", 289, 296], ["significant", "OBSERVATION_MODIFIER", 3, 14]]], ["The only virus isolated was an enterovirus found in the group of neonates negative for virus-like particles.", [["enterovirus", "ORGANISM", 31, 42], ["neonates", "ORGANISM", 65, 73], ["virus", "PROBLEM", 9, 14], ["an enterovirus", "PROBLEM", 28, 42], ["virus", "PROBLEM", 87, 92], ["virus", "OBSERVATION", 9, 14], ["enterovirus", "OBSERVATION", 31, 42]]], ["The stool samples from 78 patients (30 positive and 48 negative for virus-like particles) were negative for human rotavirus antigen as tested by enzyme-linked immunosorbent assay.", [["stool samples", "ANATOMY", 4, 17], ["stool samples", "CANCER", 4, 17], ["patients", "ORGANISM", 26, 34], ["human", "ORGANISM", 108, 113], ["rotavirus", "ORGANISM", 114, 123], ["human rotavirus antigen", "PROTEIN", 108, 131], ["patients", "SPECIES", 26, 34], ["human", "SPECIES", 108, 113], ["human", "SPECIES", 108, 113], ["rotavirus", "SPECIES", 114, 123], ["The stool samples", "TEST", 0, 17], ["virus", "TEST", 68, 73], ["human rotavirus antigen", "PROBLEM", 108, 131], ["enzyme", "TEST", 145, 151], ["immunosorbent assay", "TEST", 159, 178], ["stool", "OBSERVATION", 4, 9]]], ["In addition, only one of 33 stool specimens from the positive patients contained detectable C. difficile toxin.Symptoms related to the survey findings.Additional observations.", [["stool specimens", "ANATOMY", 28, 43], ["stool", "ORGANISM", 28, 33], ["specimens", "CANCER", 34, 43], ["patients", "ORGANISM", 62, 70], ["C. difficile toxin", "ORGANISM", 92, 110], ["C. difficile toxin", "PROTEIN", 92, 110], ["patients", "SPECIES", 62, 70], ["C. difficile", "SPECIES", 92, 104], ["C. difficile", "SPECIES", 92, 104], ["33 stool specimens", "TEST", 25, 43], ["detectable C. difficile toxin", "PROBLEM", 81, 110], ["Symptoms", "PROBLEM", 111, 119], ["the survey findings", "TEST", 131, 150], ["C. difficile", "OBSERVATION", 92, 104]]], ["Twelve infants whose stools were positive for virus-like particles on their first screening were studied at least once more one to six weeks later.", [["stools", "ANATOMY", 21, 27], ["infants", "ORGANISM", 7, 14], ["stools", "ORGANISM", 21, 27], ["infants", "SPECIES", 7, 14], ["virus", "PROBLEM", 46, 51]]], ["Five of these infants were either continuously or intermittently positive for viruslike particles on the subsequent surveys, two of the infants excreted virus-like particles for at least six weeks, and another two infants continued shedding for at least three weeks.", [["infants", "ORGANISM", 14, 21], ["infants", "ORGANISM", 136, 143], ["infants", "ORGANISM", 214, 221], ["infants", "SPECIES", 14, 21], ["infants", "SPECIES", 136, 143], ["infants", "SPECIES", 214, 221], ["viruslike particles", "PROBLEM", 78, 97]]], ["Most of the infants (11 of 12) were asymptomatic at the time of subsequent screening.Symptoms related to the survey findings.Eleven (34070) of 32 infants positive for viruslike particles were found to shed the particles at <72 hr of age (range, 6-65 hr); four of these infants were <24 hr old.", [["infants", "ORGANISM", 12, 19], ["infants", "ORGANISM", 146, 153], ["infants", "ORGANISM", 269, 276], ["infants", "SPECIES", 12, 19], ["infants", "SPECIES", 146, 153], ["infants", "SPECIES", 269, 276], ["asymptomatic", "PROBLEM", 36, 48], ["subsequent screening", "TEST", 64, 84], ["Symptoms", "PROBLEM", 85, 93], ["the survey findings", "TEST", 105, 124], ["viruslike particles", "PROBLEM", 167, 186]]], ["Three infants were delivered by Caesarean section, and two infants had unruptured membranes until operative delivery.", [["membranes", "ANATOMY", 82, 91], ["infants", "ORGANISM", 6, 13], ["infants", "ORGANISM", 59, 66], ["infants", "SPECIES", 6, 13], ["infants", "SPECIES", 59, 66], ["Caesarean section", "TREATMENT", 32, 49], ["unruptured membranes", "PROBLEM", 71, 91], ["operative delivery", "TREATMENT", 98, 116], ["unruptured", "OBSERVATION", 71, 81]]], ["None of the infants had a history of prolonged rupture of membranes (mean \u00b1 SEM interval between rupture and delivery, 1.9 \u00b1 O. 8 hr; range, 0.2-7.5 hr).Symptoms related to the survey findings.Four infants positive for virus-like particles were thought to be septic on the basis of one or more of the following characteristics: respiratory distress, hepatosplenomegaly, lethargy, and abnormally low or elevated white blood cell counts.", [["membranes", "ANATOMY", 58, 67], ["respiratory", "ANATOMY", 328, 339], ["white blood cell", "ANATOMY", 411, 427], ["rupture of membranes", "DISEASE", 47, 67], ["rupture", "DISEASE", 97, 104], ["septic", "DISEASE", 259, 265], ["respiratory distress", "DISEASE", 328, 348], ["hepatosplenomegaly", "DISEASE", 350, 368], ["lethargy", "DISEASE", 370, 378], ["infants", "ORGANISM", 12, 19], ["membranes", "CELLULAR_COMPONENT", 58, 67], ["infants", "ORGANISM", 198, 205], ["blood cell", "CELL", 417, 427], ["infants", "SPECIES", 12, 19], ["infants", "SPECIES", 198, 205], ["prolonged rupture of membranes", "PROBLEM", 37, 67], ["rupture", "PROBLEM", 97, 104], ["delivery", "TREATMENT", 109, 117], ["range", "TEST", 134, 139], ["Symptoms", "PROBLEM", 153, 161], ["the survey findings", "TEST", 173, 192], ["virus", "PROBLEM", 219, 224], ["septic", "PROBLEM", 259, 265], ["respiratory distress", "PROBLEM", 328, 348], ["hepatosplenomegaly", "PROBLEM", 350, 368], ["lethargy", "PROBLEM", 370, 378], ["abnormally low or elevated white blood cell counts", "PROBLEM", 384, 434], ["prolonged", "OBSERVATION_MODIFIER", 37, 46], ["rupture", "OBSERVATION", 47, 54], ["rupture", "OBSERVATION", 97, 104], ["septic", "OBSERVATION", 259, 265], ["respiratory distress", "OBSERVATION", 328, 348], ["hepatosplenomegaly", "OBSERVATION", 350, 368], ["lethargy", "OBSERVATION", 370, 378], ["abnormally", "OBSERVATION_MODIFIER", 384, 394], ["low", "OBSERVATION_MODIFIER", 395, 398]]], ["The bacterial cultures were negative for pathogens in all four of the infants.", [["cultures", "ANATOMY", 14, 22], ["bacterial cultures", "CELL", 4, 22], ["infants", "ORGANISM", 70, 77], ["infants", "SPECIES", 70, 77], ["The bacterial cultures", "TEST", 0, 22], ["pathogens", "PROBLEM", 41, 50], ["bacterial", "OBSERVATION_MODIFIER", 4, 13]]], ["Three of the infants had viral cultures done, which were also negative; two of these infants died.", [["infants", "ORGANISM", 13, 20], ["infants", "ORGANISM", 85, 92], ["infants", "SPECIES", 13, 20], ["infants", "SPECIES", 85, 92], ["viral cultures", "TEST", 25, 39]]], ["A postmortem examination, performed on only one infant, demonstrated pneumonia and hepatosplenomegaly but no gastrointestinal lesions.", [["gastrointestinal lesions", "ANATOMY", 109, 133], ["pneumonia", "DISEASE", 69, 78], ["hepatosplenomegaly", "DISEASE", 83, 101], ["gastrointestinal lesions", "DISEASE", 109, 133], ["gastrointestinal lesions", "PATHOLOGICAL_FORMATION", 109, 133], ["infant", "SPECIES", 48, 54], ["A postmortem examination", "TEST", 0, 24], ["pneumonia", "PROBLEM", 69, 78], ["hepatosplenomegaly", "PROBLEM", 83, 101], ["gastrointestinal lesions", "PROBLEM", 109, 133], ["pneumonia", "OBSERVATION", 69, 78], ["hepatosplenomegaly", "OBSERVATION", 83, 101], ["no", "UNCERTAINTY", 106, 108], ["gastrointestinal", "ANATOMY", 109, 125], ["lesions", "OBSERVATION", 126, 133]]], ["Virus-like particles were not seen in postmortem sections of the lung or the liver, and attempts to culture virus from these organs were unsuccessful.Vaucher et al.Mother-infant pairs.", [["sections", "ANATOMY", 49, 57], ["lung", "ANATOMY", 65, 69], ["liver", "ANATOMY", 77, 82], ["organs", "ANATOMY", 125, 131], ["Virus", "ORGANISM", 0, 5], ["postmortem sections", "MULTI-TISSUE_STRUCTURE", 38, 57], ["lung", "ORGAN", 65, 69], ["liver", "ORGAN", 77, 82], ["organs", "ORGAN", 125, 131], ["infant", "SPECIES", 171, 177], ["Virus-like particles", "PROBLEM", 0, 20], ["culture virus", "TEST", 100, 113], ["particles", "OBSERVATION", 11, 20], ["not seen", "UNCERTAINTY", 26, 34], ["lung", "ANATOMY", 65, 69], ["liver", "ANATOMY", 77, 82]]], ["In an effort to determine whether vertical transmission occurred, 13 other infants positive for virus-like particles whose mothers had gastrointestinal or flu-like illnesses within two weeks of delivery were identified in the community (not part of the survey study) (table 3).", [["gastrointestinal", "ANATOMY", 135, 151], ["gastrointestinal or flu-like illnesses", "DISEASE", 135, 173], ["infants", "ORGANISM", 75, 82], ["mothers", "ORGANISM", 123, 130], ["gastrointestinal", "ORGANISM_SUBDIVISION", 135, 151], ["infants", "SPECIES", 75, 82], ["vertical transmission", "PROBLEM", 34, 55], ["virus", "PROBLEM", 96, 101], ["gastrointestinal or flu-like illnesses", "PROBLEM", 135, 173], ["delivery", "TREATMENT", 194, 202], ["the survey study", "TEST", 249, 265], ["gastrointestinal", "ANATOMY", 135, 151]]], ["All of the mothers except one had symptoms that were predominantly gastrointestinal, including nausea, vomiting, diarrhea, and occasional fever.", [["gastrointestinal", "ANATOMY", 67, 83], ["nausea", "DISEASE", 95, 101], ["vomiting", "DISEASE", 103, 111], ["diarrhea", "DISEASE", 113, 121], ["fever", "DISEASE", 138, 143], ["mothers", "ORGANISM", 11, 18], ["gastrointestinal", "ORGAN", 67, 83], ["symptoms", "PROBLEM", 34, 42], ["nausea", "PROBLEM", 95, 101], ["vomiting", "PROBLEM", 103, 111], ["diarrhea", "PROBLEM", 113, 121], ["occasional fever", "PROBLEM", 127, 143], ["gastrointestinal", "ANATOMY", 67, 83], ["diarrhea", "OBSERVATION", 113, 121], ["occasional", "OBSERVATION_MODIFIER", 127, 137], ["fever", "OBSERVATION", 138, 143]]], ["Five of the mothers went into premature labor soon after becoming symptomatic.", [["premature labor", "DISEASE", 30, 45], ["mothers", "ORGANISM", 12, 19], ["premature labor", "PROBLEM", 30, 45], ["symptomatic", "PROBLEM", 66, 77]]], ["Two of the four mothers examined also had virus-like particles in the stool.", [["stool", "ANATOMY", 70, 75], ["mothers", "ORGANISM", 16, 23], ["stool", "ORGANISM_SUBSTANCE", 70, 75], ["virus", "PROBLEM", 42, 47], ["stool", "OBSERVATION", 70, 75]]], ["The transmission of virus-like particles across the placenta or intact membranes is suggested by the delivery of four infantspatients no. 7 and no. 8 (twins; Caesarean section) and patients no. 2 and no. 9 (vaginal deliveries)at which the amniotic membranes were not ruptured until the time of delivery.", [["placenta", "ANATOMY", 52, 60], ["membranes", "ANATOMY", 71, 80], ["vaginal", "ANATOMY", 207, 214], ["amniotic membranes", "ANATOMY", 239, 257], ["placenta", "ORGAN", 52, 60], ["membranes", "CELLULAR_COMPONENT", 71, 80], ["patients", "ORGANISM", 181, 189], ["vaginal", "ORGANISM_SUBDIVISION", 207, 214], ["amniotic membranes", "MULTI-TISSUE_STRUCTURE", 239, 257], ["patients", "SPECIES", 181, 189], ["virus", "PROBLEM", 20, 25], ["Caesarean section", "TREATMENT", 158, 175], ["vaginal deliveries", "TREATMENT", 207, 225], ["the amniotic membranes", "TREATMENT", 235, 257], ["ruptured", "PROBLEM", 267, 275], ["delivery", "TREATMENT", 294, 302], ["virus", "OBSERVATION", 20, 25], ["particles", "OBSERVATION_MODIFIER", 31, 40], ["placenta", "ANATOMY", 52, 60], ["intact membranes", "OBSERVATION", 64, 80], ["no", "UNCERTAINTY", 200, 202], ["amniotic membranes", "ANATOMY", 239, 257], ["ruptured", "OBSERVATION", 267, 275]]], ["Virus-like particles were present in meconium passed on the first day of life in all four infants.Vaucher et al.Four of the 13 infants had no gastrointestinal symptoms or other evidence of infection.", [["meconium", "ANATOMY", 37, 45], ["gastrointestinal", "ANATOMY", 142, 158], ["infection", "DISEASE", 189, 198], ["Virus-like particles", "ORGANISM", 0, 20], ["meconium", "ORGANISM_SUBSTANCE", 37, 45], ["infants", "ORGANISM", 90, 97], ["infants", "ORGANISM", 127, 134], ["gastrointestinal", "ORGAN", 142, 158], ["infants", "SPECIES", 90, 97], ["infants", "SPECIES", 127, 134], ["Virus-like particles", "PROBLEM", 0, 20], ["gastrointestinal symptoms", "PROBLEM", 142, 167], ["infection", "PROBLEM", 189, 198], ["particles", "OBSERVATION_MODIFIER", 11, 20], ["meconium", "OBSERVATION", 37, 45], ["no", "UNCERTAINTY", 139, 141], ["gastrointestinal", "ANATOMY", 142, 158], ["symptoms", "OBSERVATION", 159, 167], ["infection", "OBSERVATION", 189, 198]]], ["Two of these infants died at <24 hr of age; their deaths were due to extreme prematurity and respiratory failure.", [["respiratory", "ANATOMY", 93, 104], ["deaths", "DISEASE", 50, 56], ["prematurity", "DISEASE", 77, 88], ["respiratory failure", "DISEASE", 93, 112], ["infants", "ORGANISM", 13, 20], ["infants", "SPECIES", 13, 20], ["extreme prematurity", "PROBLEM", 69, 88], ["respiratory failure", "PROBLEM", 93, 112], ["extreme", "OBSERVATION_MODIFIER", 69, 76], ["prematurity", "OBSERVATION", 77, 88], ["respiratory failure", "OBSERVATION", 93, 112]]], ["Six of the remaining infants developed loose stools, distention, and/or bilious aspirates, and three infants had clinical and/or hematologic (leukopenia or leukocytosis) evidence of infection with negative bacterial and viral cultures.", [["stools", "ANATOMY", 45, 51], ["bilious aspirates", "ANATOMY", 72, 89], ["loose stools", "DISEASE", 39, 51], ["leukopenia", "DISEASE", 142, 152], ["leukocytosis", "DISEASE", 156, 168], ["infection", "DISEASE", 182, 191], ["infants", "ORGANISM", 21, 28], ["infants", "ORGANISM", 101, 108], ["infants", "SPECIES", 21, 28], ["infants", "SPECIES", 101, 108], ["loose stools", "PROBLEM", 39, 51], ["distention", "PROBLEM", 53, 63], ["bilious aspirates", "PROBLEM", 72, 89], ["hematologic (leukopenia", "PROBLEM", 129, 152], ["leukocytosis", "PROBLEM", 156, 168], ["infection", "PROBLEM", 182, 191], ["negative bacterial and viral cultures", "PROBLEM", 197, 234], ["loose", "OBSERVATION_MODIFIER", 39, 44], ["stools", "OBSERVATION", 45, 51], ["distention", "OBSERVATION", 53, 63], ["bilious", "ANATOMY", 72, 79], ["aspirates", "OBSERVATION", 80, 89], ["infection", "OBSERVATION", 182, 191], ["bacterial", "OBSERVATION_MODIFIER", 206, 215]]], ["The only potential pathogen identified was an echovirus in the stool of patient no. 1.", [["stool", "ANATOMY", 63, 68], ["echovirus", "DISEASE", 46, 55], ["stool", "ORGANISM_SUBSTANCE", 63, 68], ["patient", "ORGANISM", 72, 79], ["patient", "SPECIES", 72, 79], ["potential pathogen", "PROBLEM", 9, 27], ["an echovirus", "PROBLEM", 43, 55], ["potential", "UNCERTAINTY", 9, 18], ["pathogen", "OBSERVATION", 19, 27], ["echovirus", "OBSERVATION", 46, 55], ["stool", "OBSERVATION", 63, 68]]], ["Three of the infants had hepatomegaly and/or persistent conjugated hyper bilirubinemia.DiscussionOur results suggest that the presence of virus-like particles in the stool is associated with symptoms of gastrointestinal illness in neonates.", [["stool", "ANATOMY", 166, 171], ["gastrointestinal", "ANATOMY", 203, 219], ["hepatomegaly", "DISEASE", 25, 37], ["hyper bilirubinemia", "DISEASE", 67, 86], ["gastrointestinal illness", "DISEASE", 203, 227], ["infants", "ORGANISM", 13, 20], ["stool", "ORGANISM_SUBSTANCE", 166, 171], ["gastrointestinal", "ORGANISM_SUBDIVISION", 203, 219], ["neonates", "ORGANISM", 231, 239], ["infants", "SPECIES", 13, 20], ["hepatomegaly", "PROBLEM", 25, 37], ["persistent conjugated hyper bilirubinemia", "PROBLEM", 45, 86], ["virus-like particles in the stool", "PROBLEM", 138, 171], ["symptoms", "PROBLEM", 191, 199], ["gastrointestinal illness in neonates", "PROBLEM", 203, 239], ["hepatomegaly", "OBSERVATION", 25, 37], ["persistent", "OBSERVATION_MODIFIER", 45, 55], ["conjugated", "OBSERVATION_MODIFIER", 56, 66], ["hyper bilirubinemia", "OBSERVATION", 67, 86], ["virus", "OBSERVATION", 138, 143], ["stool", "OBSERVATION", 166, 171], ["gastrointestinal", "ANATOMY", 203, 219], ["illness", "OBSERVATION", 220, 227]]], ["Infants positive for virus-like particles were more likely to have gastrointestinal symptoms, including waterloss stools containing gross or occult blood, bilious gastric aspirates, and abdominal distention.", [["gastrointestinal", "ANATOMY", 67, 83], ["gross", "ANATOMY", 132, 137], ["blood", "ANATOMY", 148, 153], ["bilious gastric aspirates", "ANATOMY", 155, 180], ["abdominal", "ANATOMY", 186, 195], ["gastrointestinal symptoms", "DISEASE", 67, 92], ["waterloss stools", "DISEASE", 104, 120], ["abdominal distention", "DISEASE", 186, 206], ["gastrointestinal", "ORGAN", 67, 83], ["blood", "ORGANISM_SUBSTANCE", 148, 153], ["gastric aspirates", "MULTI-TISSUE_STRUCTURE", 163, 180], ["abdominal", "ORGANISM_SUBDIVISION", 186, 195], ["Infants", "SPECIES", 0, 7], ["virus", "PROBLEM", 21, 26], ["like particles", "PROBLEM", 27, 41], ["gastrointestinal symptoms", "PROBLEM", 67, 92], ["waterloss stools containing gross or occult blood", "PROBLEM", 104, 153], ["bilious gastric aspirates", "PROBLEM", 155, 180], ["abdominal distention", "PROBLEM", 186, 206], ["gastrointestinal", "ANATOMY", 67, 83], ["occult blood", "OBSERVATION", 141, 153], ["gastric", "ANATOMY", 163, 170], ["aspirates", "OBSERVATION", 171, 180], ["abdominal", "ANATOMY", 186, 195], ["distention", "OBSERVATION", 196, 206]]], ["Multiple symptoms and the need to discontinue oral feeding for several days were more frequent in infants positive for virus-like particles.DiscussionThe frequency with which virus-like particles were associated with gastrointestinal symptoms would tend to be underestimated as a result of our study design, because we considered only the presence or absence of symptoms seven days before or Table 3 .", [["oral", "ANATOMY", 46, 50], ["gastrointestinal", "ANATOMY", 217, 233], ["gastrointestinal symptoms", "DISEASE", 217, 242], ["oral", "ORGANISM_SUBDIVISION", 46, 50], ["infants", "ORGANISM", 98, 105], ["gastrointestinal", "ORGAN", 217, 233], ["infants", "SPECIES", 98, 105], ["Multiple symptoms", "PROBLEM", 0, 17], ["oral feeding", "TREATMENT", 46, 58], ["virus", "PROBLEM", 119, 124], ["which virus-like particles", "PROBLEM", 169, 195], ["gastrointestinal symptoms", "PROBLEM", 217, 242], ["our study", "TEST", 290, 299], ["symptoms", "PROBLEM", 362, 370]]], ["These infants were identified by a survey of the community (September I979-May 1981) and were not involved in an outbreak of gastrointestinal illness in a neonatal intensive-care unit that is described elsewhere in the present report.", [["gastrointestinal", "ANATOMY", 125, 141], ["gastrointestinal illness", "DISEASE", 125, 149], ["infants", "ORGANISM", 6, 13], ["gastrointestinal", "ORGAN", 125, 141], ["infants", "SPECIES", 6, 13], ["gastrointestinal illness", "PROBLEM", 125, 149], ["gastrointestinal", "ANATOMY", 125, 141], ["illness", "OBSERVATION", 142, 149]]], ["Gastrointestinal symptoms included water-loss stools, blood in the stool, gastric retention, bilious gastric aspirates, and abdominal distention.", [["Gastrointestinal", "ANATOMY", 0, 16], ["stools", "ANATOMY", 46, 52], ["blood", "ANATOMY", 54, 59], ["stool", "ANATOMY", 67, 72], ["gastric", "ANATOMY", 74, 81], ["bilious gastric aspirates", "ANATOMY", 93, 118], ["abdominal", "ANATOMY", 124, 133], ["water-loss stools", "DISEASE", 35, 52], ["gastric retention", "DISEASE", 74, 91], ["abdominal distention", "DISEASE", 124, 144], ["Gastrointestinal", "ORGAN", 0, 16], ["blood", "ORGANISM_SUBSTANCE", 54, 59], ["stool", "ORGANISM_SUBSTANCE", 67, 72], ["gastric", "ORGAN", 74, 81], ["gastric aspirates", "MULTI-TISSUE_STRUCTURE", 101, 118], ["abdominal", "ORGANISM_SUBDIVISION", 124, 133], ["Gastrointestinal symptoms", "PROBLEM", 0, 25], ["water-loss stools", "PROBLEM", 35, 52], ["blood in the stool", "PROBLEM", 54, 72], ["gastric retention", "PROBLEM", 74, 91], ["bilious gastric aspirates", "PROBLEM", 93, 118], ["abdominal distention", "PROBLEM", 124, 144], ["stool", "ANATOMY", 67, 72], ["gastric", "ANATOMY", 74, 81], ["retention", "OBSERVATION", 82, 91], ["gastric", "ANATOMY", 101, 108], ["aspirates", "OBSERVATION", 109, 118], ["abdominal", "ANATOMY", 124, 133], ["distention", "OBSERVATION", 134, 144]]], ["Stool specimens were examined for pleomorphic, enveloped, virus-like particles by electron microscopy.", [["Stool specimens", "ANATOMY", 0, 15], ["Stool specimens", "CANCER", 0, 15], ["Stool specimens", "TEST", 0, 15], ["pleomorphic, enveloped, virus", "PROBLEM", 34, 63], ["electron microscopy", "TEST", 82, 101]]], ["ND = not done.Discussion* Expressed in days.Discussiont Died of unrelated causes at less than one day of age. +Patients no. 7 and no. 8 were twins. \u00a7 Tested seven days after delivery.Discussionafter the time of screening.", [["Patients", "ORGANISM", 111, 119], ["Patients", "SPECIES", 111, 119], ["ND", "PROBLEM", 0, 2], ["delivery", "TREATMENT", 174, 182], ["screening", "TEST", 211, 220]]], ["The infants studied who had such findings more than seven days before or after the screening were considered asymptomatic in the data analysis.", [["infants", "ORGANISM", 4, 11], ["infants", "SPECIES", 4, 11], ["the screening", "TEST", 79, 92], ["asymptomatic", "PROBLEM", 109, 121], ["the data analysis", "TEST", 125, 142]]], ["Because our longitu-dinal observations suggest that the duration of shedding is quite variable (less than one week to more than six weeks), infants positive for viruslike particles with symptoms more than seven days before the time of screening may have shed the particles persistently.", [["infants", "ORGANISM", 140, 147], ["infants", "SPECIES", 140, 147], ["viruslike particles", "PROBLEM", 161, 180], ["symptoms", "PROBLEM", 186, 194], ["screening", "TEST", 235, 244]]], ["Additionally, direct electron microscopy is a relatively insensitive method for the detection of viral agents, and the incidence of infected infants may have been greater than that detected by this method.DiscussionMost of the infants in our study were premature and thus required intensive care or observation.", [["infants", "ORGANISM", 141, 148], ["infants", "ORGANISM", 227, 234], ["infants", "SPECIES", 141, 148], ["infants", "SPECIES", 227, 234], ["direct electron microscopy", "TEST", 14, 40], ["viral agents", "TREATMENT", 97, 109], ["infected infants", "PROBLEM", 132, 148], ["our study", "TEST", 238, 247], ["intensive care", "TREATMENT", 281, 295], ["viral", "OBSERVATION", 97, 102], ["infected", "OBSERVATION", 132, 140], ["greater", "OBSERVATION_MODIFIER", 163, 170]]], ["Our results may reflect the increased susceptibility of the immature infant to colonization and disease associated with virus-like particles or the population bias of our sample.", [["infant", "ORGANISM", 69, 75], ["infant", "SPECIES", 69, 75], ["disease", "PROBLEM", 96, 103], ["virus-like particles", "PROBLEM", 120, 140], ["our sample", "TEST", 167, 177], ["may reflect", "UNCERTAINTY", 12, 23], ["increased", "OBSERVATION_MODIFIER", 28, 37], ["susceptibility", "OBSERVATION_MODIFIER", 38, 52], ["immature", "OBSERVATION_MODIFIER", 60, 68]]], ["Maass et al. [9] have reported a similar outbreak of gastroenteritis associated with coronavirus in the stools of 15 of 24 symptomatic premature infants, and Moscovici et al. [16] have presented evidence that suggests the association of this agent with neonatal hemorrhagic enterocolitis.", [["gastroenteritis", "DISEASE", 53, 68], ["coronavirus", "DISEASE", 85, 96], ["hemorrhagic enterocolitis", "DISEASE", 262, 287], ["infants", "ORGANISM", 145, 152], ["infants", "SPECIES", 145, 152], ["gastroenteritis", "PROBLEM", 53, 68], ["coronavirus in the stools", "PROBLEM", 85, 110], ["symptomatic premature infants", "PROBLEM", 123, 152], ["this agent", "TREATMENT", 237, 247], ["neonatal hemorrhagic enterocolitis", "PROBLEM", 253, 287], ["gastroenteritis", "OBSERVATION", 53, 68], ["coronavirus", "OBSERVATION", 85, 96], ["hemorrhagic", "OBSERVATION_MODIFIER", 262, 273], ["enterocolitis", "OBSERVATION", 274, 287]]], ["None of the infants in our study developed necrotizing enterocolitis as defined-by radiographic evidence of intestinal intramural air, although many had symptoms that are associated with the early stages of the disease.Vaucher et al.It is known that suckling mice inoculated orally with mouse hepatitis virus (a coronavirus) develop a lethal systemic illness [3] ; the virus can be detected in the intestines, liver, and brain, and necrotizing lesions are evident in the intestines, liver, lungs, and lymphoid tissues.", [["intestinal intramural air", "ANATOMY", 108, 133], ["intestines", "ANATOMY", 398, 408], ["liver", "ANATOMY", 410, 415], ["brain", "ANATOMY", 421, 426], ["necrotizing lesions", "ANATOMY", 432, 451], ["intestines", "ANATOMY", 471, 481], ["liver", "ANATOMY", 483, 488], ["lungs", "ANATOMY", 490, 495], ["lymphoid tissues", "ANATOMY", 501, 517], ["necrotizing enterocolitis", "DISEASE", 43, 68], ["mouse hepatitis virus", "DISEASE", 287, 308], ["coronavirus", "DISEASE", 312, 323], ["systemic illness", "DISEASE", 342, 358], ["necrotizing lesions", "DISEASE", 432, 451], ["infants", "ORGANISM", 12, 19], ["intestinal", "ORGAN", 108, 118], ["suckling mice", "ORGANISM", 250, 263], ["mouse hepatitis virus", "ORGANISM", 287, 308], ["coronavirus", "ORGANISM", 312, 323], ["intestines", "ORGAN", 398, 408], ["liver", "ORGAN", 410, 415], ["brain", "ORGAN", 421, 426], ["necrotizing lesions", "PATHOLOGICAL_FORMATION", 432, 451], ["intestines", "ORGAN", 471, 481], ["liver", "ORGAN", 483, 488], ["lungs", "ORGAN", 490, 495], ["lymphoid tissues", "TISSUE", 501, 517], ["infants", "SPECIES", 12, 19], ["mice", "SPECIES", 259, 263], ["mouse", "SPECIES", 287, 292], ["hepatitis virus", "SPECIES", 293, 308], ["mice", "SPECIES", 259, 263], ["mouse hepatitis virus", "SPECIES", 287, 308], ["our study", "TEST", 23, 32], ["necrotizing enterocolitis", "PROBLEM", 43, 68], ["intestinal intramural air", "PROBLEM", 108, 133], ["symptoms", "PROBLEM", 153, 161], ["the disease", "PROBLEM", 207, 218], ["mouse hepatitis virus", "PROBLEM", 287, 308], ["a coronavirus)", "PROBLEM", 310, 324], ["a lethal systemic illness", "PROBLEM", 333, 358], ["the virus", "PROBLEM", 365, 374], ["necrotizing lesions", "PROBLEM", 432, 451], ["necrotizing", "OBSERVATION_MODIFIER", 43, 54], ["enterocolitis", "OBSERVATION", 55, 68], ["intestinal", "ANATOMY", 108, 118], ["intramural", "ANATOMY_MODIFIER", 119, 129], ["air", "OBSERVATION", 130, 133], ["disease", "OBSERVATION", 211, 218], ["intestines", "ANATOMY", 398, 408], ["liver", "ANATOMY", 410, 415], ["brain", "ANATOMY", 421, 426], ["necrotizing", "OBSERVATION_MODIFIER", 432, 443], ["lesions", "OBSERVATION", 444, 451], ["intestines", "ANATOMY", 471, 481], ["liver", "ANATOMY", 483, 488], ["lungs", "ANATOMY", 490, 495], ["lymphoid tissues", "OBSERVATION", 501, 517]]], ["In comparison, seven of our infants positive for virus-like particles (four from the initial survey and three from the motherinfant pairs) appeared to be septic, both clinically and hematologically.", [["septic", "DISEASE", 154, 160], ["infants", "ORGANISM", 28, 35], ["infants", "SPECIES", 28, 35], ["virus", "PROBLEM", 49, 54], ["like particles", "PROBLEM", 55, 69], ["septic", "PROBLEM", 154, 160], ["septic", "OBSERVATION", 154, 160]]], ["In each case bacterial cultures were negative as were viral cultures obtained in six of the seven infants.", [["cultures", "ANATOMY", 23, 31], ["infants", "ORGANISM", 98, 105], ["infants", "SPECIES", 98, 105], ["bacterial cultures", "TEST", 13, 31], ["viral cultures", "TEST", 54, 68]]], ["Their symptoms may have reflected a systemic infection due to the virus-like particles; however, the recovery of the particles from involved organs is necessary to establish this relationship.", [["organs", "ANATOMY", 141, 147], ["infection", "DISEASE", 45, 54], ["organs", "ORGAN", 141, 147], ["Their symptoms", "PROBLEM", 0, 14], ["a systemic infection", "PROBLEM", 34, 54], ["the virus-like particles", "PROBLEM", 62, 86], ["systemic", "OBSERVATION_MODIFIER", 36, 44], ["infection", "OBSERVATION", 45, 54]]], ["Although we are unable to link the symptoms directly with a definite viruslike particle etiology, the temporal relationship is suggestive.Vaucher et al.We have also demonstrated a changing incidence of infants positive for virus-like particles in the NICU over a lO-month observation period.", [["infants", "ORGANISM", 202, 209], ["infants", "SPECIES", 202, 209], ["the symptoms", "PROBLEM", 31, 43], ["virus", "PROBLEM", 223, 228], ["temporal", "ANATOMY_MODIFIER", 102, 110]]], ["Variation in the fringe morphology of two pleomorphic, enveloped, virus-like particles observed by electron microscopy in the stool of an infant with gastrointestinal illness (negative contrast, phosphotungstic acid).", [["stool", "ANATOMY", 126, 131], ["gastrointestinal", "ANATOMY", 150, 166], ["gastrointestinal illness", "DISEASE", 150, 174], ["phosphotungstic acid", "CHEMICAL", 195, 215], ["phosphotungstic acid", "CHEMICAL", 195, 215], ["gastrointestinal", "ORGAN", 150, 166], ["phosphotungstic acid", "SIMPLE_CHEMICAL", 195, 215], ["infant", "SPECIES", 138, 144], ["two pleomorphic, enveloped, virus-like particles", "PROBLEM", 38, 86], ["electron microscopy", "TEST", 99, 118], ["gastrointestinal illness", "PROBLEM", 150, 174], ["pleomorphic", "OBSERVATION_MODIFIER", 42, 53], ["stool", "ANATOMY", 126, 131], ["gastrointestinal", "ANATOMY", 150, 166]]], ["The stool sample was obtained from an infant in a neonatal intensive-care unit after the observation period described elsewhere in the present study.", [["stool sample", "ANATOMY", 4, 16], ["stool", "ORGANISM_SUBSTANCE", 4, 9], ["infant", "SPECIES", 38, 44], ["The stool sample", "TEST", 0, 16], ["the present study", "TEST", 131, 148], ["stool", "OBSERVATION", 4, 9]]], ["The virus-like particle at the left shows a more typical coronavirus-like appearance with numerous characteristic knob-like and bulbous projections.", [["left", "ANATOMY", 31, 35], ["bulbous projections", "PATHOLOGICAL_FORMATION", 128, 147], ["The virus-like particle", "TEST", 0, 23], ["a more typical coronavirus-like appearance", "PROBLEM", 42, 84], ["numerous characteristic knob-like and bulbous projections", "PROBLEM", 90, 147], ["virus", "OBSERVATION", 4, 9], ["particle", "OBSERVATION_MODIFIER", 15, 23], ["left", "ANATOMY_MODIFIER", 31, 35], ["more typical", "OBSERVATION_MODIFIER", 44, 56], ["coronavirus", "OBSERVATION", 57, 68], ["numerous", "OBSERVATION_MODIFIER", 90, 98], ["characteristic knob", "OBSERVATION", 99, 118], ["bulbous", "OBSERVATION_MODIFIER", 128, 135]]], ["The virus-like particle on the right shows a less distinct fringe with more widely spaced filaments that have less prominent knobs (arrows) at their distal ends. high incidence was initially associated with an unusual clustering of infants with severe gastrointestinal disease and occurred at a time when gastroenteritis associated with virus-like particles was also commonly seen in the outside community.", [["filaments", "ANATOMY", 90, 99], ["knobs", "ANATOMY", 125, 130], ["gastrointestinal", "ANATOMY", 252, 268], ["gastrointestinal disease", "DISEASE", 252, 276], ["gastroenteritis", "DISEASE", 305, 320], ["filaments", "CELLULAR_COMPONENT", 90, 99], ["infants", "ORGANISM", 232, 239], ["gastrointestinal", "ORGAN", 252, 268], ["infants", "SPECIES", 232, 239], ["The virus", "TEST", 0, 9], ["a less distinct fringe", "PROBLEM", 43, 65], ["more widely spaced filaments", "PROBLEM", 71, 99], ["severe gastrointestinal disease", "PROBLEM", 245, 276], ["gastroenteritis", "PROBLEM", 305, 320], ["virus-like particles", "PROBLEM", 337, 357], ["virus", "OBSERVATION", 4, 9], ["particle", "OBSERVATION_MODIFIER", 15, 23], ["right", "ANATOMY_MODIFIER", 31, 36], ["less distinct", "OBSERVATION_MODIFIER", 45, 58], ["fringe", "OBSERVATION_MODIFIER", 59, 65], ["more", "OBSERVATION_MODIFIER", 71, 75], ["widely", "OBSERVATION_MODIFIER", 76, 82], ["spaced", "OBSERVATION_MODIFIER", 83, 89], ["filaments", "OBSERVATION_MODIFIER", 90, 99], ["less", "OBSERVATION_MODIFIER", 110, 114], ["prominent", "OBSERVATION_MODIFIER", 115, 124], ["knobs", "OBSERVATION_MODIFIER", 125, 130], ["distal", "ANATOMY_MODIFIER", 149, 155], ["ends", "ANATOMY_MODIFIER", 156, 160], ["severe", "OBSERVATION_MODIFIER", 245, 251], ["gastrointestinal", "ANATOMY", 252, 268], ["disease", "OBSERVATION", 269, 276], ["virus", "OBSERVATION", 337, 342]]], ["The incidence of virus-like particles decreased in the nursery in parallel with the decreased detection of virus-like particles associated with gastroenteritis in the community (authors' unpublished observations).Vaucher et al.The present study did not establish the source of the colonization of virus-like particles.", [["gastroenteritis", "DISEASE", 144, 159], ["virus-like particles", "PROBLEM", 17, 37], ["virus-like particles", "PROBLEM", 107, 127], ["gastroenteritis", "PROBLEM", 144, 159], ["The present study", "TEST", 227, 244], ["the colonization of virus-like particles", "PROBLEM", 277, 317], ["virus", "OBSERVATION", 17, 22], ["particles", "OBSERVATION_MODIFIER", 28, 37], ["decreased", "OBSERVATION_MODIFIER", 38, 47], ["decreased", "OBSERVATION", 84, 93], ["virus", "OBSERVATION", 107, 112], ["like particles", "OBSERVATION_MODIFIER", 113, 127], ["gastroenteritis", "OBSERVATION", 144, 159], ["colonization", "OBSERVATION", 281, 293], ["virus", "OBSERVATION", 297, 302]]], ["However, our observations that the incidence of virus-like particles corresponded to the presence of gastroenteritis associated with virus-like particles in the community, that many infants were positive within the first 72 hr of life, and that the mothers of several of the infants had gastrointestinal symptoms shortly before delivery suggest that colonization or infection may be acquired from the mother before or during delivery.Vaucher et al.There has been much controversy over the nature of virus-like particles such as those we observed during this outbreak.", [["gastrointestinal", "ANATOMY", 287, 303], ["gastroenteritis", "DISEASE", 101, 116], ["gastrointestinal symptoms", "DISEASE", 287, 312], ["infection", "DISEASE", 366, 375], ["virus-like particles", "ORGANISM", 48, 68], ["infants", "ORGANISM", 182, 189], ["mothers", "ORGANISM", 249, 256], ["infants", "ORGANISM", 275, 282], ["gastrointestinal", "ORGAN", 287, 303], ["infants", "SPECIES", 182, 189], ["infants", "SPECIES", 275, 282], ["virus-like particles", "PROBLEM", 48, 68], ["gastroenteritis", "PROBLEM", 101, 116], ["virus", "PROBLEM", 133, 138], ["gastrointestinal symptoms", "PROBLEM", 287, 312], ["delivery", "TREATMENT", 328, 336], ["colonization", "PROBLEM", 350, 362], ["infection", "PROBLEM", 366, 375], ["delivery", "TREATMENT", 425, 433], ["virus", "PROBLEM", 499, 504], ["virus", "OBSERVATION", 48, 53], ["gastroenteritis", "OBSERVATION", 101, 116], ["virus", "OBSERVATION", 133, 138], ["colonization", "OBSERVATION", 350, 362], ["infection", "OBSERVATION", 366, 375], ["virus", "OBSERVATION", 499, 504]]], ["Because most of these particles have club-shaped or bulbous instead of the knob-like projections that are characteristic of coronaviruses [17] , they have been referred to as myxovirus-like [18] .", [["knob", "PROTEIN", 75, 79], ["coronaviruses", "PROBLEM", 124, 137], ["shaped", "OBSERVATION_MODIFIER", 42, 48], ["bulbous", "OBSERVATION_MODIFIER", 52, 59], ["knob", "OBSERVATION_MODIFIER", 75, 79], ["coronaviruses", "OBSERVATION", 124, 137]]], ["Dourmashkin et al. [19] even suggest that the \"coronavirus-like\" particles may represent a yeast-like organism such as Blastocystis.", [["coronavirus", "ORGANISM", 47, 58], ["yeast", "SPECIES", 91, 96], ["yeast", "SPECIES", 91, 96], ["the \"coronavirus-like\" particles", "PROBLEM", 42, 74], ["a yeast-like organism", "PROBLEM", 89, 110], ["Blastocystis", "PROBLEM", 119, 131], ["coronavirus", "OBSERVATION", 47, 58], ["may represent", "UNCERTAINTY", 75, 88], ["yeast", "OBSERVATION", 91, 96], ["Blastocystis", "OBSERVATION", 119, 131]]], ["Most authors agree, however, that the particles represent viruses and that they are more coronavirus-like than myxovirus-like.", [["coronavirus", "ORGANISM", 89, 100], ["viruses", "PROBLEM", 58, 65], ["coronavirus", "PROBLEM", 89, 100], ["myxovirus", "TREATMENT", 111, 120], ["viruses", "OBSERVATION", 58, 65]]], ["The myxoviruses have a narrower, more compact fringe with rigid spikes that tend to be sharp or pointed.", [["rigid spikes", "PROBLEM", 58, 70], ["narrower", "OBSERVATION_MODIFIER", 23, 31], ["rigid spikes", "OBSERVATION", 58, 70]]], ["The variation in surface projections has already been described for the avian infectious bronchitis virus [20, 21] .", [["surface", "ANATOMY", 17, 24], ["infectious bronchitis virus", "DISEASE", 78, 105], ["surface", "CELLULAR_COMPONENT", 17, 24], ["avian infectious bronchitis virus", "ORGANISM", 72, 105], ["avian infectious bronchitis virus", "SPECIES", 72, 105], ["infectious bronchitis virus", "SPECIES", 78, 105], ["The variation in surface projections", "TREATMENT", 0, 36], ["the avian infectious bronchitis virus", "PROBLEM", 68, 105], ["variation", "OBSERVATION_MODIFIER", 4, 13], ["surface", "OBSERVATION_MODIFIER", 17, 24], ["infectious", "OBSERVATION_MODIFIER", 78, 88], ["bronchitis", "OBSERVATION", 89, 99]]], ["In view of this documented evidence of variation, Caul et al. [22] believed that the important criterion for the identification of human enteric coronaviruses in clinical material is the length of the projections in conjunction with their radiating appearance rather than their shape.", [["enteric coronaviruses", "DISEASE", 137, 158], ["human", "ORGANISM", 131, 136], ["enteric coronaviruses", "ORGANISM", 137, 158], ["human", "SPECIES", 131, 136], ["human", "SPECIES", 131, 136], ["human enteric coronaviruses", "PROBLEM", 131, 158], ["coronaviruses", "OBSERVATION", 145, 158]]], ["Nonspecific cell membranes and inner mitochondrial membranes present in fecal material tend to have shorter surface projections and are not usually present in large numbers.", [["cell membranes", "ANATOMY", 12, 26], ["inner mitochondrial membranes", "ANATOMY", 31, 60], ["fecal material", "ANATOMY", 72, 86], ["surface", "ANATOMY", 108, 115], ["cell membranes", "CELLULAR_COMPONENT", 12, 26], ["inner mitochondrial membranes", "CELLULAR_COMPONENT", 31, 60], ["fecal material", "CELLULAR_COMPONENT", 72, 86], ["Nonspecific cell membranes", "PROBLEM", 0, 26], ["inner mitochondrial membranes", "PROBLEM", 31, 60], ["fecal material", "PROBLEM", 72, 86], ["cell membranes", "OBSERVATION", 12, 26], ["inner", "ANATOMY_MODIFIER", 31, 36], ["mitochondrial membranes", "OBSERVATION", 37, 60], ["fecal material", "OBSERVATION", 72, 86], ["not usually", "UNCERTAINTY", 136, 147], ["large", "OBSERVATION_MODIFIER", 159, 164], ["numbers", "OBSERVATION_MODIFIER", 165, 172]]], ["Therefore, the possession of classic petal-shaped projections must no longer be considered a prerequisite for coronavirus identification [7, 23] .", [["coronavirus", "ORGANISM", 110, 121], ["coronavirus identification", "TEST", 110, 136], ["no longer", "UNCERTAINTY", 67, 76]]], ["We think that these pleomorphic particles are somehow related to the cor-35 onaviruses because we have consistently observed them in large numbers in stools containing the more classic coronaviruses (figure 5).", [["pleomorphic particles", "ANATOMY", 20, 41], ["pleomorphic particles", "CANCER", 20, 41], ["coronaviruses", "ORGANISM", 185, 198], ["these pleomorphic particles", "PROBLEM", 14, 41], ["the cor-35 onaviruses", "PROBLEM", 65, 86], ["large numbers in stools", "PROBLEM", 133, 156], ["pleomorphic", "OBSERVATION_MODIFIER", 20, 31], ["particles", "OBSERVATION", 32, 41], ["large", "OBSERVATION_MODIFIER", 133, 138], ["numbers", "OBSERVATION_MODIFIER", 139, 146], ["stools", "OBSERVATION", 150, 156]]], ["Naqi et al. [24] , in a study of transmissible (coronaviral) enteritis of turkeys, show an electron micrograph similar to figure 5.", [["enteritis", "DISEASE", 61, 70], ["turkeys", "ORGANISM", 74, 81], ["turkeys", "SPECIES", 74, 81], ["a study", "TEST", 22, 29], ["transmissible (coronaviral) enteritis of turkeys", "PROBLEM", 33, 81], ["an electron micrograph", "TEST", 88, 110], ["enteritis", "OBSERVATION", 61, 70]]], ["Whether this variation reflects different morphologic stages in coronavirus development, an effect of intestine-associated enzymes or antibodies on fringe morphology, or strain variations remains to be determined.", [["intestine", "ANATOMY", 102, 111], ["coronavirus", "DISEASE", 64, 75], ["coronavirus", "ORGANISM", 64, 75], ["intestine", "ORGAN", 102, 111], ["intestine-associated enzymes", "PROTEIN", 102, 130], ["antibodies", "PROTEIN", 134, 144], ["coronavirus", "SPECIES", 64, 75], ["different morphologic stages", "PROBLEM", 32, 60], ["coronavirus development", "PROBLEM", 64, 87], ["intestine-associated enzymes", "PROBLEM", 102, 130], ["antibodies on fringe morphology", "PROBLEM", 134, 165], ["strain variations", "PROBLEM", 170, 187], ["different morphologic", "OBSERVATION_MODIFIER", 32, 53], ["stages", "OBSERVATION_MODIFIER", 54, 60], ["coronavirus development", "OBSERVATION", 64, 87], ["intestine", "ANATOMY", 102, 111]]], ["Our immune electron microscopic studies show definite clumping of envelopes without readily identifiable fringes next to the definite fringed particles.", [["Our immune electron microscopic studies", "TEST", 0, 39], ["definite clumping of envelopes", "PROBLEM", 45, 75], ["readily identifiable fringes", "PROBLEM", 84, 112], ["definite", "UNCERTAINTY", 45, 53], ["clumping", "OBSERVATION", 54, 62], ["particles", "OBSERVATION", 142, 151]]], ["This result may be an indication of the presence of envelope-associated viral antigens and might explain some of the variation in fringe morphology seen in the direct examination of stool specimens.", [["stool specimens", "ANATOMY", 182, 197], ["stool specimens", "ORGANISM_SUBSTANCE", 182, 197], ["envelope-associated viral antigens", "PROTEIN", 52, 86], ["envelope-associated viral antigens", "PROBLEM", 52, 86], ["the variation in fringe morphology", "PROBLEM", 113, 147], ["the direct examination", "TEST", 156, 178], ["stool specimens", "TEST", 182, 197], ["viral", "OBSERVATION", 72, 77]]]], "bb4df91230a99d430331add3f689d2af441b83a1": [["IntroductionThe syndrome, called severe acute respiratory syndrome (SARS), infected more than 8000 people early in 2003, and killed more than 770 (http://www.nature.com/nsu/031215 /031215-9.html).", [["acute respiratory syndrome", "DISEASE", 40, 66], ["SARS", "DISEASE", 68, 72], ["people", "SPECIES", 99, 105], ["The syndrome", "PROBLEM", 12, 24], ["severe acute respiratory syndrome", "PROBLEM", 33, 66], ["SARS", "PROBLEM", 68, 72], ["syndrome", "OBSERVATION", 16, 24], ["severe", "OBSERVATION_MODIFIER", 33, 39], ["acute", "OBSERVATION_MODIFIER", 40, 45], ["respiratory syndrome", "OBSERVATION", 46, 66]]], ["The genome of SARS-CoV was sequenced by several independent groups.", [["SARS-CoV", "ORGANISM", 14, 22], ["SARS-CoV", "SPECIES", 14, 22], ["SARS-CoV", "PROBLEM", 14, 22]]], ["That the SARS genome from Singapore, Canada, Hongkong, Guangzhou and Beijing in China has remained unchanged, as the infection has spread (http://www.nature.com/nsu/030505/030505-10.html) suggests that genetic vaccine maybe an efficient approach to protect from SARS-CoV infection.IntroductionThe SARS-CoV genome contains five major open reading frames (ORFs) that encode the replicase polyprotein; the spike (S), envelope (E), and M glycoproteins; and the N protein in the same order and of approximately the same size as those of other coronaviruses (Kathryn and Luis, 2003) .", [["SARS", "DISEASE", 9, 13], ["infection", "DISEASE", 117, 126], ["SARS-CoV infection", "DISEASE", 262, 280], ["SARS-CoV", "ORGANISM", 262, 270], ["SARS-CoV", "ORGANISM", 297, 305], ["spike (S)", "GENE_OR_GENE_PRODUCT", 403, 412], ["envelope (E)", "GENE_OR_GENE_PRODUCT", 414, 426], ["M glycoproteins", "GENE_OR_GENE_PRODUCT", 432, 447], ["coronaviruses", "ORGANISM", 538, 551], ["SARS genome", "DNA", 9, 20], ["SARS-CoV genome", "DNA", 297, 312], ["open reading frames", "DNA", 333, 352], ["ORFs", "DNA", 354, 358], ["replicase polyprotein", "DNA", 376, 397], ["spike (S), envelope (E), and M glycoproteins", "PROTEIN", 403, 447], ["N protein", "PROTEIN", 457, 466], ["SARS-CoV", "SPECIES", 262, 270], ["SARS-CoV", "SPECIES", 297, 305], ["the infection", "PROBLEM", 113, 126], ["genetic vaccine", "TREATMENT", 202, 217], ["an efficient approach", "TREATMENT", 224, 245], ["SARS", "PROBLEM", 262, 266], ["CoV infection", "PROBLEM", 267, 280], ["The SARS-CoV genome", "PROBLEM", 293, 312], ["the replicase polyprotein", "PROBLEM", 372, 397], ["the N protein", "TREATMENT", 453, 466], ["SARS genome", "OBSERVATION", 9, 20], ["unchanged", "OBSERVATION_MODIFIER", 99, 108], ["infection", "OBSERVATION", 117, 126], ["CoV", "OBSERVATION_MODIFIER", 267, 270], ["infection", "OBSERVATION", 271, 280]]], ["The M gene encodes a protein of 221 amino acids.", [["amino acids", "CHEMICAL", 36, 47], ["amino acids", "CHEMICAL", 36, 47], ["amino acids", "AMINO_ACID", 36, 47], ["M gene", "DNA", 4, 10], ["a protein", "TEST", 19, 28], ["amino acids", "TREATMENT", 36, 47]]], ["Analysis of the M protein revealed that a 121 amino acid hydrophilic domain on the inside of the virus particle is believed to interact with the N protein (Qin et al., 2003) .", [["amino acid", "CHEMICAL", 46, 56], ["amino acid", "CHEMICAL", 46, 56], ["amino acid", "AMINO_ACID", 46, 56], ["M protein", "PROTEIN", 16, 25], ["121 amino acid hydrophilic domain", "PROTEIN", 42, 75], ["N protein", "PROTEIN", 145, 154], ["the M protein", "TEST", 12, 25], ["a 121 amino acid hydrophilic domain", "PROBLEM", 40, 75], ["virus particle", "OBSERVATION", 97, 111]]], ["It is further reported that there exists an interaction between SARS-CoV N and M protein and the stretch of amino acids in the N protein may be critical for such protein-protein interactions (He et al., 2004) .", [["amino acids", "CHEMICAL", 108, 119], ["amino acids", "CHEMICAL", 108, 119], ["M protein", "GENE_OR_GENE_PRODUCT", 79, 88], ["amino acids", "AMINO_ACID", 108, 119], ["SARS-CoV N and M protein", "PROTEIN", 64, 88], ["N protein", "PROTEIN", 127, 136], ["SARS-CoV N and M protein", "TREATMENT", 64, 88], ["the stretch of amino acids", "TREATMENT", 93, 119], ["such protein-protein interactions", "PROBLEM", 157, 190]]], ["Whether the interaction plays role in immune responses induced by SARS-CoV infection is not clear.IntroductionThe complete N protein contains 422 amino acids.", [["SARS-CoV infection", "DISEASE", 66, 84], ["amino acids", "CHEMICAL", 146, 157], ["amino acids", "CHEMICAL", 146, 157], ["SARS-CoV", "ORGANISM", 66, 74], ["amino acids", "AMINO_ACID", 146, 157], ["N protein", "PROTEIN", 123, 132], ["SARS-CoV", "SPECIES", 66, 74], ["SARS", "PROBLEM", 66, 70], ["CoV infection", "PROBLEM", 71, 84], ["amino acids", "TREATMENT", 146, 157], ["infection", "OBSERVATION", 75, 84]]], ["It is possible that N protein plays a critical role in SARS-CoV pathogenesis.", [["SARS", "DISEASE", 55, 59], ["SARS-CoV", "ORGANISM", 55, 63], ["N protein", "PROTEIN", 20, 29], ["SARS-CoV", "SPECIES", 55, 63], ["N protein", "PROBLEM", 20, 29], ["SARS", "PROBLEM", 55, 59], ["CoV pathogenesis", "PROBLEM", 60, 76]]], ["In previous study, N protein is a representative antigen for the T-cell response in vaccine setting (Gao et al., 2003) , and the mice vaccinated with calreticulin (CRT)/N DNA were capable of significantly reducing the titer of challenging vaccinia virus expressing the N protein of SARS virus (Kim et al., 2004) .", [["T-cell", "ANATOMY", 65, 71], ["SARS", "DISEASE", 282, 286], ["T-cell", "CELL", 65, 71], ["mice", "ORGANISM", 129, 133], ["calreticulin", "GENE_OR_GENE_PRODUCT", 150, 162], ["DNA", "CELLULAR_COMPONENT", 171, 174], ["vaccinia virus", "ORGANISM", 239, 253], ["SARS virus", "ORGANISM", 282, 292], ["N protein", "PROTEIN", 19, 28], ["calreticulin", "PROTEIN", 150, 162], ["CRT", "PROTEIN", 164, 167], ["N protein", "PROTEIN", 269, 278], ["mice", "SPECIES", 129, 133], ["mice", "SPECIES", 129, 133], ["vaccinia virus", "SPECIES", 239, 253], ["SARS virus", "SPECIES", 282, 292], ["previous study", "TEST", 3, 17], ["N protein", "TEST", 19, 28], ["calreticulin (CRT", "TREATMENT", 150, 167], ["N DNA", "PROBLEM", 169, 174], ["challenging vaccinia virus", "PROBLEM", 227, 253], ["SARS virus", "PROBLEM", 282, 292]]], ["It has been reported that N DNA vaccine could induce SARS-specific T-cell proliferation and cytotoxic T cells activity, further experiments demonstrate that SARS-N administration could induce virus-specific cellular responses in human cells using SCID-PBL/hu mouse model (Jin et al., 2005; Okada et al., 2005) .", [["T-cell", "ANATOMY", 67, 73], ["cytotoxic T cells", "ANATOMY", 92, 109], ["cellular", "ANATOMY", 207, 215], ["cells", "ANATOMY", 235, 240], ["SARS", "DISEASE", 53, 57], ["SARS-N", "CHEMICAL", 157, 163], ["DNA", "CELLULAR_COMPONENT", 28, 31], ["T-cell", "CELL", 67, 73], ["cytotoxic T cells", "CELL", 92, 109], ["SARS-N", "SIMPLE_CHEMICAL", 157, 163], ["cellular", "CELL", 207, 215], ["human", "ORGANISM", 229, 234], ["cells", "CELL", 235, 240], ["SCID-PBL", "CELL", 247, 255], ["hu mouse", "ORGANISM", 256, 264], ["cytotoxic T cells", "CELL_TYPE", 92, 109], ["human cells", "CELL_TYPE", 229, 240], ["PBL", "CELL_TYPE", 252, 255], ["human", "SPECIES", 229, 234], ["mouse", "SPECIES", 259, 264], ["human", "SPECIES", 229, 234], ["mouse", "SPECIES", 259, 264], ["N DNA vaccine", "TREATMENT", 26, 39], ["SARS", "PROBLEM", 53, 57], ["specific T-cell proliferation", "PROBLEM", 58, 87], ["cytotoxic T cells activity", "PROBLEM", 92, 118], ["further experiments", "TEST", 120, 139], ["SARS-N administration", "TREATMENT", 157, 178], ["virus", "PROBLEM", 192, 197], ["SCID", "TEST", 247, 251], ["cell proliferation", "OBSERVATION", 69, 87], ["hu", "ANATOMY", 256, 258]]], ["Although more than 90% of sera obtained from convalescent SARS patients have antibodies against N (Tan et al., 2004) , N antigen did not induce a detectable serum SARS-CoV-neutralizing antibody response in mice (Buchholz et al., 2004) .IntroductionTaken these into account, we inserted the full M and N gene into pVAX1 and inoculated mice and Brandt's vole (Microtus brandti raddes) with M or N DNA alone or together to investigate the immune responses induced by these DNA immunizations.", [["sera", "ANATOMY", 26, 30], ["serum", "ANATOMY", 157, 162], ["SARS", "DISEASE", 58, 62], ["sera", "ORGANISM_SUBSTANCE", 26, 30], ["patients", "ORGANISM", 63, 71], ["N antigen", "GENE_OR_GENE_PRODUCT", 119, 128], ["serum", "ORGANISM_SUBSTANCE", 157, 162], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 163, 171], ["mice", "ORGANISM", 206, 210], ["pVAX1", "GENE_OR_GENE_PRODUCT", 313, 318], ["mice", "ORGANISM", 334, 338], ["Brandt's vole", "ORGANISM", 343, 356], ["Microtus brandti raddes", "ORGANISM", 358, 381], ["DNA", "CELLULAR_COMPONENT", 395, 398], ["DNA", "CELLULAR_COMPONENT", 470, 473], ["antibodies", "PROTEIN", 77, 87], ["N antigen", "PROTEIN", 119, 128], ["M and N gene", "DNA", 295, 307], ["pVAX1", "DNA", 313, 318], ["patients", "SPECIES", 63, 71], ["mice", "SPECIES", 206, 210], ["mice", "SPECIES", 334, 338], ["Microtus brandti", "SPECIES", 358, 374], ["mice", "SPECIES", 206, 210], ["mice", "SPECIES", 334, 338], ["Brandt's vole", "SPECIES", 343, 356], ["Microtus brandti", "SPECIES", 358, 374], ["sera", "TEST", 26, 30], ["convalescent SARS", "PROBLEM", 45, 62], ["antibodies", "TEST", 77, 87], ["Tan et al.", "TEST", 99, 109], ["N antigen", "TEST", 119, 128], ["a detectable serum SARS", "PROBLEM", 144, 167], ["CoV", "TEST", 168, 171], ["neutralizing antibody response", "TEST", 172, 202], ["the full M and N gene into pVAX1", "TREATMENT", 286, 318], ["Brandt's vole", "TREATMENT", 343, 356], ["these DNA immunizations", "TREATMENT", 464, 487]]], ["And in previous study, we have developed a SARS-CoV infection animal model with Brandt's vole (Gao et al., 2005) , so we selected this animal for challenge test to assess the capacity of M plus N DNA immunization.MiceThe female Balb/c mice were purchased from the Institute of Genetics, Chinese Academy of Sciences.", [["SARS-CoV infection", "DISEASE", 43, 61], ["DNA", "CELLULAR_COMPONENT", 196, 199], ["Mice", "ORGANISM", 213, 217], ["Balb/c mice", "ORGANISM", 228, 239], ["Mice", "SPECIES", 213, 217], ["mice", "SPECIES", 235, 239], ["SARS-CoV", "SPECIES", 43, 51], ["mice", "SPECIES", 235, 239], ["previous study", "TEST", 7, 21], ["a SARS", "PROBLEM", 41, 47], ["CoV infection", "PROBLEM", 48, 61], ["challenge test", "TEST", 146, 160], ["M plus N DNA immunization", "TREATMENT", 187, 212], ["CoV", "OBSERVATION_MODIFIER", 48, 51], ["infection", "OBSERVATION", 52, 61]]], ["The M. brandti raddes were obtained from Dr. Wang De-Hua (Institute of Zoology, Chinese Academy of Sciences).", [["M. brandti", "SPECIES", 4, 14], ["M. brandti", "SPECIES", 4, 14], ["Hua", "ANATOMY", 53, 56]]], ["Mice were kept under controlled conditions of light and temperature, with free access to a standard mouse chow and water.", [["Mice", "ORGANISM", 0, 4], ["mouse", "ORGANISM", 100, 105], ["chow", "ORGANISM_SUBDIVISION", 106, 110], ["Mice", "SPECIES", 0, 4], ["mouse", "SPECIES", 100, 105], ["mouse", "SPECIES", 100, 105], ["a standard mouse chow", "TREATMENT", 89, 110]]], ["All experiments were conducted according to the guidelines of the Beijing Animal Care for Laboratory Animals, and the protocols were approved by the Animal Care and Use Committee at the Institute of Zoology, Chinese Academy of Sciences.Plasmid constructionThe pcDNA3.1-M, N plasmid containing full-length SARS-CoV M and N cDNA were kindly provided by Professor Yang Huan-Ming (Institute of Genome, Chinese Academy of Sciences).", [["pcDNA3", "GENE_OR_GENE_PRODUCT", 260, 266], ["N plasmid", "DNA", 272, 281], ["full-length SARS-CoV M", "DNA", 293, 315], ["N cDNA", "DNA", 320, 326], ["Plasmid construction", "TREATMENT", 236, 256], ["The pcDNA3", "TREATMENT", 256, 266], ["N plasmid", "TREATMENT", 272, 281]]], ["The full-length M and N gene were cut with BamHI and Xba I, and ligated into the corresponding restriction sites of pVAX1 vector (Invitrogen, Carlsbad, CA) to create pVAX1-M and pVAX1-N.", [["BamHI", "GENE_OR_GENE_PRODUCT", 43, 48], ["Xba I", "GENE_OR_GENE_PRODUCT", 53, 58], ["pVAX1", "GENE_OR_GENE_PRODUCT", 116, 121], ["CA", "GENE_OR_GENE_PRODUCT", 152, 154], ["pVAX1-M", "GENE_OR_GENE_PRODUCT", 166, 173], ["pVAX1-N.", "GENE_OR_GENE_PRODUCT", 178, 186], ["full-length M and N gene", "DNA", 4, 28], ["BamHI", "DNA", 43, 48], ["Xba I", "DNA", 53, 58], ["restriction sites", "DNA", 95, 112], ["pVAX1 vector", "DNA", 116, 128], ["pVAX1", "DNA", 166, 171], ["pVAX1", "DNA", 178, 183], ["The full-length M and N gene", "TREATMENT", 0, 28], ["BamHI and Xba I", "TREATMENT", 43, 58], ["pVAX1 vector", "TREATMENT", 116, 128]]], ["The pair of primers: 1#, 5 -GGACATATGTCTGATAATGGACC-3 and 2#, 5 -GATGGATCCGCCTGAGTTGAA-3 containing NdeI and BamHI enzyme sites at the 5 and 3 were used to amplify the N complete gene.", [["GGACATATGTCTGATAATGGACC-3", "GENE_OR_GENE_PRODUCT", 28, 53], ["GATGGATCCGCCTGAGTTGAA-3", "GENE_OR_GENE_PRODUCT", 65, 88], ["NdeI", "GENE_OR_GENE_PRODUCT", 100, 104], ["BamHI", "GENE_OR_GENE_PRODUCT", 109, 114], ["GATGGATCCGCCTGAGTTGAA-3", "DNA", 65, 88], ["NdeI and BamHI enzyme sites", "DNA", 100, 127], ["5 and 3", "DNA", 135, 142], ["N complete gene", "DNA", 168, 183], ["GGACATATGTCTGATAATGGACC", "TEST", 28, 51], ["NdeI", "TREATMENT", 100, 104], ["BamHI enzyme sites", "TREATMENT", 109, 127]]], ["The fragment digested by NdeI and BamHI was inserted into pET21b (Novagen, Madison, WI, USA) that had been cut with the same enzymes.", [["NdeI", "GENE_OR_GENE_PRODUCT", 25, 29], ["BamHI", "GENE_OR_GENE_PRODUCT", 34, 39], ["pET21b", "GENE_OR_GENE_PRODUCT", 58, 64], ["Novagen", "GENE_OR_GENE_PRODUCT", 66, 73], ["NdeI and BamHI", "DNA", 25, 39], ["pET21b", "DNA", 58, 64], ["enzymes", "PROTEIN", 125, 132], ["The fragment", "PROBLEM", 0, 12], ["BamHI", "TREATMENT", 34, 39], ["the same enzymes", "TEST", 116, 132], ["fragment", "OBSERVATION_MODIFIER", 4, 12]]], ["The three recombinants were confirmed by restriction digestion and sequencing.Immunization and in vivo expressionBalb/c mice (n = 36) were divided into two control and four experimental groups.", [["expressionBalb/c mice", "ORGANISM", 103, 124], ["mice", "SPECIES", 120, 124], ["mice", "SPECIES", 120, 124], ["Immunization", "TREATMENT", 78, 90]]], ["The voles (n = 16) were divided into one control and three experimental groups.", [["The voles", "TEST", 0, 9]]], ["The mice of one experimental group were injected with 20 g pVAX1-N plus 20 g pVAX1 in the leg muscle by three-spot injection once a week for three times.", [["leg muscle", "ANATOMY", 90, 100], ["pVAX1-N", "CHEMICAL", 59, 66], ["mice", "ORGANISM", 4, 8], ["leg muscle", "TISSUE", 90, 100], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["20 g pVAX1", "TREATMENT", 54, 64], ["20 g pVAX1 in the leg muscle", "TREATMENT", 72, 100], ["leg muscle", "ANATOMY", 90, 100]]], ["The mice of other experimental groups received 20 g M or N alone or them together.", [["mice", "ORGANISM", 4, 8], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8]]], ["Each experimental vole received 100 g M or N recombinant alone or together.", [["vole", "ORGANISM", 18, 22]]], ["All animals were injected with 100 l 0.25% bupivacaine-HCl (Sigma, Saint Louis, MO) 24 h before DNA inoculation.", [["bupivacaine-HCl", "CHEMICAL", 43, 58], ["bupivacaine", "CHEMICAL", 43, 54], ["HCl", "CHEMICAL", 55, 58], ["animals", "ORGANISM", 4, 11], ["bupivacaine-HCl", "SIMPLE_CHEMICAL", 43, 58], ["Sigma", "SIMPLE_CHEMICAL", 60, 65], ["DNA", "CELLULAR_COMPONENT", 96, 99], ["DNA inoculation", "PROBLEM", 96, 111]]], ["Control group was injected in the same way with equal volume of pVAX1 mock vector or saline using the same injection technique and schedule (Shi et al., 2005) .", [["saline", "SIMPLE_CHEMICAL", 85, 91], ["pVAX1 mock vector", "TREATMENT", 64, 81], ["saline", "TREATMENT", 85, 91], ["the same injection technique", "TREATMENT", 98, 126]]], ["To examine in vivo expression of the vaccine, total RNA was isolated from muscle of the injection sites and treated with the DNase I (Boehhringer Mannheim, Indianapolis, IN) to delete the interference of DNA.", [["muscle", "ANATOMY", 74, 80], ["sites", "ANATOMY", 98, 103], ["muscle", "ORGAN", 74, 80], ["DNase I", "GENE_OR_GENE_PRODUCT", 125, 132], ["Indianapolis, IN", "ORGANISM", 156, 172], ["DNA", "CELLULAR_COMPONENT", 204, 207], ["DNase I", "PROTEIN", 125, 132], ["the vaccine", "TREATMENT", 33, 44], ["total RNA", "TREATMENT", 46, 55], ["the DNase I", "TREATMENT", 121, 132], ["DNA", "PROBLEM", 204, 207], ["muscle", "ANATOMY", 74, 80]]], ["The pair of primers: 3#, 5 -ATGTCTGATAATGGACCCCAATCA-3 and 4#, 5 -TTATGCCTGAGTTGAATCAG-3 , was used to detect the N expression at mRNA level.", [["ATGTCTGATAATGGACCCCAATCA-3", "GENE_OR_GENE_PRODUCT", 28, 54], ["TTATGCCTGAGTTGAATCAG-3", "GENE_OR_GENE_PRODUCT", 66, 88], ["ATGTCTGATAATGGACCCCAATCA", "TEST", 28, 52]]], ["The pair of primes: 5#, 5 -ATGGCAGACAACGGTACTATTACC-3 and 6#, 5 -TTACTGTACTAGCAAAGCAA-3 , was used for M mRNA amplification.", [["TTACTGTACTAGCAAAGCAA-3", "GENE_OR_GENE_PRODUCT", 65, 87], ["M mRNA", "RNA", 103, 109], ["ATGGCAGACAACGGTACTATTACC", "TEST", 27, 51]]], ["The RT-PCR products were detected by agarose gel and sequencing.", [["agarose", "SIMPLE_CHEMICAL", 37, 44], ["RT-PCR products", "DNA", 4, 19], ["The RT-PCR products", "TREATMENT", 0, 19], ["agarose gel", "TREATMENT", 37, 48]]], ["The PCR reaction without RT was also conducted in order to rule out the possibility of DNA contamination.Expression, purification and detection of N proteins in bacteriaFor ELISA and in vitro stimulation assay, N protein was expressed in bacteria and purified with affinity columns.", [["DNA", "CELLULAR_COMPONENT", 87, 90], ["N proteins", "PROTEIN", 147, 157], ["N protein", "PROTEIN", 211, 220], ["The PCR reaction", "TEST", 0, 16], ["DNA contamination", "PROBLEM", 87, 104], ["N proteins in bacteria", "PROBLEM", 147, 169], ["ELISA", "TEST", 173, 178], ["vitro stimulation assay", "TEST", 186, 209], ["N protein", "TEST", 211, 220], ["bacteria", "PROBLEM", 238, 246], ["affinity columns", "TREATMENT", 265, 281]]], ["E. coli BL21 was used as the cloning host for the pET21b-N and empty pET21b, and the cells were grown in Luria-Bertani medium supplemented with ampicillin (100 g/ml).", [["cells", "ANATOMY", 85, 90], ["ampicillin", "CHEMICAL", 144, 154], ["ampicillin", "CHEMICAL", 144, 154], ["E. coli", "ORGANISM", 0, 7], ["BL21", "ORGANISM", 8, 12], ["pET21b-N", "GENE_OR_GENE_PRODUCT", 50, 58], ["pET21b", "GENE_OR_GENE_PRODUCT", 69, 75], ["cells", "CELL", 85, 90], ["ampicillin", "SIMPLE_CHEMICAL", 144, 154], ["pET21b", "PROTEIN", 50, 56], ["N", "DNA", 57, 58], ["pET21b", "DNA", 69, 75], ["E. coli BL21", "SPECIES", 0, 12], ["E. coli BL21", "SPECIES", 0, 12], ["Luria-Bertani", "SPECIES", 105, 118], ["E. coli BL21", "PROBLEM", 0, 12], ["the pET21b", "TEST", 46, 56], ["the cells", "PROBLEM", 81, 90], ["Bertani medium", "TREATMENT", 111, 125], ["ampicillin", "TREATMENT", 144, 154], ["coli BL21", "OBSERVATION", 3, 12]]], ["Two and four h after induction with 1 mM isopropyl-(-d-thiogalactopyranoside, the cells were harvested and washed twice with cold buffer (50 mM Tris-HC1, 2 mM EDTA, pH 8.0) and resuspended in the same buffer, the lysozyme and Triton X-100 were added to final concentrations of 100 g/ml and 0.01%, respectively.", [["cells", "ANATOMY", 82, 87], ["isopropyl-(-d-thiogalactopyranoside", "CHEMICAL", 41, 76], ["Triton X-100", "CHEMICAL", 226, 238], ["isopropyl-(-d-thiogalactopyranoside", "CHEMICAL", 41, 76], ["Tris-HC1", "CHEMICAL", 144, 152], ["EDTA", "CHEMICAL", 159, 163], ["isopropyl-(-d-thiogalactopyranoside", "SIMPLE_CHEMICAL", 41, 76], ["cells", "CELL", 82, 87], ["EDTA", "SIMPLE_CHEMICAL", 159, 163], ["lysozyme", "GENE_OR_GENE_PRODUCT", 213, 221], ["Triton X-100", "SIMPLE_CHEMICAL", 226, 238], ["lysozyme", "PROTEIN", 213, 221], ["1 mM isopropyl-(-d-thiogalactopyranoside", "TREATMENT", 36, 76], ["the cells", "TREATMENT", 78, 87], ["cold buffer", "TREATMENT", 125, 136], ["2 mM EDTA", "TREATMENT", 154, 163], ["pH", "TEST", 165, 167], ["the lysozyme and Triton", "TREATMENT", 209, 232]]], ["Supernatants and cell lysates were resuspended in SDS-PAGE loading buffer, placed in a boiling water bath for 3 min and electrophoresed (Crack et al., 2002) , then the protein samples in SDS PAGE gel were stained by coomassie blue.Expression, purification and detection of N proteins in bacteriaThe Hitrap affinity columns (Amersham Biosciences) were used for purification of the recombinant N-(His) 6 tagged proteins followed as the product instruction.", [["Supernatants", "ANATOMY", 0, 12], ["cell lysates", "ANATOMY", 17, 29], ["samples", "ANATOMY", 176, 183], ["coomassie blue", "CHEMICAL", 216, 230], ["coomassie blue", "CHEMICAL", 216, 230], ["Supernatants", "CELL", 0, 12], ["cell lysates", "CELL", 17, 29], ["coomassie blue", "SIMPLE_CHEMICAL", 216, 230], ["N proteins", "PROTEIN", 273, 283], ["recombinant N-(His) 6 tagged proteins", "PROTEIN", 380, 417], ["coomassie blue", "SPECIES", 216, 230], ["Supernatants and cell lysates", "TREATMENT", 0, 29], ["a boiling water bath", "TREATMENT", 85, 105], ["the protein samples", "TEST", 164, 183], ["N proteins in bacteria", "PROBLEM", 273, 295], ["The Hitrap affinity columns (Amersham Biosciences", "TREATMENT", 295, 344], ["cell lysates", "OBSERVATION", 17, 29]]], ["The proteins after purification were detected by Western blot.Detection of N-specific antibody in vaccinated animalsNinety-six-well microtiter plates (Costar) were coated with 100 l of 5 g/ml of N protein per well diluted in 0.05 M bicarbonate buffer (pH 9.6) overnight at 4 \u2022 C, washed three times in PBST (0.1% Tween-20 and in PBS), blocked with 3% BSA-PBS at room temperature for 0.5 h.", [["bicarbonate", "CHEMICAL", 232, 243], ["Tween-20", "CHEMICAL", 313, 321], ["BSA", "CHEMICAL", 351, 354], ["bicarbonate", "CHEMICAL", 232, 243], ["Tween-20", "CHEMICAL", 313, 321], ["N-specific antibody", "GENE_OR_GENE_PRODUCT", 75, 94], ["bicarbonate", "SIMPLE_CHEMICAL", 232, 243], ["Tween-20", "SIMPLE_CHEMICAL", 313, 321], ["BSA", "SIMPLE_CHEMICAL", 351, 354], ["N-specific antibody", "PROTEIN", 75, 94], ["N protein", "PROTEIN", 195, 204], ["Detection", "TEST", 62, 71], ["N-specific antibody", "TREATMENT", 75, 94], ["well microtiter plates (Costar)", "TREATMENT", 127, 158], ["N protein", "TREATMENT", 195, 204], ["0.05 M bicarbonate buffer", "TREATMENT", 225, 250], ["pH", "TEST", 252, 254], ["PBST", "TEST", 302, 306]]], ["After washed three times, 100 l sera with serial dilution starting at 1:10 with 10% normal goat sera supplemented with 0.1% Tween-20 was added to each well.", [["sera", "ANATOMY", 32, 36], ["sera", "ANATOMY", 96, 100], ["Tween-20", "CHEMICAL", 124, 132], ["Tween-20", "CHEMICAL", 124, 132], ["sera", "ORGANISM_SUBSTANCE", 32, 36], ["goat", "ORGANISM", 91, 95], ["sera", "ORGANISM_SUBSTANCE", 96, 100], ["Tween-20", "SIMPLE_CHEMICAL", 124, 132], ["goat", "SPECIES", 91, 95], ["goat", "SPECIES", 91, 95], ["serial dilution", "TREATMENT", 42, 57]]], ["After extensive washings, antibodies were detected with goat anti-mouse IgG, IgG1, and IgG2a conjugated with horseradish peroxidase (1:5000, Sigma) diluted with PBST contain 3% normal goat sera.", [["sera", "ANATOMY", 189, 193], ["IgG", "GENE_OR_GENE_PRODUCT", 72, 75], ["IgG1", "GENE_OR_GENE_PRODUCT", 77, 81], ["IgG2a", "GENE_OR_GENE_PRODUCT", 87, 92], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 109, 131], ["goat", "ORGANISM", 184, 188], ["sera", "ORGANISM_SUBSTANCE", 189, 193], ["antibodies", "PROTEIN", 26, 36], ["goat anti-mouse IgG", "PROTEIN", 56, 75], ["IgG1", "PROTEIN", 77, 81], ["IgG2a", "PROTEIN", 87, 92], ["horseradish peroxidase", "PROTEIN", 109, 131], ["1:5000, Sigma", "PROTEIN", 133, 146], ["goat", "SPECIES", 56, 60], ["anti-mouse", "SPECIES", 61, 71], ["horseradish", "SPECIES", 109, 120], ["goat", "SPECIES", 184, 188], ["goat", "SPECIES", 56, 60], ["goat", "SPECIES", 184, 188], ["extensive washings", "TEST", 6, 24], ["antibodies", "TEST", 26, 36], ["goat anti-mouse IgG", "TEST", 56, 75], ["IgG1", "TEST", 77, 81], ["IgG2a", "TEST", 87, 92], ["horseradish peroxidase", "TREATMENT", 109, 131], ["PBST", "TREATMENT", 161, 165]]], ["After adding substract, the reaction was stopped with 2 M H 2 SO 4 .", [["H 2 SO 4", "CHEMICAL", 58, 66], ["substract", "TREATMENT", 13, 22], ["the reaction", "PROBLEM", 24, 36]]], ["The absorbance was measured at wavelengths of 450 or 490 nm 3550) .", [["The absorbance", "TEST", 0, 14], ["absorbance", "OBSERVATION_MODIFIER", 4, 14]]], ["Titer values of mouse antibody were assigned as the highest dilution at which the optical density was over or equal to 2.1 times than the absorbance produced by the serum of pre-immune mice at equivalent dilution.FACS and cytokine productionLymphocytes from the mice were isolated and cultured in six-well flat-bottomed plate at 2.5 \u00d7 10 6 cells/ml in RPMI-1640 (Gibco-BRL, Rockville, MD) containing 10% fetal calf serum (Hyclone) and 50 M \u2424-mercaptoethanol (2-ME) (Sigma) 4 weeks after immunization.", [["serum", "ANATOMY", 165, 170], ["cells", "ANATOMY", 340, 345], ["fetal calf serum", "ANATOMY", 404, 420], ["RPMI-1640", "CHEMICAL", 352, 361], ["\u2424-mercaptoethanol", "CHEMICAL", 440, 457], ["2-ME", "CHEMICAL", 459, 463], ["\u2424-mercaptoethanol", "CHEMICAL", 440, 457], ["2-ME", "CHEMICAL", 459, 463], ["mouse", "ORGANISM", 16, 21], ["serum", "ORGANISM_SUBSTANCE", 165, 170], ["mice", "ORGANISM", 185, 189], ["FACS", "CELL", 213, 217], ["mice", "ORGANISM", 262, 266], ["cells", "CELL", 340, 345], ["Gibco-BRL", "CELL", 363, 372], ["calf", "ORGANISM", 410, 414], ["serum", "ORGANISM_SUBSTANCE", 415, 420], ["Hyclone", "ORGANISM_SUBSTANCE", 422, 429], ["\u2424-mercaptoethanol", "SIMPLE_CHEMICAL", 440, 457], ["2-ME", "SIMPLE_CHEMICAL", 459, 463], ["mouse antibody", "PROTEIN", 16, 30], ["cytokine", "PROTEIN", 222, 230], ["mouse", "SPECIES", 16, 21], ["mice", "SPECIES", 185, 189], ["mice", "SPECIES", 262, 266], ["calf", "SPECIES", 410, 414], ["mouse", "SPECIES", 16, 21], ["mice", "SPECIES", 185, 189], ["mice", "SPECIES", 262, 266], ["Titer values", "TEST", 0, 12], ["mouse antibody", "TEST", 16, 30], ["the highest dilution", "PROBLEM", 48, 68], ["the absorbance", "TEST", 134, 148], ["the serum", "TEST", 161, 170], ["FACS", "TEST", 213, 217], ["cytokine productionLymphocytes", "PROBLEM", 222, 252], ["plate", "TEST", 320, 325], ["RPMI", "TEST", 352, 356], ["Gibco", "TEST", 363, 368], ["fetal calf serum", "TEST", 404, 420], ["immunization", "TREATMENT", 487, 499], ["optical", "OBSERVATION_MODIFIER", 82, 89], ["density", "OBSERVATION", 90, 97]]], ["The purified N protein was passed through filter (10 kDa cutoff, Millipore) to remove low molecular weight products in elution buffer, and 10 g/ml N protein was added into the medium.", [["N protein", "PROTEIN", 13, 22], ["N protein", "PROTEIN", 147, 156], ["The purified N protein", "TREATMENT", 0, 22], ["low molecular weight products", "TREATMENT", 86, 115], ["elution buffer", "TREATMENT", 119, 133]]], ["On day 2, the culture medium was supplemented with recombinant IL-2 (PeproTech EC, London, UK) at 25 U/ml.", [["IL-2", "GENE_OR_GENE_PRODUCT", 63, 67], ["EC", "CELL", 79, 81], ["UK", "GENE_OR_GENE_PRODUCT", 91, 93], ["IL", "PROTEIN", 63, 65], ["the culture medium", "TEST", 10, 28], ["recombinant IL", "TREATMENT", 51, 65]]], ["Three days after stimulation; the lymphocytes were harvested and resuspended in flow cytometric analysis buffer and Fc block.", [["lymphocytes", "ANATOMY", 34, 45], ["lymphocytes", "CELL", 34, 45], ["lymphocytes", "CELL_TYPE", 34, 45], ["stimulation", "TREATMENT", 17, 28], ["the lymphocytes", "PROBLEM", 30, 45], ["Fc block", "TREATMENT", 116, 124], ["lymphocytes", "ANATOMY", 34, 45]]], ["Then the cells were stained with phycoerythrin (PE)-labeled anti-CD8a/Lyt-2 (clone 53-6.7, Souther Biotech, Birmingham, AL) and fluorescein isothiocyanate (FITC)-labeled anti-CD4/L 3 T 4 (clone GK1.5, Souther Biotech), or isotype control antibodies for 1 h.", [["cells", "ANATOMY", 9, 14], ["PE", "CHEMICAL", 48, 50], ["fluorescein isothiocyanate", "CHEMICAL", 128, 154], ["fluorescein isothiocyanate", "CHEMICAL", 128, 154], ["FITC", "CHEMICAL", 156, 160], ["cells", "CELL", 9, 14], ["phycoerythrin", "SIMPLE_CHEMICAL", 33, 46], ["PE", "SIMPLE_CHEMICAL", 48, 50], ["anti-CD8a", "SIMPLE_CHEMICAL", 60, 69], ["Lyt-2", "GENE_OR_GENE_PRODUCT", 70, 75], ["clone", "ORGANISM", 77, 82], ["Birmingham", "SIMPLE_CHEMICAL", 108, 118], ["AL", "SIMPLE_CHEMICAL", 120, 122], ["fluorescein isothiocyanate", "SIMPLE_CHEMICAL", 128, 154], ["FITC", "SIMPLE_CHEMICAL", 156, 160], ["clone", "ORGANISM", 188, 193], ["GK1.5", "CELL", 194, 199], ["anti-CD8a", "PROTEIN", 60, 69], ["Lyt", "PROTEIN", 70, 73], ["anti-CD4", "PROTEIN", 170, 178], ["L 3 T 4", "PROTEIN", 179, 186], ["clone GK1.5", "PROTEIN", 188, 199], ["Souther Biotech", "PROTEIN", 201, 216], ["isotype control antibodies", "PROTEIN", 222, 248], ["phycoerythrin", "TEST", 33, 46], ["PE", "TEST", 48, 50], ["anti-CD8a", "TEST", 60, 69], ["Lyt", "TEST", 70, 73], ["clone", "TEST", 77, 82], ["fluorescein isothiocyanate", "TEST", 128, 154], ["FITC", "TEST", 156, 160], ["anti-CD4", "TEST", 170, 178], ["isotype control antibodies", "TREATMENT", 222, 248], ["PE", "OBSERVATION", 48, 50]]], ["After washing twice, the cells were analyzed on FACSCalibur flow cytometer (Cho et al., 2002)FACS and cytokine productionThe supernatants of lymphocytes culture were harvested and subjected to measurement for IFN-\u2425, IL-2 and IL-4 with ELISA detection kits from R&D Systems.", [["cells", "ANATOMY", 25, 30], ["supernatants", "ANATOMY", 125, 137], ["lymphocytes", "ANATOMY", 141, 152], ["cells", "CELL", 25, 30], ["lymphocytes", "CELL", 141, 152], ["IFN-\u2425", "GENE_OR_GENE_PRODUCT", 209, 214], ["IL-2", "GENE_OR_GENE_PRODUCT", 216, 220], ["IL-4", "GENE_OR_GENE_PRODUCT", 225, 229], ["cytokine", "PROTEIN", 102, 110], ["lymphocytes culture", "CELL_LINE", 141, 160], ["IFN", "PROTEIN", 209, 212], ["IL", "PROTEIN", 225, 227], ["FACS", "TEST", 93, 97], ["cytokine production", "TEST", 102, 121], ["The supernatants of lymphocytes culture", "TEST", 121, 160], ["IFN", "TEST", 209, 212], ["IL", "TEST", 216, 218], ["IL", "TEST", 225, 227], ["ELISA detection kits", "TEST", 235, 255], ["lymphocytes", "ANATOMY", 141, 152]]], ["The values of cytokine were expressed as concentrations (pg/ml) according to the standard samples curves.", [["cytokine", "PROTEIN", 14, 22], ["the standard samples curves", "TEST", 77, 104]]], ["The value of the well incubated with PBS was as blank.Lymphocyte proliferation assayAbout 50 l per well of Dulbecco's modified eagle's medium (DMEM, supplemented with 10% fetal bovine serum (FBS) and 50 M 2-ME) containing 2 or 10 g/ml N antigen were added into 96-well plate (Costar).", [["Lymphocyte", "ANATOMY", 54, 64], ["fetal bovine serum", "ANATOMY", 171, 189], ["FBS", "ANATOMY", 191, 194], ["2-ME", "CHEMICAL", 205, 209], ["Lymphocyte", "CELL", 54, 64], ["bovine", "ORGANISM", 177, 183], ["serum", "ORGANISM_SUBSTANCE", 184, 189], ["FBS", "ORGANISM_SUBSTANCE", 191, 194], ["2-ME", "SIMPLE_CHEMICAL", 205, 209], ["bovine", "SPECIES", 177, 183], ["bovine", "SPECIES", 177, 183], ["The value", "TEST", 0, 9], ["PBS", "TREATMENT", 37, 40], ["Lymphocyte proliferation assayAbout", "PROBLEM", 54, 89], ["Dulbecco", "TEST", 107, 115], ["10% fetal bovine serum (FBS", "TREATMENT", 167, 194]]], ["Bovine serum albumin (BSA, Promega, Madison, WI) at 10 g/ml was set as a nonspecific antigen control.", [["serum", "ANATOMY", 7, 12], ["Bovine", "ORGANISM", 0, 6], ["serum", "ORGANISM_SUBSTANCE", 7, 12], ["albumin", "ORGANISM_SUBSTANCE", 13, 20], ["BSA", "SIMPLE_CHEMICAL", 22, 25], ["Bovine", "SPECIES", 0, 6], ["Bovine", "SPECIES", 0, 6], ["Bovine serum albumin", "TEST", 0, 20], ["BSA", "TEST", 22, 25], ["Promega", "TEST", 27, 34], ["a nonspecific antigen control", "TREATMENT", 71, 100]]], ["After adding 50 l (approximately 10 5 cells/well) lymphocytes suspension that from immunized voles per well, the plate was incubated in a humidified CO 2 incubator at 37 \u2022 C. On day 2, human recombinant IL-2 (Sigma) was added into the culture medium with 5 U/ml.", [["cells", "ANATOMY", 38, 43], ["lymphocytes", "ANATOMY", 50, 61], ["CO 2", "CHEMICAL", 149, 153], ["cells", "CELL", 38, 43], ["lymphocytes", "CELL", 50, 61], ["voles", "ORGANISM", 93, 98], ["human", "ORGANISM", 185, 190], ["IL-2", "GENE_OR_GENE_PRODUCT", 203, 207], ["Sigma", "GENE_OR_GENE_PRODUCT", 209, 214], ["human recombinant IL-2", "PROTEIN", 185, 207], ["human", "SPECIES", 185, 190], ["human", "SPECIES", 185, 190], ["lymphocytes suspension", "TREATMENT", 50, 72], ["a humidified CO 2 incubator", "TREATMENT", 136, 163], ["human recombinant IL", "TREATMENT", 185, 205]]], ["After 3 days, 20 l of CellTiter 96 Aqueous One Solution Reagent (Promega) was added into the wells, and the plate was incubated for 4 h at 37 \u2022 C. Then the absorbance of samples at 490 nm was read (Bio-Rad, 3550).", [["samples", "ANATOMY", 170, 177], ["Promega", "ORGANISM", 65, 72], ["CellTiter", "TREATMENT", 22, 31], ["Aqueous One Solution Reagent (Promega)", "TREATMENT", 35, 73]]], ["The results were defined as stimulation index (SI) (ratio of A490 nm with N antigen and negative control).Detection of the antibody reacted to inactivated SARS-CoVThe 96-well microtiter plate (Costar) was coated with inactivated SARS-CoV particles.", [["SARS", "DISEASE", 155, 159], ["N antigen", "GENE_OR_GENE_PRODUCT", 74, 83], ["CoV", "ORGANISM", 234, 237], ["N antigen", "PROTEIN", 74, 83], ["SARS-CoV", "SPECIES", 229, 237], ["stimulation index", "TEST", 28, 45], ["ratio", "TEST", 52, 57], ["N antigen", "TEST", 74, 83], ["the antibody", "TEST", 119, 131], ["inactivated SARS", "PROBLEM", 143, 159], ["CoVThe", "TEST", 160, 166], ["well microtiter plate (Costar)", "TREATMENT", 170, 200]]], ["The value at 490 nm over or equal to 0.22 was considered as positive.", [["The value", "TEST", 0, 9], ["positive", "OBSERVATION", 60, 68]]], ["In previous study, the absorbance value of 0.22 from experimental mice is equal to 2.1-time of mean value of the mouse from the negative group (Liang GD, unpublished data).Anti-SARS-CoV animal experimentFourteen adult's M. brandti raddes were divided into two groups.", [["mice", "ORGANISM", 66, 70], ["mouse", "ORGANISM", 113, 118], ["Anti-SARS-CoV", "GENE_OR_GENE_PRODUCT", 172, 185], ["mice", "SPECIES", 66, 70], ["mouse", "SPECIES", 113, 118], ["M. brandti", "SPECIES", 220, 230], ["mice", "SPECIES", 66, 70], ["mouse", "SPECIES", 113, 118], ["M. brandti", "SPECIES", 220, 230], ["previous study", "TEST", 3, 17], ["the absorbance value", "TEST", 19, 39], ["Anti-SARS", "TEST", 172, 181], ["brandti raddes", "TREATMENT", 223, 237]]], ["Two weeks after the animals immunized with mock vector (n = 6) or M + N vaccine (n = 8) for three times, the animals were challenged with live SARS-CoV (PUMC01) as previous report (Gao et al., 2005; Qin et al., 2005) Two voles died during anesthesia manipulation.", [["M + N", "SIMPLE_CHEMICAL", 66, 71], ["animals", "ORGANISM", 109, 116], ["SARS-CoV", "ORGANISM", 143, 151], ["PUMC01", "ORGANISM", 153, 159], ["voles", "ORGANISM", 221, 226], ["SARS-CoV", "SPECIES", 143, 151], ["mock vector", "TREATMENT", 43, 54], ["M + N vaccine", "TREATMENT", 66, 79], ["anesthesia manipulation", "TREATMENT", 239, 262]]], ["Histology was performed on representative 5 m sections of lung, liver, kidney, spleen, brain, heart, pancreas, intestine, stomach, thymus, lymph node, bladder, bone marrow, testicle, prostate, ovary, uterus tissue from field mice after challenge, which were paraffin embedded and then stained with Haematoxylin & Eosin (HE) staining.", [["m sections", "ANATOMY", 44, 54], ["lung", "ANATOMY", 58, 62], ["liver", "ANATOMY", 64, 69], ["kidney", "ANATOMY", 71, 77], ["spleen", "ANATOMY", 79, 85], ["brain", "ANATOMY", 87, 92], ["heart", "ANATOMY", 94, 99], ["pancreas", "ANATOMY", 101, 109], ["intestine", "ANATOMY", 111, 120], ["stomach", "ANATOMY", 122, 129], ["thymus", "ANATOMY", 131, 137], ["lymph node", "ANATOMY", 139, 149], ["bladder", "ANATOMY", 151, 158], ["bone marrow", "ANATOMY", 160, 171], ["testicle", "ANATOMY", 173, 181], ["prostate", "ANATOMY", 183, 191], ["ovary", "ANATOMY", 193, 198], ["uterus tissue", "ANATOMY", 200, 213], ["Haematoxylin", "CHEMICAL", 298, 310], ["Eosin", "CHEMICAL", 313, 318], ["lung", "ORGAN", 58, 62], ["liver", "ORGAN", 64, 69], ["kidney", "ORGAN", 71, 77], ["spleen", "ORGAN", 79, 85], ["brain", "ORGAN", 87, 92], ["heart", "ORGAN", 94, 99], ["pancreas", "ORGAN", 101, 109], ["intestine", "ORGAN", 111, 120], ["stomach", "ORGAN", 122, 129], ["thymus", "ORGAN", 131, 137], ["lymph node", "MULTI-TISSUE_STRUCTURE", 139, 149], ["bladder", "ORGAN", 151, 158], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 160, 171], ["testicle", "ORGAN", 173, 181], ["prostate", "MULTI-TISSUE_STRUCTURE", 183, 191], ["ovary", "ORGAN", 193, 198], ["uterus tissue", "TISSUE", 200, 213], ["mice", "ORGANISM", 225, 229], ["Haematoxylin & Eosin", "SIMPLE_CHEMICAL", 298, 318], ["HE", "SIMPLE_CHEMICAL", 320, 322], ["mice", "SPECIES", 225, 229], ["mice", "SPECIES", 225, 229], ["Histology", "TEST", 0, 9], ["Haematoxylin", "TREATMENT", 298, 310], ["lung", "ANATOMY", 58, 62], ["liver", "ANATOMY", 64, 69], ["kidney", "ANATOMY", 71, 77], ["spleen", "ANATOMY", 79, 85], ["brain", "ANATOMY", 87, 92], ["heart", "ANATOMY", 94, 99], ["pancreas", "ANATOMY", 101, 109], ["intestine", "ANATOMY", 111, 120], ["stomach", "ANATOMY", 122, 129], ["thymus", "ANATOMY", 131, 137], ["lymph node", "OBSERVATION", 139, 149], ["bladder", "ANATOMY", 151, 158], ["bone marrow", "ANATOMY", 160, 171], ["testicle", "ANATOMY", 173, 181], ["prostate", "ANATOMY", 183, 191], ["ovary", "ANATOMY", 193, 198], ["uterus", "ANATOMY", 200, 206]]], ["These experiments were conducted in BSL3 bio safety laboratory.Data analysisThe values except special explanation are reported as mean \u00b1 S.E.M. Statistical analysis was performed using One Way-ANOVA.", [["Data analysis", "TEST", 63, 76], ["The values", "TEST", 76, 86], ["Statistical analysis", "TEST", 144, 164]]], ["Differences were considered statistically significant with p < 0.05.Expression of M and N in vivoTo identify the expression of pVAX1-M and pVAX1-N in vivo, the presence of M and N mRNA from mice muscle immunized with vaccine and mock DNA was analyzed.", [["muscle", "ANATOMY", 195, 201], ["pVAX1-M", "GENE_OR_GENE_PRODUCT", 127, 134], ["pVAX1-N", "GENE_OR_GENE_PRODUCT", 139, 146], ["mice", "ORGANISM", 190, 194], ["muscle", "ORGAN", 195, 201], ["DNA", "CELLULAR_COMPONENT", 234, 237], ["pVAX1", "PROTEIN", 127, 132], ["pVAX1", "PROTEIN", 139, 144], ["N", "DNA", 145, 146], ["M and N mRNA", "RNA", 172, 184], ["mice", "SPECIES", 190, 194], ["mice", "SPECIES", 190, 194], ["pVAX1", "TREATMENT", 139, 144], ["M and N mRNA from mice muscle immunized", "TREATMENT", 172, 211], ["vaccine", "TREATMENT", 217, 224], ["mock DNA", "TREATMENT", 229, 237], ["muscle", "ANATOMY", 195, 201]]], ["RT-PCR reaction with the designed primers was used to detect the M and N expression.", [["RT-PCR reaction", "TEST", 0, 15], ["the designed primers", "PROBLEM", 21, 41]]], ["The desired full-length of M cDNA is 666 nucleotide acids, while the N cDNA is 1269 nucleotide acids.", [["nucleotide acids", "CHEMICAL", 41, 57], ["1269 nucleotide acids", "CHEMICAL", 79, 100], ["nucleotide acids", "CHEMICAL", 41, 57], ["nucleotide acids", "CHEMICAL", 84, 100], ["M cDNA", "DNA", 27, 33], ["N cDNA", "DNA", 69, 75], ["nucleotide acids", "TEST", 41, 57], ["the N cDNA", "TEST", 65, 75], ["nucleotide acids", "TREATMENT", 84, 100]]], ["Thus, pVAX1-M and pVAX1-N are proven to express in immunized mice muscle (Fig. 1) .", [["muscle", "ANATOMY", 66, 72], ["pVAX1-M", "GENE_OR_GENE_PRODUCT", 6, 13], ["pVAX1-N", "GENE_OR_GENE_PRODUCT", 18, 25], ["mice", "ORGANISM", 61, 65], ["muscle", "ORGAN", 66, 72], ["pVAX1", "PROTEIN", 6, 11], ["pVAX1", "PROTEIN", 18, 23], ["mice", "SPECIES", 61, 65], ["mice", "SPECIES", 61, 65], ["pVAX1", "TEST", 6, 11], ["muscle", "ANATOMY", 66, 72]]], ["No bands were detected when the reaction was conducted without RT process (data not shown).Expression and purification of N proteinN protein with a C-terminal histidine tag was expressed in the bacteria BL21.", [["C", "CHEMICAL", 148, 149], ["histidine", "CHEMICAL", 159, 168], ["N proteinN", "GENE_OR_GENE_PRODUCT", 122, 132], ["N proteinN protein", "PROTEIN", 122, 140], ["C-terminal histidine tag", "PROTEIN", 148, 172], ["BL21", "PROTEIN", 203, 207], ["bands", "PROBLEM", 3, 8], ["the reaction", "PROBLEM", 28, 40], ["RT process", "PROBLEM", 63, 73], ["N proteinN protein", "TEST", 122, 140], ["a C-terminal histidine tag", "TREATMENT", 146, 172], ["the bacteria BL21", "PROBLEM", 190, 207], ["bands", "OBSERVATION", 3, 8], ["bacteria BL21", "OBSERVATION", 194, 207]]], ["After induction with IPTG, the volume of the desired protein increased (Fig. 2A) .", [["IPTG", "CHEMICAL", 21, 25], ["IPTG", "CHEMICAL", 21, 25], ["IPTG", "SIMPLE_CHEMICAL", 21, 25], ["IPTG", "TREATMENT", 21, 25]]], ["The soluble proteins in bacteria were treated with the Hitrap affinity columns.", [["soluble proteins", "PROTEIN", 4, 20], ["The soluble proteins in bacteria", "PROBLEM", 0, 32], ["the Hitrap affinity columns", "TREATMENT", 51, 78], ["bacteria", "OBSERVATION_MODIFIER", 24, 32]]], ["After treating, only two bands were remained in the SDS-PAGE gel (Fig. 2B) , and the bold band represents the full-length of N protein with expected molecular weight (Fig. 2C) .Analysis of the N-specific antibodies induced by the vaccineIgG titers specific to N antigen in mice sera at serial dilution were detected by standard ELISA.", [["sera", "ANATOMY", 278, 282], ["IgG", "GENE_OR_GENE_PRODUCT", 237, 240], ["N antigen", "GENE_OR_GENE_PRODUCT", 260, 269], ["mice", "ORGANISM", 273, 277], ["sera", "ORGANISM_SUBSTANCE", 278, 282], ["N protein", "PROTEIN", 125, 134], ["N-specific antibodies", "PROTEIN", 193, 214], ["vaccineIgG", "PROTEIN", 230, 240], ["N antigen", "PROTEIN", 260, 269], ["mice", "SPECIES", 273, 277], ["mice", "SPECIES", 273, 277], ["two bands", "TREATMENT", 21, 30], ["the SDS", "TREATMENT", 48, 55], ["the bold band", "TREATMENT", 81, 94], ["the full-length of N protein", "TREATMENT", 106, 134], ["Analysis", "TEST", 177, 185], ["the N-specific antibodies", "TREATMENT", 189, 214], ["the vaccineIgG titers", "TEST", 226, 247], ["serial dilution", "TEST", 286, 301]]], ["The log 10 titers were shown in Fig. 3 , It showed that N-induced IgG increased when co-injection with M (p < 0.01).", [["IgG", "GENE_OR_GENE_PRODUCT", 66, 69], ["N-induced IgG", "PROTEIN", 56, 69], ["The log 10 titers", "TEST", 0, 17], ["N-induced IgG", "PROBLEM", 56, 69]]], ["Whereas there is no significant difference between the group immunized with 20 g N vaccine alone and the group with 20 g N plus 20 g mock DNA (p = 0.276).", [["DNA", "CELLULAR_COMPONENT", 138, 141], ["20 g N vaccine", "TREATMENT", 76, 90], ["no", "UNCERTAINTY", 17, 19], ["significant", "OBSERVATION_MODIFIER", 20, 31], ["difference", "OBSERVATION_MODIFIER", 32, 42]]], ["This indicates that the antibody enhancement by M is not contributed by plasmid DNA itself.", [["plasmid", "ANATOMY", 72, 79], ["DNA", "CELLULAR_COMPONENT", 80, 83], ["plasmid DNA", "DNA", 72, 83], ["the antibody enhancement", "PROBLEM", 20, 44], ["antibody enhancement", "OBSERVATION", 24, 44], ["plasmid DNA", "OBSERVATION", 72, 83]]], ["The N antibody in sera immunized with M DNA vaccine at 1:10 was not over 2.1 times of that in pre-immune sera (n = 6), so the log value of antibody titer was expressed as one without bar.Analysis of the N-specific antibodies induced by the vaccineFrom Table 1 , we observed that IgG induced by N DNA immunization both in mouse and vole increased when coinjection with pVAX1-M.", [["sera", "ANATOMY", 18, 22], ["sera", "ANATOMY", 105, 109], ["pVAX1-M.", "CHEMICAL", 368, 376], ["N antibody", "GENE_OR_GENE_PRODUCT", 4, 14], ["sera", "ORGANISM_SUBSTANCE", 18, 22], ["DNA", "CELLULAR_COMPONENT", 40, 43], ["sera", "ORGANISM_SUBSTANCE", 105, 109], ["IgG", "GENE_OR_GENE_PRODUCT", 279, 282], ["DNA", "CELLULAR_COMPONENT", 296, 299], ["mouse", "ORGANISM", 321, 326], ["pVAX1-M.", "GENE_OR_GENE_PRODUCT", 368, 376], ["N antibody", "PROTEIN", 4, 14], ["N-specific antibodies", "PROTEIN", 203, 224], ["IgG", "PROTEIN", 279, 282], ["pVAX1", "PROTEIN", 368, 373], ["mouse", "SPECIES", 321, 326], ["mouse", "SPECIES", 321, 326], ["The N antibody in sera", "TREATMENT", 0, 22], ["M DNA vaccine", "TREATMENT", 38, 51], ["pre-immune sera", "TEST", 94, 109], ["the log value", "TEST", 122, 135], ["antibody titer", "TEST", 139, 153], ["Analysis", "TEST", 187, 195], ["the N-specific antibodies", "TREATMENT", 199, 224], ["the vaccine", "TREATMENT", 236, 247], ["IgG", "TREATMENT", 279, 282], ["N DNA immunization", "TREATMENT", 294, 312]]], ["The mouse antibodies assay showed that the mostly increased subclass of N-specific IgG induced by M was IgG2a but not IgG1.Analysis of CD8+ and CD4+ lymphocytes by flow cytometric analysisThe CD4+ and CD8+ stained cells were analyzed by the FACS scan.", [["CD8+", "ANATOMY", 135, 139], ["CD4+ lymphocytes", "ANATOMY", 144, 160], ["CD4+", "ANATOMY", 192, 196], ["CD8+ stained cells", "ANATOMY", 201, 219], ["mouse", "ORGANISM", 4, 9], ["IgG", "GENE_OR_GENE_PRODUCT", 83, 86], ["IgG2a", "GENE_OR_GENE_PRODUCT", 104, 109], ["IgG1", "GENE_OR_GENE_PRODUCT", 118, 122], ["CD8", "GENE_OR_GENE_PRODUCT", 135, 138], ["CD4", "GENE_OR_GENE_PRODUCT", 144, 147], ["CD4", "GENE_OR_GENE_PRODUCT", 192, 195], ["CD8", "GENE_OR_GENE_PRODUCT", 201, 204], ["mouse antibodies", "PROTEIN", 4, 20], ["N-specific IgG", "PROTEIN", 72, 86], ["IgG2a", "PROTEIN", 104, 109], ["IgG1", "PROTEIN", 118, 122], ["CD8", "PROTEIN", 135, 138], ["CD4", "PROTEIN", 144, 147], ["CD4", "PROTEIN", 192, 195], ["CD8", "PROTEIN", 201, 204], ["mouse", "SPECIES", 4, 9], ["mouse", "SPECIES", 4, 9], ["The mouse antibodies assay", "TEST", 0, 26], ["Analysis", "TEST", 123, 131], ["CD8", "TEST", 135, 138], ["CD4", "TEST", 144, 147], ["lymphocytes", "TEST", 149, 160], ["flow cytometric analysis", "TEST", 164, 188], ["The CD4", "TEST", 188, 195], ["CD8+ stained cells", "PROBLEM", 201, 219], ["the FACS scan", "TEST", 237, 250], ["mostly", "OBSERVATION_MODIFIER", 43, 49], ["increased", "OBSERVATION_MODIFIER", 50, 59], ["subclass", "OBSERVATION_MODIFIER", 60, 68], ["lymphocytes", "ANATOMY", 149, 160]]], ["The activated CD4+ (64.8 \u00b1 2.7% of gated cell) and CD8+ (16.6 \u00b1 0.3) cells of the group immunized with N in combination with M were more than those (CD4+: 54.9 \u00b1 3.0, CD8+: 6.3 \u00b1 0.6) of the group immunized with N vaccine alone.", [["CD4+", "ANATOMY", 14, 18], ["cell", "ANATOMY", 41, 45], ["CD8+ (16.6 \u00b1 0.3) cells", "ANATOMY", 51, 74], ["CD4", "GENE_OR_GENE_PRODUCT", 14, 17], ["cell", "CELL", 41, 45], ["CD8", "GENE_OR_GENE_PRODUCT", 51, 54], ["CD4", "GENE_OR_GENE_PRODUCT", 149, 152], ["CD8", "GENE_OR_GENE_PRODUCT", 167, 170], ["CD4", "PROTEIN", 14, 17], ["CD8", "PROTEIN", 51, 54], ["CD4", "PROTEIN", 149, 152], ["CD8", "PROTEIN", 167, 170], ["The activated CD4", "TEST", 0, 17], ["gated cell", "TEST", 35, 45], ["CD8", "TEST", 51, 54], ["cells", "TEST", 69, 74], ["CD4", "TEST", 149, 152], ["CD8", "TEST", 167, 170], ["N vaccine", "TREATMENT", 212, 221]]], ["In addition, there is no significant difference of activated CD4+ and CD8+ T cells between the group immunized with N DNA vaccine alone and mock plus N (CD4+: p = 0.14, CD8+: p = 0.69).", [["CD4+ and CD8+ T cells", "ANATOMY", 61, 82], ["CD4", "GENE_OR_GENE_PRODUCT", 61, 64], ["CD8", "GENE_OR_GENE_PRODUCT", 70, 73], ["DNA", "CELLULAR_COMPONENT", 118, 121], ["CD8", "GENE_OR_GENE_PRODUCT", 169, 172], ["CD4", "PROTEIN", 61, 64], ["CD8", "PROTEIN", 70, 73], ["T cells", "CELL_TYPE", 75, 82], ["CD4", "PROTEIN", 153, 156], ["CD8", "PROTEIN", 169, 172], ["activated CD4", "TEST", 51, 64], ["CD8+ T cells", "PROBLEM", 70, 82], ["N DNA vaccine", "TREATMENT", 116, 129], ["CD4", "TEST", 153, 156], ["p", "TEST", 159, 160], ["CD8", "TEST", 169, 172], ["p", "TEST", 175, 176], ["no", "UNCERTAINTY", 22, 24], ["significant", "OBSERVATION_MODIFIER", 25, 36]]], ["This demonstrates that the N DNA vaccine could induce the T-cell mediated response in mice and that M expression could enhance the T lymphocytes activity induced by N vaccine.Cytokines releaseWhen stimulated with N antigen, the lymphocytes from the groups immunized with N or N in combination with mock secreted significant levels of IFN-\u2425, IL-2 and IL-4 compared with control groups.", [["T-cell", "ANATOMY", 58, 64], ["T lymphocytes", "ANATOMY", 131, 144], ["lymphocytes", "ANATOMY", 228, 239], ["DNA", "CELLULAR_COMPONENT", 29, 32], ["T-cell", "CELL", 58, 64], ["mice", "ORGANISM", 86, 90], ["T lymphocytes", "CELL", 131, 144], ["N antigen", "GENE_OR_GENE_PRODUCT", 213, 222], ["lymphocytes", "CELL", 228, 239], ["IFN-\u2425", "GENE_OR_GENE_PRODUCT", 334, 339], ["IL-2", "GENE_OR_GENE_PRODUCT", 341, 345], ["IL-4", "GENE_OR_GENE_PRODUCT", 350, 354], ["T lymphocytes", "CELL_TYPE", 131, 144], ["Cytokines", "PROTEIN", 175, 184], ["N antigen", "PROTEIN", 213, 222], ["lymphocytes", "CELL_TYPE", 228, 239], ["IFN", "PROTEIN", 334, 337], ["IL", "PROTEIN", 341, 343], ["IL", "PROTEIN", 350, 352], ["mice", "SPECIES", 86, 90], ["mice", "SPECIES", 86, 90], ["the N DNA vaccine", "TREATMENT", 23, 40], ["Cytokines", "TREATMENT", 175, 184], ["N antigen", "TEST", 213, 222], ["IFN", "TEST", 334, 337], ["IL", "TEST", 341, 343], ["IL", "TREATMENT", 350, 352], ["lymphocytes", "ANATOMY", 228, 239]]], ["Moreover, the lymphocytes from the group of M plus N released more cytokines than the group only immunized with N vaccine.", [["lymphocytes", "ANATOMY", 14, 25], ["lymphocytes", "CELL", 14, 25], ["lymphocytes", "CELL_TYPE", 14, 25], ["cytokines", "PROTEIN", 67, 76], ["N vaccine", "TREATMENT", 112, 121], ["lymphocytes", "ANATOMY", 14, 25]]], ["IFN-\u2425 and IL-2 Fig. 3 .", [["IFN-\u2425", "GENE_OR_GENE_PRODUCT", 0, 5], ["IL-2 Fig. 3", "GENE_OR_GENE_PRODUCT", 10, 21], ["IFN", "PROTEIN", 0, 3], ["IL", "PROTEIN", 10, 12], ["IFN", "TEST", 0, 3]]], ["Detection of the N-specific antibody in immunized mice.", [["mice", "ORGANISM", 50, 54], ["N-specific antibody", "PROTEIN", 17, 36], ["mice", "SPECIES", 50, 54], ["mice", "SPECIES", 50, 54], ["the N-specific antibody in immunized mice", "TREATMENT", 13, 54]]], ["Antibody responses to N (n = 6) that were bled on day 28 after last immunization.", [["Antibody responses", "TEST", 0, 18], ["N (n", "TEST", 22, 26], ["last immunization", "TREATMENT", 63, 80]]], ["The mean titers of antibodies were evaluated by ELISA.", [["antibodies", "PROTEIN", 19, 29], ["The mean titers of antibodies", "TEST", 0, 29]]], ["The values were expressed in log 10, and defined as positive by using the absolute ratio of Post/Naive serum at a cutoff of 2.1. levels were increased about two-and 4.75-fold, respectively (Table 2) .Lymphocyte proliferation assayActivation and proliferation of lymphocyte play a critical role both in the humoral and cellular immune responses induced by vaccination.", [["serum", "ANATOMY", 103, 108], ["Lymphocyte", "ANATOMY", 200, 210], ["lymphocyte", "ANATOMY", 262, 272], ["cellular", "ANATOMY", 318, 326], ["serum", "ORGANISM_SUBSTANCE", 103, 108], ["Lymphocyte", "CELL", 200, 210], ["lymphocyte", "CELL", 262, 272], ["cellular", "CELL", 318, 326], ["lymphocyte", "CELL_TYPE", 262, 272], ["The values", "TEST", 0, 10], ["the absolute ratio", "TEST", 70, 88], ["Post/Naive serum", "TEST", 92, 108], ["a cutoff", "TEST", 112, 120], ["levels", "TEST", 129, 135], ["Lymphocyte proliferation assayActivation", "PROBLEM", 200, 240], ["proliferation of lymphocyte", "PROBLEM", 245, 272], ["increased", "OBSERVATION_MODIFIER", 141, 150], ["proliferation assayActivation", "OBSERVATION", 211, 240], ["proliferation", "OBSERVATION_MODIFIER", 245, 258], ["lymphocyte", "OBSERVATION", 262, 272], ["humoral", "ANATOMY", 306, 313], ["cellular immune", "OBSERVATION", 318, 333]]], ["As shown in Fig. 4 , the higher level of activity of lymphocytes stimulated by 1 or 5 g/ml N antigen was observed both in the animals immunized with N alone and the mixture of M and N compared with control.", [["lymphocytes", "ANATOMY", 53, 64], ["lymphocytes", "CELL", 53, 64], ["N antigen", "GENE_OR_GENE_PRODUCT", 91, 100], ["lymphocytes", "CELL_TYPE", 53, 64], ["Fig", "OBSERVATION", 12, 15], ["higher", "OBSERVATION_MODIFIER", 25, 31], ["activity", "OBSERVATION_MODIFIER", 41, 49]]], ["Moreover, the lymphocytes proliferation specific to N antigen was stronger in voles immunized with M + N than that in animals immunized with only N. Fig. 4 .", [["lymphocytes", "ANATOMY", 14, 25], ["lymphocytes", "CELL", 14, 25], ["N antigen", "GENE_OR_GENE_PRODUCT", 52, 61], ["lymphocytes", "CELL_TYPE", 14, 25], ["N antigen", "PROTEIN", 52, 61], ["the lymphocytes proliferation", "PROBLEM", 10, 39], ["N antigen", "TEST", 52, 61], ["lymphocytes proliferation", "OBSERVATION", 14, 39]]], ["Lymphocyte proliferation assay.", [["Lymphocyte", "ANATOMY", 0, 10], ["Lymphocyte", "CELL", 0, 10], ["Lymphocyte proliferation assay", "TEST", 0, 30], ["proliferation assay", "OBSERVATION", 11, 30]]], ["Four weeks after the last immunization, the voles were sacrificed and the single lymphocyte suspension was cultured in medium.", [["lymphocyte", "ANATOMY", 81, 91], ["voles", "ORGANISM", 44, 49], ["lymphocyte", "CELL", 81, 91], ["voles", "SPECIES", 44, 49], ["the last immunization", "TREATMENT", 17, 38], ["the single lymphocyte suspension", "TREATMENT", 70, 102]]], ["Approximately 10 5 cells were added into the 96 wells, 1 or 5 g/ml purified N antigen was used to stimulate the lymphocyte proliferation activity.", [["cells", "ANATOMY", 19, 24], ["lymphocyte", "ANATOMY", 112, 122], ["cells", "CELL", 19, 24], ["N antigen", "GENE_OR_GENE_PRODUCT", 76, 85], ["lymphocyte", "CELL", 112, 122], ["N antigen", "PROTEIN", 76, 85], ["5 g/ml purified N antigen", "TREATMENT", 60, 85], ["lymphocyte proliferation activity", "OBSERVATION", 112, 145]]], ["After 3 days, 20 L MTS solution was added into the wells, and the plate was incubated for 4 h at 37 \u2022 C. Then the absorbance of samples at 490 nm was read.", [["samples", "ANATOMY", 128, 135], ["MTS", "CHEMICAL", 19, 22], ["20 L MTS solution", "TREATMENT", 14, 31]]], ["The results were expressed as stimulation index (SI, ratio of the absorbance at OD 490 nm with N antigen and negative control).", [["N antigen", "GENE_OR_GENE_PRODUCT", 95, 104], ["N antigen", "PROTEIN", 95, 104], ["stimulation index", "TEST", 30, 47], ["the absorbance", "PROBLEM", 62, 76], ["N antigen", "TEST", 95, 104]]], ["Anti-SARS-CoV animal experiment.", [["Anti-SARS-CoV", "GENE_OR_GENE_PRODUCT", 0, 13], ["Anti-SARS", "TEST", 0, 9]]], ["The adult's Microtus brandti raddes that had been inoculated M + N (n = 7) and mock (n = 5) were challenged with SARS-CoV.", [["SARS", "DISEASE", 113, 117], ["Microtus brandti", "ORGANISM", 12, 28], ["SARS-CoV", "ORGANISM", 113, 121], ["Microtus brandti", "SPECIES", 12, 28], ["Microtus brandti", "SPECIES", 12, 28], ["SARS-CoV", "SPECIES", 113, 121], ["mock (n", "TEST", 79, 86]]], ["Fourteen days after challenge, the number of mice that did not die and had no pathological changes in lung were showed.Reaction of the antibody to inactivated SARS-CoVThe reaction of IgG antibody to complete SARS-CoV particle in sera (1:10) was detected by ELISA.", [["lung", "ANATOMY", 102, 106], ["sera", "ANATOMY", 229, 233], ["SARS", "DISEASE", 159, 163], ["mice", "ORGANISM", 45, 49], ["lung", "ORGAN", 102, 106], ["IgG antibody", "GENE_OR_GENE_PRODUCT", 183, 195], ["CoV", "ORGANISM", 213, 216], ["sera", "ORGANISM_SUBSTANCE", 229, 233], ["IgG antibody", "PROTEIN", 183, 195], ["mice", "SPECIES", 45, 49], ["mice", "SPECIES", 45, 49], ["SARS-CoV", "SPECIES", 208, 216], ["pathological changes in lung", "PROBLEM", 78, 106], ["the antibody", "PROBLEM", 131, 143], ["inactivated SARS", "PROBLEM", 147, 163], ["CoVThe reaction", "PROBLEM", 164, 179], ["IgG antibody", "TEST", 183, 195], ["complete SARS", "TEST", 199, 212], ["CoV particle in sera", "TEST", 213, 233], ["lung", "ANATOMY", 102, 106]]], ["The result indicated that only the mice immunized with N together with M vaccine could produce the positive reaction to inactivated SARS-CoV (n = 4), and the value is 0.69 \u00b1 0.35.", [["SARS", "DISEASE", 132, 136], ["mice", "ORGANISM", 35, 39], ["SARS-CoV", "ORGANISM", 132, 140], ["mice", "SPECIES", 35, 39], ["mice", "SPECIES", 35, 39], ["SARS-CoV", "SPECIES", 132, 140], ["M vaccine", "TREATMENT", 71, 80], ["the positive reaction", "PROBLEM", 95, 116], ["CoV (n", "TEST", 137, 143], ["the value", "TEST", 154, 163]]], ["However, the sera from the mice immunized with mock, M or N plasmid alone (n \u2265 4) could not.", [["sera", "ANATOMY", 13, 17], ["sera", "ORGANISM_SUBSTANCE", 13, 17], ["mice", "ORGANISM", 27, 31], ["mice", "SPECIES", 27, 31], ["mice", "SPECIES", 27, 31]]], ["Fig. 5 shows that no M. brandti raddes immunized with M plus N died 2 weeks after challenged with SARS-CoV (0/7), whereas most animals that had been immunized with mock vector died (3/5), and from the results of carefully observation and microscopic examination, the syndrome of the voles challenged with virus is like the infection syndrome in human being.", [["infection syndrome", "DISEASE", 323, 341], ["M. brandti raddes", "ORGANISM", 21, 38], ["SARS-CoV", "ORGANISM", 98, 106], ["animals", "ORGANISM", 127, 134], ["voles", "ORGANISM", 283, 288], ["human", "ORGANISM", 345, 350], ["M. brandti", "SPECIES", 21, 31], ["human", "SPECIES", 345, 350], ["M. brandti", "SPECIES", 21, 31], ["SARS-CoV", "SPECIES", 98, 106], ["human", "SPECIES", 345, 350], ["SARS", "PROBLEM", 98, 102], ["carefully observation", "TEST", 212, 233], ["microscopic examination", "TEST", 238, 261], ["the syndrome", "PROBLEM", 263, 275], ["virus", "PROBLEM", 305, 310], ["the infection syndrome", "PROBLEM", 319, 341], ["no", "UNCERTAINTY", 18, 20], ["infection", "OBSERVATION", 323, 332]]], ["The data of microscopic inspection showed that all voles (5/5) challenged with virus had the obvious pathological changes in lung, whereas only one of seven animals that had been inoculated with the mixture of M and N had the pathologic changes in lung.Histological analysis of the pulmonary sectionsAfter the voles challenged with live SARS-CoV, pulmonary alveoli of the control animals were destroyed extensively with haemorrhage.", [["lung", "ANATOMY", 125, 129], ["lung", "ANATOMY", 248, 252], ["pulmonary sections", "ANATOMY", 282, 300], ["pulmonary alveoli", "ANATOMY", 347, 364], ["SARS", "DISEASE", 337, 341], ["haemorrhage", "DISEASE", 420, 431], ["lung", "ORGAN", 125, 129], ["animals", "ORGANISM", 157, 164], ["lung", "ORGAN", 248, 252], ["pulmonary sections", "MULTI-TISSUE_STRUCTURE", 282, 300], ["voles", "ORGANISM", 310, 315], ["SARS-CoV", "ORGANISM", 337, 345], ["pulmonary alveoli", "MULTI-TISSUE_STRUCTURE", 347, 364], ["animals", "ORGANISM", 380, 387], ["SARS-CoV", "SPECIES", 337, 345], ["microscopic inspection", "TEST", 12, 34], ["virus", "PROBLEM", 79, 84], ["the obvious pathological changes in lung", "PROBLEM", 89, 129], ["the pathologic changes in lung", "PROBLEM", 222, 252], ["Histological analysis", "TEST", 253, 274], ["the pulmonary sections", "TEST", 278, 300], ["haemorrhage", "PROBLEM", 420, 431], ["obvious", "OBSERVATION_MODIFIER", 93, 100], ["pathological", "OBSERVATION", 101, 113], ["lung", "ANATOMY", 125, 129], ["inoculated", "OBSERVATION_MODIFIER", 179, 189], ["pathologic", "OBSERVATION", 226, 236], ["lung", "ANATOMY", 248, 252], ["pulmonary", "ANATOMY", 282, 291], ["pulmonary", "ANATOMY", 347, 356], ["alveoli", "ANATOMY_MODIFIER", 357, 364], ["haemorrhage", "OBSERVATION", 420, 431]]], ["The inflammation cells invasion and the pul-monary space compression were also observed in the lung section (Fig. 6) .", [["inflammation cells", "ANATOMY", 4, 22], ["lung section", "ANATOMY", 95, 107], ["inflammation", "DISEASE", 4, 16], ["inflammation cells", "CELL", 4, 22], ["lung", "ORGAN", 95, 99], ["The inflammation cells invasion", "PROBLEM", 0, 31], ["the pul-monary space compression", "PROBLEM", 36, 68], ["inflammation cells", "OBSERVATION", 4, 22], ["invasion", "OBSERVATION_MODIFIER", 23, 31], ["pul", "ANATOMY", 40, 43], ["monary space", "ANATOMY", 44, 56], ["compression", "OBSERVATION", 57, 68], ["lung", "ANATOMY", 95, 99]]], ["Moreover, the variable features include kidney, spleen and liver haemorrhage, variable amounts of multinucleated giant cells and monocytes were detected.", [["kidney", "ANATOMY", 40, 46], ["spleen", "ANATOMY", 48, 54], ["liver", "ANATOMY", 59, 64], ["multinucleated giant cells", "ANATOMY", 98, 124], ["monocytes", "ANATOMY", 129, 138], ["kidney, spleen and liver haemorrhage", "DISEASE", 40, 76], ["kidney", "ORGAN", 40, 46], ["spleen", "ORGAN", 48, 54], ["liver", "ORGAN", 59, 64], ["multinucleated giant cells", "CELL", 98, 124], ["monocytes", "CELL", 129, 138], ["multinucleated giant cells", "CELL_TYPE", 98, 124], ["monocytes", "CELL_TYPE", 129, 138], ["kidney, spleen and liver haemorrhage", "PROBLEM", 40, 76], ["multinucleated giant cells", "PROBLEM", 98, 124], ["monocytes", "PROBLEM", 129, 138], ["kidney", "ANATOMY", 40, 46], ["spleen", "ANATOMY", 48, 54], ["liver", "ANATOMY", 59, 64], ["haemorrhage", "OBSERVATION", 65, 76], ["variable", "OBSERVATION_MODIFIER", 78, 86], ["amounts", "OBSERVATION_MODIFIER", 87, 94], ["multinucleated", "OBSERVATION_MODIFIER", 98, 112], ["giant cells", "OBSERVATION", 113, 124], ["monocytes", "OBSERVATION_MODIFIER", 129, 138]]], ["However, the lung pathological changes were found in only one of seven voles immunized with M plus N with the features of alveolar cell hyperplasia and calcify of kidney tubule, and no obvious pathological changes were observed in the lung, liver, kidney and the other organs inspected in other six vaccinated animals.DiscussionIn this study, we successfully constructed pVAX1-M and pVAX1-N expression plasmid containing the full-length M and N cDNA isolated from the SARS patient who was killed by the disease.", [["lung", "ANATOMY", 13, 17], ["alveolar cell", "ANATOMY", 122, 135], ["kidney tubule", "ANATOMY", 163, 176], ["lung", "ANATOMY", 235, 239], ["liver", "ANATOMY", 241, 246], ["kidney", "ANATOMY", 248, 254], ["organs", "ANATOMY", 269, 275], ["SARS", "DISEASE", 468, 472], ["lung", "ORGAN", 13, 17], ["alveolar cell", "CELL", 122, 135], ["kidney tubule", "MULTI-TISSUE_STRUCTURE", 163, 176], ["lung", "ORGAN", 235, 239], ["liver", "ORGAN", 241, 246], ["kidney", "ORGAN", 248, 254], ["organs", "ORGAN", 269, 275], ["pVAX1-M", "GENE_OR_GENE_PRODUCT", 371, 378], ["pVAX1-N", "GENE_OR_GENE_PRODUCT", 383, 390], ["patient", "ORGANISM", 473, 480], ["pVAX1-M and pVAX1-N expression plasmid", "DNA", 371, 409], ["N cDNA", "DNA", 443, 449], ["patient", "SPECIES", 473, 480], ["the lung pathological changes", "PROBLEM", 9, 38], ["alveolar cell hyperplasia", "PROBLEM", 122, 147], ["calcify of kidney tubule", "PROBLEM", 152, 176], ["obvious pathological changes", "PROBLEM", 185, 213], ["this study", "TEST", 331, 341], ["pVAX1", "TREATMENT", 383, 388], ["N expression plasmid", "TREATMENT", 389, 409], ["N cDNA", "TREATMENT", 443, 449], ["the disease", "PROBLEM", 499, 510], ["lung", "ANATOMY", 13, 17], ["pathological", "OBSERVATION", 18, 30], ["alveolar cell hyperplasia", "OBSERVATION", 122, 147], ["kidney", "ANATOMY", 163, 169], ["tubule", "ANATOMY_MODIFIER", 170, 176], ["no", "UNCERTAINTY", 182, 184], ["obvious", "OBSERVATION_MODIFIER", 185, 192], ["pathological", "OBSERVATION", 193, 205], ["lung", "ANATOMY", 235, 239], ["liver", "ANATOMY", 241, 246], ["kidney", "ANATOMY", 248, 254], ["disease", "OBSERVATION", 503, 510]]], ["In vivo and in vitro assay (data not shown) demonstrated that the vaccines could express in eukaryotic cells.", [["cells", "ANATOMY", 103, 108], ["cells", "CELL", 103, 108], ["eukaryotic cells", "CELL_TYPE", 92, 108], ["vitro assay", "TEST", 15, 26], ["the vaccines", "TREATMENT", 62, 74], ["eukaryotic cells", "OBSERVATION", 92, 108]]], ["In order to get the N protein for detection of specific antibodies and the T-cell mediated responses, we constructed the prokaryotic expression plasmid pET21b-N.", [["T-cell", "ANATOMY", 75, 81], ["T-cell", "CELL", 75, 81], ["pET21b", "GENE_OR_GENE_PRODUCT", 152, 158], ["N protein", "PROTEIN", 20, 29], ["specific antibodies", "PROTEIN", 47, 66], ["prokaryotic expression plasmid", "DNA", 121, 151], ["pET21b", "DNA", 152, 158], ["the N protein", "TEST", 16, 29], ["specific antibodies", "TEST", 47, 66]]], ["The recombinant could correctly express N protein in BL21 bacteria and the expression volume increased after induced by IPTG.DiscussionFurther ELISA analysis demonstrates that co-expression of M with N protein could enhance the production of the N-specific antibody in Balb/c, and the major increased antibody subclass in Balb/c is IgG2a, which is consistent with Th1 immuno-response.", [["IPTG", "CHEMICAL", 120, 124], ["IPTG", "CHEMICAL", 120, 124], ["BL21 bacteria", "GENE_OR_GENE_PRODUCT", 53, 66], ["Balb/c", "ORGANISM", 269, 275], ["Balb/c", "ORGANISM", 322, 328], ["IgG2a", "GENE_OR_GENE_PRODUCT", 332, 337], ["Th1", "GENE_OR_GENE_PRODUCT", 364, 367], ["N protein", "PROTEIN", 40, 49], ["N protein", "PROTEIN", 200, 209], ["N-specific antibody", "PROTEIN", 246, 265], ["Balb/c", "PROTEIN", 269, 275], ["antibody subclass", "PROTEIN", 301, 318], ["Balb", "PROTEIN", 322, 326], ["IgG2a", "PROTEIN", 332, 337], ["BL21", "SPECIES", 53, 57], ["N protein in BL21 bacteria", "PROBLEM", 40, 66], ["the expression volume", "PROBLEM", 71, 92], ["DiscussionFurther ELISA analysis", "TEST", 125, 157], ["co-expression of M", "PROBLEM", 176, 194], ["N protein", "PROBLEM", 200, 209], ["the N", "TEST", 242, 247], ["specific antibody in Balb/c", "PROBLEM", 248, 275], ["the major increased antibody subclass", "PROBLEM", 281, 318], ["IgG2a", "PROBLEM", 332, 337], ["volume", "OBSERVATION_MODIFIER", 86, 92], ["increased", "OBSERVATION_MODIFIER", 93, 102], ["increased", "OBSERVATION_MODIFIER", 291, 300], ["antibody subclass", "OBSERVATION", 301, 318], ["consistent with", "UNCERTAINTY", 348, 363]]], ["This result is helpful for us to explain the observation that highlevel nucleocapsid antibodies were found in the patients infected by SARS-CoV.DiscussionSince plasmid DNA itself is a potential adjuvant, in order to rule out the possibility that the immunity enhancement by M is contributed by different amounts of plasmid DNA, the N-specific antibody from the mice had been immunized with mock plus SARS-N was measured and the result revealed that there was no significance between the group of mock plus N and only N. Using the complete SARS-CoV as the capture antigen, ELISA assay shows that the absorbance value of samples from mice immunized with M and N together are positive, whereas all the sera from only M or N vaccine immunized mice is negative.DiscussionCD4+ T-cell mediated cellular response is very important when assess the efficacy of anti-viral vaccine, our study show that when stimulating lymphocytes with 10 g/ml N antigen, the CD4+ lymphocytes of the mice immunized with N or M + N vaccine is more than the mice injected with mock or M alone, and co-expression of M with N can enhance CD4+ T cells activity against N antigen.DiscussionCell-mediated cytotoxicity is another essential defense against viral pathogens, and most cytotoxic T cells are CD8+ and recognize specific antigen presented on MHC class I. That SARS-M enhances the CD8+ T cells activity specific to N antigen indicates that M could augment the cytotoxicity provoked by N DNA immunization.DiscussionT-cell-derived cytokines release represents an important defense mechanism against virus infection.", [["plasmid", "ANATOMY", 315, 322], ["samples", "ANATOMY", 619, 626], ["sera", "ANATOMY", 699, 703], ["DiscussionCD4+ T-cell", "ANATOMY", 756, 777], ["cellular", "ANATOMY", 787, 795], ["lymphocytes", "ANATOMY", 908, 919], ["CD4+ lymphocytes", "ANATOMY", 948, 964], ["CD4+", "ANATOMY", 1106, 1110], ["T cells", "ANATOMY", 1111, 1118], ["cytotoxic T cells", "ANATOMY", 1246, 1263], ["CD8+ T cells", "ANATOMY", 1355, 1367], ["cell", "ANATOMY", 1490, 1494], ["SARS", "DISEASE", 135, 139], ["infection", "DISEASE", 1577, 1586], ["patients", "ORGANISM", 114, 122], ["SARS-CoV", "ORGANISM", 135, 143], ["DNA", "CELLULAR_COMPONENT", 168, 171], ["DNA", "CELLULAR_COMPONENT", 323, 326], ["mice", "ORGANISM", 361, 365], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 539, 547], ["mice", "ORGANISM", 632, 636], ["sera", "ORGANISM_SUBSTANCE", 699, 703], ["mice", "ORGANISM", 739, 743], ["T-cell", "CELL", 771, 777], ["cellular", "CELL", 787, 795], ["lymphocytes", "CELL", 908, 919], ["N antigen", "GENE_OR_GENE_PRODUCT", 933, 942], ["CD4", "GENE_OR_GENE_PRODUCT", 948, 951], ["mice", "ORGANISM", 972, 976], ["M + N vaccine", "ORGANISM", 997, 1010], ["mice", "ORGANISM", 1028, 1032], ["CD4", "GENE_OR_GENE_PRODUCT", 1106, 1109], ["T cells", "CELL", 1111, 1118], ["N antigen", "GENE_OR_GENE_PRODUCT", 1136, 1145], ["cytotoxic T cells", "CELL", 1246, 1263], ["CD8", "GENE_OR_GENE_PRODUCT", 1268, 1271], ["SARS-M", "GENE_OR_GENE_PRODUCT", 1335, 1341], ["CD8", "GENE_OR_GENE_PRODUCT", 1355, 1358], ["N antigen", "GENE_OR_GENE_PRODUCT", 1389, 1398], ["DNA", "CELLULAR_COMPONENT", 1461, 1464], ["DiscussionT-cell", "CELL", 1478, 1494], ["highlevel nucleocapsid antibodies", "PROTEIN", 62, 95], ["plasmid DNA", "DNA", 315, 326], ["N-specific antibody", "PROTEIN", 332, 351], ["lymphocytes", "CELL_TYPE", 908, 919], ["N antigen", "PROTEIN", 933, 942], ["CD4", "PROTEIN", 948, 951], ["CD4", "PROTEIN", 1106, 1109], ["T cells", "CELL_TYPE", 1111, 1118], ["N antigen", "PROTEIN", 1136, 1145], ["cytotoxic T cells", "CELL_TYPE", 1246, 1263], ["CD8", "PROTEIN", 1268, 1271], ["CD8", "PROTEIN", 1355, 1358], ["N antigen", "PROTEIN", 1389, 1398], ["cytokines", "PROTEIN", 1503, 1512], ["patients", "SPECIES", 114, 122], ["mice", "SPECIES", 361, 365], ["mice", "SPECIES", 632, 636], ["mice", "SPECIES", 739, 743], ["mice", "SPECIES", 972, 976], ["mice", "SPECIES", 1028, 1032], ["SARS-CoV", "SPECIES", 135, 143], ["mice", "SPECIES", 361, 365], ["SARS-CoV", "SPECIES", 539, 547], ["mice", "SPECIES", 632, 636], ["mice", "SPECIES", 739, 743], ["mice", "SPECIES", 972, 976], ["mice", "SPECIES", 1028, 1032], ["highlevel nucleocapsid antibodies", "PROBLEM", 62, 95], ["the immunity enhancement", "PROBLEM", 246, 270], ["plasmid DNA", "TREATMENT", 315, 326], ["the N-specific antibody", "TEST", 328, 351], ["the capture antigen", "TEST", 551, 570], ["ELISA assay", "TEST", 572, 583], ["the absorbance value", "TEST", 595, 615], ["the sera", "TEST", 695, 703], ["anti-viral vaccine", "TREATMENT", 851, 869], ["our study", "TEST", 871, 880], ["lymphocytes", "TEST", 908, 919], ["the CD4", "TEST", 944, 951], ["M + N vaccine", "TREATMENT", 997, 1010], ["viral pathogens", "PROBLEM", 1220, 1235], ["most cytotoxic T cells", "PROBLEM", 1241, 1263], ["CD8", "TEST", 1268, 1271], ["the CD8", "TEST", 1351, 1358], ["T cells activity", "PROBLEM", 1360, 1376], ["N antigen", "TEST", 1389, 1398], ["the cytotoxicity", "PROBLEM", 1430, 1446], ["N DNA immunization", "TREATMENT", 1459, 1477], ["cell-derived cytokines release", "TREATMENT", 1490, 1520], ["virus infection", "PROBLEM", 1571, 1586]]], ["The production of Th1 cytokine IFN-\u2425 and IL-2 of lymphocytes immunized with M plus N by stimulation is significant increased compared with those of lymphocytes immunized with only N, which is in accor- dance with the result that the major increased antibody subclass against N antigen induced by M is IgG2a.DiscussionThe experiments of anti-SARS-CoV in M. brandti radde support that the immunity induced by N in combination with M DNA immunization could protect the animals from the virus challenge.DiscussionIt is not clear why the M administration can enhance the N-induced antibody production and T lymphocyte activity.", [["lymphocytes", "ANATOMY", 49, 60], ["lymphocytes", "ANATOMY", 148, 159], ["T lymphocyte", "ANATOMY", 600, 612], ["Th1", "GENE_OR_GENE_PRODUCT", 18, 21], ["IFN", "GENE_OR_GENE_PRODUCT", 31, 34], ["IL-2", "GENE_OR_GENE_PRODUCT", 41, 45], ["lymphocytes", "CELL", 49, 60], ["lymphocytes", "CELL", 148, 159], ["antibody subclass against N antigen", "GENE_OR_GENE_PRODUCT", 249, 284], ["IgG2a", "GENE_OR_GENE_PRODUCT", 301, 306], ["anti-SARS-CoV", "ORGANISM", 336, 349], ["M. brandti", "ORGANISM", 353, 363], ["radde", "ORGANISM", 364, 369], ["DNA", "CELLULAR_COMPONENT", 431, 434], ["T lymphocyte", "CELL", 600, 612], ["Th1 cytokine", "PROTEIN", 18, 30], ["IFN", "PROTEIN", 31, 34], ["lymphocytes", "CELL_TYPE", 49, 60], ["lymphocytes", "CELL_TYPE", 148, 159], ["antibody subclass", "PROTEIN", 249, 266], ["N antigen", "PROTEIN", 275, 284], ["IgG2a", "PROTEIN", 301, 306], ["M. brandti", "SPECIES", 353, 363], ["anti-SARS-CoV", "SPECIES", 336, 349], ["M. brandti", "SPECIES", 353, 363], ["Th1 cytokine IFN", "TEST", 18, 34], ["IL", "TEST", 41, 43], ["lymphocytes immunized", "TREATMENT", 49, 70], ["the major increased antibody subclass", "PROBLEM", 229, 266], ["M DNA immunization", "TREATMENT", 429, 447], ["the virus challenge", "TREATMENT", 479, 498], ["the M administration", "TREATMENT", 529, 549], ["the N-induced antibody production", "PROBLEM", 562, 595], ["T lymphocyte activity", "PROBLEM", 600, 621], ["significant", "OBSERVATION_MODIFIER", 103, 114], ["increased", "OBSERVATION_MODIFIER", 115, 124], ["lymphocyte activity", "OBSERVATION", 602, 621]]], ["Since analysis of the M protein revealed that a 121 amino acid hydrophilic domain on the inside of the virus particle is believed to interact with the N protein, and additional mammalian two-hybrid assay had proved the possible interactions between SARS-CoV N and the M protein (He et al., 2004) .", [["amino acid", "CHEMICAL", 52, 62], ["amino acid", "CHEMICAL", 52, 62], ["amino acid", "AMINO_ACID", 52, 62], ["SARS-CoV N", "GENE_OR_GENE_PRODUCT", 249, 259], ["M protein", "PROTEIN", 22, 31], ["121 amino acid hydrophilic domain", "PROTEIN", 48, 81], ["N protein", "PROTEIN", 151, 160], ["SARS-CoV N", "PROTEIN", 249, 259], ["M protein", "PROTEIN", 268, 277], ["the M protein", "TEST", 18, 31], ["a 121 amino acid hydrophilic domain", "PROBLEM", 46, 81], ["the virus particle", "PROBLEM", 99, 117], ["the N protein", "TREATMENT", 147, 160], ["hybrid assay", "TEST", 191, 203], ["virus particle", "OBSERVATION", 103, 117]]], ["We suppose that the N antigen maybe reveal more B-cell and T-cell epitopes when the M protein interacts with it.", [["B-cell", "ANATOMY", 48, 54], ["T-cell", "ANATOMY", 59, 65], ["N antigen", "GENE_OR_GENE_PRODUCT", 20, 29], ["B-cell", "CELL", 48, 54], ["T-cell", "CELL", 59, 65], ["N antigen", "PROTEIN", 20, 29], ["B-cell and T-cell epitopes", "PROTEIN", 48, 74], ["M protein", "PROTEIN", 84, 93], ["the N antigen", "TEST", 16, 29]]], ["From previous study, linking a Marek's disease virus type 1 VP22 or new castle disease virus to an antigen could improve the DNA vaccine potency (Hung et al., 2002; Termeer et al., 2000) .", [["Marek's disease", "DISEASE", 31, 46], ["Marek's disease virus type 1", "ORGANISM", 31, 59], ["VP22", "GENE_OR_GENE_PRODUCT", 60, 64], ["DNA", "CELLULAR_COMPONENT", 125, 128], ["castle disease virus", "SPECIES", 72, 92], ["Marek's disease virus type 1 VP22 or new castle disease virus", "SPECIES", 31, 92], ["previous study", "TEST", 5, 19], ["a Marek's disease virus type 1 VP22", "PROBLEM", 29, 64], ["new castle disease virus", "PROBLEM", 68, 92], ["an antigen", "TEST", 96, 106], ["new", "OBSERVATION_MODIFIER", 68, 71], ["castle disease", "OBSERVATION", 72, 86]]], ["Because M antigen is also a virus antigen, we suppose that it can enhance the efficacy of the N DNA vaccine.", [["M antigen", "GENE_OR_GENE_PRODUCT", 8, 17], ["DNA", "CELLULAR_COMPONENT", 96, 99], ["M antigen", "PROTEIN", 8, 17], ["a virus antigen", "PROBLEM", 26, 41], ["the N DNA vaccine", "TREATMENT", 90, 107]]], ["According to this, M antigen is a potential new adjuvant.DiscussionIt is predicted from the basic nature of N peptide that it may assist in RNA binding and has a novel nuclear function with playing an important role in pathogenesis for SARS-CoV.", [["nuclear", "ANATOMY", 168, 175], ["SARS-CoV", "DISEASE", 236, 244], ["N peptide", "CHEMICAL", 108, 117], ["M antigen", "GENE_OR_GENE_PRODUCT", 19, 28], ["nuclear", "CELLULAR_COMPONENT", 168, 175], ["SARS-CoV", "ORGANISM", 236, 244], ["M antigen", "PROTEIN", 19, 28], ["SARS-CoV", "SPECIES", 236, 244], ["new adjuvant", "TREATMENT", 44, 56], ["N peptide", "TREATMENT", 108, 117], ["RNA binding", "PROBLEM", 140, 151], ["SARS", "PROBLEM", 236, 240], ["new", "OBSERVATION_MODIFIER", 44, 47], ["adjuvant", "OBSERVATION", 48, 56]]], ["DNA construct encoding CRT linked to a SARS-CoV N antigen is capable of generating strong N-specific humoral and cellular immune responses and may potentially be useful for control of infection with SARS-CoV (Gao et al., 2003) .", [["cellular", "ANATOMY", 113, 121], ["SARS", "DISEASE", 39, 43], ["infection", "DISEASE", 184, 193], ["SARS", "DISEASE", 199, 203], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["SARS-CoV N antigen", "GENE_OR_GENE_PRODUCT", 39, 57], ["cellular", "CELL", 113, 121], ["SARS-CoV", "ORGANISM", 199, 207], ["CRT", "PROTEIN", 23, 26], ["SARS-CoV N antigen", "PROTEIN", 39, 57], ["SARS-CoV", "SPECIES", 39, 47], ["SARS-CoV", "SPECIES", 199, 207], ["DNA construct encoding CRT", "PROBLEM", 0, 26], ["a SARS", "TEST", 37, 43], ["CoV N antigen", "TEST", 44, 57], ["infection", "PROBLEM", 184, 193], ["SARS", "PROBLEM", 199, 203], ["infection", "OBSERVATION", 184, 193]]], ["Although antibody specific to N had no significant protective efficacy in mouse model, the data that M protein can enhance the specific immunity induced by N DNA immunization is helpful to inves-tigate the SARS pathogenesis during the course of SARS-CoV infection and further to design potential vaccines based on Tcell-medicated responses.", [["SARS", "DISEASE", 206, 210], ["SARS-CoV infection", "DISEASE", 245, 263], ["mouse", "ORGANISM", 74, 79], ["M protein", "GENE_OR_GENE_PRODUCT", 101, 110], ["DNA", "CELLULAR_COMPONENT", 158, 161], ["SARS-CoV", "ORGANISM", 245, 253], ["Tcell", "SIMPLE_CHEMICAL", 314, 319], ["M protein", "PROTEIN", 101, 110], ["mouse", "SPECIES", 74, 79], ["mouse", "SPECIES", 74, 79], ["SARS-CoV", "SPECIES", 245, 253], ["significant protective efficacy in mouse model", "PROBLEM", 39, 85], ["M protein", "PROBLEM", 101, 110], ["DNA immunization", "TREATMENT", 158, 174], ["the SARS pathogenesis", "PROBLEM", 202, 223], ["SARS", "PROBLEM", 245, 249], ["CoV infection", "PROBLEM", 250, 263], ["potential vaccines", "TREATMENT", 286, 304], ["Tcell-medicated responses", "TREATMENT", 314, 339], ["infection", "OBSERVATION", 254, 263]]]], "aa62c4043f23099f705b68ae7694fe307f41db5f": [["IntroductionThe mammalian brain consists of numerous neuronal and non-neuronal cell types whose function is supported by an extensive network of blood vessels.", [["brain", "ANATOMY", 26, 31], ["neuronal", "ANATOMY", 53, 61], ["non-neuronal cell", "ANATOMY", 66, 83], ["blood vessels", "ANATOMY", 145, 158], ["brain", "ORGAN", 26, 31], ["neuronal", "CELL", 53, 61], ["non-neuronal cell types", "CELL", 66, 89], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 145, 158], ["neuronal and non-neuronal cell types", "CELL_TYPE", 53, 89], ["mammalian", "ANATOMY_MODIFIER", 16, 25], ["brain", "ANATOMY", 26, 31], ["numerous", "OBSERVATION_MODIFIER", 44, 52], ["neuronal", "OBSERVATION", 53, 61], ["non-neuronal cell types", "OBSERVATION", 66, 89], ["extensive", "OBSERVATION_MODIFIER", 124, 133], ["blood vessels", "ANATOMY", 145, 158]]], ["Neurons are the main processing unit in the brain, coordinating and processing complex functions, including movement, memory and cognition.", [["Neurons", "ANATOMY", 0, 7], ["brain", "ANATOMY", 44, 49], ["Neurons", "CELL", 0, 7], ["brain", "ORGAN", 44, 49], ["main", "OBSERVATION_MODIFIER", 16, 20], ["brain", "ANATOMY", 44, 49]]], ["Neurons do not store substrates for energy generation and require a continuous supply of blood to provide them with oxygen and glucose for energy.", [["Neurons", "ANATOMY", 0, 7], ["blood", "ANATOMY", 89, 94], ["oxygen", "CHEMICAL", 116, 122], ["glucose", "CHEMICAL", 127, 134], ["oxygen", "CHEMICAL", 116, 122], ["glucose", "CHEMICAL", 127, 134], ["Neurons", "CELL", 0, 7], ["blood", "ORGANISM_SUBSTANCE", 89, 94], ["oxygen", "SIMPLE_CHEMICAL", 116, 122], ["glucose", "SIMPLE_CHEMICAL", 127, 134], ["a continuous supply of blood", "TREATMENT", 66, 94], ["oxygen", "TREATMENT", 116, 122]]], ["It has been shown that different levels of activity elicit commensurate changes in cerebral blood flow (CBF) and cerebral blood volume (CBV).", [["cerebral", "ANATOMY", 83, 91], ["blood", "ANATOMY", 92, 97], ["cerebral", "ANATOMY", 113, 121], ["blood", "ANATOMY", 122, 127], ["cerebral blood", "MULTI-TISSUE_STRUCTURE", 83, 97], ["cerebral blood", "MULTI-TISSUE_STRUCTURE", 113, 127], ["cerebral blood flow", "TEST", 83, 102], ["CBF", "TEST", 104, 107], ["cerebral blood volume", "TEST", 113, 134], ["different", "OBSERVATION_MODIFIER", 23, 32], ["levels", "OBSERVATION_MODIFIER", 33, 39], ["cerebral blood", "ANATOMY", 83, 97], ["cerebral blood", "ANATOMY", 113, 127]]], ["[1] [2] [3] [4] In fact, human brain imaging studies, such as BOLD fMRI (blood oxygen level dependent functional magnetic resonance imaging), use these changes in blood oxygenation which are influenced by changes in CBF to infer neural activity.", [["brain", "ANATOMY", 31, 36], ["blood", "ANATOMY", 73, 78], ["blood", "ANATOMY", 163, 168], ["neural", "ANATOMY", 229, 235], ["oxygen", "CHEMICAL", 79, 85], ["oxygen", "CHEMICAL", 79, 85], ["[1] [2] [3] [4", "SIMPLE_CHEMICAL", 0, 14], ["human", "ORGANISM", 25, 30], ["brain", "ORGAN", 31, 36], ["blood", "ORGANISM_SUBSTANCE", 73, 78], ["oxygen", "SIMPLE_CHEMICAL", 79, 85], ["blood", "ORGANISM_SUBSTANCE", 163, 168], ["CBF", "PROTEIN", 216, 219], ["human", "SPECIES", 25, 30], ["human", "SPECIES", 25, 30], ["human brain imaging studies", "TEST", 25, 52], ["BOLD fMRI", "TEST", 62, 71], ["blood oxygen level", "TEST", 73, 91], ["functional magnetic resonance imaging", "TEST", 102, 139], ["blood oxygenation", "TEST", 163, 180], ["neural activity", "OBSERVATION", 229, 244]]], ["5, 6 In most studies, increases in blood oxygenation result from disproportionate increases in CBF relative to oxygen metabolism.", [["blood", "ANATOMY", 35, 40], ["oxygen", "CHEMICAL", 111, 117], ["oxygen", "CHEMICAL", 111, 117], ["blood", "ORGANISM_SUBSTANCE", 35, 40], ["oxygen", "SIMPLE_CHEMICAL", 111, 117], ["CBF", "PROTEIN", 95, 98], ["blood oxygenation", "TEST", 35, 52], ["disproportionate increases in CBF", "PROBLEM", 65, 98], ["oxygen metabolism", "TREATMENT", 111, 128], ["increases", "OBSERVATION_MODIFIER", 22, 31], ["blood oxygenation", "OBSERVATION", 35, 52], ["disproportionate", "OBSERVATION_MODIFIER", 65, 81], ["increases", "OBSERVATION_MODIFIER", 82, 91], ["oxygen metabolism", "OBSERVATION", 111, 128]]], ["7, 8 There is increasing evidence that certain types of neurons can play a significant role in blood flow regulation.", [["neurons", "ANATOMY", 56, 63], ["blood", "ANATOMY", 95, 100], ["neurons", "CELL", 56, 63], ["blood", "ORGANISM_SUBSTANCE", 95, 100], ["blood flow regulation", "TEST", 95, 116], ["increasing", "OBSERVATION_MODIFIER", 14, 24], ["significant", "OBSERVATION_MODIFIER", 75, 86], ["blood flow", "OBSERVATION", 95, 105]]], ["[9] [10] [11] [12] [13] [14] [15] For example, slice experiments show vaso-dilatory and -constrictive effects from stimulation of vasoactive intestinal peptide (VIP) and somatostatin (SOM)-expressing interneurons, respectively.", [["interneurons", "ANATOMY", 200, 212], ["[9] [10] [11] [12] [13] [14] [15]", "CHEMICAL", 0, 33], ["[9] [10] [11] [12] [13] [14] [15]", "SIMPLE_CHEMICAL", 0, 33], ["vasoactive intestinal peptide", "GENE_OR_GENE_PRODUCT", 130, 159], ["VIP", "GENE_OR_GENE_PRODUCT", 161, 164], ["somatostatin", "GENE_OR_GENE_PRODUCT", 170, 182], ["SOM", "GENE_OR_GENE_PRODUCT", 184, 187], ["interneurons", "CELL", 200, 212], ["slice experiments", "TEST", 47, 64], ["vaso", "TEST", 70, 74], ["constrictive effects", "PROBLEM", 89, 109], ["vasoactive intestinal peptide", "TREATMENT", 130, 159], ["somatostatin (SOM", "TREATMENT", 170, 187], ["constrictive", "OBSERVATION", 89, 101], ["intestinal", "ANATOMY", 141, 151]]], ["9, 10 Understanding what types of neurons regulate cerebral blood flow will provide vital insight for a more accurate interpretation of fMRI data in health and disease conditions.", [["neurons", "ANATOMY", 34, 41], ["cerebral blood", "ANATOMY", 51, 65], ["neurons", "CELL", 34, 41], ["cerebral blood", "MULTI-TISSUE_STRUCTURE", 51, 65], ["cerebral blood flow", "TEST", 51, 70]]], ["Since brain disorders are often associated with neuronal dysfunction which can alter functional hyperemic changes, [16] [17] [18] [19] understanding the role of different neuronal sub-types on cerebral blood flow might enable the use of vascularbased fMRI methods like BOLD fMRI, CBF fMRI (e.g. arterial spin labeling) 20 or CBV fMRI (e.g. vascular space occupancy or VASO) [21] [22] [23] to detect brain dysfunction as well as monitor disease progression.IntroductionThere are two general types of neurons, excitatory and inhibitory.", [["brain", "ANATOMY", 6, 11], ["neuronal", "ANATOMY", 48, 56], ["neuronal", "ANATOMY", 171, 179], ["cerebral", "ANATOMY", 193, 201], ["blood", "ANATOMY", 202, 207], ["arterial", "ANATOMY", 295, 303], ["vascular", "ANATOMY", 340, 348], ["brain", "ANATOMY", 399, 404], ["neurons", "ANATOMY", 499, 506], ["brain disorders", "DISEASE", 6, 21], ["neuronal dysfunction", "DISEASE", 48, 68], ["brain dysfunction", "DISEASE", 399, 416], ["brain", "ORGAN", 6, 11], ["neuronal", "CELL", 48, 56], ["[16] [17] [18] [19", "SIMPLE_CHEMICAL", 115, 133], ["neuronal", "CELL", 171, 179], ["cerebral blood", "MULTI-TISSUE_STRUCTURE", 193, 207], ["arterial", "MULTI-TISSUE_STRUCTURE", 295, 303], ["vascular", "MULTI-TISSUE_STRUCTURE", 340, 348], ["brain", "ORGAN", 399, 404], ["neurons", "CELL", 499, 506], ["CBF", "PROTEIN", 280, 283], ["brain disorders", "PROBLEM", 6, 21], ["neuronal dysfunction", "PROBLEM", 48, 68], ["functional hyperemic changes", "PROBLEM", 85, 113], ["cerebral blood flow", "TEST", 193, 212], ["vascularbased fMRI methods", "TEST", 237, 263], ["BOLD fMRI", "TEST", 269, 278], ["CBF fMRI", "TEST", 280, 288], ["arterial spin labeling", "TEST", 295, 317], ["CBV fMRI", "TEST", 325, 333], ["VASO", "TEST", 368, 372], ["brain dysfunction", "PROBLEM", 399, 416], ["disease progression", "PROBLEM", 436, 455], ["brain", "ANATOMY", 6, 11], ["disorders", "OBSERVATION", 12, 21], ["vascular", "ANATOMY", 340, 348], ["brain", "ANATOMY", 399, 404], ["dysfunction", "OBSERVATION", 405, 416]]], ["Excitatory neurons propagate activity to their connected network, which includes inhibitory neurons.", [["Excitatory neurons", "ANATOMY", 0, 18], ["inhibitory neurons", "ANATOMY", 81, 99], ["Excitatory neurons", "CELL", 0, 18], ["neurons", "CELL", 92, 99], ["Excitatory neurons", "CELL_TYPE", 0, 18], ["inhibitory neurons", "CELL_TYPE", 81, 99]]], ["Inhibitory neurons suppress the propagation of spiking activity via the release of the neurotransmitter GABA.", [["neurons", "ANATOMY", 11, 18], ["GABA", "CHEMICAL", 104, 108], ["GABA", "CHEMICAL", 104, 108], ["neurons", "CELL", 11, 18], ["GABA", "SIMPLE_CHEMICAL", 104, 108], ["Inhibitory neurons", "TREATMENT", 0, 18]]], ["They work to shape and restrict the activity encoded by neural networks.", [["neural networks", "ANATOMY", 56, 71], ["neural networks", "MULTI-TISSUE_STRUCTURE", 56, 71]]], ["In addition, it is known that some inhibitory neurons can release vasoactive molecules, such as nitric oxide (NO), which is catalyzed by the enzyme nitric oxide synthase (NOS).", [["neurons", "ANATOMY", 46, 53], ["nitric oxide", "CHEMICAL", 96, 108], ["NO", "CHEMICAL", 110, 112], ["nitric oxide", "CHEMICAL", 148, 160], ["nitric oxide", "CHEMICAL", 96, 108], ["NO", "CHEMICAL", 110, 112], ["nitric oxide", "CHEMICAL", 148, 160], ["neurons", "CELL", 46, 53], ["nitric oxide", "SIMPLE_CHEMICAL", 96, 108], ["NO", "SIMPLE_CHEMICAL", 110, 112], ["nitric oxide synthase", "GENE_OR_GENE_PRODUCT", 148, 169], ["NOS", "GENE_OR_GENE_PRODUCT", 171, 174], ["inhibitory neurons", "CELL_TYPE", 35, 53], ["enzyme nitric oxide synthase", "PROTEIN", 141, 169], ["NOS", "PROTEIN", 171, 174], ["some inhibitory neurons", "PROBLEM", 30, 53], ["vasoactive molecules", "TREATMENT", 66, 86], ["nitric oxide", "TREATMENT", 96, 108], ["the enzyme nitric oxide synthase", "TREATMENT", 137, 169]]], ["It has also been reported that some inhibitory neurons are located close to intra-cortical arterial vasculature.", [["neurons", "ANATOMY", 47, 54], ["intra-cortical arterial vasculature", "ANATOMY", 76, 111], ["neurons", "CELL", 47, 54], ["intra-cortical arterial vasculature", "MULTI-TISSUE_STRUCTURE", 76, 111], ["inhibitory neurons", "CELL_TYPE", 36, 54], ["some inhibitory neurons", "PROBLEM", 31, 54], ["intra-cortical", "ANATOMY_MODIFIER", 76, 90], ["arterial", "ANATOMY_MODIFIER", 91, 99], ["vasculature", "ANATOMY", 100, 111]]], ["10, 24 These properties position inhibitory neurons as potentially vital regulators of local blood supply.", [["neurons", "ANATOMY", 44, 51], ["blood", "ANATOMY", 93, 98], ["neurons", "CELL", 44, 51], ["blood", "ORGANISM_SUBSTANCE", 93, 98], ["local blood supply", "TREATMENT", 87, 105]]], ["Numerous signaling pathways have been identified, both direct and indirect, by which neuronal activity can produce local changes in arterial diameter and blood flow.", [["neuronal", "ANATOMY", 85, 93], ["arterial", "ANATOMY", 132, 140], ["blood", "ANATOMY", 154, 159], ["neuronal", "CELL", 85, 93], ["arterial", "MULTI-TISSUE_STRUCTURE", 132, 140], ["blood", "ORGANISM_SUBSTANCE", 154, 159], ["Numerous signaling pathways", "PROBLEM", 0, 27], ["local changes in arterial diameter and blood flow", "PROBLEM", 115, 164], ["signaling pathways", "OBSERVATION", 9, 27], ["arterial", "ANATOMY", 132, 140], ["diameter", "OBSERVATION_MODIFIER", 141, 149], ["blood flow", "OBSERVATION", 154, 164]]], ["11 Since the arterio-venous pressure difference is roughly constant, blood flow regulation is essentially accomplished via dilation and constriction of vascular contractile elements (e.g. smooth muscle) in cerebral arteries, arterioles and some capillary segments.", [["arterio-venous", "ANATOMY", 13, 27], ["blood", "ANATOMY", 69, 74], ["vascular", "ANATOMY", 152, 160], ["smooth muscle", "ANATOMY", 188, 201], ["cerebral arteries", "ANATOMY", 206, 223], ["arterioles", "ANATOMY", 225, 235], ["capillary segments", "ANATOMY", 245, 263], ["arterio-venous", "MULTI-TISSUE_STRUCTURE", 13, 27], ["blood", "ORGANISM_SUBSTANCE", 69, 74], ["vascular", "MULTI-TISSUE_STRUCTURE", 152, 160], ["smooth muscle", "TISSUE", 188, 201], ["cerebral arteries", "MULTI-TISSUE_STRUCTURE", 206, 223], ["arterioles", "MULTI-TISSUE_STRUCTURE", 225, 235], ["capillary segments", "TISSUE", 245, 263], ["vascular contractile elements", "DNA", 152, 181], ["the arterio-venous pressure difference", "TEST", 9, 47], ["blood flow regulation", "TEST", 69, 90], ["dilation", "PROBLEM", 123, 131], ["constriction of vascular contractile elements", "PROBLEM", 136, 181], ["pressure", "OBSERVATION_MODIFIER", 28, 36], ["difference", "OBSERVATION", 37, 47], ["roughly", "OBSERVATION_MODIFIER", 51, 58], ["constant", "OBSERVATION_MODIFIER", 59, 67], ["blood flow", "OBSERVATION", 69, 79], ["dilation", "OBSERVATION", 123, 131], ["constriction", "OBSERVATION", 136, 148], ["vascular", "ANATOMY", 152, 160], ["contractile elements", "OBSERVATION", 161, 181], ["smooth muscle", "ANATOMY", 188, 201], ["cerebral arteries", "ANATOMY", 206, 223], ["arterioles", "ANATOMY_MODIFIER", 225, 235], ["some", "ANATOMY_MODIFIER", 240, 244], ["capillary", "ANATOMY_MODIFIER", 245, 254], ["segments", "ANATOMY_MODIFIER", 255, 263]]], ["[25] [26] [27] [28] Studies focusing on excitatory neurons (glutamatergic) have shown they release vasoactive molecules, such as prostaglandin E2, following pyramidal cell and NMDA receptor activation.", [["excitatory neurons", "ANATOMY", 40, 58], ["pyramidal cell", "ANATOMY", 157, 171], ["prostaglandin E2", "CHEMICAL", 129, 145], ["NMDA", "CHEMICAL", 176, 180], ["prostaglandin E2", "CHEMICAL", 129, 145], ["NMDA", "CHEMICAL", 176, 180], ["[25] [26] [27", "SIMPLE_CHEMICAL", 0, 13], ["neurons", "CELL", 51, 58], ["glutamatergic", "CELL", 60, 73], ["prostaglandin E2", "SIMPLE_CHEMICAL", 129, 145], ["pyramidal cell", "CELL", 157, 171], ["NMDA receptor", "GENE_OR_GENE_PRODUCT", 176, 189], ["excitatory neurons", "CELL_TYPE", 40, 58], ["NMDA receptor", "PROTEIN", 176, 189], ["vasoactive molecules", "TREATMENT", 99, 119], ["prostaglandin E2", "TREATMENT", 129, 145], ["pyramidal cell", "TREATMENT", 157, 171], ["NMDA receptor activation", "TREATMENT", 176, 200], ["vasoactive molecules", "OBSERVATION", 99, 119], ["pyramidal cell", "OBSERVATION", 157, 171]]], ["29, 30 Studies focusing on inhibitory neurons have shown they can increase local cerebral blood flow separately from excitatory neuron activity.", [["inhibitory neurons", "ANATOMY", 27, 45], ["cerebral", "ANATOMY", 81, 89], ["blood", "ANATOMY", 90, 95], ["excitatory neuron", "ANATOMY", 117, 134], ["neurons", "CELL", 38, 45], ["cerebral blood", "MULTI-TISSUE_STRUCTURE", 81, 95], ["neuron", "CELL", 128, 134], ["inhibitory neurons", "CELL_TYPE", 27, 45], ["inhibitory neurons", "TEST", 27, 45], ["local cerebral blood flow", "TEST", 75, 100], ["cerebral blood", "ANATOMY", 81, 95], ["excitatory neuron activity", "OBSERVATION", 117, 143]]], ["10, 13, 14, 24 It is evident from these studies that neurons do not regulate blood flow in the same manner, and that not all neurons may be capable of generating changes in local perfusion.IntroductionThe goal of this work is to determine the role of some populations of inhibitory neurons on CBF regulation.", [["neurons", "ANATOMY", 53, 60], ["blood", "ANATOMY", 77, 82], ["neurons", "ANATOMY", 125, 132], ["neurons", "ANATOMY", 282, 289], ["neurons", "CELL", 53, 60], ["blood", "ORGANISM_SUBSTANCE", 77, 82], ["neurons", "CELL", 125, 132], ["neurons", "CELL", 282, 289], ["inhibitory neurons", "CELL_TYPE", 271, 289], ["CBF", "PROTEIN", 293, 296], ["these studies", "TEST", 34, 47], ["blood flow", "TEST", 77, 87], ["local perfusion", "TEST", 173, 188], ["CBF regulation", "TREATMENT", 293, 307], ["local perfusion", "OBSERVATION", 173, 188]]], ["To this end, we used cre-recombinase transgenic mouse lines that target different populations of inhibitory neurons to insert the optogenetic protein Channelrhodopsin-2 (ChR2) by viral transduction and directly stimulate the cells of interest using narrow-band light (e.g. 473 nm).", [["inhibitory neurons", "ANATOMY", 97, 115], ["cells", "ANATOMY", 225, 230], ["mouse", "ORGANISM", 48, 53], ["neurons", "CELL", 108, 115], ["Channelrhodopsin-2", "GENE_OR_GENE_PRODUCT", 150, 168], ["ChR2", "GENE_OR_GENE_PRODUCT", 170, 174], ["cells", "CELL", 225, 230], ["cre-recombinase transgenic mouse lines", "CELL_LINE", 21, 59], ["inhibitory neurons", "CELL_TYPE", 97, 115], ["optogenetic protein", "PROTEIN", 130, 149], ["Channelrhodopsin-2", "PROTEIN", 150, 168], ["ChR2", "PROTEIN", 170, 174], ["mouse", "SPECIES", 48, 53], ["mouse", "SPECIES", 48, 53], ["transgenic mouse lines", "TREATMENT", 37, 59], ["inhibitory neurons", "TREATMENT", 97, 115], ["the optogenetic protein Channelrhodopsin", "TREATMENT", 126, 166], ["viral transduction", "TREATMENT", 179, 197], ["narrow-band light", "TREATMENT", 249, 266]]], ["We performed the experiments in mice that expressed ChR2 in the following protein targets of inhibitory neurons: parvalbumin (PV), vasoactive intestinal peptide (VIP), somatostatin (SOM or SST) and nitric oxide synthase (NOS).", [["neurons", "ANATOMY", 104, 111], ["nitric oxide", "CHEMICAL", 198, 210], ["nitric oxide", "CHEMICAL", 198, 210], ["mice", "ORGANISM", 32, 36], ["ChR2", "GENE_OR_GENE_PRODUCT", 52, 56], ["neurons", "CELL", 104, 111], ["parvalbumin", "GENE_OR_GENE_PRODUCT", 113, 124], ["PV", "GENE_OR_GENE_PRODUCT", 126, 128], ["vasoactive intestinal peptide", "GENE_OR_GENE_PRODUCT", 131, 160], ["VIP", "GENE_OR_GENE_PRODUCT", 162, 165], ["somatostatin", "GENE_OR_GENE_PRODUCT", 168, 180], ["SOM", "GENE_OR_GENE_PRODUCT", 182, 185], ["SST", "GENE_OR_GENE_PRODUCT", 189, 192], ["nitric oxide synthase", "GENE_OR_GENE_PRODUCT", 198, 219], ["NOS", "GENE_OR_GENE_PRODUCT", 221, 224], ["ChR2", "PROTEIN", 52, 56], ["inhibitory neurons", "CELL_TYPE", 93, 111], ["parvalbumin", "PROTEIN", 113, 124], ["PV", "PROTEIN", 126, 128], ["SST", "PROTEIN", 189, 192], ["nitric oxide synthase", "PROTEIN", 198, 219], ["NOS", "PROTEIN", 221, 224], ["mice", "SPECIES", 32, 36], ["mice", "SPECIES", 32, 36], ["parvalbumin (PV)", "TREATMENT", 113, 129], ["vasoactive intestinal peptide", "TREATMENT", 131, 160], ["VIP)", "TREATMENT", 162, 166], ["somatostatin (SOM", "TREATMENT", 168, 185], ["SST)", "TREATMENT", 189, 193], ["nitric oxide synthase", "TREATMENT", 198, 219], ["intestinal", "ANATOMY", 142, 152]]], ["These genetic targets are not all independent, mice targeting PV-and VIP-expressing neurons show little overlap, 31,32 while many NOS-expressing neurons also express SOM.", [["neurons", "ANATOMY", 84, 91], ["neurons", "ANATOMY", 145, 152], ["mice", "ORGANISM", 47, 51], ["PV", "GENE_OR_GENE_PRODUCT", 62, 64], ["VIP", "GENE_OR_GENE_PRODUCT", 69, 72], ["neurons", "CELL", 84, 91], ["NOS", "GENE_OR_GENE_PRODUCT", 130, 133], ["neurons", "CELL", 145, 152], ["PV-and VIP-expressing neurons", "CELL_LINE", 62, 91], ["NOS", "PROTEIN", 130, 133], ["mice", "SPECIES", 47, 51], ["mice", "SPECIES", 47, 51], ["PV", "SPECIES", 62, 64], ["PV", "TEST", 62, 64], ["little overlap", "PROBLEM", 97, 111]]], ["33, 34 In general, PV neurons are very active in response to sensory input and are also known to fire spontaneously at high rates.", [["PV neurons", "ANATOMY", 19, 29], ["PV neurons", "CELL", 19, 29], ["PV neurons", "CELL_TYPE", 19, 29], ["PV", "SPECIES", 19, 21], ["sensory input", "TEST", 61, 74], ["very", "OBSERVATION_MODIFIER", 34, 38], ["active", "OBSERVATION", 39, 45]]], ["35, 36 VIP neurons show similar but more complex activity patterns compared to PV neurons.", [["neurons", "ANATOMY", 11, 18], ["PV neurons", "ANATOMY", 79, 89], ["VIP neurons", "CELL", 7, 18], ["PV neurons", "CELL", 79, 89], ["PV neurons", "CELL_TYPE", 79, 89], ["more complex", "OBSERVATION_MODIFIER", 36, 48], ["activity", "OBSERVATION", 49, 57]]], ["37 SOM neurons on the other hand tend to fire at lower rates and even become hyperpolarized during sensory input (e.g. whisking), indicating a potential role in enhancing sensory processing.", [["neurons", "ANATOMY", 7, 14], ["hand", "ANATOMY", 28, 32], ["SOM neurons", "CELL", 3, 14], ["enhancing", "OBSERVATION_MODIFIER", 161, 170], ["sensory processing", "OBSERVATION", 171, 189]]], ["34, 35, 38 The function of NOS neurons is less clear, but they have been implicated in sleep regulation.", [["NOS neurons", "ANATOMY", 27, 38], ["NOS", "GENE_OR_GENE_PRODUCT", 27, 30], ["NOS neurons", "CELL_TYPE", 27, 38], ["NOS neurons", "PROBLEM", 27, 38], ["less", "OBSERVATION_MODIFIER", 42, 46], ["clear", "OBSERVATION", 47, 52]]], ["39 Since these inhibitory neuron populations compose a large fraction of all inhibitory neurons with accessible genetic targets, they were selected for experimentation and whisker stimulation was used to verify that neuro-vascular regulation is present in each mouse model.", [["inhibitory neuron populations", "ANATOMY", 15, 44], ["inhibitory neurons", "ANATOMY", 77, 95], ["neuro-vascular", "ANATOMY", 216, 230], ["neuron populations", "CELL", 26, 44], ["neurons", "CELL", 88, 95], ["mouse", "ORGANISM", 261, 266], ["inhibitory neuron populations", "CELL_TYPE", 15, 44], ["inhibitory neurons", "CELL_TYPE", 77, 95], ["mouse", "SPECIES", 261, 266], ["mouse", "SPECIES", 261, 266], ["experimentation and whisker stimulation", "TREATMENT", 152, 191], ["large", "OBSERVATION_MODIFIER", 55, 60]]], ["We considered the following guiding hypotheses: (1) inhibitory neuron populations expressing NOS are able to regulate CBF in a dose-dependent manner, (2) inhibitory neuron populations that do not express NOS do not have a significant impact on CBF regulation, and (3) inhibitory neuron populations capable of firing at high rates (i.e. PV) can regulate CBF in a dose-dependent manner but only at high stimulation frequencies (likely due to metabolic depletion).Animal preparationA total of 29 mice (male, 23-32 g; three to nine months old) were obtained from the Jackson Laboratory (Bar Harbor, ME) coding for the enzyme cre-recombinase in the genome of the targeted inhibitory neurons (PV-cre, n \u00bc 8 strain B6.129P2-Pv(albtm1(cre)Arbr)/J; VIP-cre, n \u00bc 7 strain VIP(tm1(cre)Zjh)/J; SOM-cre, n \u00bc 8 strain B6N.Cg-SST(tm2.1(cre)Zjh]/J; NOS-cre, n \u00bc 6 strain B6.129S-Nos1(tm1.1(cre/ERT2)Zjh)/J).", [["neuron", "ANATOMY", 63, 69], ["neuron", "ANATOMY", 165, 171], ["neuron", "ANATOMY", 279, 285], ["neurons", "ANATOMY", 678, 685], ["neuron populations", "CELL", 63, 81], ["NOS", "GENE_OR_GENE_PRODUCT", 93, 96], ["neuron populations", "CELL", 165, 183], ["NOS", "GENE_OR_GENE_PRODUCT", 204, 207], ["neuron populations", "CELL", 279, 297], ["mice", "ORGANISM", 493, 497], ["neurons", "CELL", 678, 685], ["cre", "GENE_OR_GENE_PRODUCT", 690, 693], ["n \u00bc 8 strain B6", "ORGANISM", 695, 710], ["129P2-Pv", "GENE_OR_GENE_PRODUCT", 711, 719], ["albtm1(cre)Arbr", "GENE_OR_GENE_PRODUCT", 720, 735], ["VIP-cre", "GENE_OR_GENE_PRODUCT", 740, 747], ["NOS-cre", "GENE_OR_GENE_PRODUCT", 833, 840], ["129S-Nos1", "GENE_OR_GENE_PRODUCT", 858, 867], ["NOS", "PROTEIN", 93, 96], ["CBF", "PROTEIN", 118, 121], ["NOS", "PROTEIN", 204, 207], ["CBF", "PROTEIN", 244, 247], ["inhibitory neuron populations", "CELL_TYPE", 268, 297], ["CBF", "PROTEIN", 353, 356], ["enzyme cre-recombinase", "PROTEIN", 614, 636], ["inhibitory neurons", "CELL_TYPE", 667, 685], ["PV", "PROTEIN", 687, 689], ["cre", "PROTEIN", 690, 693], ["129P2", "PROTEIN", 711, 716], ["J; VIP-cre", "DNA", 737, 747], ["J; SOM-cre", "DNA", 779, 789], ["SST", "DNA", 811, 814], ["NOS", "DNA", 833, 836], ["cre", "DNA", 837, 840], ["129S", "PROTEIN", 858, 862], ["Nos1", "PROTEIN", 863, 867], ["tm1.1", "PROTEIN", 868, 873], ["cre", "PROTEIN", 874, 877], ["ERT2", "PROTEIN", 878, 882], ["Zjh", "PROTEIN", 883, 886], ["J", "DNA", 888, 889], ["mice", "SPECIES", 493, 497], ["mice", "SPECIES", 493, 497], ["inhibitory neuron populations", "PROBLEM", 154, 183], ["CBF regulation", "TEST", 244, 258], ["inhibitory neuron populations", "PROBLEM", 268, 297], ["metabolic depletion", "PROBLEM", 440, 459], ["the enzyme cre-recombinase", "PROBLEM", 610, 636], ["PV", "TEST", 687, 689], ["cre", "TEST", 690, 693], ["Pv", "TEST", 717, 719], ["albtm1", "TEST", 720, 726], ["cre", "TEST", 727, 730], ["Arbr", "TEST", 731, 735], ["VIP", "TEST", 740, 743], ["cre", "TEST", 744, 747], ["strain VIP", "TEST", 755, 765], ["cre", "TEST", 770, 773], ["Zjh", "TEST", 774, 777], ["SOM", "TEST", 782, 785], ["cre", "TEST", 786, 789], ["\u00bc", "TEST", 793, 794], ["strain", "TEST", 797, 803], ["B6N.Cg", "TEST", 804, 810], ["SST", "TEST", 811, 814], ["cre", "TEST", 821, 824], ["Zjh", "TEST", 825, 828], ["NOS", "TEST", 833, 836], ["cre", "TEST", 837, 840], ["Nos1", "TEST", 863, 867], ["cre", "TEST", 874, 877], ["ERT2", "TEST", 878, 882], ["Zjh", "TEST", 883, 886], ["metabolic depletion", "OBSERVATION", 440, 459]]], ["All procedures performed followed an experimental protocol approved by the University of Pittsburgh Institutional Animal Care and Use Committee (IACUC) in accordance with the standards for humane animal care and use as set by the Animal Welfare Act (AWA), the National Institute of Health Guide for the Care and Use of Laboratory Animals and ARRIVE (Animal Research: Reporting in Vivo Experiments).", [["All procedures", "TREATMENT", 0, 14], ["an experimental protocol", "TREATMENT", 34, 58], ["humane animal care", "TREATMENT", 189, 207]]], ["Expression of the optogenetic protein Channelrhodopsin-2 (ChR2) was achieved by intra-cortical injection with AAV-DIO-ChR2(H134R)-YFP obtained from the University of North Carolina Viral Vector Core.", [["intra-cortical", "ANATOMY", 80, 94], ["Channelrhodopsin-2", "GENE_OR_GENE_PRODUCT", 38, 56], ["ChR2", "GENE_OR_GENE_PRODUCT", 58, 62], ["AAV", "ORGANISM", 110, 113], ["ChR2", "GENE_OR_GENE_PRODUCT", 118, 122], ["YFP", "GENE_OR_GENE_PRODUCT", 130, 133], ["optogenetic protein", "PROTEIN", 18, 37], ["Channelrhodopsin-2", "PROTEIN", 38, 56], ["ChR2", "PROTEIN", 58, 62], ["ChR2", "PROTEIN", 118, 122], ["H134R", "PROTEIN", 123, 128], ["YFP", "PROTEIN", 130, 133], ["the optogenetic protein Channelrhodopsin-2 (ChR2)", "TREATMENT", 14, 63], ["AAV", "TEST", 110, 113]]], ["Mice were anesthetized with ketamine (75 mg/kg) and xylazine (10 mg/kg) and placed in a stereotaxic frame (Narishige Inc., Tokyo, Japan) for craniotomy, head-plate installation, and viral injection.", [["head", "ANATOMY", 153, 157], ["ketamine", "CHEMICAL", 28, 36], ["xylazine", "CHEMICAL", 52, 60], ["ketamine", "CHEMICAL", 28, 36], ["xylazine", "CHEMICAL", 52, 60], ["Mice", "ORGANISM", 0, 4], ["ketamine", "SIMPLE_CHEMICAL", 28, 36], ["xylazine", "SIMPLE_CHEMICAL", 52, 60], ["Mice", "SPECIES", 0, 4], ["ketamine", "TREATMENT", 28, 36], ["xylazine", "TREATMENT", 52, 60], ["craniotomy", "TREATMENT", 141, 151], ["head-plate installation", "TREATMENT", 153, 176], ["viral injection", "TREATMENT", 182, 197], ["craniotomy", "OBSERVATION", 141, 151], ["head", "ANATOMY", 153, 157], ["plate", "ANATOMY", 158, 163], ["viral injection", "OBSERVATION", 182, 197]]], ["Supplementary oxygen (40% balanced by air) was administered via nose cone at 500 mL/min.", [["oxygen", "CHEMICAL", 14, 20], ["oxygen", "CHEMICAL", 14, 20], ["oxygen", "SIMPLE_CHEMICAL", 14, 20], ["Supplementary oxygen", "TREATMENT", 0, 20]]], ["Body temperature was maintained at 38 C (measured under the abdomen) using a DC feedback unit.", [["Body", "ANATOMY", 0, 4], ["abdomen", "ANATOMY", 60, 67], ["DC", "ANATOMY", 77, 79], ["Body", "ORGANISM_SUBDIVISION", 0, 4], ["abdomen", "ORGANISM_SUBDIVISION", 60, 67], ["Body temperature", "TEST", 0, 16], ["a DC feedback unit", "TREATMENT", 75, 93], ["abdomen", "ANATOMY", 60, 67]]], ["Surgery consisted of removing the skin over the skull and exposing the bone until dry.", [["skin", "ANATOMY", 34, 38], ["skull", "ANATOMY", 48, 53], ["bone", "ANATOMY", 71, 75], ["skin", "ORGAN", 34, 38], ["skull", "ORGAN", 48, 53], ["bone", "TISSUE", 71, 75], ["Surgery", "TREATMENT", 0, 7], ["the skin over the skull", "TREATMENT", 30, 53], ["skin", "ANATOMY", 34, 38], ["skull", "ANATOMY", 48, 53], ["bone", "ANATOMY", 71, 75]]], ["The aluminum head plate (Narishige Inc.) contains an 8 mm round opening that was positioned over the area of interest and then the plate was cemented onto the skull using VetBond (3M Inc.) and dental cement.", [["skull", "ANATOMY", 159, 164], ["aluminum", "CHEMICAL", 4, 12], ["aluminum", "CHEMICAL", 4, 12], ["skull", "ORGAN", 159, 164], ["The aluminum head plate (Narishige Inc.)", "TREATMENT", 0, 40], ["an 8 mm round opening", "PROBLEM", 50, 71], ["VetBond (3M Inc.) and dental cement", "TREATMENT", 171, 206], ["aluminum", "OBSERVATION", 4, 12], ["head plate", "ANATOMY", 13, 23], ["8 mm", "OBSERVATION_MODIFIER", 53, 57], ["round", "OBSERVATION_MODIFIER", 58, 63], ["opening", "OBSERVATION", 64, 71], ["area", "OBSERVATION_MODIFIER", 101, 105], ["plate", "OBSERVATION_MODIFIER", 131, 136], ["cemented", "OBSERVATION", 141, 149], ["skull", "ANATOMY", 159, 164], ["cement", "OBSERVATION", 200, 206]]], ["A craniotomy 4-mm in diameter was performed over the somatosensory cortex centered around 3 mm lateral and 1.5 mm posterior from the Bregma.", [["somatosensory cortex", "ANATOMY", 53, 73], ["somatosensory cortex", "CANCER", 53, 73], ["A craniotomy", "TREATMENT", 0, 12], ["craniotomy", "OBSERVATION", 2, 12], ["-mm", "OBSERVATION_MODIFIER", 14, 17], ["somatosensory cortex", "ANATOMY", 53, 73], ["3 mm", "OBSERVATION_MODIFIER", 90, 94], ["lateral", "OBSERVATION_MODIFIER", 95, 102], ["1.5 mm", "OBSERVATION_MODIFIER", 107, 113], ["posterior", "ANATOMY_MODIFIER", 114, 123], ["Bregma", "ANATOMY", 133, 139]]], ["Mice were then placed under the microscope to visualize the virus injection (Figure 1 (a) and (b)).", [["Mice", "ORGANISM", 0, 4], ["Mice", "SPECIES", 0, 4], ["the virus injection", "TREATMENT", 56, 75]]], ["A glass micro-pipette was used to inject small amounts of virus at depths of 300 mm and 600 mm into the somato-sensory cortex.", [["somato-sensory cortex", "ANATOMY", 104, 125], ["somato-sensory cortex", "CANCER", 104, 125], ["A glass micro-pipette", "TREATMENT", 0, 21], ["small amounts of virus", "PROBLEM", 41, 63], ["glass micro-pipette", "OBSERVATION", 2, 21], ["sensory cortex", "ANATOMY", 111, 125]]], ["A small amount of fluorescent dye (200 mM SR-101) was used to visualize virus delivery in the targeted locations.", [["SR-101", "CHEMICAL", 42, 48], ["fluorescent dye", "SIMPLE_CHEMICAL", 18, 33], ["fluorescent dye", "TREATMENT", 18, 33], ["mM SR", "TEST", 39, 44], ["virus delivery", "TREATMENT", 72, 86], ["small", "OBSERVATION_MODIFIER", 2, 7], ["amount", "OBSERVATION_MODIFIER", 8, 14], ["fluorescent dye", "OBSERVATION", 18, 33]]], ["The total injected volume was about 0.1 ml.", [["The total injected volume", "TREATMENT", 0, 25]]], ["A custom cover glass consisting of a 4-mm round cover glass glued on a 5-mm round cover glass (CS-4R and CS-5R, Warner Instruments Inc.) was cemented onto the skull to maintain visual access to the brain.", [["skull", "ANATOMY", 159, 164], ["brain", "ANATOMY", 198, 203], ["CS-4R", "CHEMICAL", 95, 100], ["skull", "ORGAN", 159, 164], ["brain", "ORGAN", 198, 203], ["A custom cover glass", "TREATMENT", 0, 20], ["a 4-mm round cover glass glued", "TREATMENT", 35, 65], ["a 5-mm round cover glass", "TREATMENT", 69, 93], ["CS", "TEST", 95, 97], ["Warner Instruments Inc.", "TREATMENT", 112, 135], ["custom", "OBSERVATION_MODIFIER", 2, 8], ["cover glass", "OBSERVATION", 9, 20], ["4-mm", "OBSERVATION_MODIFIER", 37, 41], ["round", "OBSERVATION_MODIFIER", 42, 47], ["glass glued", "OBSERVATION", 54, 65], ["skull", "ANATOMY", 159, 164], ["brain", "ANATOMY", 198, 203]]], ["Aseptic procedures were followed and mice were allowed two to three weeks for recovery.", [["mice", "ORGANISM", 37, 41], ["mice", "SPECIES", 37, 41], ["mice", "SPECIES", 37, 41], ["Aseptic procedures", "TREATMENT", 0, 18]]], ["During recovery the mice were acclimated to a custom treadmill for awake head-fixed data collection.", [["head", "ANATOMY", 73, 77], ["mice", "ORGANISM", 20, 24], ["head", "ORGANISM_SUBDIVISION", 73, 77], ["mice", "SPECIES", 20, 24], ["mice", "SPECIES", 20, 24], ["a custom treadmill", "TREATMENT", 44, 62], ["awake head", "TEST", 67, 77], ["fixed data collection", "PROBLEM", 78, 99], ["head", "ANATOMY", 73, 77]]], ["The NOS mouse model is an inducible creER line, and Tamoxifen (75 mg/kg) was administered one to two weeks postsurgery following protocol described in the Jackson Laboratory's website.Probe placementA fluorescence microscope (MVX-10, Olympus Inc., Japan) was used to identify the ChR2-YFP expression region (whisker somato-sensory cortex).", [["creER line", "ANATOMY", 36, 46], ["somato-sensory cortex", "ANATOMY", 316, 337], ["Tamoxifen", "CHEMICAL", 52, 61], ["Tamoxifen", "CHEMICAL", 52, 61], ["NOS", "GENE_OR_GENE_PRODUCT", 4, 7], ["mouse", "ORGANISM", 8, 13], ["creER line", "CELL", 36, 46], ["Tamoxifen", "SIMPLE_CHEMICAL", 52, 61], ["ChR2", "GENE_OR_GENE_PRODUCT", 280, 284], ["YFP", "GENE_OR_GENE_PRODUCT", 285, 288], ["sensory cortex", "MULTI-TISSUE_STRUCTURE", 323, 337], ["creER line", "CELL_LINE", 36, 46], ["ChR2", "PROTEIN", 280, 284], ["YFP expression region", "DNA", 285, 306], ["mouse", "SPECIES", 8, 13], ["mouse", "SPECIES", 8, 13], ["an inducible creER line", "TREATMENT", 23, 46], ["Tamoxifen", "TREATMENT", 52, 61], ["Probe placementA fluorescence microscope", "TEST", 184, 224], ["MVX", "TEST", 226, 229], ["NOS mouse model", "OBSERVATION", 4, 19], ["inducible", "OBSERVATION_MODIFIER", 26, 35], ["creER line", "OBSERVATION", 36, 46], ["sensory cortex", "ANATOMY", 323, 337]]], ["A Laser Doppler Flowmeter (LDF; Periflux 5000/411, Perimed AB, Jarfalla, Sweden) and an optic fiber (S-405-HP, core diameter of 125 mm; ThorLabs, Inc., Newton, NJ) were placed over the cover glass facing the expressing region while avoiding large surface vessels (Figure 1(a) and (b) ).", [["optic fiber", "ANATOMY", 88, 99], ["surface vessels", "ANATOMY", 247, 262], ["surface vessels", "MULTI-TISSUE_STRUCTURE", 247, 262], ["A Laser Doppler Flowmeter", "TEST", 0, 25], ["LDF", "TEST", 27, 30], ["Periflux", "TEST", 32, 40], ["Perimed", "TEST", 51, 58], ["AB", "TEST", 59, 61], ["Jarfalla", "TEST", 63, 71], ["an optic fiber", "TEST", 85, 99], ["HP", "TEST", 107, 109], ["ThorLabs", "TEST", 136, 144], ["Newton, NJ)", "TREATMENT", 152, 163], ["125 mm", "OBSERVATION_MODIFIER", 128, 134], ["large", "OBSERVATION_MODIFIER", 241, 246], ["surface", "ANATOMY_MODIFIER", 247, 254], ["vessels", "ANATOMY", 255, 262]]], ["LDF was used to acquire CBF data and the optic fiber was used to deliver the photostimulus.", [["optic fiber", "ANATOMY", 41, 52], ["optic fiber", "MULTI-TISSUE_STRUCTURE", 41, 52], ["CBF", "PROTEIN", 24, 27], ["LDF", "TEST", 0, 3], ["CBF data", "TEST", 24, 32], ["the optic fiber", "TREATMENT", 37, 52], ["the photostimulus", "TREATMENT", 73, 90]]], ["The LDF probe used has a tip diameter of 450 mm and operating wavelength of 780 nm.", [["LDF probe", "DNA", 4, 13], ["The LDF probe", "TREATMENT", 0, 13], ["a tip diameter", "TREATMENT", 23, 37], ["tip", "OBSERVATION_MODIFIER", 25, 28], ["diameter", "OBSERVATION_MODIFIER", 29, 37], ["450 mm", "OBSERVATION_MODIFIER", 41, 47], ["780 nm", "OBSERVATION_MODIFIER", 76, 82]]], ["Because each probe was placed under the fluorescence microscope, the fiber and probe were placed at a 60 angle.", [["fiber", "ANATOMY", 69, 74], ["fiber", "CELLULAR_COMPONENT", 69, 74], ["the fluorescence microscope", "TEST", 36, 63], ["the fiber and probe", "TREATMENT", 65, 84]]], ["An air puffer was also placed in front of the contralateral whisker pad to stimulate the somato-sensory cortex (Figure 1(a) ).Experimental designPhoto-stimulation and whisker stimulation experiments were performed in all animals under awake head-fixed conditions.", [["somato-sensory cortex", "ANATOMY", 89, 110], ["head", "ANATOMY", 241, 245], ["sensory cortex", "MULTI-TISSUE_STRUCTURE", 96, 110], ["head", "ORGANISM_SUBDIVISION", 241, 245], ["An air puffer", "TREATMENT", 0, 13], ["Experimental designPhoto-stimulation", "TREATMENT", 126, 162], ["whisker stimulation experiments", "TREATMENT", 167, 198], ["air puffer", "OBSERVATION", 3, 13], ["contralateral", "ANATOMY_MODIFIER", 46, 59], ["whisker pad", "OBSERVATION", 60, 71], ["sensory cortex", "ANATOMY", 96, 110]]], ["The photo-stimulus was delivered using a power-adjustable, TTL-controlled, 473 nm laser diode unit (CrystaLaser Inc., Reno, NV) connected to the optic fiber.", [["optic fiber", "ANATOMY", 145, 156], ["optic fiber", "MULTI-TISSUE_STRUCTURE", 145, 156], ["The photo", "TREATMENT", 0, 9], ["a power-adjustable", "TREATMENT", 39, 57], ["nm laser diode unit", "TREATMENT", 79, 98], ["CrystaLaser", "TREATMENT", 100, 111], ["Reno", "TREATMENT", 118, 122], ["the optic fiber", "TREATMENT", 141, 156]]], ["The laser power at the tip of the fiber was set to 1 mW measured using a power meter (Melles Griot 13PM001, IDEX Inc., Rochester, NY).", [["fiber", "ANATOMY", 34, 39], ["fiber", "CELLULAR_COMPONENT", 34, 39], ["The laser power", "TREATMENT", 0, 15], ["laser", "OBSERVATION_MODIFIER", 4, 9], ["power", "OBSERVATION_MODIFIER", 10, 15], ["tip", "OBSERVATION_MODIFIER", 23, 26], ["fiber", "OBSERVATION_MODIFIER", 34, 39]]], ["Air puffs were delivered using a pressure injector (Toohey Spritzer, Toohey Company, Fairfield, NJ) set to 30 psi.", [["Air puffs", "TREATMENT", 0, 9], ["a pressure injector", "TREATMENT", 31, 50]]], ["The photo-stimulus pulse duration and frequency were varied to modulate the amount of evoked activity and examine its impact on hemodynamic responses.", [["The photo-stimulus pulse duration", "TREATMENT", 0, 33]]], ["The photo-or whisker stimulation paradigm is described in Figure 1 (c).", [["The photo", "TREATMENT", 0, 9], ["whisker stimulation paradigm", "TREATMENT", 13, 41]]], ["In short, pulses of light (d \u00bc 30, 10 or 2 ms in duration; A \u00bc 1 mW) were delivered at an interval (I) corresponding to frequencies of either 5, 10, 20 or 40 Hz over a stimulation period (D) of either 1 s every 30 s (inter-stimulus interval or ISI) or 4 s every 40 s.", [["short", "OBSERVATION_MODIFIER", 3, 8]]], ["At least 10 stimulation trials were collected for each stimulation parameter set.", [["stimulation trials", "TREATMENT", 12, 30], ["each stimulation parameter", "TEST", 50, 76]]], ["These photo-stimulation parameters were selected based on previous experiments from our group.", [["These photo-stimulation parameters", "TEST", 0, 34]]], ["14, 40, 41 For whisker stimulation, the pulse duration and frequency were fixed to 50 ms and 5 Hz, respectively.", [["whisker stimulation", "TREATMENT", 15, 34], ["the pulse duration", "TEST", 36, 54]]], ["Although photo-stimulation and whisker stimulation initiate cortical activity in different neuronal populations (inhibitory and excitatory, respectively), whisker stimulation allowed us to verify that the physiological neurovascular mechanism was not disrupted.", [["cortical", "ANATOMY", 60, 68], ["neuronal populations", "ANATOMY", 91, 111], ["neurovascular", "ANATOMY", 219, 232], ["cortical", "MULTI-TISSUE_STRUCTURE", 60, 68], ["neuronal populations", "CELL", 91, 111], ["neurovascular", "MULTI-TISSUE_STRUCTURE", 219, 232], ["neuronal populations", "CELL_TYPE", 91, 111], ["photo-stimulation", "TREATMENT", 9, 26], ["whisker stimulation", "TREATMENT", 31, 50], ["cortical activity", "PROBLEM", 60, 77], ["whisker stimulation", "TREATMENT", 155, 174], ["the physiological neurovascular mechanism", "PROBLEM", 201, 242], ["cortical activity", "OBSERVATION", 60, 77], ["neurovascular", "ANATOMY", 219, 232]]], ["Additional experiments were conducted in a subset of mice to serve as control experiments.", [["mice", "ORGANISM", 53, 57], ["mice", "SPECIES", 53, 57], ["mice", "SPECIES", 53, 57]]], ["In these experiments, the optic fiber and LDF probe were positioned in a non-expressing region of the visible cortex.", [["optic fiber", "ANATOMY", 26, 37], ["cortex", "ANATOMY", 110, 116], ["optic fiber", "MULTI-TISSUE_STRUCTURE", 26, 37], ["LDF", "GENE_OR_GENE_PRODUCT", 42, 45], ["cortex", "CANCER", 110, 116], ["LDF probe", "DNA", 42, 51], ["the optic fiber and LDF probe", "TREATMENT", 22, 51], ["optic fiber", "OBSERVATION", 26, 37], ["visible cortex", "OBSERVATION", 102, 116]]], ["Control experiments were also performed in NOS-cre mice (NOS-creER) prior to Tamoxifen administration.", [["Tamoxifen", "CHEMICAL", 77, 86], ["Tamoxifen", "CHEMICAL", 77, 86], ["NOS-cre", "GENE_OR_GENE_PRODUCT", 43, 50], ["NOS-creER", "GENE_OR_GENE_PRODUCT", 57, 66], ["Tamoxifen", "SIMPLE_CHEMICAL", 77, 86], ["NOS", "PROTEIN", 43, 46], ["NOS", "PROTEIN", 57, 60], ["mice", "SPECIES", 51, 55], ["mice", "SPECIES", 51, 55], ["Tamoxifen administration", "TREATMENT", 77, 101]]], ["In these experiments, the LDF probe and optic fiber were placed over whisker somatosensory cortex.", [["optic fiber", "ANATOMY", 40, 51], ["somatosensory cortex", "ANATOMY", 77, 97], ["optic fiber", "MULTI-TISSUE_STRUCTURE", 40, 51], ["somatosensory cortex", "CANCER", 77, 97], ["LDF probe", "DNA", 26, 35], ["the LDF probe", "TREATMENT", 22, 35], ["optic fiber", "TREATMENT", 40, 51], ["optic fiber", "OBSERVATION", 40, 51], ["somatosensory cortex", "OBSERVATION", 77, 97]]], ["Stimulation triggers and LDF data were recorded at 1 kHz (MP150, Biopac Systems Inc., Goleta, CA).Data analysisAll data were analyzed using Matlab (Mathworks, Natick, MA, USA).", [["Stimulation triggers", "TEST", 0, 20], ["LDF data", "TEST", 25, 33], ["MP150", "TEST", 58, 63], ["Data analysis", "TEST", 98, 111], ["All data", "TEST", 111, 119]]], ["Time series of the changes in cerebral blood flow evoked by whisker or photo-stimulation were obtained from the LDF data.", [["cerebral", "ANATOMY", 30, 38], ["blood", "ANATOMY", 39, 44], ["cerebral blood", "MULTI-TISSUE_STRUCTURE", 30, 44], ["the changes", "TEST", 15, 26], ["cerebral blood flow", "TEST", 30, 49], ["photo-stimulation", "TEST", 71, 88], ["the LDF data", "TEST", 108, 120]]], ["The LDF time series were low-pass filtered with a rectangular cut-off of 4 Hz and down-sampled to 10 Hz.", [["The LDF time series", "TEST", 0, 19], ["a rectangular cut", "TREATMENT", 48, 65]]], ["Small linear trends were removed from each trial by considering only data over the 4 s preceding stimulation onset (baseline) and the last 4 s of each trial.", [["Small linear trends", "PROBLEM", 0, 19], ["linear", "OBSERVATION_MODIFIER", 6, 12], ["trends", "OBSERVATION_MODIFIER", 13, 19]]], ["Lastly, time series from trials with common stimulation parameters were averaged and then normalized by their pre-stimulation baseline level.", [["common stimulation parameters", "TEST", 37, 66]]], ["Changes in CBF were measured from the average time series as the average value 1 to 4 s after stimulation onset (for 1-s photo-stimulation) or 4 to 7 s after photostimulation (for 4-s photo-stimulation).", [["CBF", "PROTEIN", 11, 14], ["Changes in CBF", "PROBLEM", 0, 14], ["the average value", "TEST", 61, 78], ["stimulation onset", "TEST", 94, 111], ["photostimulation", "TREATMENT", 158, 174]]], ["Significant differences in CBF response amplitude were tested relative to baseline using a t-test (p < 0.05).", [["CBF", "PROTEIN", 27, 30], ["CBF response amplitude", "TEST", 27, 49], ["a t-test", "TEST", 89, 97]]], ["42 In addition, a linear mixed-effect model was used on the CBF amplitude as a function of pulse duration and frequency to test for significant relationships and account for multiple comparisons 42 (p < 0.05).", [["CBF", "PROTEIN", 60, 63], ["a linear mixed-effect model", "PROBLEM", 16, 43], ["the CBF amplitude", "TEST", 56, 73], ["test", "TEST", 123, 127], ["multiple comparisons", "TEST", 174, 194], ["linear", "OBSERVATION_MODIFIER", 18, 24], ["mixed", "OBSERVATION_MODIFIER", 25, 30]]], ["We considered a particular inhibitory neuron population to play a significant role in regulating CBF if photo-stimulation evoked significant changes from baseline in at least three out of six parameters tested and showed a significant relationship to either pulse duration or frequency.", [["neuron", "ANATOMY", 38, 44], ["neuron population", "CELL", 38, 55], ["CBF", "PROTEIN", 97, 100], ["significant changes", "PROBLEM", 129, 148]]], ["We report average values AE standard deviation throughout the manuscript and figures.ImmunostainingMice were anesthetized with sodium pentobarbital (Euthasol Solution, Virbac Animal Health Inc., Fort Worth, TX) and sacrificed by transcardial perfusion with 0.1 M phosphate buffer solution (PBS) followed by perfusion with 4% paraformaldehyde (PFA; EMS, Hatfield, PA, USA) in 0.1 M PBS (pH 7.4).", [["transcardial", "ANATOMY", 229, 241], ["sodium pentobarbital", "CHEMICAL", 127, 147], ["phosphate buffer", "CHEMICAL", 263, 279], ["sodium pentobarbital", "CHEMICAL", 127, 147], ["Euthasol", "CHEMICAL", 149, 157], ["phosphate", "CHEMICAL", 263, 272], ["paraformaldehyde", "CHEMICAL", 325, 341], ["PFA", "CHEMICAL", 343, 346], ["EMS", "CHEMICAL", 348, 351], ["Mice", "ORGANISM", 99, 103], ["sodium pentobarbital", "SIMPLE_CHEMICAL", 127, 147], ["Euthasol", "SIMPLE_CHEMICAL", 149, 157], ["phosphate buffer solution", "SIMPLE_CHEMICAL", 263, 288], ["paraformaldehyde", "SIMPLE_CHEMICAL", 325, 341], ["PFA", "SIMPLE_CHEMICAL", 343, 346], ["Mice", "SPECIES", 99, 103], ["ImmunostainingMice", "TREATMENT", 85, 103], ["sodium pentobarbital (Euthasol Solution", "TREATMENT", 127, 166], ["TX)", "TREATMENT", 207, 210], ["0.1 M phosphate buffer solution", "TREATMENT", 257, 288], ["4% paraformaldehyde (PFA", "TREATMENT", 322, 346], ["pH", "TEST", 386, 388]]], ["Brains were removed and fixed in 4% PFA solution overnight at 4 C, and then left in 30% sucrose for two nights at 4 C. Sections were cut on a freezing microtome from frontal to parietal cortex covering the cranial window area and series of 20 to 50 mm thick coronal sections were mounted on Superfrost Plus slides for storage at \u00c080 C until use, or collected into a 24 well culture plate filled with PBS for storage at 4 C. Glass or free-floating sections were washed three times in PBS for 5 min each and were blocked and permeabilized overnight at 4 C in a solution containing 0.2% Triton X-100, 5% bovine serum albumin and 10% donkey serum in PBS.", [["Brains", "ANATOMY", 0, 6], ["frontal", "ANATOMY", 166, 173], ["parietal cortex", "ANATOMY", 177, 192], ["cranial window area", "ANATOMY", 206, 225], ["coronal sections", "ANATOMY", 258, 274], ["sections", "ANATOMY", 447, 455], ["serum", "ANATOMY", 608, 613], ["serum", "ANATOMY", 637, 642], ["sucrose", "CHEMICAL", 88, 95], ["Triton X-100", "CHEMICAL", 584, 596], ["PFA", "CHEMICAL", 36, 39], ["sucrose", "CHEMICAL", 88, 95], ["Brains", "ORGAN", 0, 6], ["PFA", "SIMPLE_CHEMICAL", 36, 39], ["sucrose", "SIMPLE_CHEMICAL", 88, 95], ["frontal", "MULTI-TISSUE_STRUCTURE", 166, 173], ["parietal cortex", "MULTI-TISSUE_STRUCTURE", 177, 192], ["Triton X-100", "SIMPLE_CHEMICAL", 584, 596], ["bovine", "ORGANISM", 601, 607], ["serum", "ORGANISM_SUBSTANCE", 608, 613], ["albumin", "GENE_OR_GENE_PRODUCT", 614, 621], ["donkey", "ORGANISM", 630, 636], ["serum", "ORGANISM_SUBSTANCE", 637, 642], ["bovine", "SPECIES", 601, 607], ["donkey", "SPECIES", 630, 636], ["bovine", "SPECIES", 601, 607], ["4% PFA solution", "TREATMENT", 33, 48], ["a freezing microtome", "TREATMENT", 140, 160], ["storage", "TREATMENT", 318, 325], ["a 24 well culture plate", "TREATMENT", 364, 387], ["PBS", "TREATMENT", 400, 403], ["storage", "TREATMENT", 408, 415], ["free-floating sections", "TREATMENT", 433, 455], ["PBS", "TREATMENT", 483, 486], ["a solution", "TREATMENT", 557, 567], ["5% bovine serum albumin", "TREATMENT", 598, 621], ["10% donkey serum in PBS", "TREATMENT", 626, 649], ["left", "ANATOMY_MODIFIER", 76, 80], ["parietal", "ANATOMY_MODIFIER", 177, 185], ["cortex", "ANATOMY_MODIFIER", 186, 192], ["cranial window", "ANATOMY", 206, 220]]], ["The following primary antibodies were then applied for 72 h at 4 C: YFP (1:500, chicken anti-GFP polyclonal, ab13970, Abcam Inc., Cambridge, MA), Parvalbumin (1:500 rabbit anti-parvalbumin polyclonal, ab11427 Abcam), VIP (1:600, rabbit anti-VIP polyclonal, Immunostar, Hudson, WI), SOM (1:600, rabbit anti-SST polyclonal, HPA019472 Sigma-Aldrich, St. Loius, MO), NOS (1:500, goat anti-NOS1 polyclonal, NB100-858, Novus Biologicals, LLC, Centennial, CO).", [["Parvalbumin", "CHEMICAL", 146, 157], ["NB100-858", "CHEMICAL", 402, 411], ["YFP", "SIMPLE_CHEMICAL", 68, 71], ["chicken", "ORGANISM", 80, 87], ["Parvalbumin", "SIMPLE_CHEMICAL", 146, 157], ["rabbit", "ORGANISM", 165, 171], ["Abcam", "GENE_OR_GENE_PRODUCT", 209, 214], ["VIP", "SIMPLE_CHEMICAL", 217, 220], ["rabbit", "ORGANISM", 229, 235], ["rabbit", "ORGANISM", 294, 300], ["St. Loius", "SIMPLE_CHEMICAL", 347, 356], ["MO", "ORGANISM", 358, 360], ["NOS", "GENE_OR_GENE_PRODUCT", 363, 366], ["goat", "ORGANISM", 375, 379], ["primary antibodies", "PROTEIN", 14, 32], ["NOS", "PROTEIN", 363, 366], ["chicken", "SPECIES", 80, 87], ["rabbit", "SPECIES", 165, 171], ["rabbit", "SPECIES", 229, 235], ["rabbit", "SPECIES", 294, 300], ["goat", "SPECIES", 375, 379], ["chicken", "SPECIES", 80, 87], ["rabbit", "SPECIES", 165, 171], ["rabbit", "SPECIES", 229, 235], ["rabbit", "SPECIES", 294, 300], ["goat", "SPECIES", 375, 379], ["The following primary antibodies", "TREATMENT", 0, 32], ["YFP", "TEST", 68, 71], ["ab", "TEST", 109, 111], ["Abcam", "TEST", 118, 123], ["Parvalbumin", "TEST", 146, 157], ["ab", "TEST", 201, 203], ["VIP", "TEST", 217, 220], ["LLC", "ANATOMY", 432, 435]]], ["After washing in PBS for 30 min, the tissue was incubated with the cross-absorbed secondary antibody donkey anti-chicken Alexa488 for YFP, donkey anti-goat Alexa594 for NOS, and donkey anti-rabbit Alexa594 for PV, SOM, and VIP for 2 h at room temperature with secondary antibodies diluted 1:500 in PBS.", [["tissue", "ANATOMY", 37, 43], ["Alexa488", "CHEMICAL", 121, 129], ["Alexa594", "CHEMICAL", 197, 205], ["tissue", "TISSUE", 37, 43], ["Alexa488", "SIMPLE_CHEMICAL", 121, 129], ["YFP", "GENE_OR_GENE_PRODUCT", 134, 137], ["donkey", "ORGANISM", 139, 145], ["anti-goat Alexa594", "SIMPLE_CHEMICAL", 146, 164], ["NOS", "GENE_OR_GENE_PRODUCT", 169, 172], ["donkey", "ORGANISM", 178, 184], ["anti-rabbit Alexa594", "SIMPLE_CHEMICAL", 185, 205], ["PV", "SIMPLE_CHEMICAL", 210, 212], ["VIP", "SIMPLE_CHEMICAL", 223, 226], ["cross-absorbed secondary antibody donkey anti-chicken Alexa488 for YFP, donkey anti-goat Alexa594", "PROTEIN", 67, 164], ["NOS", "PROTEIN", 169, 172], ["secondary antibodies", "PROTEIN", 260, 280], ["donkey", "SPECIES", 101, 107], ["donkey", "SPECIES", 139, 145], ["donkey", "SPECIES", 178, 184], ["anti-rabbit", "SPECIES", 185, 196], ["donkey", "SPECIES", 139, 145], ["anti-rabbit", "SPECIES", 185, 196], ["PV", "SPECIES", 210, 212], ["PBS", "TREATMENT", 17, 20], ["NOS", "PROBLEM", 169, 172], ["donkey anti-rabbit Alexa594", "TREATMENT", 178, 205], ["PV", "PROBLEM", 210, 212], ["VIP", "TREATMENT", 223, 226], ["secondary antibodies", "TREATMENT", 260, 280], ["tissue", "ANATOMY", 37, 43]]], ["The slides were thoroughly rinsed in PBS before sections were mounted with cover glass.ImmunostainingImmunostained sections were imaged by confocal microscopy (Nikon A1 Spectral Confocal, Japan) using a 40\u00c2 objective lens.", [["sections", "ANATOMY", 48, 56], ["sections", "ANATOMY", 115, 123], ["The slides", "TREATMENT", 0, 10], ["ImmunostainingImmunostained sections", "TEST", 87, 123], ["confocal microscopy", "TEST", 139, 158]]], ["Imaging settings were optimized to eliminate background staining in all channels after calibrating the laser intensity, signal offset and amplifier gain on slices treated without primary antibody.", [["slices", "ANATOMY", 156, 162], ["primary antibody", "PROTEIN", 179, 195], ["Imaging settings", "TEST", 0, 16], ["background staining in all channels", "PROBLEM", 45, 80], ["the laser intensity", "TEST", 99, 118], ["signal offset", "PROBLEM", 120, 133], ["amplifier gain on slices", "PROBLEM", 138, 162], ["primary antibody", "PROBLEM", 179, 195]]], ["Other than making moderate adjustments for contrast and brightness, the images were not manipulated.", [["the images", "TEST", 68, 78], ["moderate", "OBSERVATION_MODIFIER", 18, 26]]], ["Images were acquired from sections covering the YFP-expressing region in the somato-sensory cortex (four to five sections).", [["sections", "ANATOMY", 26, 34], ["somato-sensory cortex", "ANATOMY", 77, 98], ["sections", "ANATOMY", 113, 121], ["YFP", "GENE_OR_GENE_PRODUCT", 48, 51], ["somato-sensory cortex", "CANCER", 77, 98], ["YFP", "PROTEIN", 48, 51], ["Images", "TEST", 0, 6], ["sensory cortex", "ANATOMY", 84, 98]]], ["We used ImageJ (NIH, USA) to analyze the images and count cells.ResultsAll animals injected with AAV-DIO-ChR2(H134R)-YFP showed expression of Channelrhodopsin-2 in somato-sensory cortex around one week post-virus (or Tamoxifen) injection.", [["cells", "ANATOMY", 58, 63], ["somato-sensory cortex", "ANATOMY", 164, 185], ["Tamoxifen", "CHEMICAL", 217, 226], ["Tamoxifen", "CHEMICAL", 217, 226], ["cells", "CELL", 58, 63], ["animals", "ORGANISM", 75, 82], ["AAV", "ORGANISM", 97, 100], ["ChR2", "GENE_OR_GENE_PRODUCT", 105, 109], ["YFP", "GENE_OR_GENE_PRODUCT", 117, 120], ["Channelrhodopsin-2", "GENE_OR_GENE_PRODUCT", 142, 160], ["sensory cortex", "MULTI-TISSUE_STRUCTURE", 171, 185], ["Tamoxifen", "SIMPLE_CHEMICAL", 217, 226], ["count cells", "CELL_TYPE", 52, 63], ["ChR2", "PROTEIN", 105, 109], ["H134R", "PROTEIN", 110, 115], ["YFP", "PROTEIN", 117, 120], ["Channelrhodopsin-2", "PROTEIN", 142, 160], ["the images", "TEST", 37, 47], ["count cells", "TEST", 52, 63], ["AAV", "TEST", 97, 100], ["Channelrhodopsin", "TEST", 142, 158], ["Tamoxifen) injection", "TREATMENT", 217, 237], ["sensory cortex", "ANATOMY", 171, 185]]], ["Expression was verified using fluorescence microscopy (Figure 2 (a) to (d)) and two-photon microscopy as evidenced by the fluorescence of YFP along cell membranes (Figure 2 (e) to (h)).", [["cell membranes", "ANATOMY", 148, 162], ["YFP", "GENE_OR_GENE_PRODUCT", 138, 141], ["cell membranes", "CELLULAR_COMPONENT", 148, 162], ["YFP", "PROTEIN", 138, 141], ["fluorescence microscopy", "TEST", 30, 53], ["two-photon microscopy", "TEST", 80, 101], ["cell membranes", "OBSERVATION", 148, 162]]], ["Experiments were performed after the expression stabilized, two to three weeks post-injection, during which time they were acclimated to our awake headfix treadmill for experimentation.Expression assessmentTo determine the specificity of the neuronal populations targeted, we first describe the expression profile by immunostaining.", [["neuronal", "ANATOMY", 242, 250], ["neuronal populations", "CELL", 242, 262], ["Expression assessment", "TEST", 185, 206], ["immunostaining", "TEST", 317, 331]]], ["In VIP-cre mice, expression was similar to previous reports.", [["VIP", "GENE_OR_GENE_PRODUCT", 3, 6], ["cre", "GENE_OR_GENE_PRODUCT", 7, 10], ["mice", "SPECIES", 11, 15], ["mice", "SPECIES", 11, 15]]], ["43, 44 Bitufted anatomical features were evident in VIP and YFP-labeled cells (Figure 3(a) ).", [["cells", "ANATOMY", 72, 77], ["VIP", "GENE_OR_GENE_PRODUCT", 52, 55], ["YFP", "GENE_OR_GENE_PRODUCT", 60, 63], ["cells", "CELL", 72, 77], ["VIP and YFP-labeled cells", "CELL_LINE", 52, 77]]], ["There was a tendency for VIP\u00fe cells to preferentially exist in Layers II/III, although immunostaining also showed them in high numbers in deeper layers.", [["VIP\u00fe cells", "ANATOMY", 25, 35], ["VIP\u00fe cells", "CELL", 25, 35], ["layers", "TISSUE", 145, 151], ["VIP\u00fe cells", "CELL_LINE", 25, 35], ["Layers II/III", "CELL_LINE", 63, 76], ["VIP\u00fe cells", "TREATMENT", 25, 35], ["immunostaining", "TEST", 87, 101], ["high numbers", "OBSERVATION", 122, 134], ["deeper layers", "OBSERVATION_MODIFIER", 138, 151]]], ["Counter-staining for YFP showed that most of ChR2-YFP(\u00fe) cells in this region were also VIP\u00fe (74.4%, Table 1 ).", [["ChR2-YFP(\u00fe) cells", "ANATOMY", 45, 62], ["YFP", "GENE_OR_GENE_PRODUCT", 21, 24], ["ChR2", "GENE_OR_GENE_PRODUCT", 45, 49], ["YFP", "GENE_OR_GENE_PRODUCT", 50, 53], ["VIP", "GENE_OR_GENE_PRODUCT", 88, 91], ["YFP", "PROTEIN", 21, 24], ["ChR2", "PROTEIN", 45, 49], ["YFP(\u00fe) cells", "CELL_LINE", 50, 62], ["YFP", "TEST", 21, 24], ["ChR2", "TEST", 45, 49], ["cells in this region", "PROBLEM", 57, 77], ["VIP\u00fe", "TEST", 88, 92]]], ["In general, VIP immunostaining was faint and positive identification often required verification among adjacent sections.", [["sections", "ANATOMY", 112, 120], ["VIP", "GENE_OR_GENE_PRODUCT", 12, 15], ["sections", "MULTI-TISSUE_STRUCTURE", 112, 120], ["VIP", "PROTEIN", 12, 15], ["VIP immunostaining", "TEST", 12, 30]]], ["Many of the YFP\u00fe/ VIP\u00c0 cells appeared to have bitufted anatomical features suggesting that these cells are also VIP\u00c0 but the staining was sufficiently faint to prevent positive identification.", [["YFP\u00fe/ VIP\u00c0 cells", "ANATOMY", 12, 28], ["cells", "ANATOMY", 97, 102], ["YFP", "GENE_OR_GENE_PRODUCT", 12, 15], ["cells", "CELL", 97, 102], ["VIP\u00c0", "GENE_OR_GENE_PRODUCT", 112, 116], ["YFP\u00fe/ VIP\u00c0 cells", "CELL_LINE", 12, 28], ["the YFP\u00fe/ VIP\u00c0 cells", "TEST", 8, 28], ["bitufted anatomical features", "PROBLEM", 46, 74], ["these cells", "PROBLEM", 91, 102], ["the staining", "TEST", 121, 133], ["positive identification", "PROBLEM", 168, 191]]], ["Nonetheless, a large fraction of YFP\u00fe cells were also VIP\u00fe.Expression assessmentIn PV-cre mice, expression was similar to that published in this mouse model.", [["YFP\u00fe cells", "ANATOMY", 33, 43], ["YFP", "GENE_OR_GENE_PRODUCT", 33, 36], ["cells", "CELL", 38, 43], ["cre", "GENE_OR_GENE_PRODUCT", 86, 89], ["mouse", "ORGANISM", 145, 150], ["YFP\u00fe cells", "CELL_LINE", 33, 43], ["VIP\u00fe", "PROTEIN", 54, 58], ["mice", "SPECIES", 90, 94], ["mouse", "SPECIES", 145, 150], ["mice", "SPECIES", 90, 94], ["mouse", "SPECIES", 145, 150], ["a large fraction of YFP\u00fe cells", "PROBLEM", 13, 43], ["large", "OBSERVATION_MODIFIER", 15, 20], ["fraction", "OBSERVATION_MODIFIER", 21, 29], ["YFP\u00fe cells", "OBSERVATION", 33, 43]]], ["31, 32, 45 PV\u00fe cells were found in higher numbers in middle and deeper cortical layers ( Figure 3(b) ).", [["PV\u00fe cells", "ANATOMY", 11, 20], ["cortical layers", "ANATOMY", 71, 86], ["\u00fe cells", "CELL", 13, 20], ["cortical layers", "TISSUE", 71, 86], ["PV\u00fe cells", "TEST", 11, 20], ["higher", "OBSERVATION_MODIFIER", 35, 41], ["numbers", "OBSERVATION_MODIFIER", 42, 49], ["middle", "ANATOMY_MODIFIER", 53, 59], ["deeper", "ANATOMY_MODIFIER", 64, 70], ["cortical", "ANATOMY_MODIFIER", 71, 79], ["layers", "ANATOMY_MODIFIER", 80, 86]]], ["Counter-staining for YFP expression showed co-labeled PV\u00fe cells in this region, especially in deeper layers (Figure 3(b) ).", [["PV\u00fe cells", "ANATOMY", 54, 63], ["YFP", "GENE_OR_GENE_PRODUCT", 21, 24], ["PV\u00fe cells", "CELL", 54, 63], ["layers", "TISSUE", 101, 107], ["YFP", "PROTEIN", 21, 24], ["co-labeled PV\u00fe cells", "CELL_LINE", 43, 63], ["PV", "SPECIES", 54, 56], ["YFP expression", "TEST", 21, 35], ["co-labeled PV\u00fe cells", "PROBLEM", 43, 63], ["PV\u00fe cells", "OBSERVATION", 54, 63]]], ["Quantification of labeled cells showed that 86% of YFP\u00fe cells were also PV\u00fe (Table 1) .", [["cells", "ANATOMY", 26, 31], ["YFP\u00fe cells", "ANATOMY", 51, 61], ["cells", "CELL", 26, 31], ["YFP", "GENE_OR_GENE_PRODUCT", 51, 54], ["cells", "CELL", 56, 61], ["YFP\u00fe cells", "CELL_LINE", 51, 61], ["PV", "SPECIES", 72, 74], ["Quantification of labeled cells", "TEST", 0, 31], ["YFP\u00fe cells", "TEST", 51, 61], ["PV", "TEST", 72, 74]]], ["No apparent preference for YFP\u00fe/PV\u00c0 negative was observed, also these cells did not appear to be pyramidal based on negative long-range projections extending out of this region.", [["cells", "ANATOMY", 70, 75], ["YFP\u00fe", "GENE_OR_GENE_PRODUCT", 27, 31], ["PV\u00c0", "GENE_OR_GENE_PRODUCT", 32, 35], ["cells", "CELL", 70, 75], ["YFP\u00fe", "PROTEIN", 27, 31], ["PV\u00c0", "PROTEIN", 32, 35], ["YFP\u00fe/PV\u00c0", "TEST", 27, 35]]], ["In SOM-cre mice, SOM and YFP immunostaining showed large numbers of positive cells throughout the somato-sensory cortex.", [["cells", "ANATOMY", 77, 82], ["somato-sensory cortex", "ANATOMY", 98, 119], ["SOM-cre", "GENE_OR_GENE_PRODUCT", 3, 10], ["mice", "ORGANISM", 11, 15], ["YFP", "GENE_OR_GENE_PRODUCT", 25, 28], ["cells", "CELL", 77, 82], ["sensory cortex", "MULTI-TISSUE_STRUCTURE", 105, 119], ["YFP", "PROTEIN", 25, 28], ["positive cells", "CELL_TYPE", 68, 82], ["mice", "SPECIES", 11, 15], ["mice", "SPECIES", 11, 15], ["YFP immunostaining", "TEST", 25, 43], ["large numbers of positive cells", "PROBLEM", 51, 82], ["large", "OBSERVATION_MODIFIER", 51, 56], ["numbers", "OBSERVATION_MODIFIER", 57, 64], ["positive cells", "OBSERVATION", 68, 82], ["sensory cortex", "ANATOMY", 105, 119]]], ["SOM labeled cells spanned layers II-VI, with higher preference to Layer II/III (Figure 3(c) ).", [["cells", "ANATOMY", 12, 17], ["cells", "CELL", 12, 17], ["SOM labeled cells", "CELL_LINE", 0, 17], ["Layer II", "PROTEIN", 66, 74], ["SOM labeled cells", "PROBLEM", 0, 17]]], ["Co-labeling for YFP showed that most YFP\u00fe were also SOM\u00fe (80%, Table 1 and Figure 3 (c)).", [["YFP", "GENE_OR_GENE_PRODUCT", 16, 19], ["YFP", "GENE_OR_GENE_PRODUCT", 37, 40], ["YFP", "PROTEIN", 16, 19], ["YFP", "PROTEIN", 37, 40], ["YFP", "TEST", 16, 19]]], ["Our findings are in agreement with previous reports for the distribution of somatostatin neurons.", [["somatostatin neurons", "ANATOMY", 76, 96], ["somatostatin", "CHEMICAL", 76, 88], ["somatostatin neurons", "CELL", 76, 96], ["somatostatin neurons", "PROBLEM", 76, 96], ["somatostatin neurons", "OBSERVATION", 76, 96]]], ["31, 34, 46 In NOS-cre mice, NOS\u00fe cells were also found throughout the cortex, similar to SOM-expressing cells (Figure 3(d) ).", [["NOS\u00fe cells", "ANATOMY", 28, 38], ["cortex", "ANATOMY", 70, 76], ["cells", "ANATOMY", 104, 109], ["NOS", "GENE_OR_GENE_PRODUCT", 14, 17], ["cre", "GENE_OR_GENE_PRODUCT", 18, 21], ["mice", "ORGANISM", 22, 26], ["NOS", "GENE_OR_GENE_PRODUCT", 28, 31], ["cortex", "CANCER", 70, 76], ["cells", "CELL", 104, 109], ["NOS", "PROTEIN", 14, 17], ["NOS\u00fe cells", "CELL_LINE", 28, 38], ["SOM-expressing cells", "CELL_LINE", 89, 109], ["mice", "SPECIES", 22, 26], ["mice", "SPECIES", 22, 26], ["NOS", "TEST", 14, 17], ["NOS\u00fe cells", "PROBLEM", 28, 38], ["cortex", "ANATOMY", 70, 76]]], ["YFP co-labeling showed some cells with significant arborization that remained in the local region and most cells were present in upper Layer II/III and also Layer VI (Figure 3(d) ).", [["cells", "ANATOMY", 28, 33], ["cells", "ANATOMY", 107, 112], ["YFP", "GENE_OR_GENE_PRODUCT", 0, 3], ["cells", "CELL", 28, 33], ["cells", "CELL", 107, 112], ["Layer VI", "PROTEIN", 157, 165], ["YFP co-labeling", "TEST", 0, 15], ["some cells", "PROBLEM", 23, 33], ["significant arborization", "PROBLEM", 39, 63], ["some cells", "OBSERVATION", 23, 33], ["significant", "OBSERVATION_MODIFIER", 39, 50], ["arborization", "OBSERVATION_MODIFIER", 51, 63], ["local", "ANATOMY_MODIFIER", 85, 90], ["region", "ANATOMY_MODIFIER", 91, 97], ["most cells", "OBSERVATION", 102, 112], ["upper Layer", "OBSERVATION_MODIFIER", 129, 140]]], ["This is consistent with previous reports indicating that NOS\u00fe cells can be preferentially located in these layers.", [["NOS\u00fe cells", "ANATOMY", 57, 67], ["NOS", "GENE_OR_GENE_PRODUCT", 57, 60], ["cells", "CELL", 62, 67], ["layers", "TISSUE", 107, 113], ["NOS", "PROTEIN", 57, 60], ["NOS\u00fe cells", "PROBLEM", 57, 67], ["consistent with", "UNCERTAINTY", 8, 23], ["\u00fe cells", "OBSERVATION", 60, 67], ["layers", "OBSERVATION_MODIFIER", 107, 113]]], ["33, 43 Most YFP\u00fe neurons were also NOS\u00fe (74.8%, Table 1 ) and, similar to the other models, no evident features from other cells types for YFP\u00fe/ NOS\u00c0 cells were observed.", [["YFP\u00fe neurons", "ANATOMY", 12, 24], ["cells", "ANATOMY", 123, 128], ["YFP\u00fe/ NOS\u00c0 cells", "ANATOMY", 139, 155], ["YFP", "GENE_OR_GENE_PRODUCT", 12, 15], ["neurons", "CELL", 17, 24], ["NOS", "GENE_OR_GENE_PRODUCT", 35, 38], ["cells", "CELL", 123, 128], ["YFP", "GENE_OR_GENE_PRODUCT", 139, 142], ["NOS\u00c0", "GENE_OR_GENE_PRODUCT", 145, 149], ["YFP", "PROTEIN", 12, 15], ["NOS", "PROTEIN", 35, 38], ["YFP\u00fe/ NOS\u00c0 cells", "CELL_LINE", 139, 155], ["NOS", "TEST", 35, 38], ["YFP\u00fe/ NOS\u00c0 cells", "PROBLEM", 139, 155], ["no evident", "UNCERTAINTY", 92, 102]]], ["We also observed high and low expressing NOS neurons in some sections, in agreement with previous reports of Type I and II NOS populations.", [["NOS neurons", "ANATOMY", 41, 52], ["sections", "ANATOMY", 61, 69], ["NOS", "GENE_OR_GENE_PRODUCT", 41, 44], ["Type I", "GENE_OR_GENE_PRODUCT", 109, 115], ["NOS", "GENE_OR_GENE_PRODUCT", 123, 126], ["NOS neurons", "CELL_TYPE", 41, 52], ["Type I and II NOS populations", "CELL_LINE", 109, 138], ["Type I and II NOS populations", "PROBLEM", 109, 138], ["high", "OBSERVATION_MODIFIER", 17, 21]]], ["33 Whisker and photo-stimulation of VIP-cre, PV-cre, SOM-cre and NOS-cre mice To verify that photo-stimulation did not elicit changes in CBF in the absence of ChR2, we performed two types of control experiments.", [["VIP-cre", "GENE_OR_GENE_PRODUCT", 36, 43], ["PV-cre", "GENE_OR_GENE_PRODUCT", 45, 51], ["SOM-cre", "GENE_OR_GENE_PRODUCT", 53, 60], ["NOS", "GENE_OR_GENE_PRODUCT", 65, 68], ["CBF", "SIMPLE_CHEMICAL", 137, 140], ["ChR2", "GENE_OR_GENE_PRODUCT", 159, 163], ["VIP-cre, PV-cre, SOM-cre", "DNA", 36, 60], ["NOS", "PROTEIN", 65, 68], ["CBF", "PROTEIN", 137, 140], ["ChR2", "PROTEIN", 159, 163], ["mice", "SPECIES", 73, 77], ["mice", "SPECIES", 73, 77], ["VIP-cre", "TEST", 36, 43], ["PV", "TEST", 45, 47], ["NOS", "TEST", 65, 68], ["changes in CBF", "PROBLEM", 126, 140], ["control experiments", "TREATMENT", 191, 210]]], ["Data acquired from non-expressing regions in the experimental mouse models did not show significant changes in CBF following photo-stimulation.", [["mouse", "ORGANISM", 62, 67], ["CBF", "PROTEIN", 111, 114], ["mouse", "SPECIES", 62, 67], ["mouse", "SPECIES", 62, 67], ["significant changes in CBF", "PROBLEM", 88, 114], ["photo-stimulation", "TREATMENT", 125, 142], ["significant", "OBSERVATION_MODIFIER", 88, 99], ["changes", "OBSERVATION", 100, 107]]], ["In addition, data acquired from whisker somatosensory cortex of NOS-cre animals prior to Tamoxifen administration showed no significant changes in CBF for any of the photo-stimulation parameters tested.", [["somatosensory cortex", "ANATOMY", 40, 60], ["Tamoxifen", "CHEMICAL", 89, 98], ["Tamoxifen", "CHEMICAL", 89, 98], ["somatosensory cortex", "MULTI-TISSUE_STRUCTURE", 40, 60], ["NOS", "GENE_OR_GENE_PRODUCT", 64, 67], ["cre", "GENE_OR_GENE_PRODUCT", 68, 71], ["Tamoxifen", "SIMPLE_CHEMICAL", 89, 98], ["NOS", "PROTEIN", 64, 67], ["CBF", "PROTEIN", 147, 150], ["NOS", "TEST", 64, 67], ["Tamoxifen administration", "TREATMENT", 89, 113], ["significant changes in CBF", "PROBLEM", 124, 150], ["the photo-stimulation parameters", "TEST", 162, 194], ["no", "UNCERTAINTY", 121, 123], ["significant", "OBSERVATION_MODIFIER", 124, 135], ["changes", "OBSERVATION", 136, 143]]], ["These findings are in agreement with previous studies by our group using similar photo-stimulation parameters in non-transgenic mice or mice expressing GFP.", [["mice", "ORGANISM", 128, 132], ["mice", "ORGANISM", 136, 140], ["GFP", "GENE_OR_GENE_PRODUCT", 152, 155], ["GFP", "PROTEIN", 152, 155], ["mice", "SPECIES", 128, 132], ["mice", "SPECIES", 136, 140], ["mice", "SPECIES", 128, 132], ["mice", "SPECIES", 136, 140], ["previous studies", "TEST", 37, 53], ["similar photo-stimulation parameters", "TREATMENT", 73, 109]]], ["40 Whisker stimulation for 1 or 4 s evoked detectable CBF responses in all mice (Figure 4 , black lines).", [["mice", "ORGANISM", 75, 79], ["black lines", "CELL", 92, 103], ["CBF", "PROTEIN", 54, 57], ["mice", "SPECIES", 75, 79], ["mice", "SPECIES", 75, 79], ["detectable CBF responses", "PROBLEM", 43, 67]]], ["On average, 1-s whisker stimulation generated increases in CBF of 15.8% across the mouse models used, while 4-s whisker stimulation generated average increases of 10.6%.", [["mouse", "ORGANISM", 83, 88], ["CBF", "PROTEIN", 59, 62], ["mouse", "SPECIES", 83, 88], ["mouse", "SPECIES", 83, 88], ["CBF", "TEST", 59, 62], ["increases", "OBSERVATION_MODIFIER", 46, 55]]], ["The average time-to-peak measured from the LDF responses was 2.6 s for 1-s whisker stimulation and 2.9 s for 4-s whisker stimulation.", [["the LDF responses", "TEST", 39, 56]]], ["Although some variability was observed in these responses, all but one were significant with p < 0.02 ( Figure 5 , black bars).", [["p", "TEST", 93, 94], ["variability", "OBSERVATION_MODIFIER", 14, 25]]], ["Altogether, whisker stimulation generated CBF responses with typical temporal features in all mice indicating that the neurovascular mechanism is not impaired.Expression assessmentIn VIP-cre mice, photo-stimulation for 1 s appeared to evoke small increases in CBF after the stimulation period, but these increases did not reach significance except for photo-stimulation at 20 Hz (p \u00bc 0.043; Figure 4 )).", [["neurovascular", "ANATOMY", 119, 132], ["mice", "ORGANISM", 94, 98], ["neurovascular", "MULTI-TISSUE_STRUCTURE", 119, 132], ["VIP", "GENE_OR_GENE_PRODUCT", 183, 186], ["CBF", "PROTEIN", 42, 45], ["CBF", "PROTEIN", 260, 263], ["mice", "SPECIES", 94, 98], ["mice", "SPECIES", 191, 195], ["mice", "SPECIES", 94, 98], ["CBF responses", "TEST", 42, 55], ["photo-stimulation", "TREATMENT", 197, 214], ["small increases in CBF", "PROBLEM", 241, 263], ["the stimulation period", "TREATMENT", 270, 292], ["photo-stimulation", "TREATMENT", 352, 369], ["neurovascular", "ANATOMY", 119, 132], ["not", "UNCERTAINTY", 146, 149], ["impaired", "OBSERVATION", 150, 158], ["small", "OBSERVATION_MODIFIER", 241, 246], ["increases", "OBSERVATION_MODIFIER", 247, 256]]], ["Fast changes in LDF signal around photo-stimulation (shaded blue bar in Figure 4 ) onset and off-set are artifactual and due to interference between the LDF probe and the photo-stimulus.", [["LDF", "PROTEIN", 16, 19], ["LDF probe", "DNA", 153, 162], ["Fast changes", "PROBLEM", 0, 12], ["LDF signal", "TEST", 16, 26], ["photo-stimulation (shaded blue bar", "TREATMENT", 34, 68], ["the LDF probe", "TREATMENT", 149, 162], ["the photo-stimulus", "TREATMENT", 167, 185]]], ["The change in CBF amplitude immediately following 4-s photo-stimulation was not significant for most of the photo-stimulation parameters tested (Figure 4 (b), Supplementary Figure 2 Figure 5 (c) and (d)).", [["CBF", "PROTEIN", 14, 17], ["CBF amplitude", "TEST", 14, 27], ["4-s photo-stimulation", "TREATMENT", 50, 71], ["the photo-stimulation parameters", "TEST", 104, 136], ["Figure", "TEST", 145, 151], ["change", "OBSERVATION_MODIFIER", 4, 10]]], ["The amplitude of the CBF changes appeared to scale with the photo-stimulus pulse duration for 1-s photo-stimulation ( Figure 5(e) ), but this trend was not significant (p \u00bc 0.09) and not present for responses evoked by 4-s photo-stimulation ( Figure 5(g) ).", [["CBF", "PROTEIN", 21, 24], ["the CBF changes", "PROBLEM", 17, 32], ["the photo", "TEST", 56, 65], ["amplitude", "OBSERVATION_MODIFIER", 4, 13], ["CBF changes", "OBSERVATION", 21, 32]]], ["On the other hand, the amplitude of the CBF response scaled with stimulation frequency for 1-s photo-stimulation (p \u00bc 0.02; Figure 5 (b) and (f)) but not 4-s photo-stimulation ( Figure 5(g) and (h) ).Expression assessmentIn PV-cre mice, photo-stimulation for either 1 or 4 s at 5 Hz did not evoke typical CBF responses (Figure 4 (c) and (d)), especially when compared to the responses evoked by whisker stimulation.", [["CBF", "PROTEIN", 40, 43], ["CBF", "PROTEIN", 305, 308], ["mice", "SPECIES", 231, 235], ["stimulation frequency", "TREATMENT", 65, 86], ["Expression assessmentIn", "TEST", 200, 223], ["PV", "TEST", 224, 226], ["photo-stimulation", "TREATMENT", 237, 254], ["CBF responses", "TEST", 305, 318], ["Figure", "TEST", 320, 326]]], ["Evident latent increases in CBF were observed 14 to 18 s after .", [["CBF", "PROTEIN", 28, 31], ["latent increases in CBF", "PROBLEM", 8, 31], ["latent", "OBSERVATION_MODIFIER", 8, 14], ["increases", "OBSERVATION_MODIFIER", 15, 24]]], ["Linear regression analyses showed no relationship between the CBF response amplitude immediately after stimulation and the photo-stimulus pulse duration or frequency (p > 0.44) except for 4-s photo-stimulation at different frequencies (p \u00bc 0.026; Figure 5 (d) and (h)).", [["CBF", "PROTEIN", 62, 65], ["Linear regression analyses", "TEST", 0, 26], ["stimulation", "TREATMENT", 103, 114], ["the photo-stimulus pulse duration", "TEST", 119, 152], ["frequency", "TEST", 156, 165], ["Figure", "TEST", 247, 253], ["no relationship", "UNCERTAINTY", 34, 49], ["response amplitude", "OBSERVATION", 66, 84]]], ["However, the relationship between the latent CBF response (14 to 18 s after stimulation onset) and the stimulation frequency was significant (p < 0.008) for 1-and 4-s photo-stimulation experiments.", [["CBF", "PROTEIN", 45, 48], ["the stimulation frequency", "TEST", 99, 124], ["latent", "OBSERVATION_MODIFIER", 38, 44], ["CBF", "OBSERVATION_MODIFIER", 45, 48], ["response", "OBSERVATION_MODIFIER", 49, 57]]], ["Different from VIP-cre and PV-cre mice, 1-and 4-s photo-stimulation at 5 Hz in SOM mice evoked evident increases in CBF (Figure 4 (e) and (f)).", [["VIP-cre", "GENE_OR_GENE_PRODUCT", 15, 22], ["PV", "GENE_OR_GENE_PRODUCT", 27, 29], ["cre", "GENE_OR_GENE_PRODUCT", 30, 33], ["mice", "ORGANISM", 83, 87], ["CBF", "PROTEIN", 116, 119], ["mice", "SPECIES", 34, 38], ["mice", "SPECIES", 83, 87], ["mice", "SPECIES", 34, 38], ["VIP-cre", "TEST", 15, 22], ["PV", "TEST", 27, 29], ["CBF", "TEST", 116, 119], ["increases", "OBSERVATION_MODIFIER", 103, 112]]], ["Temporally, the increase in CBF that follows stimulation onset peaked between 1.7 and 2.1 s for both 1 and 4-s photo-stimulation periods.", [["CBF", "PROTEIN", 28, 31], ["the increase in CBF", "PROBLEM", 12, 31], ["increase", "OBSERVATION_MODIFIER", 16, 24]]], ["In addition, the increase in CBF was consistently followed by a CBF undershoot that bottomed around 4 s for 1-s photo-stimulation and around 6 s for 4-s photo-stimulation.", [["CBF", "PROTEIN", 29, 32], ["CBF", "PROTEIN", 64, 67], ["the increase in CBF", "PROBLEM", 13, 32], ["a CBF undershoot", "PROBLEM", 62, 78], ["increase", "OBSERVATION_MODIFIER", 17, 25]]], ["For the 1-s photo-stimulation experiments, the CBF response amplitude was significantly modulated by the photo-stimulus pulse width (p \u00bc 0.0001/0.004/0.1 for 30/10/2 ms pulse durations, respectively; Figure 5 (e)) and frequency (p < 0.0008 for 10, 20 and 40 Hz, respectively; Figure 5 (f)).", [["CBF", "PROTEIN", 47, 50], ["the CBF response amplitude", "TEST", 43, 69], ["the photo", "TEST", 101, 110], ["pulse width", "TEST", 120, 131], ["p", "TEST", 133, 134], ["pulse durations", "TEST", 169, 184], ["Figure", "TEST", 200, 206]]], ["A significant relationship was observed for the CBF response amplitude following 4-s photostimulation at different frequencies ( Figure 5(g) ).", [["CBF", "PROTEIN", 48, 51], ["the CBF response amplitude", "TEST", 44, 70], ["4-s photostimulation", "TREATMENT", 81, 101], ["significant", "OBSERVATION_MODIFIER", 2, 13]]], ["The CBF increase evoked by 4-s stimulation occurred during the photo-stimulation period (shaded blue region), which is artifactually impacted by the photostimulus but mostly restricted to the onset and offset periods (Figure 4 (f) and Supplementary Figure 2(f) ).", [["CBF", "PROTEIN", 4, 7], ["the photo-stimulation period", "TREATMENT", 59, 87], ["the photostimulus", "TREATMENT", 145, 162], ["increase", "OBSERVATION_MODIFIER", 8, 16], ["impacted", "OBSERVATION_MODIFIER", 133, 141]]], ["For this reason, we only considered CBF responses following the stimulation period.", [["CBF", "PROTEIN", 36, 39], ["the stimulation period", "TREATMENT", 60, 82]]], ["More importantly, a latent increase similar to that observed in PV mice was also observed around 15 s following stimulation onset that was significantly (p < 0.0001) modulated by the stimulation frequency ( Supplementary Figure 2(f) ).Expression assessmentFor NOS-cre mice, photo-stimulation for 1 s also generated significant increases in CBF that shared similarities with the responses obtained in SOM-cre mice, but with notable differences.", [["PV mice", "ORGANISM", 64, 71], ["NOS", "GENE_OR_GENE_PRODUCT", 260, 263], ["cre", "GENE_OR_GENE_PRODUCT", 264, 267], ["CBF", "SIMPLE_CHEMICAL", 340, 343], ["cre", "GENE_OR_GENE_PRODUCT", 404, 407], ["mice", "ORGANISM", 408, 412], ["NOS", "PROTEIN", 260, 263], ["CBF", "PROTEIN", 340, 343], ["mice", "SPECIES", 67, 71], ["mice", "SPECIES", 268, 272], ["mice", "SPECIES", 408, 412], ["PV", "SPECIES", 64, 66], ["mice", "SPECIES", 268, 272], ["Expression assessment", "TEST", 235, 256], ["NOS", "TEST", 260, 263], ["photo-stimulation", "TREATMENT", 274, 291], ["significant increases in CBF", "PROBLEM", 315, 343], ["latent", "OBSERVATION_MODIFIER", 20, 26], ["increase", "OBSERVATION_MODIFIER", 27, 35], ["significant", "OBSERVATION_MODIFIER", 315, 326], ["increases", "OBSERVATION_MODIFIER", 327, 336]]], ["NOS-cre mice showed Since typical vascular responses evoked by stimulation peak several seconds after stimulation onset, we measured CBF changes 2-4 s after onset for 1-s stimulation (panels a, b, e and f) and 4-7 s after onset for 4-s stimulation (panels c, d, g and h).", [["vascular", "ANATOMY", 34, 42], ["NOS", "GENE_OR_GENE_PRODUCT", 0, 3], ["cre", "GENE_OR_GENE_PRODUCT", 4, 7], ["vascular", "MULTI-TISSUE_STRUCTURE", 34, 42], ["NOS", "PROTEIN", 0, 3], ["CBF", "PROTEIN", 133, 136], ["mice", "SPECIES", 8, 12], ["mice", "SPECIES", 8, 12], ["typical vascular responses", "PROBLEM", 26, 52], ["stimulation onset", "PROBLEM", 102, 119], ["CBF changes", "TEST", 133, 144], ["panels", "TEST", 184, 190], ["vascular", "ANATOMY", 34, 42]]], ["Significant differences from baseline are denoted by (white , p < 0.05). robust increases in CBF following optogenetic stimulation, but did not show an undershoot or latent increase following stimulation (Figure 4(g) and (h) and Supplementary Figure 2(g) and (h) ).", [["CBF", "PROTEIN", 93, 96], ["optogenetic stimulation", "TREATMENT", 107, 130], ["an undershoot", "PROBLEM", 149, 162], ["increases", "OBSERVATION_MODIFIER", 80, 89], ["latent", "OBSERVATION_MODIFIER", 166, 172], ["increase", "OBSERVATION_MODIFIER", 173, 181]]], ["All CBF increases to 1-s photo-stimulation were significant (p \u00bc 0.005/ 0.022/0.029 for 30/10/2 ms pulse duration, respectively, and p \u00bc 0.013/0.011/0.012 for 10/20/40 Hz, respectively; Figure 5(a) and (b) ).", [["CBF", "PROTEIN", 4, 7], ["All CBF increases", "TEST", 0, 17], ["pulse duration", "TEST", 99, 113], ["Hz", "TEST", 168, 170], ["increases", "OBSERVATION_MODIFIER", 8, 17]]], ["The peak CBF response was between 1.8 and 2.3 s for 1-s photo-stimulation and between 2.7 and 4.8 s for 4-s photo-stimulation.", [["CBF", "PROTEIN", 9, 12], ["The peak CBF response", "TEST", 0, 21]]], ["We observed larger variability for the CBF responses to 4-s photo-stimulation partly due to the fast CBF response peak and return to baseline.", [["CBF", "PROTEIN", 39, 42], ["CBF", "PROTEIN", 101, 104], ["the CBF responses", "TEST", 35, 52], ["photo-stimulation", "TREATMENT", 60, 77], ["the fast CBF response peak", "PROBLEM", 92, 118], ["larger", "OBSERVATION_MODIFIER", 12, 18], ["variability", "OBSERVATION_MODIFIER", 19, 30]]], ["Increasing the frequency of 4-s photo-stimulation induced prolonged CBF increases that returned to baseline 25 to 30 s after stimulation onset (vs. 5 to 10 s for all other responses in NOS-cre mice).", [["NOS-cre", "GENE_OR_GENE_PRODUCT", 185, 192], ["CBF", "PROTEIN", 68, 71], ["NOS", "PROTEIN", 185, 188], ["mice", "SPECIES", 193, 197], ["prolonged CBF increases", "PROBLEM", 58, 81], ["stimulation onset", "PROBLEM", 125, 142], ["increases", "OBSERVATION_MODIFIER", 72, 81]]], ["Linear regression analyses showed significant relationships between CBF response and all photo-stimulation parameters tested ( Figure 5 (e) to (h) with p < 0.01).", [["CBF", "PROTEIN", 68, 71], ["Linear regression analyses", "TEST", 0, 26], ["CBF response", "TEST", 68, 80], ["all photo-stimulation parameters", "TEST", 85, 117], ["significant", "OBSERVATION_MODIFIER", 34, 45]]], ["Interestingly, photo-stimulation for 1-or 4-s with pulse durations of 10 or 30 ms produced CBF responses that were similar (or larger) in magnitude to whisker-evoked CBF responses.", [["CBF", "PROTEIN", 91, 94], ["CBF", "PROTEIN", 166, 169], ["photo-stimulation", "TREATMENT", 15, 32], ["pulse durations", "TEST", 51, 66], ["CBF responses", "TEST", 91, 104]]], ["Similar increases were also observed in SOM-cre mice (Figure 4 (e) to (h)).", [["mice", "ORGANISM", 48, 52], ["mice", "SPECIES", 48, 52], ["mice", "SPECIES", 48, 52], ["increases", "OBSERVATION_MODIFIER", 8, 17]]], ["Photo-stimulation of NOS-cre mice for longer pulse durations or higher stimulation frequencies produced the largest CBF increases out of all the mouse models tested (Figures 4 and 5 ).DiscussionWe investigated the role of sub-types of inhibitory neurons on the regulation of cerebral blood flow using different transgenic mouse models (PV-cre, VIP-cre, SOM-cre and NOS-cre).", [["inhibitory neurons", "ANATOMY", 235, 253], ["cerebral", "ANATOMY", 275, 283], ["blood", "ANATOMY", 284, 289], ["NOS", "GENE_OR_GENE_PRODUCT", 21, 24], ["cre", "GENE_OR_GENE_PRODUCT", 25, 28], ["mouse", "ORGANISM", 145, 150], ["neurons", "CELL", 246, 253], ["cerebral blood", "MULTI-TISSUE_STRUCTURE", 275, 289], ["mouse", "ORGANISM", 322, 327], ["PV-cre", "GENE_OR_GENE_PRODUCT", 336, 342], ["VIP-cre", "GENE_OR_GENE_PRODUCT", 344, 351], ["SOM-cre", "GENE_OR_GENE_PRODUCT", 353, 360], ["NOS-cre", "GENE_OR_GENE_PRODUCT", 365, 372], ["NOS", "PROTEIN", 21, 24], ["CBF", "PROTEIN", 116, 119], ["inhibitory neurons", "CELL_TYPE", 235, 253], ["PV-cre, VIP-cre, SOM-cre", "DNA", 336, 360], ["NOS", "DNA", 365, 368], ["cre", "DNA", 369, 372], ["mice", "SPECIES", 29, 33], ["mouse", "SPECIES", 145, 150], ["mouse", "SPECIES", 322, 327], ["mouse", "SPECIES", 145, 150], ["mouse", "SPECIES", 322, 327], ["NOS", "TEST", 21, 24], ["longer pulse durations", "PROBLEM", 38, 60], ["higher stimulation frequencies", "PROBLEM", 64, 94], ["the largest CBF", "TEST", 104, 119], ["Figures", "TEST", 166, 173], ["inhibitory neurons", "PROBLEM", 235, 253], ["cerebral blood flow", "TEST", 275, 294], ["different transgenic mouse models", "TREATMENT", 301, 334], ["PV", "TEST", 336, 338], ["cre", "TEST", 339, 342], ["VIP", "TEST", 344, 347], ["largest", "OBSERVATION_MODIFIER", 108, 115]]], ["Channelrhosopin-2 was virally expressed in somato-sensory cortex.", [["somato-sensory cortex", "ANATOMY", 43, 64], ["Channelrhosopin-2", "GENE_OR_GENE_PRODUCT", 0, 17], ["somato-sensory cortex", "CANCER", 43, 64], ["Channelrhosopin", "TREATMENT", 0, 15], ["sensory cortex", "ANATOMY", 50, 64]]], ["To ensure the neurovascular mechanisms were not perturbed by surgery or viral transduction, whisker stimulation was used to determine whether typical CBF responses were present in all mouse models.", [["neurovascular", "ANATOMY", 14, 27], ["neurovascular", "MULTI-TISSUE_STRUCTURE", 14, 27], ["CBF", "SIMPLE_CHEMICAL", 150, 153], ["mouse", "ORGANISM", 184, 189], ["CBF", "PROTEIN", 150, 153], ["mouse", "SPECIES", 184, 189], ["mouse", "SPECIES", 184, 189], ["viral transduction", "TREATMENT", 72, 90], ["whisker stimulation", "TREATMENT", 92, 111], ["typical CBF responses", "PROBLEM", 142, 163], ["neurovascular", "ANATOMY", 14, 27]]], ["We observed typical CBF responses evoked by whisker stimulation, with average peak amplitude of 13.2% taking place 2 to 4 s following onset and subsided 10 to 15 s after stimulus cessation.", [["CBF", "PROTEIN", 20, 23], ["whisker stimulation", "TEST", 44, 63], ["average peak amplitude", "TEST", 70, 92]]], ["Photo-stimulation of SOM-cre and NOS-cre mice produced significant increases in CBF that were similar to that evoked by whisker stimulation.", [["SOM-cre", "GENE_OR_GENE_PRODUCT", 21, 28], ["NOS", "GENE_OR_GENE_PRODUCT", 33, 36], ["cre", "GENE_OR_GENE_PRODUCT", 37, 40], ["NOS", "PROTEIN", 33, 36], ["CBF", "PROTEIN", 80, 83], ["mice", "SPECIES", 41, 45], ["NOS", "TEST", 33, 36], ["significant increases in CBF", "PROBLEM", 55, 83], ["significant", "OBSERVATION_MODIFIER", 55, 66], ["increases", "OBSERVATION_MODIFIER", 67, 76]]], ["Photo-stimulation in NOS-cre mice produced significant CBF responses (overall average increase of 19.2%) that scaled with the stimulus pulse duration and frequency.", [["NOS", "GENE_OR_GENE_PRODUCT", 21, 24], ["cre", "GENE_OR_GENE_PRODUCT", 25, 28], ["NOS", "PROTEIN", 21, 24], ["CBF", "PROTEIN", 55, 58], ["mice", "SPECIES", 29, 33], ["Photo-stimulation", "TEST", 0, 17], ["significant CBF responses", "PROBLEM", 43, 68], ["the stimulus pulse duration", "TEST", 122, 149]]], ["The amplitude of the CBF responses in these mice was similar to those produced by whisker stimulation; however, in SOM-cre mice, CBF increases (11.1% on average) were followed by prominent post-stimulation undershoots.", [["mice", "ORGANISM", 44, 48], ["SOM-cre", "GENE_OR_GENE_PRODUCT", 115, 122], ["mice", "ORGANISM", 123, 127], ["CBF", "PROTEIN", 21, 24], ["CBF", "PROTEIN", 129, 132], ["mice", "SPECIES", 44, 48], ["mice", "SPECIES", 123, 127], ["CBF", "TEST", 129, 132], ["amplitude", "OBSERVATION_MODIFIER", 4, 13], ["prominent", "OBSERVATION_MODIFIER", 179, 188], ["post-stimulation", "OBSERVATION_MODIFIER", 189, 205]]], ["Photo-stimulation in VIP-cre mice did not produce significant changes in CBF except for 1-s photo-stimulation at frequencies over 5 Hz.", [["VIP-cre", "GENE_OR_GENE_PRODUCT", 21, 28], ["CBF", "PROTEIN", 73, 76], ["mice", "SPECIES", 29, 33], ["Photo-stimulation", "TREATMENT", 0, 17], ["significant changes in CBF", "PROBLEM", 50, 76]]], ["Also, photo-stimulation in PVcre mice did not produce typical increases in CBF, rather slow and latent increases in CBF were observed that scaled with stimulus duration and frequency and peaked 14 to 18 s after stimulation onset.", [["PVcre", "ORGANISM", 27, 32], ["mice", "ORGANISM", 33, 37], ["CBF", "SIMPLE_CHEMICAL", 116, 119], ["CBF", "PROTEIN", 75, 78], ["CBF", "PROTEIN", 116, 119], ["mice", "SPECIES", 33, 37], ["mice", "SPECIES", 33, 37], ["photo-stimulation", "TREATMENT", 6, 23], ["typical increases in CBF", "PROBLEM", 54, 78], ["latent increases in CBF", "PROBLEM", 96, 119], ["stimulus duration", "TEST", 151, 168], ["frequency", "TEST", 173, 182], ["increases", "OBSERVATION_MODIFIER", 62, 71], ["slow", "OBSERVATION_MODIFIER", 87, 91], ["latent", "OBSERVATION_MODIFIER", 96, 102], ["increases", "OBSERVATION_MODIFIER", 103, 112]]], ["Control experiments performed in non-expressing regions of these mice or in NOS-cre mice prior to Tamoxifen administration showed no changes in CBF following photo-stimulation.", [["Tamoxifen", "CHEMICAL", 98, 107], ["Tamoxifen", "CHEMICAL", 98, 107], ["mice", "ORGANISM", 65, 69], ["NOS", "GENE_OR_GENE_PRODUCT", 76, 79], ["cre", "GENE_OR_GENE_PRODUCT", 80, 83], ["Tamoxifen", "SIMPLE_CHEMICAL", 98, 107], ["CBF", "SIMPLE_CHEMICAL", 144, 147], ["NOS", "PROTEIN", 76, 79], ["CBF", "PROTEIN", 144, 147], ["mice", "SPECIES", 65, 69], ["mice", "SPECIES", 84, 88], ["mice", "SPECIES", 65, 69], ["mice", "SPECIES", 84, 88], ["Tamoxifen administration", "TREATMENT", 98, 122], ["changes in CBF", "PROBLEM", 133, 147], ["photo-stimulation", "TREATMENT", 158, 175], ["no", "UNCERTAINTY", 130, 132]]], ["Collectively, our results indicate that NOS-expressing inhibitory neurons are able to strongly regulate local CBF, while SOM-expressing inhibitory neurons can both increase and provide an undershoot in CBF.", [["inhibitory neurons", "ANATOMY", 55, 73], ["neurons", "ANATOMY", 147, 154], ["NOS", "GENE_OR_GENE_PRODUCT", 40, 43], ["neurons", "CELL", 66, 73], ["CBF", "GENE_OR_GENE_PRODUCT", 110, 113], ["SOM", "GENE_OR_GENE_PRODUCT", 121, 124], ["neurons", "CELL", 147, 154], ["NOS", "PROTEIN", 40, 43], ["inhibitory neurons", "CELL_TYPE", 55, 73], ["CBF", "PROTEIN", 110, 113], ["SOM", "PROTEIN", 121, 124], ["inhibitory neurons", "CELL_TYPE", 136, 154], ["CBF", "PROTEIN", 202, 205], ["an undershoot in CBF", "PROBLEM", 185, 205]]], ["On the other hand, VIP and PVexpressing neurons do not appear to play a significant role in local CBF regulation.", [["PVexpressing neurons", "ANATOMY", 27, 47], ["VIP", "GENE_OR_GENE_PRODUCT", 19, 22], ["PVexpressing neurons", "CELL", 27, 47], ["PVexpressing neurons", "CELL_TYPE", 27, 47], ["CBF", "PROTEIN", 98, 101], ["local CBF regulation", "TEST", 92, 112]]], ["These findings build on previous studies to clarify the role and impact of subpopulations of neurons on local blood flow regulation.", [["neurons", "ANATOMY", 93, 100], ["blood", "ANATOMY", 110, 115], ["neurons", "CELL", 93, 100], ["blood", "ORGANISM_SUBSTANCE", 110, 115], ["previous studies", "TEST", 24, 40], ["local blood flow regulation", "TEST", 104, 131], ["subpopulations", "OBSERVATION", 75, 89]]], ["More importantly, our findings suggest that dysfunction in NOS or SOM neurons can have a significant impact on CBF responses that could be detected by vascular-sensitive brain imaging methods, like BOLD, CBF (e.g. arterial spin labeling) or CBV (e.g. VASO) fMRI.DiscussionTwo-photon microscopy images acquired prior to experimentation revealed numerous ChR2-YFP neurons in the somato-sensory cortex of all models used.", [["SOM neurons", "ANATOMY", 66, 77], ["vascular", "ANATOMY", 151, 159], ["brain", "ANATOMY", 170, 175], ["arterial", "ANATOMY", 214, 222], ["ChR2-YFP neurons", "ANATOMY", 353, 369], ["somato-sensory cortex", "ANATOMY", 377, 398], ["NOS", "GENE_OR_GENE_PRODUCT", 59, 62], ["CBF", "SIMPLE_CHEMICAL", 111, 114], ["vascular", "MULTI-TISSUE_STRUCTURE", 151, 159], ["brain", "ORGAN", 170, 175], ["arterial", "MULTI-TISSUE_STRUCTURE", 214, 222], ["ChR2", "GENE_OR_GENE_PRODUCT", 353, 357], ["YFP", "GENE_OR_GENE_PRODUCT", 358, 361], ["sensory cortex", "MULTI-TISSUE_STRUCTURE", 384, 398], ["NOS", "PROTEIN", 59, 62], ["CBF", "PROTEIN", 111, 114], ["CBF", "PROTEIN", 204, 207], ["ChR2", "PROTEIN", 353, 357], ["dysfunction in NOS", "PROBLEM", 44, 62], ["SOM neurons", "PROBLEM", 66, 77], ["CBF", "TEST", 204, 207], ["arterial spin labeling", "TEST", 214, 236], ["CBV", "TEST", 241, 244], ["fMRI", "TEST", 257, 261], ["Two-photon microscopy images", "TEST", 272, 300], ["experimentation", "TEST", 319, 334], ["dysfunction", "OBSERVATION", 44, 55], ["significant", "OBSERVATION_MODIFIER", 89, 100], ["vascular", "ANATOMY", 151, 159], ["YFP neurons", "OBSERVATION", 358, 369], ["sensory cortex", "ANATOMY", 384, 398]]], ["Immunostaining post-experimentation verified that the mouse models successfully targeted large fractions of the inhibitory neuron cell types of interest (INTI).", [["inhibitory neuron cell", "ANATOMY", 112, 134], ["mouse", "ORGANISM", 54, 59], ["neuron cell", "CELL", 123, 134], ["inhibitory neuron cell types", "CELL_TYPE", 112, 140], ["mouse", "SPECIES", 54, 59], ["mouse", "SPECIES", 54, 59], ["Immunostaining post-experimentation", "TEST", 0, 35], ["large", "OBSERVATION_MODIFIER", 89, 94], ["fractions", "OBSERVATION_MODIFIER", 95, 104], ["inhibitory neuron cell", "OBSERVATION", 112, 134]]], ["We cannot rule out the possibility that non-overlapping YFP\u00fe expression can introduce unwanted, non-specific responses.", [["YFP", "GENE_OR_GENE_PRODUCT", 56, 59], ["YFP", "PROTEIN", 56, 59]]], ["We believe non-specific effects are not significant for several reasons.", [["non-specific effects", "PROBLEM", 11, 31]]], ["First, anatomical assessment of this population cells (YFP\u00fe/INTI\u00c0) did not reveal long-range connections to thalamus or the contra-lateral hemisphere, suggesting that these neurons are not pyramidal.", [["cells", "ANATOMY", 48, 53], ["thalamus", "ANATOMY", 108, 116], ["contra-lateral hemisphere", "ANATOMY", 124, 149], ["neurons", "ANATOMY", 173, 180], ["cells", "CELL", 48, 53], ["YFP", "GENE_OR_GENE_PRODUCT", 55, 58], ["thalamus", "MULTI-TISSUE_STRUCTURE", 108, 116], ["contra-lateral hemisphere", "MULTI-TISSUE_STRUCTURE", 124, 149], ["neurons", "CELL", 173, 180], ["population cells", "CELL_TYPE", 37, 53], ["YFP", "PROTEIN", 55, 58], ["INTI\u00c0", "CELL_LINE", 60, 65], ["anatomical assessment", "TEST", 7, 28], ["this population cells", "TEST", 32, 53], ["YFP\u00fe/INTI\u00c0)", "TEST", 55, 66], ["long-range connections to thalamus or the contra-lateral hemisphere", "PROBLEM", 82, 149], ["thalamus", "ANATOMY", 108, 116], ["contra-lateral hemisphere", "ANATOMY", 124, 149]]], ["This reinforces the notion that non-specific effects, if present, likely stem from other types of inhibitory neurons.", [["inhibitory neurons", "ANATOMY", 98, 116], ["neurons", "CELL", 109, 116], ["inhibitory neurons", "CELL_TYPE", 98, 116], ["inhibitory neurons", "PROBLEM", 98, 116]]], ["Second, the targeted neuronal populations are, in general, genetically distinct, with the exception of SOM and NOS mice.", [["neuronal populations", "ANATOMY", 21, 41], ["neuronal populations", "CELL", 21, 41], ["NOS", "GENE_OR_GENE_PRODUCT", 111, 114], ["mice", "ORGANISM", 115, 119], ["mice", "SPECIES", 115, 119], ["neuronal populations", "OBSERVATION", 21, 41]]], ["Third, all the models we tested show slightly different CBF response features.", [["CBF", "PROTEIN", 56, 59], ["slightly different CBF response features", "PROBLEM", 37, 77], ["slightly", "OBSERVATION_MODIFIER", 37, 45], ["different CBF", "OBSERVATION", 46, 59], ["response features", "OBSERVATION", 60, 77]]], ["Cross-talk between models would likely show more similar responses between models.DiscussionAn important consideration in our experiments is that in some mice, YFP expression was biased to the upper layers (see Figure 3 ).", [["upper layers", "ANATOMY", 193, 205], ["mice", "ORGANISM", 154, 158], ["YFP", "GENE_OR_GENE_PRODUCT", 160, 163], ["upper layers", "TISSUE", 193, 205], ["YFP", "PROTEIN", 160, 163], ["mice", "SPECIES", 154, 158], ["mice", "SPECIES", 154, 158], ["more similar", "OBSERVATION_MODIFIER", 44, 56], ["upper layers", "OBSERVATION_MODIFIER", 193, 205]]], ["It is possible that some of our results preferentially report regulation properties from cell populations that preferentially exist in upper layers.", [["cell", "ANATOMY", 89, 93], ["upper layers", "ANATOMY", 135, 147], ["cell populations", "CELL", 89, 105], ["upper layers", "TISSUE", 135, 147], ["cell populations", "PROBLEM", 89, 105], ["cell populations", "OBSERVATION", 89, 105], ["upper layers", "OBSERVATION_MODIFIER", 135, 147]]], ["However, we consistently observed expression spanning Layers III and V, with most variability in Layer VI expression.", [["Layer VI", "GENE_OR_GENE_PRODUCT", 97, 105], ["Layer VI", "PROTEIN", 97, 105]]], ["Inhibitory neurons that preferentially exist in this layer tend to be PV\u00fe or NOS\u00fe.", [["neurons", "ANATOMY", 11, 18], ["neurons", "CELL", 11, 18], ["PV\u00fe", "GENE_OR_GENE_PRODUCT", 70, 73], ["NOS", "GENE_OR_GENE_PRODUCT", 77, 80], ["NOS", "PROTEIN", 77, 80]]], ["In addition, considering that photo-stimulus delivery at the surface of the cortex has difficulty reaching deeper layers, it is possible that our experiments did not completely capture the role of these cells.", [["surface", "ANATOMY", 61, 68], ["cortex", "ANATOMY", 76, 82], ["cells", "ANATOMY", 203, 208], ["surface", "CELLULAR_COMPONENT", 61, 68], ["cortex", "CANCER", 76, 82], ["layers", "TISSUE", 114, 120], ["cells", "CELL", 203, 208], ["photo-stimulus delivery", "TREATMENT", 30, 53], ["cortex", "ANATOMY_MODIFIER", 76, 82], ["deeper layers", "OBSERVATION_MODIFIER", 107, 120]]], ["Nonetheless, previous experiments from our laboratory suggest that the photo-stimulus parameters chosen influence Layer V/VI neuron activity.", [["Layer V", "GENE_OR_GENE_PRODUCT", 114, 121], ["our laboratory", "TEST", 39, 53], ["the photo-stimulus parameters", "TEST", 67, 96]]], ["14, 40 We also note variability in the CBF responses evoked by whisker stimulation.", [["CBF", "PROTEIN", 39, 42]]], ["We believe this might be due to several possibilities, such as mice whisking frequently especially after whisker stimulation, 47 variability of the expressing region not completely overlapping with the whisker region, and variable placement of the puffer.", [["mice", "ORGANISM", 63, 67], ["mice", "SPECIES", 63, 67], ["mice", "SPECIES", 63, 67], ["whisker stimulation", "TREATMENT", 105, 124], ["variable placement of the puffer", "TREATMENT", 222, 254], ["might be due to", "UNCERTAINTY", 16, 31], ["variable", "OBSERVATION_MODIFIER", 222, 230], ["placement", "OBSERVATION_MODIFIER", 231, 240]]], ["Although we used systematic methods to minimize these sources of variability, our primary goal for whisker stimulation was to verify that neuro-vascular regulation was present in our experimental models, which we observed.DiscussionIt is not surprising that NOS-and SOM-expressing inhibitory neurons are able to regulate or influence local CBF.", [["neuro-vascular", "ANATOMY", 138, 152], ["inhibitory neurons", "ANATOMY", 281, 299], ["NOS", "GENE_OR_GENE_PRODUCT", 258, 261], ["SOM", "GENE_OR_GENE_PRODUCT", 266, 269], ["neurons", "CELL", 292, 299], ["NOS", "PROTEIN", 258, 261], ["SOM", "PROTEIN", 266, 269], ["inhibitory neurons", "CELL_TYPE", 281, 299], ["CBF", "PROTEIN", 340, 343], ["systematic methods", "TREATMENT", 17, 35], ["whisker stimulation", "TREATMENT", 99, 118], ["neuro-vascular regulation", "PROBLEM", 138, 163]]], ["Nitric oxide is freely diffusible and a potent vasodilator.", [["Nitric oxide", "CHEMICAL", 0, 12], ["Nitric oxide", "CHEMICAL", 0, 12], ["Nitric oxide", "SIMPLE_CHEMICAL", 0, 12], ["Nitric oxide", "TREATMENT", 0, 12], ["a potent vasodilator", "TREATMENT", 38, 58]]], ["NOS-expressing inhibitory neurons also generally express SOM, 24, 33, 48 such that vascular regulation is likely mediated by the activity-dependent release of NO from these neurons.", [["neurons", "ANATOMY", 26, 33], ["vascular", "ANATOMY", 83, 91], ["neurons", "ANATOMY", 173, 180], ["NO", "CHEMICAL", 159, 161], ["NO", "CHEMICAL", 159, 161], ["NOS", "GENE_OR_GENE_PRODUCT", 0, 3], ["neurons", "CELL", 26, 33], ["vascular", "MULTI-TISSUE_STRUCTURE", 83, 91], ["NO", "GENE_OR_GENE_PRODUCT", 159, 161], ["neurons", "CELL", 173, 180], ["NOS", "PROTEIN", 0, 3], ["expressing inhibitory neurons", "CELL_TYPE", 4, 33], ["vascular", "ANATOMY", 83, 91]]], ["Their vascular association has been investigated, 24 although differences relative to other neuronal populations, layer distribution, or location along the vascular tree remain unknown.", [["vascular", "ANATOMY", 6, 14], ["neuronal", "ANATOMY", 92, 100], ["vascular tree", "ANATOMY", 156, 169], ["vascular", "MULTI-TISSUE_STRUCTURE", 6, 14], ["neuronal", "CELL", 92, 100], ["vascular tree", "MULTI-TISSUE_STRUCTURE", 156, 169], ["vascular", "ANATOMY", 6, 14], ["neuronal", "OBSERVATION_MODIFIER", 92, 100], ["populations", "OBSERVATION", 101, 112], ["layer", "OBSERVATION_MODIFIER", 114, 119], ["distribution", "OBSERVATION_MODIFIER", 120, 132], ["vascular", "ANATOMY", 156, 164], ["tree", "ANATOMY_MODIFIER", 165, 169]]], ["Somatostatin is a neuropeptide expressed by SOM neurons and this neuronal population is more genetically diverse, at least compared to PV and VIP-expressing inhibitory neurons, with additional sub-types.", [["SOM neurons", "ANATOMY", 44, 55], ["neuronal", "ANATOMY", 65, 73], ["neurons", "ANATOMY", 168, 175], ["Somatostatin", "CHEMICAL", 0, 12], ["Somatostatin", "CHEMICAL", 0, 12], ["Somatostatin", "GENE_OR_GENE_PRODUCT", 0, 12], ["SOM neurons", "CELL", 44, 55], ["neuronal", "CELL", 65, 73], ["PV", "GENE_OR_GENE_PRODUCT", 135, 137], ["VIP", "GENE_OR_GENE_PRODUCT", 142, 145], ["neurons", "CELL", 168, 175], ["SOM neurons", "CELL_TYPE", 44, 55], ["PV and VIP-expressing inhibitory neurons", "CELL_TYPE", 135, 175], ["Somatostatin", "TREATMENT", 0, 12], ["a neuropeptide", "TREATMENT", 16, 30]]], ["SOM-expressing inhibitory neurons include neurons that express NOS, neuropeptide-Y (NPY), calbindin (CB), calretinin (CR), cholecystokinin (CCK) and substance-P.", [["inhibitory neurons", "ANATOMY", 15, 33], ["neurons", "ANATOMY", 42, 49], ["CCK", "CHEMICAL", 140, 143], ["SOM", "GENE_OR_GENE_PRODUCT", 0, 3], ["neurons", "CELL", 26, 33], ["neurons", "CELL", 42, 49], ["NOS", "GENE_OR_GENE_PRODUCT", 63, 66], ["neuropeptide-Y", "GENE_OR_GENE_PRODUCT", 68, 82], ["NPY", "GENE_OR_GENE_PRODUCT", 84, 87], ["calbindin", "GENE_OR_GENE_PRODUCT", 90, 99], ["CB", "GENE_OR_GENE_PRODUCT", 101, 103], ["calretinin", "GENE_OR_GENE_PRODUCT", 106, 116], ["CR", "GENE_OR_GENE_PRODUCT", 118, 120], ["cholecystokinin", "GENE_OR_GENE_PRODUCT", 123, 138], ["CCK", "GENE_OR_GENE_PRODUCT", 140, 143], ["substance-P.", "GENE_OR_GENE_PRODUCT", 149, 161], ["expressing inhibitory neurons", "CELL_TYPE", 4, 33], ["NOS", "PROTEIN", 63, 66], ["calbindin", "PROTEIN", 90, 99], ["CB", "PROTEIN", 101, 103], ["calretinin", "PROTEIN", 106, 116], ["CR", "PROTEIN", 118, 120], ["calbindin (CB)", "TREATMENT", 90, 104], ["calretinin (CR", "TEST", 106, 120], ["cholecystokinin (CCK", "TEST", 123, 143]]], ["34, 49 Previous studies have highlighted the role of activating VIP, SOM and NOS neurons on neurovascular coupling and CBF responses.", [["NOS neurons", "ANATOMY", 77, 88], ["neurovascular", "ANATOMY", 92, 105], ["VIP", "GENE_OR_GENE_PRODUCT", 64, 67], ["SOM", "GENE_OR_GENE_PRODUCT", 69, 72], ["NOS neurons", "GENE_OR_GENE_PRODUCT", 77, 88], ["neurovascular", "MULTI-TISSUE_STRUCTURE", 92, 105], ["VIP", "PROTEIN", 64, 67], ["CBF", "PROTEIN", 119, 122], ["Previous studies", "TEST", 7, 23], ["activating VIP", "TREATMENT", 53, 67], ["CBF responses", "TEST", 119, 132], ["neurovascular", "ANATOMY", 92, 105]]], ["In vitro studies in brain slices with direct electrical stimulation or neuropeptide application showed VIP and NOS neurons produce increases in local microvascular diameter, while NPY and SOM produced vasoconstriction.", [["brain slices", "ANATOMY", 20, 32], ["NOS neurons", "ANATOMY", 111, 122], ["microvascular", "ANATOMY", 150, 163], ["brain slices", "MULTI-TISSUE_STRUCTURE", 20, 32], ["VIP", "GENE_OR_GENE_PRODUCT", 103, 106], ["NOS neurons", "GENE_OR_GENE_PRODUCT", 111, 122], ["microvascular", "TISSUE", 150, 163], ["NPY", "GENE_OR_GENE_PRODUCT", 180, 183], ["vitro studies", "TEST", 3, 16], ["brain slices", "TEST", 20, 32], ["direct electrical stimulation", "TREATMENT", 38, 67], ["neuropeptide application", "TREATMENT", 71, 95], ["VIP and NOS neurons", "PROBLEM", 103, 122], ["vasoconstriction", "PROBLEM", 201, 217], ["brain", "ANATOMY", 20, 25], ["increases", "OBSERVATION_MODIFIER", 131, 140], ["local", "OBSERVATION_MODIFIER", 144, 149], ["microvascular diameter", "OBSERVATION", 150, 172], ["vasoconstriction", "OBSERVATION", 201, 217]]], ["10 Similar findings were reported in slice experiments by Perrenoud et al., 24 where neuronal stimulation via bath application of serotonin produced dilations and constrictions.", [["neuronal", "ANATOMY", 85, 93], ["serotonin", "CHEMICAL", 130, 139], ["serotonin", "CHEMICAL", 130, 139], ["neuronal", "CELL", 85, 93], ["serotonin", "SIMPLE_CHEMICAL", 130, 139], ["neuronal stimulation", "TREATMENT", 85, 105], ["serotonin produced dilations", "TREATMENT", 130, 158], ["constrictions", "PROBLEM", 163, 176], ["dilations", "OBSERVATION", 149, 158]]], ["In this study, application of an NPY-receptor antagonist blocked vasoconstriction, while application of a NOS inhibitor blocked vasodilation, indicating that NPY interneurons mediate vasoconstriction and NOS neurons mediate vasodilation.", [["NPY interneurons", "ANATOMY", 158, 174], ["NOS neurons", "ANATOMY", 204, 215], ["NPY-receptor antagonist", "GENE_OR_GENE_PRODUCT", 33, 56], ["NOS", "GENE_OR_GENE_PRODUCT", 106, 109], ["NPY interneurons", "GENE_OR_GENE_PRODUCT", 158, 174], ["NOS neurons", "GENE_OR_GENE_PRODUCT", 204, 215], ["NOS", "PROTEIN", 106, 109], ["this study", "TEST", 3, 13], ["an NPY-receptor antagonist blocked vasoconstriction", "TREATMENT", 30, 81], ["a NOS inhibitor blocked vasodilation", "TREATMENT", 104, 140], ["NPY interneurons mediate vasoconstriction", "PROBLEM", 158, 199], ["NOS neurons mediate vasodilation", "PROBLEM", 204, 236]]], ["A recent in vivo study corroborated the activity of NPY inhibitory neurons in the generation of vascular constrictions.", [["neurons", "ANATOMY", 67, 74], ["vascular", "ANATOMY", 96, 104], ["NPY", "GENE_OR_GENE_PRODUCT", 52, 55], ["neurons", "CELL", 67, 74], ["vascular", "MULTI-TISSUE_STRUCTURE", 96, 104], ["A recent in vivo study", "TEST", 0, 22], ["NPY inhibitory neurons", "PROBLEM", 52, 74], ["vascular constrictions", "ANATOMY", 96, 118]]], ["13 While we did not study this particular sub-type, our in vivo results are consistent with these reports since photo-stimulation of SOM neurons can target both NOS-and NPY-expressing inhibitory neurons and yielded increases and undershoots in CBF following photo-stimulation as observed in Figure 4 .", [["SOM neurons", "ANATOMY", 133, 144], ["inhibitory neurons", "ANATOMY", 184, 202], ["SOM neurons", "CELL", 133, 144], ["NOS", "GENE_OR_GENE_PRODUCT", 161, 164], ["NPY", "GENE_OR_GENE_PRODUCT", 169, 172], ["neurons", "CELL", 195, 202], ["SOM neurons", "CELL_TYPE", 133, 144], ["NOS", "PROTEIN", 161, 164], ["NPY", "PROTEIN", 169, 172], ["expressing inhibitory neurons", "CELL_TYPE", 173, 202], ["CBF", "PROTEIN", 244, 247], ["SOM neurons", "PROBLEM", 133, 144], ["photo-stimulation", "TREATMENT", 258, 275], ["increases", "OBSERVATION_MODIFIER", 215, 224]]], ["While it is evident that NOS-expressing neurons can produce prominent increases in CBF, experiments in SOM mice with the application of a NOS blocker could also be performed to further evaluate neuro-vascular constrictions.", [["neurons", "ANATOMY", 40, 47], ["neuro-vascular", "ANATOMY", 194, 208], ["NOS", "GENE_OR_GENE_PRODUCT", 25, 28], ["neurons", "CELL", 40, 47], ["mice", "ORGANISM", 107, 111], ["NOS", "GENE_OR_GENE_PRODUCT", 138, 141], ["NOS", "PROTEIN", 25, 28], ["expressing neurons", "CELL_TYPE", 29, 47], ["CBF", "PROTEIN", 83, 86], ["NOS", "PROTEIN", 138, 141], ["mice", "SPECIES", 107, 111], ["mice", "SPECIES", 107, 111], ["prominent increases in CBF", "PROBLEM", 60, 86], ["a NOS blocker", "TREATMENT", 136, 149], ["neuro-vascular constrictions", "PROBLEM", 194, 222], ["prominent", "OBSERVATION_MODIFIER", 60, 69], ["increases", "OBSERVATION_MODIFIER", 70, 79]]], ["Lastly, it is worth noting that a small fraction of PV neurons can be targeted in the SOM-cre mouse model we used, which could partly explain the latent increase observed in photo-stimulation responses at higher frequency in these mice (Supplementary Figure 2(f) ).", [["PV neurons", "ANATOMY", 52, 62], ["PV neurons", "CELL", 52, 62], ["mouse", "ORGANISM", 94, 99], ["mice", "ORGANISM", 231, 235], ["PV neurons", "CELL_TYPE", 52, 62], ["mouse", "SPECIES", 94, 99], ["mice", "SPECIES", 231, 235], ["mouse", "SPECIES", 94, 99], ["a small fraction of PV neurons", "PROBLEM", 32, 62], ["the latent increase", "PROBLEM", 142, 161], ["photo-stimulation responses", "TREATMENT", 174, 201], ["small", "OBSERVATION_MODIFIER", 34, 39], ["fraction", "OBSERVATION", 40, 48], ["PV neurons", "ANATOMY", 52, 62], ["latent", "OBSERVATION_MODIFIER", 146, 152], ["increase", "OBSERVATION_MODIFIER", 153, 161]]], ["50 VIP is expressed by 10-15% of GABAergic cells in the barrel cortex.", [["GABAergic cells", "ANATOMY", 33, 48], ["barrel cortex", "ANATOMY", 56, 69], ["VIP", "GENE_OR_GENE_PRODUCT", 3, 6], ["GABAergic cells", "CELL", 33, 48], ["barrel cortex", "MULTI-TISSUE_STRUCTURE", 56, 69], ["GABAergic cells", "CELL_TYPE", 33, 48], ["GABAergic cells", "OBSERVATION", 33, 48], ["barrel cortex", "ANATOMY", 56, 69]]], ["44 The largest concentration (60%) of VIP-expressing neurons is in layer II/III, although VIP cells can be found in all cortical layers, and are anatomically characterized by vertically spanning arborizations that are bipolar/modified-bipolar and bitufted.", [["neurons", "ANATOMY", 53, 60], ["VIP cells", "ANATOMY", 90, 99], ["cortical layers", "ANATOMY", 120, 135], ["bipolar", "DISEASE", 218, 225], ["bipolar", "DISEASE", 235, 242], ["VIP", "GENE_OR_GENE_PRODUCT", 38, 41], ["neurons", "CELL", 53, 60], ["layer II/III", "GENE_OR_GENE_PRODUCT", 67, 79], ["VIP cells", "CELL", 90, 99], ["cortical layers", "TISSUE", 120, 135], ["VIP", "PROTEIN", 38, 41], ["expressing neurons", "CELL_TYPE", 42, 60], ["layer II/III", "CELL_LINE", 67, 79], ["VIP cells", "CELL_LINE", 90, 99], ["The largest concentration", "TEST", 3, 28], ["VIP", "TEST", 38, 41], ["VIP cells", "PROBLEM", 90, 99], ["vertically spanning arborizations", "PROBLEM", 175, 208], ["bipolar/modified-bipolar and bitufted", "PROBLEM", 218, 255], ["largest", "OBSERVATION_MODIFIER", 7, 14], ["concentration", "OBSERVATION_MODIFIER", 15, 28], ["neurons", "ANATOMY", 53, 60], ["VIP cells", "OBSERVATION", 90, 99], ["all", "ANATOMY_MODIFIER", 116, 119], ["cortical", "ANATOMY_MODIFIER", 120, 128], ["layers", "ANATOMY_MODIFIER", 129, 135], ["vertically", "OBSERVATION_MODIFIER", 175, 185]]], ["43, 44, 51 VIP neurons are not fast spiking and are active during various brain states including but not limited to locomotion, non-locomotion, visual stimulation, and even under light anesthesia.", [["neurons", "ANATOMY", 15, 22], ["brain", "ANATOMY", 74, 79], ["VIP neurons", "CELL", 11, 22], ["brain", "ORGAN", 74, 79], ["non-locomotion", "PROBLEM", 128, 142], ["visual stimulation", "TEST", 144, 162], ["light anesthesia", "TREATMENT", 179, 195], ["active", "OBSERVATION", 52, 58]]], ["44, 52 Optogenetic stimulation of VIP-cre mice showed small increases in blood flow following stimulation that were smaller compared to the whisker CBF response.", [["blood", "ANATOMY", 73, 78], ["increases in blood flow", "DISEASE", 60, 83], ["VIP", "GENE_OR_GENE_PRODUCT", 34, 37], ["cre", "GENE_OR_GENE_PRODUCT", 38, 41], ["blood", "ORGANISM_SUBSTANCE", 73, 78], ["VIP", "PROTEIN", 34, 37], ["CBF", "PROTEIN", 148, 151], ["mice", "SPECIES", 42, 46], ["Optogenetic stimulation", "TEST", 7, 30], ["VIP-cre mice", "TEST", 34, 46], ["small increases in blood flow", "PROBLEM", 54, 83], ["stimulation", "TREATMENT", 94, 105], ["small", "OBSERVATION_MODIFIER", 54, 59], ["increases", "OBSERVATION_MODIFIER", 60, 69], ["blood flow", "OBSERVATION", 73, 83], ["smaller", "OBSERVATION_MODIFIER", 116, 123]]], ["Nonetheless, our results show some capacity by VIP neurons to generate vasodilation as reported by Cauli et al. 10 Although large numbers of PV\u00fe cells expressed ChR2-YFP, optogenetic stimulation of these cells did not produce typical changes in CBF.", [["VIP neurons", "ANATOMY", 47, 58], ["PV\u00fe cells", "ANATOMY", 141, 150], ["cells", "ANATOMY", 204, 209], ["VIP neurons", "CELL", 47, 58], ["PV\u00fe cells", "CELL", 141, 150], ["ChR2-YFP", "GENE_OR_GENE_PRODUCT", 161, 169], ["cells", "CELL", 204, 209], ["VIP neurons", "CELL_TYPE", 47, 58], ["PV\u00fe cells", "CELL_LINE", 141, 150], ["ChR2", "PROTEIN", 161, 165], ["YFP", "PROTEIN", 166, 169], ["CBF", "PROTEIN", 245, 248], ["PV", "SPECIES", 141, 143], ["some capacity", "PROBLEM", 30, 43], ["ChR2", "TEST", 161, 165], ["optogenetic stimulation of these cells", "PROBLEM", 171, 209], ["typical changes in CBF", "PROBLEM", 226, 248], ["large", "OBSERVATION_MODIFIER", 124, 129], ["numbers", "OBSERVATION_MODIFIER", 130, 137], ["PV", "ANATOMY", 141, 143]]], ["Higher stimulus frequencies did produce latent increases in CBF ( Figure 5(a) and (b) ).", [["CBF", "PROTEIN", 60, 63], ["Higher stimulus frequencies", "PROBLEM", 0, 27], ["latent increases in CBF", "PROBLEM", 40, 63], ["latent", "OBSERVATION_MODIFIER", 40, 46], ["increases", "OBSERVATION_MODIFIER", 47, 56]]], ["This is interesting considering PV interneurons comprise about 40% of all GABAergic cells in the cortex.", [["PV interneurons", "ANATOMY", 32, 47], ["GABAergic cells", "ANATOMY", 74, 89], ["cortex", "ANATOMY", 97, 103], ["PV interneurons", "CELL", 32, 47], ["GABAergic cells", "CELL", 74, 89], ["cortex", "CANCER", 97, 103], ["GABAergic cells", "CELL_TYPE", 74, 89], ["PV interneurons", "PROBLEM", 32, 47], ["GABAergic cells", "OBSERVATION", 74, 89], ["cortex", "ANATOMY_MODIFIER", 97, 103]]], ["31 They generally consist of basket and chandelier-shaped cells and are known for their fast spiking, non-adapting properties.", [["basket", "ANATOMY", 29, 35], ["cells", "ANATOMY", 58, 63], ["cells", "CELL", 58, 63], ["basket and chandelier-shaped cells", "CELL_TYPE", 29, 63], ["shaped cells", "OBSERVATION", 51, 63]]], ["51, 53 In the somatosensory cortex, they are responsible for high frequency gamma oscillations, which are associated with strong cortical network activity.", [["somatosensory cortex", "ANATOMY", 14, 34], ["cortical network", "ANATOMY", 129, 145], ["somatosensory cortex", "CANCER", 14, 34], ["cortical network", "MULTI-TISSUE_STRUCTURE", 129, 145], ["high frequency gamma oscillations", "PROBLEM", 61, 94], ["somatosensory cortex", "ANATOMY", 14, 34], ["responsible for", "UNCERTAINTY", 45, 60], ["high frequency", "OBSERVATION_MODIFIER", 61, 75], ["gamma oscillations", "OBSERVATION", 76, 94], ["strong", "OBSERVATION_MODIFIER", 122, 128], ["cortical network activity", "OBSERVATION", 129, 154]]], ["54 More importantly, gamma oscillation strength is also known to correlate strongly with blood flow changes, including slower hemodynamic fluctuations.", [["blood", "ANATOMY", 89, 94], ["blood", "ORGANISM_SUBSTANCE", 89, 94], ["gamma oscillation strength", "TEST", 21, 47], ["blood flow changes", "PROBLEM", 89, 107], ["slower hemodynamic fluctuations", "PROBLEM", 119, 150], ["slower", "OBSERVATION_MODIFIER", 119, 125], ["hemodynamic fluctuations", "OBSERVATION", 126, 150]]], ["[55] [56] [57] The slow increases in CBF observed with PV neuron stimulation show, to first approximation, a complex relationship.", [["[55] [56] [57]", "SIMPLE_CHEMICAL", 0, 14], ["CBF", "PROTEIN", 37, 40], ["The slow increases in CBF", "PROBLEM", 15, 40], ["PV neuron stimulation", "TEST", 55, 76]]], ["Our findings are different from a previous study where photo-stimulation of PV\u00fe neurons elicited vasoconstriction of local arterioles in brain slices.", [["PV\u00fe neurons", "ANATOMY", 76, 87], ["arterioles", "ANATOMY", 123, 133], ["brain slices", "ANATOMY", 137, 149], ["PV\u00fe neurons", "CELL", 76, 87], ["arterioles", "MULTI-TISSUE_STRUCTURE", 123, 133], ["brain slices", "MULTI-TISSUE_STRUCTURE", 137, 149], ["PV\u00fe neurons", "CELL_TYPE", 76, 87], ["PV", "SPECIES", 76, 78], ["a previous study", "TEST", 32, 48], ["vasoconstriction of local arterioles in brain slices", "PROBLEM", 97, 149], ["different", "OBSERVATION_MODIFIER", 17, 26], ["vasoconstriction", "OBSERVATION", 97, 113], ["local arterioles", "OBSERVATION", 117, 133], ["brain", "ANATOMY", 137, 142]]], ["45 This difference might be due to in vitro vs. in vivo experimentation.", [["might be due to", "UNCERTAINTY", 19, 34]]], ["PV neurons are not known for their vasoactive properties, weakly expressing nitric oxide and having little or no expression of vasoactive intestinal peptide.", [["PV neurons", "ANATOMY", 0, 10], ["nitric oxide", "CHEMICAL", 76, 88], ["nitric oxide", "CHEMICAL", 76, 88], ["PV neurons", "CELL", 0, 10], ["nitric oxide", "SIMPLE_CHEMICAL", 76, 88], ["vasoactive intestinal peptide", "GENE_OR_GENE_PRODUCT", 127, 156], ["PV neurons", "CELL_TYPE", 0, 10], ["PV", "SPECIES", 0, 2], ["their vasoactive properties", "TREATMENT", 29, 56], ["nitric oxide", "TREATMENT", 76, 88], ["vasoactive intestinal peptide", "TREATMENT", 127, 156], ["intestinal", "ANATOMY", 138, 148]]], ["32, 33 Their high-frequency spiking properties would imply high metabolic demands upon highfrequency stimulation which might explain the latent increase in CBF we observe with high-frequency photostimulation.", [["CBF", "PROTEIN", 156, 159], ["high metabolic demands", "PROBLEM", 59, 81], ["highfrequency stimulation", "TREATMENT", 87, 112], ["the latent increase in CBF", "PROBLEM", 133, 159], ["high-frequency photostimulation", "TREATMENT", 176, 207], ["high", "OBSERVATION_MODIFIER", 59, 63], ["metabolic demands", "OBSERVATION", 64, 81], ["latent", "OBSERVATION_MODIFIER", 137, 143], ["increase", "OBSERVATION_MODIFIER", 144, 152]]], ["Another possibility can be a rebound in activity from the pyramidal neurons that were previously inhibited, causing an increase in CBF.", [["pyramidal neurons", "ANATOMY", 58, 75], ["pyramidal neurons", "CELL", 58, 75], ["pyramidal neurons", "CELL_TYPE", 58, 75], ["CBF", "PROTEIN", 131, 134], ["a rebound in activity from the pyramidal neurons", "PROBLEM", 27, 75], ["an increase in CBF", "PROBLEM", 116, 134], ["possibility can be", "UNCERTAINTY", 8, 26], ["rebound", "OBSERVATION_MODIFIER", 29, 36], ["pyramidal neurons", "ANATOMY", 58, 75], ["increase", "OBSERVATION_MODIFIER", 119, 127]]], ["Considering their abundance in cortex and their connections to other cells (mainly pyramidal cells), they may indirectly regulate blood flow by inhibiting VIP or nitric oxide (NO) release through cortical circuits.", [["cortex", "ANATOMY", 31, 37], ["cells", "ANATOMY", 69, 74], ["pyramidal cells", "ANATOMY", 83, 98], ["blood", "ANATOMY", 130, 135], ["cortical", "ANATOMY", 196, 204], ["nitric oxide", "CHEMICAL", 162, 174], ["NO", "CHEMICAL", 176, 178], ["nitric oxide", "CHEMICAL", 162, 174], ["NO", "CHEMICAL", 176, 178], ["cortex", "CANCER", 31, 37], ["cells", "CELL", 69, 74], ["pyramidal cells", "CELL", 83, 98], ["blood", "ORGANISM_SUBSTANCE", 130, 135], ["VIP", "GENE_OR_GENE_PRODUCT", 155, 158], ["nitric oxide", "SIMPLE_CHEMICAL", 162, 174], ["NO", "SIMPLE_CHEMICAL", 176, 178], ["cortical", "MULTI-TISSUE_STRUCTURE", 196, 204], ["pyramidal cells", "CELL_TYPE", 83, 98], ["blood flow", "TEST", 130, 140], ["VIP or nitric oxide", "TREATMENT", 155, 174], ["abundance", "OBSERVATION_MODIFIER", 18, 27], ["cortex", "ANATOMY_MODIFIER", 31, 37], ["pyramidal cells", "OBSERVATION", 83, 98], ["cortical circuits", "OBSERVATION", 196, 213]]], ["Additional studies are necessary to determine the physiological mechanism underlying these slow increases in CBF, including electrophysiological monitoring of cortical activity.DiscussionOur results show similarities and differences compared to experiments performed in our laboratory using VGAT-ChR2 mice.", [["cortical", "ANATOMY", 159, 167], ["cortical", "MULTI-TISSUE_STRUCTURE", 159, 167], ["VGAT", "GENE_OR_GENE_PRODUCT", 291, 295], ["mice", "ORGANISM", 301, 305], ["CBF", "PROTEIN", 109, 112], ["VGAT", "PROTEIN", 291, 295], ["ChR2", "PROTEIN", 296, 300], ["mice", "SPECIES", 301, 305], ["Additional studies", "TEST", 0, 18], ["these slow increases in CBF", "PROBLEM", 85, 112], ["electrophysiological monitoring", "TEST", 124, 155], ["slow", "OBSERVATION_MODIFIER", 91, 95], ["increases", "OBSERVATION_MODIFIER", 96, 105], ["cortical activity", "OBSERVATION", 159, 176]]], ["14 Photo-stimulation of VGAT-ChR2 mice under light ketamine anesthesia produced temporal CBF responses that were similar to those produced by NOS and SOM mice in this study.", [["ketamine", "CHEMICAL", 51, 59], ["ketamine", "CHEMICAL", 51, 59], ["VGAT", "GENE_OR_GENE_PRODUCT", 24, 28], ["ChR2", "ORGANISM", 29, 33], ["mice", "ORGANISM", 34, 38], ["ketamine", "SIMPLE_CHEMICAL", 51, 59], ["NOS", "GENE_OR_GENE_PRODUCT", 142, 145], ["mice", "ORGANISM", 154, 158], ["VGAT", "PROTEIN", 24, 28], ["ChR2", "PROTEIN", 29, 33], ["CBF", "PROTEIN", 89, 92], ["mice", "SPECIES", 34, 38], ["mice", "SPECIES", 154, 158], ["light ketamine anesthesia", "TREATMENT", 45, 70], ["this study", "TEST", 162, 172]]], ["For more direct comparison, we also performed awake head-fixed experiments in VGAT-ChR2 mice (n \u00bc 4, Supplementary Figure 3) .", [["head", "ORGANISM_SUBDIVISION", 52, 56], ["mice", "ORGANISM", 88, 92], ["ChR2", "PROTEIN", 83, 87], ["mice", "SPECIES", 88, 92]]], ["Interestingly, optogenetic stimulation under awake conditions produced CBF responses that peaked a few seconds earlier (and showed a milder modulation to optogenetic pulse duration) compared to our previous study.", [["CBF", "PROTEIN", 71, 74], ["CBF responses", "TEST", 71, 84], ["a milder modulation to optogenetic pulse duration", "PROBLEM", 131, 180], ["our previous study", "TEST", 194, 212]]], ["We verified these CBF response features by performing experiments in these mice under light-ketamine anesthesia (data not shown).", [["ketamine", "CHEMICAL", 92, 100], ["ketamine", "CHEMICAL", 92, 100], ["mice", "ORGANISM", 75, 79], ["CBF", "PROTEIN", 18, 21], ["mice", "SPECIES", 75, 79], ["mice", "SPECIES", 75, 79], ["light-ketamine anesthesia", "TREATMENT", 86, 111], ["CBF response", "OBSERVATION", 18, 30]]], ["In our previous study, we also found that pharmacological blockade of NOS suppressed increases in CBF evoked by inhibitory neuron activity.", [["neuron", "ANATOMY", 123, 129], ["NOS", "GENE_OR_GENE_PRODUCT", 70, 73], ["CBF", "SIMPLE_CHEMICAL", 98, 101], ["neuron", "CELL", 123, 129], ["NOS", "PROTEIN", 70, 73], ["CBF", "PROTEIN", 98, 101], ["our previous study", "TEST", 3, 21], ["pharmacological blockade", "TREATMENT", 42, 66]]], ["14 Since VGAT-ChR2 mice target inhibitory neurons, we hypothesize that of photo-stimulation of most inhibitory neurons would produce, at least to first approximation, a weighted combination of photo-stimulating individual sub-populations.", [["neurons", "ANATOMY", 42, 49], ["inhibitory neurons", "ANATOMY", 100, 118], ["VGAT", "GENE_OR_GENE_PRODUCT", 9, 13], ["mice", "ORGANISM", 19, 23], ["neurons", "CELL", 42, 49], ["neurons", "CELL", 111, 118], ["VGAT", "PROTEIN", 9, 13], ["ChR2", "PROTEIN", 14, 18], ["inhibitory neurons", "CELL_TYPE", 31, 49], ["inhibitory neurons", "CELL_TYPE", 100, 118], ["mice", "SPECIES", 19, 23], ["mice", "SPECIES", 19, 23], ["photo-stimulation", "TREATMENT", 74, 91], ["photo-stimulating individual sub-populations", "TREATMENT", 193, 237]]], ["This hypothesis of course ignores the impact of initiating activity in sub-populations of inhibitory neurons on network activity and vascular regulation.", [["inhibitory neurons", "ANATOMY", 90, 108], ["network", "ANATOMY", 112, 119], ["vascular", "ANATOMY", 133, 141], ["neurons", "CELL", 101, 108], ["network", "MULTI-TISSUE_STRUCTURE", 112, 119], ["vascular", "MULTI-TISSUE_STRUCTURE", 133, 141], ["inhibitory neurons", "CELL_TYPE", 90, 108], ["inhibitory neurons", "PROBLEM", 90, 108], ["vascular", "ANATOMY", 133, 141]]], ["It is also important to consider that differences in the experimental condition (light anesthesia vs. awake) might make comparisons difficult.", [["light anesthesia", "TREATMENT", 81, 97]]], ["Nonetheless, CBF undershoot responses were observed following CBF increases for stronger photostimuli (i.e. 30 ms pulse duration at 5 Hz or 20 Hz frequency), but not as evident as those observed in SOM mice.", [["mice", "ORGANISM", 202, 206], ["CBF", "PROTEIN", 13, 16], ["CBF", "PROTEIN", 62, 65], ["mice", "SPECIES", 202, 206], ["mice", "SPECIES", 202, 206], ["CBF increases", "TEST", 62, 75], ["stronger photostimuli", "PROBLEM", 80, 101]]], ["Interestingly, CBF undershoot responses were also observed after NOS blockade in our ketamineanesthetized VGAT experiments.", [["CBF", "SIMPLE_CHEMICAL", 15, 18], ["NOS", "GENE_OR_GENE_PRODUCT", 65, 68], ["CBF", "PROTEIN", 15, 18], ["NOS", "PROTEIN", 65, 68], ["NOS blockade", "TREATMENT", 65, 77]]], ["Therefore, our studies support the notion that SOM-NPY neuron activity likely generate decreases or undershoots in CBF.Implications and future workOur findings corroborate the strong influence of NOS-(and SOM) expressing inhibitory neurons on cerebral blood flow by producing increases in CBF that are similar or even exceed those produced by sensory stimulation.", [["neurons", "ANATOMY", 232, 239], ["cerebral blood", "ANATOMY", 243, 257], ["SOM-NPY", "GENE_OR_GENE_PRODUCT", 47, 54], ["NOS", "GENE_OR_GENE_PRODUCT", 196, 199], ["neurons", "CELL", 232, 239], ["cerebral blood", "MULTI-TISSUE_STRUCTURE", 243, 257], ["CBF", "SIMPLE_CHEMICAL", 289, 292], ["CBF", "PROTEIN", 115, 118], ["NOS", "PROTEIN", 196, 199], ["inhibitory neurons", "CELL_TYPE", 221, 239], ["CBF", "PROTEIN", 289, 292], ["our studies", "TEST", 11, 22], ["cerebral blood flow", "TEST", 243, 262], ["increases in CBF", "PROBLEM", 276, 292], ["decreases", "OBSERVATION_MODIFIER", 87, 96], ["cerebral blood", "ANATOMY", 243, 257], ["increases", "OBSERVATION_MODIFIER", 276, 285], ["sensory stimulation", "OBSERVATION", 343, 362]]], ["Our findings suggest that dysfunction in NOS neurons can attenuate the positive CBF response, while dysfunction in SOM neurons can work to attenuate both positive (via dysfunction in NOS sub-types) and negative (via dysfunction in NPY sub-types) CBF responses.", [["NOS neurons", "ANATOMY", 41, 52], ["SOM neurons", "ANATOMY", 115, 126], ["NOS neurons", "GENE_OR_GENE_PRODUCT", 41, 52], ["SOM neurons", "CELL", 115, 126], ["NOS", "GENE_OR_GENE_PRODUCT", 183, 186], ["NPY", "GENE_OR_GENE_PRODUCT", 231, 234], ["NOS neurons", "CELL_TYPE", 41, 52], ["CBF", "PROTEIN", 80, 83], ["SOM neurons", "CELL_TYPE", 115, 126], ["NOS", "PROTEIN", 183, 186], ["CBF", "PROTEIN", 246, 249], ["dysfunction in NOS neurons", "PROBLEM", 26, 52], ["the positive CBF response", "PROBLEM", 67, 92], ["dysfunction in SOM neurons", "PROBLEM", 100, 126], ["positive (via dysfunction", "PROBLEM", 154, 179], ["dysfunction", "PROBLEM", 216, 227], ["dysfunction", "OBSERVATION", 26, 37]]], ["Our results also show minor influences from PV and VIP inhibitory neurons, suggesting that dysfunction in these neurons will not have as significant of an influence on CBF responses.", [["VIP inhibitory neurons", "ANATOMY", 51, 73], ["neurons", "ANATOMY", 112, 119], ["VIP inhibitory", "GENE_OR_GENE_PRODUCT", 51, 65], ["neurons", "CELL", 66, 73], ["neurons", "CELL", 112, 119], ["CBF", "SIMPLE_CHEMICAL", 168, 171], ["VIP inhibitory neurons", "CELL_TYPE", 51, 73], ["CBF", "PROTEIN", 168, 171], ["minor influences from PV and VIP inhibitory neurons", "PROBLEM", 22, 73], ["dysfunction in these neurons", "PROBLEM", 91, 119], ["dysfunction", "OBSERVATION", 91, 102]]], ["However, dysfunction in these neuronal populations is likely to have a profound impact on network activity, which might disrupt changes in CBF in a more complicated manner.", [["neuronal", "ANATOMY", 30, 38], ["neuronal populations", "CELL", 30, 50], ["CBF", "PROTEIN", 139, 142], ["dysfunction in these neuronal populations", "PROBLEM", 9, 50], ["dysfunction", "OBSERVATION", 9, 20], ["profound", "OBSERVATION_MODIFIER", 71, 79], ["impact", "OBSERVATION", 80, 86], ["network activity", "OBSERVATION", 90, 106]]], ["The metabolic contribution of these neuronal populations also needs to be investigated since changes in local oxygen consumption can also impact fMRI signals.", [["neuronal", "ANATOMY", 36, 44], ["oxygen", "CHEMICAL", 110, 116], ["oxygen", "CHEMICAL", 110, 116], ["neuronal populations", "CELL", 36, 56], ["oxygen", "SIMPLE_CHEMICAL", 110, 116], ["these neuronal populations", "PROBLEM", 30, 56], ["local oxygen consumption", "TREATMENT", 104, 128], ["fMRI signals", "TEST", 145, 157], ["metabolic", "OBSERVATION_MODIFIER", 4, 13], ["neuronal populations", "OBSERVATION", 36, 56]]], ["Studies in additional mice including pharmacological strategies and electrophysiological recordings are necessary to further establish the mechanisms and relative contributions of our findings.Implications and future workLastly, while photo-stimulation of these neuronal populations is essential to determine whether these cell types can modulate local CBF, this mode of stimulation does not engage neuronal activity in a physiological manner.", [["neuronal", "ANATOMY", 262, 270], ["cell", "ANATOMY", 323, 327], ["neuronal", "ANATOMY", 399, 407], ["mice", "ORGANISM", 22, 26], ["neuronal", "CELL", 262, 270], ["cell", "CELL", 323, 327], ["CBF", "MULTI-TISSUE_STRUCTURE", 353, 356], ["neuronal", "CELL", 399, 407], ["CBF", "PROTEIN", 353, 356], ["mice", "SPECIES", 22, 26], ["mice", "SPECIES", 22, 26], ["Studies", "TEST", 0, 7], ["pharmacological strategies", "TREATMENT", 37, 63], ["electrophysiological recordings", "TEST", 68, 99], ["local CBF", "TEST", 347, 356]]], ["Physiologically relevant approaches could involve pharmacological intervention or the up-and down-regulation of spiking activity using optogenetic silencers, step-function opsins or chemogenetics.", [["optogenetic silencers", "DNA", 135, 156], ["pharmacological intervention", "TREATMENT", 50, 78], ["optogenetic silencers", "TREATMENT", 135, 156], ["chemogenetics", "PROBLEM", 182, 195]]], ["These approaches would more directly uncover the impact of dysfunction in specific cell types on local CBF modulation.", [["cell", "ANATOMY", 83, 87], ["cell", "CELL", 83, 87], ["CBF", "PROTEIN", 103, 106], ["dysfunction", "PROBLEM", 59, 70], ["local CBF modulation", "TREATMENT", 97, 117], ["dysfunction", "OBSERVATION", 59, 70], ["specific cell types", "OBSERVATION", 74, 93], ["local CBF modulation", "OBSERVATION", 97, 117]]], ["Our group is currently testing these approaches.FundingThe author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by NIH grants R01-NS-094404 (to AV), F31-NS106764 (to CR) and R01-AR063772 (to SR).FundingMBK, XY, CFR and ALV contributed to the data acquisition and analysis of the data.", [["R01-NS-094404", "CHEMICAL", 226, 239], ["R01-AR063772", "CHEMICAL", 274, 286], ["NS-094404", "CELL", 230, 239], ["R01-AR063772", "SIMPLE_CHEMICAL", 274, 286], ["ALV", "SPECIES", 319, 322], ["CR", "TEST", 266, 268], ["R01", "TEST", 274, 277], ["CFR", "TEST", 311, 314], ["ALV", "PROBLEM", 319, 322], ["the data acquisition", "TEST", 338, 358], ["analysis of the data", "TEST", 363, 383], ["ALV", "ANATOMY", 319, 322]]], ["MBK, CFR, SER and ALV contributed to the interpretation of the data.Supplemental materialSupplemental material for this paper can be found at the journal website: http://journals.sagepub.com/home/jcb.", [["MBK", "SIMPLE_CHEMICAL", 0, 3], ["MBK", "TEST", 0, 3], ["CFR", "TEST", 5, 8], ["the data", "TEST", 59, 67], ["Supplemental material", "TREATMENT", 68, 89], ["Supplemental material", "TREATMENT", 89, 110], ["ALV", "ANATOMY", 18, 21]]]], "PMC7331862": [["IntroductionThe coronavirus disease 2019 (COVID-19) is a global pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).", [["coronavirus disease", "DISEASE", 16, 35], ["COVID-19", "CHEMICAL", 42, 50], ["acute respiratory syndrome coronavirus", "DISEASE", 100, 138], ["coronavirus", "ORGANISM", 16, 27], ["COVID-19", "ORGANISM", 42, 50], ["SARS-CoV-2", "ORGANISM", 142, 152], ["coronavirus disease 2019 (COVID-19", "SPECIES", 16, 50], ["severe acute respiratory syndrome coronavirus", "SPECIES", 93, 138], ["SARS-CoV-2", "SPECIES", 142, 152], ["The coronavirus disease", "PROBLEM", 12, 35], ["COVID", "TEST", 42, 47], ["a global pandemic", "PROBLEM", 55, 72], ["the novel severe acute respiratory syndrome coronavirus", "PROBLEM", 83, 138], ["CoV", "TEST", 147, 150], ["coronavirus disease", "OBSERVATION", 16, 35], ["global", "OBSERVATION_MODIFIER", 57, 63], ["pandemic", "OBSERVATION", 64, 72], ["severe", "OBSERVATION_MODIFIER", 93, 99], ["acute", "OBSERVATION_MODIFIER", 100, 105], ["respiratory syndrome", "OBSERVATION", 106, 126]]], ["By binding to the angiotensin-converting enzyme 2 (ACE2) receptor, the S1 subset of the surface spike protein elicits the production of angiotensin 1.", [["surface", "ANATOMY", 88, 95], ["angiotensin", "CHEMICAL", 18, 29], ["angiotensin", "CHEMICAL", 136, 147], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 18, 49], ["ACE2", "GENE_OR_GENE_PRODUCT", 51, 55], ["surface", "CELLULAR_COMPONENT", 88, 95], ["angiotensin 1", "GENE_OR_GENE_PRODUCT", 136, 149], ["angiotensin-converting enzyme 2 (ACE2) receptor", "PROTEIN", 18, 65], ["S1", "PROTEIN", 71, 73], ["surface spike protein", "PROTEIN", 88, 109], ["angiotensin 1", "PROTEIN", 136, 149], ["the angiotensin", "TEST", 14, 29], ["enzyme", "TEST", 41, 47], ["angiotensin", "TREATMENT", 136, 147]]], ["The ACE then converts angiotensin 1 to angiotensin 2, which in turn binds to the angiotensin receptor, upregulating the levels of endothelin-1 (ET-1).", [["angiotensin", "CHEMICAL", 22, 33], ["angiotensin", "CHEMICAL", 39, 50], ["angiotensin", "CHEMICAL", 81, 92], ["ACE", "GENE_OR_GENE_PRODUCT", 4, 7], ["angiotensin 1", "GENE_OR_GENE_PRODUCT", 22, 35], ["angiotensin 2", "GENE_OR_GENE_PRODUCT", 39, 52], ["angiotensin receptor", "GENE_OR_GENE_PRODUCT", 81, 101], ["endothelin-1", "GENE_OR_GENE_PRODUCT", 130, 142], ["ET-1", "GENE_OR_GENE_PRODUCT", 144, 148], ["ACE", "PROTEIN", 4, 7], ["angiotensin receptor", "PROTEIN", 81, 101], ["endothelin-1 (ET-1", "PROTEIN", 130, 148], ["The ACE", "TREATMENT", 0, 7], ["angiotensin", "TREATMENT", 22, 33], ["angiotensin", "TREATMENT", 39, 50], ["the angiotensin receptor", "TREATMENT", 77, 101], ["endothelin", "TEST", 130, 140]]], ["This results in a widespread inflammatory response with the release of pro-inflammatory cytokines and interleukins [1, 2].", [["pro-inflammatory cytokines", "PROTEIN", 71, 97], ["interleukins", "PROTEIN", 102, 114], ["a widespread inflammatory response", "PROBLEM", 16, 50], ["pro-inflammatory cytokines", "TREATMENT", 71, 97], ["widespread", "OBSERVATION_MODIFIER", 18, 28], ["inflammatory", "OBSERVATION", 29, 41], ["pro-inflammatory cytokines", "OBSERVATION", 71, 97]]], ["The large-scale unregulated production of interleukins, particularly interleukin-6 (IL-6), stimulates several downstream pathways, increasing the production of acute-phase reactants like C-reactive protein (CRP), and increases mobilization of neutrophils [3].", [["neutrophils", "ANATOMY", 243, 254], ["interleukins", "GENE_OR_GENE_PRODUCT", 42, 54], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 69, 82], ["IL-6", "GENE_OR_GENE_PRODUCT", 84, 88], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 187, 205], ["CRP", "GENE_OR_GENE_PRODUCT", 207, 210], ["neutrophils", "CELL", 243, 254], ["interleukins", "PROTEIN", 42, 54], ["interleukin-6 (IL-6", "PROTEIN", 69, 88], ["C-reactive protein", "PROTEIN", 187, 205], ["CRP", "PROTEIN", 207, 210], ["neutrophils", "CELL_TYPE", 243, 254], ["interleukins", "PROBLEM", 42, 54], ["interleukin", "TEST", 69, 80], ["acute-phase reactants", "PROBLEM", 160, 181], ["C-reactive protein", "PROBLEM", 187, 205], ["CRP", "TEST", 207, 210], ["increases mobilization of neutrophils", "PROBLEM", 217, 254], ["large", "OBSERVATION_MODIFIER", 4, 9], ["-scale", "OBSERVATION_MODIFIER", 9, 15], ["unregulated", "OBSERVATION_MODIFIER", 16, 27], ["production", "OBSERVATION_MODIFIER", 28, 38], ["acute", "OBSERVATION_MODIFIER", 160, 165], ["reactive protein", "OBSERVATION", 189, 205], ["increases", "OBSERVATION_MODIFIER", 217, 226], ["mobilization", "OBSERVATION_MODIFIER", 227, 239]]], ["This, along with stress-induced neutrophilia, likely explains the relative lymphopenia seen in severe manifestations of the SARS-CoV-2 infection [4-6].IntroductionSeveral studies have sought to demonstrate the clinical utility and feasibility of the neutrophil-to-lymphocyte ratio (NLR) in predicting COVID-19 outcomes [6].", [["neutrophil", "ANATOMY", 250, 260], ["neutrophilia", "DISEASE", 32, 44], ["lymphopenia", "DISEASE", 75, 86], ["SARS-CoV-2 infection", "DISEASE", 124, 144], ["SARS-CoV-2", "ORGANISM", 124, 134], ["neutrophil", "CELL", 250, 260], ["lymphocyte", "CELL", 264, 274], ["neutrophil", "CELL_TYPE", 250, 260], ["SARS-CoV-2", "SPECIES", 124, 134], ["stress-induced neutrophilia", "PROBLEM", 17, 44], ["the relative lymphopenia", "PROBLEM", 62, 86], ["severe manifestations", "PROBLEM", 95, 116], ["the SARS", "PROBLEM", 120, 128], ["CoV-2 infection", "PROBLEM", 129, 144], ["IntroductionSeveral studies", "TEST", 151, 178], ["the neutrophil", "TEST", 246, 260], ["lymphocyte ratio", "TEST", 264, 280], ["NLR", "TEST", 282, 285], ["COVID", "TEST", 301, 306], ["neutrophilia", "OBSERVATION", 32, 44], ["likely explains", "UNCERTAINTY", 46, 61], ["relative", "OBSERVATION_MODIFIER", 66, 74], ["lymphopenia", "OBSERVATION", 75, 86], ["severe", "OBSERVATION_MODIFIER", 95, 101]]], ["A high NLR value at admission has been proposed as suggestive of COVID-19, while confirmatory tests are pending and a rising NLR has been shown to be associated with worse clinical outcomes in severe COVID-19.", [["NLR", "GENE_OR_GENE_PRODUCT", 7, 10], ["NLR", "GENE_OR_GENE_PRODUCT", 125, 128], ["NLR", "PROTEIN", 7, 10], ["NLR", "PROTEIN", 125, 128], ["A high NLR value", "PROBLEM", 0, 16], ["COVID", "TEST", 65, 70], ["confirmatory tests", "TEST", 81, 99], ["a rising NLR", "PROBLEM", 116, 128], ["severe COVID", "PROBLEM", 193, 205], ["suggestive of", "UNCERTAINTY", 51, 64]]], ["While the NLR is well studied, a similar biomarker ratio, the lymphocyte-to-CRP ratio (LCR), has, so far, not been utilized.", [["lymphocyte", "ANATOMY", 62, 72], ["NLR", "GENE_OR_GENE_PRODUCT", 10, 13], ["lymphocyte", "CELL", 62, 72], ["CRP", "GENE_OR_GENE_PRODUCT", 76, 79], ["NLR", "PROTEIN", 10, 13], ["CRP", "PROTEIN", 76, 79], ["a similar biomarker ratio", "TEST", 31, 56], ["the lymphocyte", "TEST", 58, 72], ["CRP ratio", "TEST", 76, 85]]], ["Typically, the LCR is used as a prognostic marker for several types of cancers, including colon and gastric carcinomas [7-10].", [["cancers", "ANATOMY", 71, 78], ["colon", "ANATOMY", 90, 95], ["gastric carcinomas", "ANATOMY", 100, 118], ["cancers", "DISEASE", 71, 78], ["colon and gastric carcinomas", "DISEASE", 90, 118], ["cancers", "CANCER", 71, 78], ["colon", "CANCER", 90, 95], ["gastric carcinomas", "CANCER", 100, 118], ["LCR", "DNA", 15, 18], ["cancers", "PROBLEM", 71, 78], ["colon and gastric carcinomas", "PROBLEM", 90, 118], ["cancers", "OBSERVATION", 71, 78], ["colon", "ANATOMY", 90, 95], ["gastric", "ANATOMY", 100, 107], ["carcinomas", "OBSERVATION", 108, 118]]], ["The rationale behind this is that the LCR serves as a good surrogate of the complex host-tumor immunological interactions that result in a systemic inflammatory process, which is believed to contribute towards the pathogenesis and progression of these carcinomas [11].", [["tumor", "ANATOMY", 89, 94], ["carcinomas", "ANATOMY", 252, 262], ["tumor", "DISEASE", 89, 94], ["carcinomas", "DISEASE", 252, 262], ["tumor", "CANCER", 89, 94], ["carcinomas", "CANCER", 252, 262], ["LCR", "DNA", 38, 41], ["tumor immunological interactions", "PROBLEM", 89, 121], ["a systemic inflammatory process", "PROBLEM", 137, 168], ["the pathogenesis", "PROBLEM", 210, 226], ["these carcinomas", "PROBLEM", 246, 262], ["tumor", "OBSERVATION", 89, 94], ["systemic", "OBSERVATION_MODIFIER", 139, 147], ["inflammatory", "OBSERVATION", 148, 160], ["believed to contribute", "UNCERTAINTY", 179, 201], ["progression", "OBSERVATION_MODIFIER", 231, 242], ["carcinomas", "OBSERVATION", 252, 262]]], ["Since COVID-19 also precipitates a systemic inflammatory response, it follows that the LCR may also be a good proxy marker in this disease process and may carry prognostic value.IntroductionThe present study aims to shed light on whether LCR and NLR can, in fact, be used as reliable predictors for adverse outcomes.", [["COVID-19", "CHEMICAL", 6, 14], ["COVID-19", "CHEMICAL", 6, 14], ["COVID-19", "GENE_OR_GENE_PRODUCT", 6, 14], ["LCR", "CELLULAR_COMPONENT", 87, 90], ["NLR", "GENE_OR_GENE_PRODUCT", 246, 249], ["COVID-19", "DNA", 6, 14], ["LCR", "DNA", 87, 90], ["LCR", "DNA", 238, 241], ["NLR", "PROTEIN", 246, 249], ["COVID", "TEST", 6, 11], ["a systemic inflammatory response", "PROBLEM", 33, 65], ["this disease process", "PROBLEM", 126, 146], ["LCR", "TEST", 238, 241], ["NLR", "TEST", 246, 249], ["adverse outcomes", "PROBLEM", 299, 315], ["systemic", "OBSERVATION_MODIFIER", 35, 43], ["inflammatory response", "OBSERVATION", 44, 65]]], ["We further analyzed their predictive capability by subdividing adverse complications and correlating the LCR and NLR ratios observed in each instance.Study design and participants ::: Materials and MethodsThis retrospective cohort study included consecutive adult inpatients (\u2265 18 years old) from Abington Hospital-Jefferson Health, PA, USA.", [["NLR", "GENE_OR_GENE_PRODUCT", 113, 116], ["inpatients", "ORGANISM", 264, 274], ["LCR", "DNA", 105, 108], ["NLR", "PROTEIN", 113, 116], ["participants", "SPECIES", 167, 179], ["subdividing adverse complications", "PROBLEM", 51, 84], ["the LCR", "TEST", 101, 108], ["NLR ratios", "TEST", 113, 123], ["NLR ratios", "OBSERVATION", 113, 123]]], ["All patients had a confirmed diagnosis of COVID-19 between March 1, 2020 and May 10, 2020.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["COVID", "TEST", 42, 47]]], ["This study was conducted in compliance with the ethical standards of the responsible institution on human subjects as well as with the Helsinki Declaration.", [["human", "ORGANISM", 100, 105], ["human", "SPECIES", 100, 105], ["human", "SPECIES", 100, 105], ["This study", "TEST", 0, 10]]], ["The study was approved by the Institutional Review Board (IRB).Patient and public involvement ::: Materials and MethodsThe study was retrospective in design, data was obtained by chart review and there were no direct patient interactions.", [["patient", "ORGANISM", 217, 224], ["Patient", "SPECIES", 63, 70], ["patient", "SPECIES", 217, 224], ["The study", "TEST", 0, 9], ["Methods", "TREATMENT", 112, 119], ["The study", "TEST", 119, 128]]], ["No patient was involved in the design, recruitment and conduct of the study.", [["patient", "ORGANISM", 3, 10], ["patient", "SPECIES", 3, 10], ["the study", "TEST", 66, 75]]], ["The development of research question and outcome measures were influenced by common inpatient outcomes for hospitalized patients and the results of this study will not be directly disseminated to study participants.Data collection ::: Materials and MethodsClinical, demographic, laboratory, treatment, and outcome data were extracted from electronic medical records (Sunrise) using a standardized data collection form.", [["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128], ["participants", "SPECIES", 202, 214], ["this study", "TEST", 148, 158], ["treatment", "TREATMENT", 291, 300], ["a standardized data collection", "TEST", 382, 412]]], ["All authors contributed to data retrieval and an independent author adjudicated any difference in interpretation between the data extractors.", [["data retrieval", "TREATMENT", 27, 41]]], ["SARS-CoV-2 was detected in respiratory specimens (throat swabs) by next-generation sequencing or real-time qualitative polymerase chain reaction (RT-qPCR) methods.", [["respiratory specimens", "ANATOMY", 27, 48], ["throat swabs", "ANATOMY", 50, 62], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["throat swabs", "ORGANISM_SUBDIVISION", 50, 62], ["SARS-CoV", "SPECIES", 0, 8], ["SARS-CoV", "TEST", 0, 8], ["respiratory specimens", "TEST", 27, 48], ["throat swabs", "TEST", 50, 62], ["qualitative polymerase chain reaction", "PROBLEM", 107, 144], ["respiratory", "ANATOMY", 27, 38]]], ["The laboratory values, cutoff variables and methods for laboratory confirmation of SARS-CoV-2 infection were standardized.", [["SARS", "DISEASE", 83, 87], ["infection", "DISEASE", 94, 103], ["SARS-CoV-2", "ORGANISM", 83, 93], ["SARS-CoV-2", "SPECIES", 83, 93], ["The laboratory values", "TEST", 0, 21], ["cutoff variables", "TEST", 23, 39], ["methods", "TEST", 44, 51], ["laboratory confirmation", "TEST", 56, 79], ["SARS", "PROBLEM", 83, 87], ["CoV", "PROBLEM", 88, 91], ["2 infection", "PROBLEM", 92, 103]]], ["Data regarding baseline comorbidities included a history of diabetes mellitus (DM), hypertension (HTN), chronic kidney disease (CKD) and coronary artery disease (CAD).", [["kidney", "ANATOMY", 112, 118], ["coronary artery", "ANATOMY", 137, 152], ["diabetes mellitus", "DISEASE", 60, 77], ["DM", "DISEASE", 79, 81], ["hypertension", "DISEASE", 84, 96], ["HTN", "DISEASE", 98, 101], ["chronic kidney disease", "DISEASE", 104, 126], ["CKD", "DISEASE", 128, 131], ["coronary artery disease", "DISEASE", 137, 160], ["CAD", "DISEASE", 162, 165], ["kidney", "ORGAN", 112, 118], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 137, 152], ["baseline comorbidities", "PROBLEM", 15, 37], ["diabetes mellitus", "PROBLEM", 60, 77], ["DM)", "PROBLEM", 79, 82], ["hypertension (HTN)", "PROBLEM", 84, 102], ["chronic kidney disease", "PROBLEM", 104, 126], ["CKD)", "PROBLEM", 128, 132], ["coronary artery disease (CAD)", "PROBLEM", 137, 166], ["diabetes mellitus", "OBSERVATION", 60, 77], ["hypertension", "OBSERVATION", 84, 96], ["chronic", "OBSERVATION_MODIFIER", 104, 111], ["kidney", "ANATOMY", 112, 118], ["disease", "OBSERVATION", 119, 126], ["CKD", "OBSERVATION", 128, 131], ["coronary artery", "ANATOMY", 137, 152], ["disease", "OBSERVATION", 153, 160]]], ["In-hospital medications used included hydroxychloroquine (HCQ), tocilizumab, steroids and anticoagulation (AC).", [["hydroxychloroquine", "CHEMICAL", 38, 56], ["HCQ", "CHEMICAL", 58, 61], ["tocilizumab", "CHEMICAL", 64, 75], ["steroids", "CHEMICAL", 77, 85], ["hydroxychloroquine", "CHEMICAL", 38, 56], ["HCQ", "CHEMICAL", 58, 61], ["steroids", "CHEMICAL", 77, 85], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 38, 56], ["HCQ", "SIMPLE_CHEMICAL", 58, 61], ["tocilizumab", "SIMPLE_CHEMICAL", 64, 75], ["steroids", "SIMPLE_CHEMICAL", 77, 85], ["In-hospital medications", "TREATMENT", 0, 23], ["hydroxychloroquine (HCQ)", "TREATMENT", 38, 62], ["tocilizumab", "TREATMENT", 64, 75], ["steroids", "TREATMENT", 77, 85], ["anticoagulation (AC)", "TREATMENT", 90, 110]]], ["Routine blood work included coagulation profile, complete blood count, serum biochemical tests (renal function, CRP, D-dimer, lactate dehydrogenase (LDH), myocardial enzymes (troponin T (TnT)) and serum ferritin.", [["blood", "ANATOMY", 8, 13], ["blood", "ANATOMY", 58, 63], ["serum", "ANATOMY", 71, 76], ["renal", "ANATOMY", 96, 101], ["myocardial", "ANATOMY", 155, 165], ["serum", "ANATOMY", 197, 202], ["lactate", "CHEMICAL", 126, 133], ["lactate", "CHEMICAL", 126, 133], ["blood", "ORGANISM_SUBSTANCE", 8, 13], ["blood", "ORGANISM_SUBSTANCE", 58, 63], ["serum", "ORGANISM_SUBSTANCE", 71, 76], ["renal", "ORGAN", 96, 101], ["CRP", "GENE_OR_GENE_PRODUCT", 112, 115], ["D-dimer", "GENE_OR_GENE_PRODUCT", 117, 124], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 126, 147], ["LDH", "SIMPLE_CHEMICAL", 149, 152], ["myocardial enzymes", "GENE_OR_GENE_PRODUCT", 155, 173], ["troponin T", "GENE_OR_GENE_PRODUCT", 175, 185], ["TnT", "GENE_OR_GENE_PRODUCT", 187, 190], ["serum", "ORGANISM_SUBSTANCE", 197, 202], ["ferritin", "GENE_OR_GENE_PRODUCT", 203, 211], ["CRP", "PROTEIN", 112, 115], ["D-dimer", "PROTEIN", 117, 124], ["lactate dehydrogenase", "PROTEIN", 126, 147], ["LDH", "PROTEIN", 149, 152], ["myocardial enzymes", "PROTEIN", 155, 173], ["troponin T", "PROTEIN", 175, 185], ["TnT", "PROTEIN", 187, 190], ["serum ferritin", "PROTEIN", 197, 211], ["Routine blood work", "TEST", 0, 18], ["coagulation profile", "TEST", 28, 47], ["complete blood count", "TEST", 49, 69], ["serum biochemical tests", "TEST", 71, 94], ["renal function", "TEST", 96, 110], ["CRP", "TEST", 112, 115], ["D-dimer", "TEST", 117, 124], ["lactate dehydrogenase", "TEST", 126, 147], ["LDH", "TEST", 149, 152], ["myocardial enzymes", "TEST", 155, 173], ["troponin T", "TEST", 175, 185], ["TnT", "TEST", 187, 190], ["serum ferritin", "TEST", 197, 211], ["renal", "ANATOMY", 96, 101], ["myocardial", "ANATOMY", 155, 165]]], ["Chest radiographs or computed tomography (CT) scans were also done for most inpatients where clinically indicated.", [["Chest radiographs", "TEST", 0, 17], ["computed tomography (CT) scans", "TEST", 21, 51]]], ["Acute cardiac injury was diagnosed if serum levels of cardiac biomarkers (TnT) were above the 99th percentile upper reference limit in conjunction with new abnormalities on the electrocardiography (EKG) and transthoracic echocardiography (TTE).", [["cardiac", "ANATOMY", 6, 13], ["serum", "ANATOMY", 38, 43], ["cardiac", "ANATOMY", 54, 61], ["cardiac injury", "DISEASE", 6, 20], ["cardiac", "ORGAN", 6, 13], ["serum", "ORGANISM_SUBSTANCE", 38, 43], ["cardiac", "ORGAN", 54, 61], ["TnT", "GENE_OR_GENE_PRODUCT", 74, 77], ["TnT", "PROTEIN", 74, 77], ["Acute cardiac injury", "PROBLEM", 0, 20], ["serum levels", "TEST", 38, 50], ["cardiac biomarkers", "TEST", 54, 72], ["TnT", "TEST", 74, 77], ["new abnormalities", "PROBLEM", 152, 169], ["the electrocardiography", "TEST", 173, 196], ["EKG", "TEST", 198, 201], ["transthoracic echocardiography", "TEST", 207, 237], ["TTE", "TEST", 239, 242], ["cardiac", "ANATOMY", 6, 13], ["injury", "OBSERVATION", 14, 20], ["cardiac", "ANATOMY", 54, 61]]], ["The criteria for discharge were absence of fever, freedom from symptoms, substantial clinical or radiological improvement for at least 1 day.Statistical analysis ::: Materials and MethodsContinuous variables were presented as mean and standard deviations (SD); categorical variables were reported in percentages and proportions.", [["fever", "DISEASE", 43, 48], ["fever", "PROBLEM", 43, 48], ["symptoms", "PROBLEM", 63, 71], ["standard deviations (SD); categorical variables", "PROBLEM", 235, 282], ["substantial", "OBSERVATION_MODIFIER", 73, 84]]], ["A Chi-square (\u03c72) test was used for comparison of categorical data; Fisher\u2019s exact test was only adopted if the expected count in more than 20% cells was less than 5.", [["cells", "ANATOMY", 144, 149], ["cells", "CELL", 144, 149], ["A Chi-square (\u03c72) test", "TEST", 0, 22], ["categorical data", "TEST", 50, 66], ["Fisher\u2019s exact test", "TEST", 68, 87], ["the expected count", "TEST", 108, 126]]], ["To quantify the association between the dichotomous categorical variables, an unadjusted odds ratio (OR) was obtained using the Cochran-Mantel-Haenszel method.", [["an unadjusted odds ratio", "TEST", 75, 99], ["Haenszel method", "TREATMENT", 143, 158]]], ["To explore the risk factors and gauge the impact of potential effect modifiers (covariates) on our endpoints (in-hospital death, need for an upgrade, ventilators and dialysis) binomial and multinomial logistic regression models were applied as appropriate.", [["death", "DISEASE", 122, 127], ["the risk factors", "PROBLEM", 11, 27], ["potential effect modifiers", "TREATMENT", 52, 78], ["an upgrade", "TREATMENT", 138, 148], ["ventilators", "TREATMENT", 150, 161], ["dialysis", "TREATMENT", 166, 174], ["binomial", "TREATMENT", 176, 184], ["multinomial logistic regression models", "TREATMENT", 189, 227]]], ["The differences in the baseline comorbidities (DM, HTN, CAD, CKD) and medication use (HCQ, tocilizumab, remdesivir, AC and steroids) were accounted for to obtain an adjusted odds ratio (aOR) for all outcomes.", [["DM", "DISEASE", 47, 49], ["HTN", "DISEASE", 51, 54], ["CAD", "DISEASE", 56, 59], ["CKD", "DISEASE", 61, 64], ["HCQ", "CHEMICAL", 86, 89], ["tocilizumab", "CHEMICAL", 91, 102], ["remdesivir", "CHEMICAL", 104, 114], ["AC", "CHEMICAL", 116, 118], ["steroids", "CHEMICAL", 123, 131], ["HCQ", "CHEMICAL", 86, 89], ["remdesivir", "CHEMICAL", 104, 114], ["steroids", "CHEMICAL", 123, 131], ["HCQ", "SIMPLE_CHEMICAL", 86, 89], ["tocilizumab", "SIMPLE_CHEMICAL", 91, 102], ["remdesivir", "SIMPLE_CHEMICAL", 104, 114], ["AC", "SIMPLE_CHEMICAL", 116, 118], ["the baseline comorbidities", "PROBLEM", 19, 45], ["DM", "PROBLEM", 47, 49], ["HTN", "PROBLEM", 51, 54], ["CAD", "PROBLEM", 56, 59], ["CKD", "PROBLEM", 61, 64], ["medication use", "TREATMENT", 70, 84], ["HCQ", "TREATMENT", 86, 89], ["tocilizumab", "TREATMENT", 91, 102], ["remdesivir", "TREATMENT", 104, 114], ["AC", "TREATMENT", 116, 118], ["steroids", "TREATMENT", 123, 131]]], ["The Hosmer-Lemeshow (HL) goodness-of-fit test was used to predict the fitness of logistic regression models for applicability to categorical data.", [["fit test", "TEST", 37, 45], ["categorical data", "TEST", 129, 145]]], ["For normally and abnormally distributed continuous data, an independent sample t-test and Mann-Whitney U test were utilized, respectively.", [["an independent sample t-test", "TEST", 57, 85], ["Mann-Whitney U test", "TEST", 90, 109], ["abnormally", "OBSERVATION_MODIFIER", 17, 27], ["distributed", "OBSERVATION_MODIFIER", 28, 39]]], ["A one-way analysis of variance (ANOVA) was used to compare differences in the mean of continuous variables for multiple in-hospital complications.", [["multiple in-hospital complications", "PROBLEM", 111, 145]]], ["A two-sided \u03b1 of less than 0.05 was considered statistically significant corroborating inference from a 95% confidence interval (CI).", [["CI", "TEST", 129, 131], ["sided", "ANATOMY_MODIFIER", 6, 11]]], ["Statistical analyses were performed using the SPSS software (version 25).Demographics and baseline characteristics ::: ResultsA total of 176 consecutive patients with a confirmed diagnosis of COVID-19 were included in our study.", [["patients", "ORGANISM", 153, 161], ["patients", "SPECIES", 153, 161], ["Statistical analyses", "TEST", 0, 20], ["the SPSS software", "TEST", 42, 59], ["COVID", "TEST", 192, 197], ["our study", "TEST", 218, 227]]], ["Patients were divided into two comparison groups: low NLR (< 10) versus high NLR (> 11), and low LCR (< 100) and high LCR (> 101).", [["Patients", "ORGANISM", 0, 8], ["NLR", "PROTEIN", 54, 57], ["NLR", "PROTEIN", 77, 80], ["LCR", "DNA", 118, 121], ["Patients", "SPECIES", 0, 8], ["low NLR", "PROBLEM", 50, 57], ["high NLR", "PROBLEM", 72, 80], ["low LCR", "PROBLEM", 93, 100], ["high LCR", "PROBLEM", 113, 121]]], ["The mean age for NLR patients was 63.6 versus 61.6 and for LCR groups, it was 62.6 versus 63.7 years.", [["patients", "ORGANISM", 21, 29], ["NLR", "PROTEIN", 17, 20], ["patients", "SPECIES", 21, 29], ["NLR", "TEST", 17, 20]]], ["The baseline comorbidities across all groups were comparable except that the higher LCR group had female predominance.", [["The baseline comorbidities", "PROBLEM", 0, 26], ["female predominance", "OBSERVATION", 98, 117]]], ["The proportions of underlying comorbidities between low and high NLR groups included DM (83.9% vs. 16.1%), HTN (86.9% vs. 13.1%), CAD (93.1% vs. 6.1%), CKD (87.1% vs. 12.9%), and chronic obstructive pulmonary disease (COPD) (91.7% vs. 8.3%) respectively.", [["pulmonary", "ANATOMY", 199, 208], ["DM", "DISEASE", 85, 87], ["HTN", "DISEASE", 107, 110], ["CAD", "DISEASE", 130, 133], ["CKD", "DISEASE", 152, 155], ["chronic obstructive pulmonary disease", "DISEASE", 179, 216], ["COPD", "DISEASE", 218, 222], ["pulmonary", "ORGAN", 199, 208], ["NLR", "PROTEIN", 65, 68], ["underlying comorbidities", "PROBLEM", 19, 43], ["low and high NLR groups", "PROBLEM", 52, 75], ["DM", "PROBLEM", 85, 87], ["HTN", "PROBLEM", 107, 110], ["CAD", "PROBLEM", 130, 133], ["CKD", "TEST", 152, 155], ["chronic obstructive pulmonary disease", "PROBLEM", 179, 216], ["COPD)", "PROBLEM", 218, 223], ["comorbidities", "OBSERVATION", 30, 43], ["chronic", "OBSERVATION_MODIFIER", 179, 186], ["obstructive", "OBSERVATION_MODIFIER", 187, 198], ["pulmonary", "ANATOMY", 199, 208], ["disease", "OBSERVATION", 209, 216], ["COPD", "OBSERVATION", 218, 222]]], ["These percentages for low and high LCR groups were: DM (21.1% vs. 78.9%), HTN (23.0% vs. 80.0%), CAD (19.4% vs. 80.6%), CKD (25% vs. 75%), and COPD (16.7% vs. 83.3%), respectively.", [["DM", "DISEASE", 52, 54], ["HTN", "DISEASE", 74, 77], ["CAD", "DISEASE", 97, 100], ["CKD", "DISEASE", 120, 123], ["COPD", "DISEASE", 143, 147], ["These percentages", "TEST", 0, 17], ["low and high LCR groups", "PROBLEM", 22, 45], ["DM", "PROBLEM", 52, 54], ["HTN", "PROBLEM", 74, 77], ["CAD", "PROBLEM", 97, 100], ["CKD", "TEST", 120, 123], ["COPD", "PROBLEM", 143, 147], ["low", "OBSERVATION_MODIFIER", 22, 25], ["COPD", "OBSERVATION", 143, 147]]], ["Patients in both NLR and LCR groups had similar proportions of medication use (HCQ, tocilizumab, AC, steroids) across both groups (P value \u2265 0.05) (Fig. 1, Table 1).In interventions ::: Mean differences in NLR and LCR ::: ResultsThe mean difference in the levels of NLR and LCR between patients on definitive COVID-19 therapy compared to those not receiving therapy were mostly identical across its respective groups with few exceptions.", [["HCQ", "CHEMICAL", 79, 82], ["tocilizumab", "CHEMICAL", 84, 95], ["steroids", "CHEMICAL", 101, 109], ["COVID-19", "CHEMICAL", 309, 317], ["HCQ", "CHEMICAL", 79, 82], ["steroids", "CHEMICAL", 101, 109], ["COVID-19", "CHEMICAL", 309, 317], ["Patients", "ORGANISM", 0, 8], ["HCQ", "SIMPLE_CHEMICAL", 79, 82], ["tocilizumab", "SIMPLE_CHEMICAL", 84, 95], ["AC", "SIMPLE_CHEMICAL", 97, 99], ["NLR", "GENE_OR_GENE_PRODUCT", 266, 269], ["patients", "ORGANISM", 286, 294], ["NLR", "PROTEIN", 17, 20], ["NLR", "PROTEIN", 206, 209], ["LCR", "DNA", 214, 217], ["NLR", "PROTEIN", 266, 269], ["LCR", "DNA", 274, 277], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 286, 294], ["medication use", "TREATMENT", 63, 77], ["HCQ", "TREATMENT", 79, 82], ["tocilizumab", "TREATMENT", 84, 95], ["AC", "TREATMENT", 97, 99], ["steroids", "TREATMENT", 101, 109], ["Mean differences", "PROBLEM", 186, 202], ["NLR", "TEST", 206, 209], ["The mean difference", "PROBLEM", 229, 248], ["NLR", "TEST", 266, 269], ["LCR", "TEST", 274, 277], ["definitive COVID", "TREATMENT", 298, 314], ["therapy", "TREATMENT", 318, 325], ["therapy", "TREATMENT", 358, 365], ["LCR", "ANATOMY", 25, 28], ["mean", "OBSERVATION_MODIFIER", 233, 237], ["difference", "OBSERVATION_MODIFIER", 238, 248], ["NLR", "OBSERVATION", 266, 269], ["LCR", "OBSERVATION_MODIFIER", 274, 277]]], ["On day 1 of presentation, the mean NLR for patients receiving HCQ versus no HCQ were 8 \u00b1 9 versus 5 \u00b1 4 (P = 0.15), tocilizumab versus no tocilizumab 8 \u00b1 6 versus 7 \u00b1 9 (P = 0.84), AC versus no AC 10 \u00b1 16 versus 7 \u00b1 5 (P = 0.19) and steroids versus no steroids 6 \u00b1 5 versus 8 \u00b1 9 (P = 0.51), respectively.", [["HCQ", "CHEMICAL", 62, 65], ["HCQ", "CHEMICAL", 76, 79], ["steroids", "CHEMICAL", 233, 241], ["steroids", "CHEMICAL", 252, 260], ["HCQ", "CHEMICAL", 62, 65], ["HCQ", "CHEMICAL", 76, 79], ["steroids", "CHEMICAL", 233, 241], ["steroids", "CHEMICAL", 252, 260], ["patients", "ORGANISM", 43, 51], ["HCQ", "SIMPLE_CHEMICAL", 62, 65], ["HCQ", "SIMPLE_CHEMICAL", 76, 79], ["NLR", "PROTEIN", 35, 38], ["patients", "SPECIES", 43, 51], ["HCQ", "TREATMENT", 62, 65], ["HCQ", "TEST", 76, 79], ["tocilizumab", "TEST", 116, 127], ["tocilizumab", "TEST", 138, 149], ["AC", "TEST", 181, 183], ["AC", "TEST", 194, 196], ["P", "TEST", 219, 220], ["steroids", "TREATMENT", 233, 241], ["steroids", "TREATMENT", 252, 260]]], ["Similarly, there was no significant difference in the post-treatment mean values of NLR in patients who received HCQ versus no HCQ (9 \u00b1 11 vs. 5 \u00b1 3, P = 0.28), tocilizumab versus no tocilizumab (10 \u00b1 14 vs. 9 \u00b1 9, P = 0.74), and steroids versus no steroids (11 \u00b1 14 vs. 8 \u00b1 9, P = 0.16) respectively.", [["HCQ", "CHEMICAL", 113, 116], ["HCQ", "CHEMICAL", 127, 130], ["tocilizumab", "CHEMICAL", 161, 172], ["tocilizumab", "CHEMICAL", 183, 194], ["steroids", "CHEMICAL", 230, 238], ["steroids", "CHEMICAL", 249, 257], ["HCQ", "CHEMICAL", 113, 116], ["HCQ", "CHEMICAL", 127, 130], ["steroids", "CHEMICAL", 230, 238], ["steroids", "CHEMICAL", 249, 257], ["NLR", "GENE_OR_GENE_PRODUCT", 84, 87], ["patients", "ORGANISM", 91, 99], ["HCQ", "SIMPLE_CHEMICAL", 113, 116], ["HCQ", "SIMPLE_CHEMICAL", 127, 130], ["tocilizumab", "SIMPLE_CHEMICAL", 161, 172], ["tocilizumab", "SIMPLE_CHEMICAL", 183, 194], ["steroids", "SIMPLE_CHEMICAL", 230, 238], ["NLR", "PROTEIN", 84, 87], ["patients", "SPECIES", 91, 99], ["significant difference", "PROBLEM", 24, 46], ["NLR", "TEST", 84, 87], ["HCQ", "TREATMENT", 113, 116], ["HCQ", "TREATMENT", 127, 130], ["tocilizumab", "TREATMENT", 161, 172], ["tocilizumab", "TREATMENT", 183, 194], ["P", "TEST", 215, 216], ["steroids", "TREATMENT", 230, 238], ["steroids", "TREATMENT", 249, 257], ["no", "UNCERTAINTY", 21, 23], ["significant", "OBSERVATION_MODIFIER", 24, 35], ["difference", "OBSERVATION_MODIFIER", 36, 46]]], ["The mean NLR for patients on AC was significantly higher compared to the no AC group (15 \u00b1 17 vs. 7 \u00b1 7, P = 0.02).", [["patients", "ORGANISM", 17, 25], ["NLR", "PROTEIN", 9, 12], ["patients", "SPECIES", 17, 25], ["The mean NLR", "TEST", 0, 12], ["AC", "TEST", 29, 31]]], ["The mean LCR values closely followed the overall trend of mean NLR ratios.", [["NLR", "GENE_OR_GENE_PRODUCT", 63, 66], ["LCR", "DNA", 9, 12], ["NLR", "PROTEIN", 63, 66], ["The mean LCR values", "TEST", 0, 19], ["mean NLR ratios", "TEST", 58, 73]]], ["The mean LCR in HCQ versus no HCQ was 563 \u00b1 1,632 versus 6,820 \u00b1 30,751 (P = 0.28), tocilizumab versus no tocilizumab 681 \u00b1 1,238 versus 1,851 \u00b1 14,221 (P = 0.64), AC versus no AC (1,117 \u00b1 2,882 vs. 1,759 \u00b1 1,427, P = 0.80) and steroids versus no steroids (766 \u00b1 1,247 vs. 1,816 \u00b1 1,414,122, P = 0.69) respectively.", [["HCQ", "CHEMICAL", 16, 19], ["HCQ", "CHEMICAL", 30, 33], ["steroids", "CHEMICAL", 228, 236], ["steroids", "CHEMICAL", 247, 255], ["HCQ", "CHEMICAL", 16, 19], ["HCQ", "CHEMICAL", 30, 33], ["steroids", "CHEMICAL", 228, 236], ["steroids", "CHEMICAL", 247, 255], ["HCQ", "SIMPLE_CHEMICAL", 16, 19], ["LCR", "DNA", 9, 12], ["The mean LCR", "TEST", 0, 12], ["HCQ", "TEST", 16, 19], ["HCQ", "TEST", 30, 33], ["P", "TEST", 73, 74], ["tocilizumab", "TEST", 84, 95], ["tocilizumab", "TEST", 106, 117], ["P", "TEST", 153, 154], ["AC", "TEST", 164, 166], ["AC", "TEST", 177, 179], ["P", "TEST", 214, 215], ["steroids", "TREATMENT", 228, 236], ["steroids", "TREATMENT", 247, 255], ["P", "TEST", 292, 293]]], ["On day 7, the mean LCR for the patients on tocilizumab was significantly higher than those not on tocilizumab (2,718 \u00b1 3,418 vs. 461 \u00b1 1,034, P = 0.00).", [["tocilizumab", "CHEMICAL", 43, 54], ["tocilizumab", "CHEMICAL", 98, 109], ["patients", "ORGANISM", 31, 39], ["tocilizumab", "SIMPLE_CHEMICAL", 43, 54], ["tocilizumab", "SIMPLE_CHEMICAL", 98, 109], ["LCR", "DNA", 19, 22], ["patients", "SPECIES", 31, 39], ["the mean LCR", "TEST", 10, 22], ["tocilizumab", "TEST", 43, 54], ["tocilizumab", "TEST", 98, 109], ["P", "TEST", 142, 143]]], ["The mean LCR for patients on HCQ versus no HCQ (918 \u00b1 2,085 vs. 1,654 \u00b1 1,224, P = 0.36), steroids versus no steroids (1,183 \u00b1 208 vs. 893 \u00b1 2,047, P = 0.50) and AC versus no AC (1,633 \u00b1 3,094 vs. 783 \u00b1 1,661, P = 0.18) were not significantly different (Fig. 2).In outcomes ::: Mean differences in NLR and LCR ::: ResultsMean differences in NLR and LCR for hard clinical outcomes such as in-hospital mortality and resource allocation were also calculated.", [["HCQ", "CHEMICAL", 29, 32], ["HCQ", "CHEMICAL", 43, 46], ["steroids", "CHEMICAL", 90, 98], ["steroids", "CHEMICAL", 109, 117], ["HCQ", "CHEMICAL", 29, 32], ["HCQ", "CHEMICAL", 43, 46], ["steroids", "CHEMICAL", 90, 98], ["steroids", "CHEMICAL", 109, 117], ["patients", "ORGANISM", 17, 25], ["HCQ", "SIMPLE_CHEMICAL", 29, 32], ["HCQ", "SIMPLE_CHEMICAL", 43, 46], ["LCR", "DNA", 9, 12], ["NLR", "PROTEIN", 298, 301], ["LCR", "DNA", 306, 309], ["NLR", "PROTEIN", 341, 344], ["LCR", "DNA", 349, 352], ["patients", "SPECIES", 17, 25], ["The mean LCR", "TEST", 0, 12], ["HCQ", "TEST", 29, 32], ["HCQ", "TEST", 43, 46], ["P", "TEST", 79, 80], ["steroids", "TREATMENT", 90, 98], ["steroids", "TREATMENT", 109, 117], ["P", "TEST", 148, 149], ["AC", "TEST", 162, 164], ["AC", "TEST", 175, 177], ["P", "TEST", 210, 211], ["Mean differences", "PROBLEM", 278, 294], ["NLR", "TEST", 298, 301], ["NLR", "TEST", 341, 344], ["LCR", "TEST", 349, 352], ["resource allocation", "TEST", 414, 433]]], ["The mean NLR and LCR differences on day 1 of admission were not significantly different between patients requiring an upgrade (10 \u00b1 13 vs. 6 \u00b1 5, P = 0.06; 4,010 vs. 493, P = 0.25), ventilator support (9 \u00b1 12 vs. 6 \u00b1 5, P = 0.05; 3,675 vs. 515, P = 0.26) and dialysis (11 \u00b1 8 vs. 7 \u00b1 8, P = 0.20; 712 vs. 1,688, P = 0.82) compared to corresponding patients not requiring an upgrade, ventilator and dialysis.", [["patients", "ORGANISM", 96, 104], ["patients", "ORGANISM", 348, 356], ["NLR", "PROTEIN", 9, 12], ["LCR", "DNA", 17, 20], ["patients", "SPECIES", 96, 104], ["patients", "SPECIES", 348, 356], ["The mean NLR", "TEST", 0, 12], ["an upgrade", "TEST", 115, 125], ["P", "TEST", 146, 147], ["P", "TEST", 171, 172], ["ventilator support", "TREATMENT", 182, 200], ["P", "TEST", 220, 221], ["P", "TEST", 245, 246], ["dialysis", "TREATMENT", 259, 267], ["P", "TEST", 287, 288], ["P", "TEST", 312, 313], ["an upgrade", "TREATMENT", 371, 381], ["ventilator", "TREATMENT", 383, 393], ["dialysis", "TREATMENT", 398, 406], ["LCR", "OBSERVATION_MODIFIER", 17, 20], ["differences", "OBSERVATION_MODIFIER", 21, 32]]], ["Similarly, the mean difference in NLR and LCR in patients surviving compared to patients who died on presentation was identical (7 \u00b1 9 vs. 9 \u00b1 6, P = 0.42; 1,784 vs. 474, P = 0.67), respectively.", [["NLR", "GENE_OR_GENE_PRODUCT", 34, 37], ["patients", "ORGANISM", 49, 57], ["patients", "ORGANISM", 80, 88], ["NLR", "PROTEIN", 34, 37], ["LCR", "DNA", 42, 45], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 80, 88], ["NLR", "TEST", 34, 37], ["P", "TEST", 146, 147], ["P", "TEST", 171, 172], ["mean", "OBSERVATION_MODIFIER", 15, 19], ["difference", "OBSERVATION_MODIFIER", 20, 30], ["LCR", "OBSERVATION_MODIFIER", 42, 45]]], ["On day 7, higher means of NLR were associated with a higher requirement for invasive mechanical ventilation (IMV) (12 \u00b1 10 vs. 7 \u00b1 10, P = 0.01) and increased mortality (19 \u00b1 13 vs. 7 \u00b1 9, P \u2264 0.0001).", [["NLR", "GENE_OR_GENE_PRODUCT", 26, 29], ["NLR", "PROTEIN", 26, 29], ["higher means of NLR", "PROBLEM", 10, 29], ["invasive mechanical ventilation", "TREATMENT", 76, 107], ["increased mortality", "PROBLEM", 149, 168], ["mechanical ventilation", "OBSERVATION", 85, 107]]], ["Higher mean LCR was associated with a higher need for an upgrade (1,784 vs. 452, P = 0.001) and IMV (1,592 vs. 489, P = 0.01).", [["LCR", "DNA", 12, 15], ["Higher mean LCR", "PROBLEM", 0, 15], ["an upgrade", "TEST", 54, 64], ["P", "TEST", 81, 82], ["IMV", "TEST", 96, 99], ["P", "TEST", 116, 117]]], ["The mean LCR for surviving patients was higher compared to non-surviving patients (1,011 vs. 632, P = 0.04).", [["patients", "ORGANISM", 27, 35], ["patients", "ORGANISM", 73, 81], ["LCR", "DNA", 9, 12], ["patients", "SPECIES", 27, 35], ["patients", "SPECIES", 73, 81], ["The mean LCR", "TEST", 0, 12], ["P", "TEST", 98, 99]]], ["(Fig. 2; Supplementary Materials 1, 2, www.jocmr.org).In complications ::: Mean differences in NLR and LCR ::: ResultsIn terms of in-hospital complications, patients with new-onset atrial fibrillation (AF) in conjunction with sepsis had the highest mean of NLR (27.65 \u00b1 37.48), while patients with heart failure and AF had the highest mean value of LCR (8,177.46 \u00b1 11,468.12).", [["atrial", "ANATOMY", 181, 187], ["heart", "ANATOMY", 298, 303], ["atrial fibrillation", "DISEASE", 181, 200], ["AF", "DISEASE", 202, 204], ["sepsis", "DISEASE", 226, 232], ["heart failure", "DISEASE", 298, 311], ["AF", "DISEASE", 316, 318], ["patients", "ORGANISM", 157, 165], ["atrial", "MULTI-TISSUE_STRUCTURE", 181, 187], ["patients", "ORGANISM", 284, 292], ["heart", "ORGAN", 298, 303], ["NLR", "PROTEIN", 95, 98], ["LCR", "DNA", 103, 106], ["NLR", "PROTEIN", 257, 260], ["LCR", "DNA", 349, 352], ["patients", "SPECIES", 157, 165], ["patients", "SPECIES", 284, 292], ["Mean differences", "PROBLEM", 75, 91], ["NLR", "TEST", 95, 98], ["in-hospital complications", "PROBLEM", 130, 155], ["new-onset atrial fibrillation", "PROBLEM", 171, 200], ["AF", "PROBLEM", 202, 204], ["sepsis", "PROBLEM", 226, 232], ["NLR", "TEST", 257, 260], ["heart failure", "PROBLEM", 298, 311], ["AF", "PROBLEM", 316, 318], ["LCR", "TEST", 349, 352], ["atrial", "ANATOMY", 181, 187], ["fibrillation", "OBSERVATION", 188, 200], ["sepsis", "OBSERVATION", 226, 232], ["heart", "ANATOMY", 298, 303], ["failure", "OBSERVATION", 304, 311]]], ["The detailed rates and mean values are given in Supplementary Materials 3, 4 (www. jocmr.org).ORs of outcomes ::: ResultsOn presentation, the unadjusted OR for in-hospital mortality (OR 1.6, 0.5 - 5.5, P = 0.63), need for upgrade to intensive care unit (ICU) (OR 1.7, 0.7 - 4.1, P = 0.30), and requirement for IMV (OR 1.5, 0.6 - 3.5, P = 0.46) and dialysis (OR 2.5, 0.6 - 10.3, P = 0.39) were not significantly different between patients with high NLR (> 11) and those with low NLR.", [["patients", "ORGANISM", 429, 437], ["NLR", "GENE_OR_GENE_PRODUCT", 478, 481], ["NLR", "PROTEIN", 448, 451], ["NLR", "PROTEIN", 478, 481], ["patients", "SPECIES", 429, 437], ["The detailed rates", "TEST", 0, 18], ["mean values", "TEST", 23, 34], ["P", "TEST", 279, 280], ["IMV", "TEST", 310, 313], ["P", "TEST", 334, 335], ["dialysis", "TREATMENT", 348, 356], ["P", "TEST", 378, 379], ["high NLR", "PROBLEM", 443, 451], ["low NLR", "PROBLEM", 474, 481]]], ["By contrast, the unadjusted odds for LCR served as reliable predictors for primary endpoints at presentation.", [["LCR", "DNA", 37, 40], ["LCR", "TEST", 37, 40], ["primary endpoints", "PROBLEM", 75, 92]]], ["High LCR (> 101) was associated with a significantly higher odds of IMV and upgrade (OR 2.5, 1.3 - 5.0, P = 0.01; OR 2.9, 1.47 - 6.1, P = 0.004), respectively.", [["LCR", "DNA", 5, 8], ["High LCR", "TEST", 0, 8], ["IMV", "TEST", 68, 71], ["upgrade", "TEST", 76, 83], ["P", "TEST", 104, 105], ["P", "TEST", 134, 135]]], ["The odds of need for dialysis (OR 1.8, 0.4 - 7.1, P = 0.63) and mortality (OR 0.71, 0.3 - 1.8, P = 0.62) were identical between patients with high NLR and low NLR on day 1 (Tables 2, 3, Fig. 3).ORs of outcomes ::: ResultsOn day 7 of hospitalization, high NLR was associated with higher odds of in-hospital mortality (OR 11.0, 3.6 - 33.0, P < 0.0001) and a higher requirement for IMV (OR 3.3, 1.4 - 7.7, P = 0.008).", [["patients", "ORGANISM", 128, 136], ["NLR", "GENE_OR_GENE_PRODUCT", 255, 258], ["NLR", "PROTEIN", 147, 150], ["NLR", "PROTEIN", 159, 162], ["NLR", "PROTEIN", 255, 258], ["patients", "SPECIES", 128, 136], ["dialysis", "TREATMENT", 21, 29], ["P", "TEST", 50, 51], ["mortality", "TEST", 64, 73], ["P", "TEST", 95, 96], ["high NLR", "PROBLEM", 142, 150], ["low NLR", "PROBLEM", 155, 162], ["high NLR", "PROBLEM", 250, 258], ["a higher requirement", "PROBLEM", 354, 374], ["IMV", "TEST", 379, 382], ["P", "TEST", 403, 404], ["low NLR", "OBSERVATION_MODIFIER", 155, 162]]], ["There was no significant difference in the need for upgrade to ICU (OR 2.4, 1.0 - 5.4, P = 0.06) and dialysis between the two groups (OR 1.2, 0.2 - 6.1, P = 0.81).", [["significant difference", "PROBLEM", 13, 35], ["P", "TEST", 87, 88], ["dialysis", "TREATMENT", 101, 109], ["P", "TEST", 153, 154], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35]]], ["Patients in the low LCR group had significantly higher odds of mortality (OR 0.2, 0.06 - 0.47, P = 0.001), while there was no significant difference in the need for an upgrade (P = 0.16), IMV (P = 0.21) and dialysis (0.70) between low and high LCR groups.ORs of outcomes ::: ResultsA multivariate regression model was used to adjust the observed odds ratios for baseline comorbidities and medications, including DM, HTN, CKD, CAD, use of AC at home, HCQ, tocilizumab, steroids and therapeutic AC during a hospital stay.", [["DM", "DISEASE", 412, 414], ["HTN", "DISEASE", 416, 419], ["CKD", "DISEASE", 421, 424], ["CAD", "DISEASE", 426, 429], ["AC", "CHEMICAL", 438, 440], ["HCQ", "CHEMICAL", 450, 453], ["tocilizumab", "CHEMICAL", 455, 466], ["steroids", "CHEMICAL", 468, 476], ["HCQ", "CHEMICAL", 450, 453], ["steroids", "CHEMICAL", 468, 476], ["Patients", "ORGANISM", 0, 8], ["HCQ", "SIMPLE_CHEMICAL", 450, 453], ["tocilizumab", "SIMPLE_CHEMICAL", 455, 466], ["steroids", "SIMPLE_CHEMICAL", 468, 476], ["Patients", "SPECIES", 0, 8], ["mortality", "TEST", 63, 72], ["an upgrade", "TEST", 165, 175], ["P", "TEST", 177, 178], ["IMV", "TEST", 188, 191], ["P", "TEST", 193, 194], ["dialysis", "TREATMENT", 207, 215], ["baseline comorbidities", "PROBLEM", 362, 384], ["medications", "TREATMENT", 389, 400], ["DM", "PROBLEM", 412, 414], ["HTN", "PROBLEM", 416, 419], ["CKD", "PROBLEM", 421, 424], ["CAD", "PROBLEM", 426, 429], ["AC", "TREATMENT", 438, 440], ["HCQ", "TREATMENT", 450, 453], ["tocilizumab", "TREATMENT", 455, 466], ["steroids", "TREATMENT", 468, 476], ["therapeutic AC", "TREATMENT", 481, 495], ["no", "UNCERTAINTY", 123, 125], ["significant", "OBSERVATION_MODIFIER", 126, 137], ["difference", "OBSERVATION", 138, 148], ["CKD", "OBSERVATION", 421, 424]]], ["The adjusted odds values were consistent with unadjusted ORs indicating no influence of covariates as shown in Tables 2 and 3.Limitations ::: DiscussionThe findings of our study should be interpreted in light of its limitations.", [["The adjusted odds values", "TEST", 0, 24], ["our study", "TEST", 168, 177]]], ["Due to the retrospective non-randomized nature of the study, a causal relationship could not be ascertained.", [["the study", "TEST", 50, 59]]], ["Although the overall findings were adjusted for covariates, including baseline comorbidities and medications, the impact of unmeasured confounders such as initiation of several complementary therapies at the treating physician\u2019s discretion, could not be determined.", [["baseline comorbidities", "PROBLEM", 70, 92], ["medications", "TREATMENT", 97, 108], ["unmeasured confounders", "PROBLEM", 124, 146], ["several complementary therapies", "TREATMENT", 169, 200]]], ["Based on our clinical experience, the average duration of any therapy for COVID-19 was less than 7 days; therefore, we chose to use day 1 and day 7 laboratory values.", [["any therapy", "TREATMENT", 58, 69], ["COVID", "TEST", 74, 79]]], ["However, given the variable frequency of laboratory specimen collection, it is not possible for us to ascertain if these truly represented pre- and post-treatment values accurately in all cases.", [["specimen", "ANATOMY", 52, 60], ["laboratory specimen collection", "TEST", 41, 71]]], ["Moreover, by excluding patients still in the hospital, the case fatality ratio in our study cannot reflect the true mortality of COVID-19.", [["COVID-19", "CHEMICAL", 129, 137], ["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["our study", "TEST", 82, 91], ["COVID", "TEST", 129, 134]]], ["Lastly, the interpretation of our findings might be limited by the sample size.", [["size", "OBSERVATION_MODIFIER", 74, 78]]], ["However, by adjusting the adult patients with confirmed disease, we believe that our population is the best representative of the real-world cohort.Conclusions ::: DiscussionA high LCR at presentation appears to predict an increased need for IMV and intensive care.", [["patients", "ORGANISM", 32, 40], ["LCR", "DNA", 181, 184], ["patients", "SPECIES", 32, 40], ["IMV", "SPECIES", 242, 245], ["disease", "PROBLEM", 56, 63], ["DiscussionA high LCR", "PROBLEM", 164, 184], ["IMV", "TREATMENT", 242, 245], ["intensive care", "TREATMENT", 250, 264], ["disease", "OBSERVATION", 56, 63], ["increased", "OBSERVATION", 223, 232]]], ["A high NLR and low LCR, after COVID-19 therapy, predict higher odds of mortality.", [["NLR", "GENE_OR_GENE_PRODUCT", 7, 10], ["NLR", "PROTEIN", 7, 10], ["LCR", "DNA", 19, 22], ["A high NLR and low LCR", "PROBLEM", 0, 22], ["COVID-19 therapy", "TREATMENT", 30, 46], ["high", "OBSERVATION_MODIFIER", 2, 6], ["NLR", "OBSERVATION", 7, 10], ["low LCR", "OBSERVATION_MODIFIER", 15, 22]]], ["Large-scale studies are needed to validate our findings.", [["Large-scale studies", "TEST", 0, 19]]]], "5b60301e9d674b0058ae8c19bd248cb71d35c04c": [["IntroductionSeveral new scoring systems have been developed over recent years to assess the degree of organ failure (e.g., Acute Physiology and Chronic Health Evaluation [APACHE] II, APACHE III, Sequential Organ Failure Assessment [SOFA], Simplified Acute Physiology Score [SAPS] II, and Multiple Organ Dysfunction Score [MODS] ).", [["organ", "ANATOMY", 102, 107], ["organ failure", "DISEASE", 102, 115], ["Organ Dysfunction", "DISEASE", 297, 314], ["MODS", "DISEASE", 322, 326], ["organ", "ORGAN", 102, 107], ["IntroductionSeveral new scoring systems", "PROBLEM", 0, 39], ["organ failure", "PROBLEM", 102, 115], ["Acute Physiology", "PROBLEM", 123, 139], ["Chronic Health Evaluation", "TEST", 144, 169], ["APACHE III", "TEST", 183, 193], ["Sequential Organ Failure", "PROBLEM", 195, 219], ["Simplified Acute Physiology Score", "PROBLEM", 239, 272], ["SAPS] II", "PROBLEM", 274, 282], ["Multiple Organ Dysfunction Score", "PROBLEM", 288, 320], ["organ", "ANATOMY", 102, 107], ["failure", "OBSERVATION", 108, 115], ["Acute", "OBSERVATION_MODIFIER", 123, 128], ["Organ", "ANATOMY", 206, 211], ["Failure", "OBSERVATION", 212, 219], ["Acute", "OBSERVATION_MODIFIER", 250, 255], ["Multiple", "OBSERVATION_MODIFIER", 288, 296], ["Organ", "ANATOMY", 297, 302], ["Dysfunction", "OBSERVATION", 303, 314]]], ["Most of these were models generated based on the concepts of sepsis, severe sepsis and septic shock.", [["sepsis", "DISEASE", 61, 67], ["sepsis", "DISEASE", 76, 82], ["septic shock", "DISEASE", 87, 99], ["sepsis", "PROBLEM", 61, 67], ["severe sepsis", "PROBLEM", 69, 82], ["septic shock", "PROBLEM", 87, 99], ["sepsis", "OBSERVATION", 61, 67], ["severe", "OBSERVATION_MODIFIER", 69, 75], ["sepsis", "OBSERVATION", 76, 82], ["septic shock", "OBSERVATION", 87, 99]]], ["In 2001, an International Sepsis Definition Conference updated these terms in order to facilitate standardized enrolment into clinical trials, but due to their simplicity and easy use physicians rapidly adopted them for daily clinical practice [1] .IntroductionHowever, few of these scoring systems are focused on ventilator-associated pneumonia (VAP), the leading cause of nosocomial infection in critically ill patients requiring mechanical ventilation [2] .", [["Sepsis", "DISEASE", 26, 32], ["pneumonia", "DISEASE", 336, 345], ["VAP", "DISEASE", 347, 350], ["infection", "DISEASE", 385, 394], ["critically ill", "DISEASE", 398, 412], ["patients", "ORGANISM", 413, 421], ["patients", "SPECIES", 413, 421], ["pneumonia", "PROBLEM", 336, 345], ["VAP", "PROBLEM", 347, 350], ["nosocomial infection", "PROBLEM", 374, 394], ["mechanical ventilation", "TREATMENT", 432, 454], ["few", "OBSERVATION_MODIFIER", 270, 273], ["pneumonia", "OBSERVATION", 336, 345], ["nosocomial", "OBSERVATION_MODIFIER", 374, 384], ["infection", "OBSERVATION", 385, 394]]], ["The approach to VAP severity has been traditionally based on three clinical items: The underlying disease, the time of onset, and the causative microorganism.", [["VAP", "DISEASE", 16, 19], ["VAP severity", "PROBLEM", 16, 28], ["The underlying disease", "PROBLEM", 83, 105], ["the causative microorganism", "PROBLEM", 130, 157], ["VAP", "OBSERVATION", 16, 19], ["underlying", "OBSERVATION_MODIFIER", 87, 97], ["disease", "OBSERVATION", 98, 105]]], ["The VAP-PIRO score ( Table 1 ) [3] , based on the PIRO system (predisposition, insult, response, organ dysfunction), has been recently developed by our group and endeavors to identify different risk levels for VAP.", [["organ", "ANATOMY", 97, 102], ["organ dysfunction", "DISEASE", 97, 114], ["VAP", "DISEASE", 210, 213], ["organ", "ORGAN", 97, 102], ["The VAP-PIRO score", "TEST", 0, 18], ["the PIRO system", "TREATMENT", 46, 61], ["insult", "PROBLEM", 79, 85], ["organ dysfunction", "PROBLEM", 97, 114], ["VAP", "PROBLEM", 210, 213]]], ["This score stratifies patients with VAP into mortality risk groups and correlates these with health-care resource use in VAP patients.", [["VAP", "DISEASE", 36, 39], ["VAP", "DISEASE", 121, 124], ["patients", "ORGANISM", 22, 30], ["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 22, 30], ["patients", "SPECIES", 125, 133], ["VAP into mortality risk groups", "PROBLEM", 36, 66], ["VAP patients", "TREATMENT", 121, 133]]], ["The PIRO concept, a conceptual framework for understanding sepsis [1] , is a classification scheme that could stratify patients based on their predisposing conditions, the nature and extent of the insult, the nature and magnitude of the host response, and the degree of the concomitant organ dysfunction.", [["organ", "ANATOMY", 286, 291], ["sepsis", "DISEASE", 59, 65], ["organ dysfunction", "DISEASE", 286, 303], ["patients", "ORGANISM", 119, 127], ["organ", "ORGAN", 286, 291], ["patients", "SPECIES", 119, 127], ["sepsis", "PROBLEM", 59, 65], ["the insult", "PROBLEM", 193, 203], ["the concomitant organ dysfunction", "PROBLEM", 270, 303], ["insult", "OBSERVATION", 197, 203], ["host response", "OBSERVATION", 237, 250], ["concomitant organ dysfunction", "OBSERVATION", 274, 303]]], ["Conceptually, PIRO was modeled on the TNM (tumor, nodes, metastases) classification [4] which has been successfully used to define prognostic indicators in clinical oncology.", [["tumor", "ANATOMY", 43, 48], ["nodes", "ANATOMY", 50, 55], ["metastases", "ANATOMY", 57, 67], ["tumor", "DISEASE", 43, 48], ["tumor", "CANCER", 43, 48], ["nodes", "MULTI-TISSUE_STRUCTURE", 50, 55], ["PIRO", "PROTEIN", 14, 18], ["the TNM (tumor, nodes", "PROBLEM", 34, 55], ["metastases", "PROBLEM", 57, 67], ["tumor", "OBSERVATION", 43, 48], ["nodes", "OBSERVATION", 50, 55], ["metastases", "OBSERVATION", 57, 67]]], ["PIRO was introduced as a hypothesis-generating model for future research, but its practical applications were limited.", [["PIRO", "CHEMICAL", 0, 4], ["PIRO", "GENE_OR_GENE_PRODUCT", 0, 4], ["PIRO", "PROTEIN", 0, 4], ["PIRO", "TREATMENT", 0, 4]]], ["The aim of this chapter is to describe a new approach to the prognosis of VAP based on the PIRO concept focusing in its main components and their relative impact on VAP severity and prognosis.", [["VAP", "DISEASE", 74, 77], ["VAP", "DISEASE", 165, 168], ["VAP", "PROBLEM", 74, 77], ["VAP severity", "PROBLEM", 165, 177]]], ["Figure 1 shows the mortality rate in ICU patients with VAP classified according to the VAP-PIRO score.Genetic FactorsDespite considerable advances in our understanding of the biology of pneumonia, improvements in clinical outcomes have been sporadic and, with few notable exceptions, because of improvements in supportive care rather than specific therapies.", [["VAP", "DISEASE", 55, 58], ["VAP", "DISEASE", 87, 90], ["pneumonia", "DISEASE", 186, 195], ["patients", "ORGANISM", 41, 49], ["PIRO", "PROTEIN", 91, 95], ["patients", "SPECIES", 41, 49], ["VAP", "PROBLEM", 55, 58], ["pneumonia", "PROBLEM", 186, 195], ["supportive care", "TREATMENT", 311, 326], ["specific therapies", "TREATMENT", 339, 357], ["pneumonia", "OBSERVATION", 186, 195]]], ["As a result, morbidity, mortality, and costs remain high.Genetic FactorsAlthough it is clear that gene sequencing and manipulation of experimental models have provided a better approach for insight into the biology of the inflammatory response to infection, these technologies and their application to the study of naturally occurring human genetic variation have yet to provide the same insight or clinical benefit.", [["infection", "DISEASE", 247, 256], ["human", "ORGANISM", 335, 340], ["human", "SPECIES", 335, 340], ["human", "SPECIES", 335, 340], ["morbidity", "PROBLEM", 13, 22], ["costs", "TEST", 39, 44], ["gene sequencing", "TREATMENT", 98, 113], ["infection", "PROBLEM", 247, 256], ["the study", "TEST", 302, 311], ["high", "OBSERVATION", 52, 56], ["inflammatory", "OBSERVATION_MODIFIER", 222, 234], ["infection", "OBSERVATION", 247, 256]]], ["Variations in genes encoding important components of the inflammatory response and the microbial recognition system are likely to be involved in the development of pneumonia.", [["pneumonia", "DISEASE", 164, 173], ["the inflammatory response", "PROBLEM", 53, 78], ["pneumonia", "PROBLEM", 164, 173], ["inflammatory", "OBSERVATION_MODIFIER", 57, 69], ["likely to be", "UNCERTAINTY", 120, 132], ["pneumonia", "OBSERVATION", 164, 173]]], ["In contrast to entities such as community-acquired pneumonia (CAP) or meningitis where 'the genetic approach' is being developed with some success, there are still scarce data that link VAP to genetic variability [5] [6] [7] [8] [9] .Genetic FactorsIn addition, genetics may explain the wide variation in the individual response to infection that has puzzled clinicians for long.", [["pneumonia", "DISEASE", 51, 60], ["CAP", "DISEASE", 62, 65], ["meningitis", "DISEASE", 70, 80], ["VAP", "DISEASE", 186, 189], ["infection", "DISEASE", 332, 341], ["[5] [6] [7] [8] [9]", "SIMPLE_CHEMICAL", 213, 232], ["community-acquired pneumonia (CAP)", "PROBLEM", 32, 66], ["meningitis", "PROBLEM", 70, 80], ["genetic variability", "TEST", 193, 212], ["Genetic Factors", "PROBLEM", 234, 249], ["the wide variation", "PROBLEM", 283, 301], ["infection", "PROBLEM", 332, 341], ["pneumonia", "OBSERVATION", 51, 60], ["meningitis", "OBSERVATION", 70, 80], ["infection", "OBSERVATION", 332, 341]]], ["VAP phenotypes can range from septic shock to a very well compartmentalized consolidation on x-ray accompanied by low grade hypoxemia.", [["VAP", "DISEASE", 0, 3], ["septic shock", "DISEASE", 30, 42], ["hypoxemia", "DISEASE", 124, 133], ["VAP phenotypes", "PROBLEM", 0, 14], ["septic shock", "PROBLEM", 30, 42], ["a very well compartmentalized consolidation", "PROBLEM", 46, 89], ["x-ray", "TEST", 93, 98], ["low grade hypoxemia", "PROBLEM", 114, 133], ["septic shock", "OBSERVATION", 30, 42], ["very", "OBSERVATION_MODIFIER", 48, 52], ["consolidation", "OBSERVATION", 76, 89], ["low grade", "OBSERVATION_MODIFIER", 114, 123], ["hypoxemia", "OBSERVATION", 124, 133]]], ["Fortunately, novel therapeutic strategies are currently being developed in experimental models to modulate the inflammatory response in the host and may be available at the bedside in the near future.Underlying DiseasesChronic obstructive pulmonary disease Chronic obstructive pulmonary disease (COPD) is a risk factor for nosocomial lower respiratory tract infections.", [["pulmonary", "ANATOMY", 239, 248], ["pulmonary", "ANATOMY", 277, 286], ["lower respiratory tract", "ANATOMY", 334, 357], ["Chronic obstructive pulmonary disease", "DISEASE", 219, 256], ["Chronic obstructive pulmonary disease", "DISEASE", 257, 294], ["COPD", "DISEASE", 296, 300], ["lower respiratory tract infections", "DISEASE", 334, 368], ["pulmonary", "ORGAN", 239, 248], ["pulmonary", "ORGAN", 277, 286], ["lower", "ORGANISM_SUBDIVISION", 334, 339], ["respiratory tract", "ORGANISM_SUBDIVISION", 340, 357], ["novel therapeutic strategies", "TREATMENT", 13, 41], ["Underlying Diseases", "PROBLEM", 200, 219], ["Chronic obstructive pulmonary disease", "PROBLEM", 219, 256], ["Chronic obstructive pulmonary disease (COPD", "PROBLEM", 257, 300], ["a risk factor", "PROBLEM", 305, 318], ["nosocomial lower respiratory tract infections", "PROBLEM", 323, 368], ["inflammatory", "OBSERVATION", 111, 123], ["Diseases", "OBSERVATION", 211, 219], ["Chronic", "OBSERVATION_MODIFIER", 219, 226], ["obstructive", "OBSERVATION_MODIFIER", 227, 238], ["pulmonary", "ANATOMY", 239, 248], ["disease", "OBSERVATION", 249, 256], ["Chronic", "OBSERVATION_MODIFIER", 257, 264], ["obstructive", "OBSERVATION_MODIFIER", 265, 276], ["pulmonary", "ANATOMY", 277, 286], ["disease", "OBSERVATION", 287, 294], ["COPD", "OBSERVATION", 296, 300], ["lower", "ANATOMY_MODIFIER", 334, 339], ["respiratory tract", "ANATOMY", 340, 357], ["infections", "OBSERVATION", 358, 368]]], ["The incidence of VAP in intubated COPD patients has been estimated to range between 6 and 33 % [10] .", [["VAP", "DISEASE", 17, 20], ["COPD", "DISEASE", 34, 38], ["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["VAP", "PROBLEM", 17, 20], ["intubated COPD", "PROBLEM", 24, 38], ["VAP", "OBSERVATION", 17, 20], ["COPD", "OBSERVATION", 34, 38]]], ["Tracheo-bronchial colonization, local and systemic immunosuppression and frequent antibiotic treatment are factors predisposing to VAP in these patients.", [["bronchial", "ANATOMY", 8, 17], ["VAP", "DISEASE", 131, 134], ["bronchial", "MULTI-TISSUE_STRUCTURE", 8, 17], ["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 144, 152], ["Tracheo", "TREATMENT", 0, 7], ["bronchial colonization", "PROBLEM", 8, 30], ["local and systemic immunosuppression", "TREATMENT", 32, 68], ["frequent antibiotic treatment", "TREATMENT", 73, 102], ["VAP", "PROBLEM", 131, 134], ["bronchial", "ANATOMY", 8, 17], ["colonization", "OBSERVATION", 18, 30], ["systemic", "OBSERVATION_MODIFIER", 42, 50], ["immunosuppression", "OBSERVATION", 51, 68]]], ["However, the impact of COPD on VAP mortality remains controversial.", [["COPD", "DISEASE", 23, 27], ["VAP", "DISEASE", 31, 34], ["COPD", "PROBLEM", 23, 27], ["VAP mortality", "PROBLEM", 31, 44], ["COPD", "OBSERVATION", 23, 27]]], ["Our group [11] demonstrated that COPD was associated with higher mortality rates in patients with VAP.", [["COPD", "DISEASE", 33, 37], ["VAP", "DISEASE", 98, 101], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["COPD", "PROBLEM", 33, 37], ["higher mortality rates", "PROBLEM", 58, 80], ["VAP", "PROBLEM", 98, 101], ["COPD", "OBSERVATION", 33, 37]]], ["However, after adjustment for confounding factors, COPD was not independently associated with mortality in these patients.", [["COPD", "DISEASE", 51, 55], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["confounding factors", "PROBLEM", 30, 49], ["COPD", "PROBLEM", 51, 55], ["COPD", "OBSERVATION", 51, 55]]], ["In contrast, Nseir et al. [12] reported that VAP was associated with higher mortality rates and longer duration of mechanical ventilation and intensive care unit (ICU) stay in COPD patients, and was independently associated with ICU mortality.Immunocompromised hostA huge number of immunocompromised patients are admitted to the ICU and immunosuppression has been recognized as an independent risk factor for infectious morbidity and mortality [13] .", [["VAP", "DISEASE", 45, 48], ["COPD", "DISEASE", 176, 180], ["patients", "ORGANISM", 181, 189], ["patients", "ORGANISM", 300, 308], ["patients", "SPECIES", 181, 189], ["patients", "SPECIES", 300, 308], ["VAP", "PROBLEM", 45, 48], ["higher mortality rates", "PROBLEM", 69, 91], ["mechanical ventilation", "TREATMENT", 115, 137], ["immunocompromised", "PROBLEM", 282, 299], ["immunosuppression", "TREATMENT", 337, 354], ["infectious morbidity", "PROBLEM", 409, 429], ["mechanical ventilation", "OBSERVATION", 115, 137], ["huge", "OBSERVATION_MODIFIER", 267, 271], ["number", "OBSERVATION_MODIFIER", 272, 278], ["immunocompromised", "OBSERVATION", 282, 299]]], ["In addition, immunosuppression represents a risk factor for multidrug-resistant pathogens in VAP and should be considered in treatment decisions.", [["VAP", "DISEASE", 93, 96], ["immunosuppression", "TREATMENT", 13, 30], ["a risk factor", "PROBLEM", 42, 55], ["multidrug-resistant pathogens", "PROBLEM", 60, 89], ["VAP", "PROBLEM", 93, 96]]], ["As has been described by Nseir et al. [12] , a significantly greater proportion of immunosuppressed patients received antibiotic therapy before and during ICU admission, being more likely to be colonized and/or infected by multidrug resistant organisms.", [["immunosuppressed", "DISEASE", 83, 99], ["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108], ["antibiotic therapy", "TREATMENT", 118, 136], ["multidrug resistant organisms", "PROBLEM", 223, 252], ["immunosuppressed", "OBSERVATION", 83, 99], ["colonized", "OBSERVATION", 194, 203]]], ["However, despite the evidence available, current guidelines for treatment of VAP and or hospital-acquired pneumonia (HAP)/VAP do not consider patients who are known to be immunosuppressed because of human immunodeficiency virus (HIV) infection, hematologic malignancy, chemotherapy-induced neutropenia or organ transplantation [14] , factors likely to determine prognosis.Trauma patientsTrauma deaths have a classic trimodal distribution.", [["hematologic malignancy", "ANATOMY", 245, 267], ["organ", "ANATOMY", 305, 310], ["VAP", "DISEASE", 77, 80], ["pneumonia", "DISEASE", 106, 115], ["HAP", "DISEASE", 117, 120], ["VAP", "DISEASE", 122, 125], ["human immunodeficiency virus (HIV) infection", "DISEASE", 199, 243], ["malignancy", "DISEASE", 257, 267], ["neutropenia", "DISEASE", 290, 301], ["Trauma", "DISEASE", 372, 378], ["Trauma", "DISEASE", 387, 393], ["deaths", "DISEASE", 394, 400], ["patients", "ORGANISM", 142, 150], ["human immunodeficiency virus", "ORGANISM", 199, 227], ["HIV", "ORGANISM", 229, 232], ["organ", "ORGAN", 305, 310], ["patients", "ORGANISM", 379, 387], ["patients", "SPECIES", 142, 150], ["human immunodeficiency virus (HIV", "SPECIES", 199, 232], ["patients", "SPECIES", 379, 387], ["human immunodeficiency virus", "SPECIES", 199, 227], ["HIV", "SPECIES", 229, 232], ["current guidelines", "TREATMENT", 41, 59], ["treatment", "TREATMENT", 64, 73], ["VAP", "PROBLEM", 77, 80], ["hospital-acquired pneumonia (HAP)", "PROBLEM", 88, 121], ["VAP", "PROBLEM", 122, 125], ["human immunodeficiency virus", "PROBLEM", 199, 227], ["HIV) infection", "PROBLEM", 229, 243], ["hematologic malignancy", "PROBLEM", 245, 267], ["chemotherapy", "TREATMENT", 269, 281], ["neutropenia", "PROBLEM", 290, 301], ["organ transplantation", "TREATMENT", 305, 326], ["Trauma", "PROBLEM", 372, 378], ["Trauma deaths", "PROBLEM", 387, 400], ["pneumonia", "OBSERVATION", 106, 115], ["classic", "OBSERVATION_MODIFIER", 408, 415], ["trimodal distribution", "OBSERVATION", 416, 437]]], ["Late death (3 days to 3 weeks postinjury) occurs in more than 25 % of the patients, in whom infection is the principal cause of death and is associated with high rates of extracranial complications, like pneumonia, that determine the final outcome.", [["extracranial", "ANATOMY", 171, 183], ["death", "DISEASE", 5, 10], ["infection", "DISEASE", 92, 101], ["death", "DISEASE", 128, 133], ["extracranial complications", "DISEASE", 171, 197], ["pneumonia", "DISEASE", 204, 213], ["patients", "ORGANISM", 74, 82], ["extracranial", "ANATOMICAL_SYSTEM", 171, 183], ["patients", "SPECIES", 74, 82], ["Late death", "PROBLEM", 0, 10], ["infection", "PROBLEM", 92, 101], ["death", "PROBLEM", 128, 133], ["extracranial complications", "PROBLEM", 171, 197], ["pneumonia", "PROBLEM", 204, 213], ["infection", "OBSERVATION", 92, 101], ["extracranial", "ANATOMY", 171, 183], ["complications", "OBSERVATION", 184, 197], ["pneumonia", "OBSERVATION", 204, 213]]], ["In fact, Bronchard et al. [15] , in trauma patients, described that for patients developing pneumonia there was a higher risk of secondary cerebral injury, increased intra-cranial pressure, hypotension, fever and hypoxemia that would worsen outcomes in such patients.", [["cerebral", "ANATOMY", 139, 147], ["intra-cranial", "ANATOMY", 166, 179], ["trauma", "DISEASE", 36, 42], ["pneumonia", "DISEASE", 92, 101], ["cerebral injury", "DISEASE", 139, 154], ["hypotension", "DISEASE", 190, 201], ["fever", "DISEASE", 203, 208], ["hypoxemia", "DISEASE", 213, 222], ["patients", "ORGANISM", 43, 51], ["patients", "ORGANISM", 72, 80], ["cerebral", "ORGAN", 139, 147], ["patients", "ORGANISM", 258, 266], ["patients", "SPECIES", 43, 51], ["patients", "SPECIES", 72, 80], ["patients", "SPECIES", 258, 266], ["pneumonia", "PROBLEM", 92, 101], ["secondary cerebral injury", "PROBLEM", 129, 154], ["increased intra-cranial pressure", "PROBLEM", 156, 188], ["hypotension", "PROBLEM", 190, 201], ["fever", "PROBLEM", 203, 208], ["hypoxemia", "PROBLEM", 213, 222], ["pneumonia", "OBSERVATION", 92, 101], ["secondary", "OBSERVATION_MODIFIER", 129, 138], ["cerebral", "ANATOMY", 139, 147], ["injury", "OBSERVATION", 148, 154], ["increased", "OBSERVATION_MODIFIER", 156, 165], ["intra-cranial pressure", "OBSERVATION", 166, 188], ["hypotension", "OBSERVATION", 190, 201], ["fever", "OBSERVATION", 203, 208], ["hypoxemia", "OBSERVATION", 213, 222]]], ["Therefore, in trauma patients, early identification of subjects at a high risk of developing VAP reduces morbidity and costs.Trauma patientsTrauma patients exhibit greater incidences of early-onset VAP, which accounts for 30 -40 % of cases [15] .", [["trauma", "DISEASE", 14, 20], ["VAP", "DISEASE", 93, 96], ["Trauma", "DISEASE", 125, 131], ["Trauma", "DISEASE", 140, 146], ["VAP", "DISEASE", 198, 201], ["patients", "ORGANISM", 21, 29], ["patients", "ORGANISM", 132, 140], ["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 21, 29], ["patients", "SPECIES", 132, 140], ["patients", "SPECIES", 147, 155], ["VAP reduces morbidity", "PROBLEM", 93, 114], ["Trauma", "PROBLEM", 125, 131], ["Trauma", "PROBLEM", 140, 146], ["early-onset VAP", "PROBLEM", 186, 201], ["VAP", "OBSERVATION", 93, 96], ["greater", "OBSERVATION_MODIFIER", 164, 171], ["early", "OBSERVATION_MODIFIER", 186, 191], ["-onset", "OBSERVATION_MODIFIER", 191, 197], ["VAP", "OBSERVATION", 198, 201]]], ["Most reports regarding microorganisms indicate that methicillin-sensitive Staphylococcus aureus (MSSA) is the predominant pathogen in multiple-trauma patients in coma, and nasal MSSA colonization at the time of severe injury may increase the risk of MSSA pneumonia [16] .", [["nasal", "ANATOMY", 172, 177], ["methicillin", "CHEMICAL", 52, 63], ["Staphylococcus aureus", "DISEASE", 74, 95], ["MSSA", "CHEMICAL", 97, 101], ["trauma", "DISEASE", 143, 149], ["coma", "DISEASE", 162, 166], ["MSSA", "CHEMICAL", 178, 182], ["MSSA", "CHEMICAL", 250, 254], ["pneumonia", "DISEASE", 255, 264], ["methicillin", "CHEMICAL", 52, 63], ["methicillin-sensitive Staphylococcus aureus", "ORGANISM", 52, 95], ["MSSA", "CANCER", 97, 101], ["patients", "ORGANISM", 150, 158], ["Staphylococcus aureus", "SPECIES", 74, 95], ["patients", "SPECIES", 150, 158], ["Staphylococcus aureus", "SPECIES", 74, 95], ["MSSA", "SPECIES", 97, 101], ["microorganisms", "PROBLEM", 23, 37], ["methicillin-sensitive Staphylococcus aureus", "PROBLEM", 52, 95], ["MSSA", "PROBLEM", 97, 101], ["coma", "PROBLEM", 162, 166], ["nasal MSSA colonization", "PROBLEM", 172, 195], ["severe injury", "PROBLEM", 211, 224], ["MSSA pneumonia", "PROBLEM", 250, 264], ["Staphylococcus aureus", "OBSERVATION", 74, 95], ["predominant", "OBSERVATION_MODIFIER", 110, 121], ["pathogen", "OBSERVATION_MODIFIER", 122, 130], ["multiple", "OBSERVATION_MODIFIER", 134, 142], ["nasal", "ANATOMY", 172, 177], ["MSSA", "OBSERVATION", 178, 182], ["severe", "OBSERVATION_MODIFIER", 211, 217], ["injury", "OBSERVATION", 218, 224], ["MSSA", "OBSERVATION_MODIFIER", 250, 254], ["pneumonia", "OBSERVATION", 255, 264]]], ["As length of stay increases, causal pathogens are likely to switch to antibiotic-resistant bacteria.", [["causal pathogens", "PROBLEM", 29, 45], ["antibiotic", "TREATMENT", 70, 80], ["resistant bacteria", "PROBLEM", 81, 99]]], ["Rangel et al. [17] reported that the presence of multi-drug resistance (Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia, and methicillin-resistant S. aureus [MRSA]) in respiratory isolates increased from A New Approach to Ventilator-associated Pneumonia Based on the PIRO System 483 XII 27 % to 52 % after 5 days of admission.", [["methicillin", "CHEMICAL", 155, 166], ["Pneumonia", "DISEASE", 274, 283], ["methicillin", "CHEMICAL", 155, 166], ["Pseudomonas aeruginosa", "ORGANISM", 72, 94], ["Acinetobacter baumannii", "ORGANISM", 96, 119], ["Stenotrophomonas maltophilia", "ORGANISM", 121, 149], ["methicillin-resistant S. aureus", "ORGANISM", 155, 186], ["MRSA", "ORGANISM", 188, 192], ["Pseudomonas aeruginosa", "SPECIES", 72, 94], ["Acinetobacter baumannii", "SPECIES", 96, 119], ["Stenotrophomonas maltophilia", "SPECIES", 121, 149], ["S. aureus", "SPECIES", 177, 186], ["MRSA", "SPECIES", 188, 192], ["Pseudomonas aeruginosa", "SPECIES", 72, 94], ["Acinetobacter baumannii", "SPECIES", 96, 119], ["Stenotrophomonas maltophilia", "SPECIES", 121, 149], ["S. aureus", "SPECIES", 177, 186], ["MRSA", "SPECIES", 188, 192], ["multi-drug resistance (Pseudomonas aeruginosa", "PROBLEM", 49, 94], ["Acinetobacter baumannii", "PROBLEM", 96, 119], ["Stenotrophomonas maltophilia", "PROBLEM", 121, 149], ["methicillin-resistant S. aureus", "PROBLEM", 155, 186], ["MRSA", "PROBLEM", 188, 192], ["respiratory isolates", "PROBLEM", 198, 218], ["A New Approach", "TREATMENT", 234, 248], ["Pneumonia", "PROBLEM", 274, 283], ["the PIRO System", "TEST", 293, 308], ["XII", "TEST", 313, 316], ["Pneumonia", "OBSERVATION", 274, 283]]], ["Therefore, in comatose patients, coverage with a beta-lactam active against MSSA is mandatory when early VAP is suspected, however treatment of late onset VAP should be based on local bacteriologic patterns and antimicrobial susceptibility.Components of the VAP-PIRO Score: Insult BacteremiaIn HAP, bacteremia occurs in 8 to 20 % of the episodes [18] and is associated with high mortality rates [19] , but because many of these studies were not designed to investigate attributable mortality, little is known regarding its real impact on VAP patients.", [["comatose", "DISEASE", 14, 22], ["beta-lactam", "CHEMICAL", 49, 60], ["MSSA", "CHEMICAL", 76, 80], ["VAP", "DISEASE", 105, 108], ["VAP", "DISEASE", 155, 158], ["VAP", "DISEASE", 258, 261], ["HAP", "DISEASE", 294, 297], ["bacteremia", "DISEASE", 299, 309], ["VAP", "DISEASE", 538, 541], ["patients", "ORGANISM", 23, 31], ["beta-lactam", "GENE_OR_GENE_PRODUCT", 49, 60], ["MSSA", "CANCER", 76, 80], ["patients", "ORGANISM", 542, 550], ["patients", "SPECIES", 23, 31], ["patients", "SPECIES", 542, 550], ["a beta-lactam active", "TREATMENT", 47, 67], ["MSSA", "PROBLEM", 76, 80], ["early VAP", "PROBLEM", 99, 108], ["late onset VAP", "PROBLEM", 144, 158], ["local bacteriologic patterns", "TEST", 178, 206], ["antimicrobial susceptibility", "TEST", 211, 239], ["the VAP", "PROBLEM", 254, 261], ["Insult BacteremiaIn HAP", "PROBLEM", 274, 297], ["bacteremia", "PROBLEM", 299, 309], ["high mortality rates", "PROBLEM", 374, 394], ["these studies", "TEST", 422, 435], ["VAP patients", "TREATMENT", 538, 550], ["antimicrobial susceptibility", "OBSERVATION", 211, 239], ["VAP", "OBSERVATION", 258, 261], ["bacteremia", "OBSERVATION", 299, 309]]], ["Agbaht et al. [20] found that bacteremic-VAP was independently associated with increased ICU mortality.", [["VAP", "DISEASE", 41, 44], ["bacteremic", "PROBLEM", 30, 40], ["VAP", "PROBLEM", 41, 44], ["increased ICU mortality", "PROBLEM", 79, 102], ["bacteremic", "OBSERVATION", 30, 40], ["VAP", "OBSERVATION", 41, 44]]], ["Moreover bacteremic episodes occurred later during the ICU stay and were more frequent in previously hospitalized patients.", [["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122], ["Moreover bacteremic episodes", "PROBLEM", 0, 28], ["bacteremic", "OBSERVATION", 9, 19]]], ["MRSA was found to be an independent risk factor for bacteremia and Depuydt et al. [21] reported a high mortality rate in MRSA bacteremia associated with nosocomial pneumonia,PathogensConsideration of the particularities of each ICU's ecology should provide a more rational basis for selecting initial therapy for VAP patients before culture results are available.", [["bacteremia", "DISEASE", 52, 62], ["bacteremia", "DISEASE", 126, 136], ["nosocomial pneumonia", "DISEASE", 153, 173], ["VAP", "DISEASE", 313, 316], ["patients", "ORGANISM", 317, 325], ["MRSA", "SPECIES", 0, 4], ["MRSA", "SPECIES", 121, 125], ["patients", "SPECIES", 317, 325], ["MRSA", "SPECIES", 0, 4], ["MRSA", "SPECIES", 121, 125], ["MRSA", "PROBLEM", 0, 4], ["bacteremia", "PROBLEM", 52, 62], ["a high mortality rate", "PROBLEM", 96, 117], ["MRSA bacteremia", "PROBLEM", 121, 136], ["nosocomial pneumonia", "PROBLEM", 153, 173], ["Pathogens", "PROBLEM", 174, 183], ["selecting initial therapy", "TREATMENT", 283, 308], ["VAP patients", "PROBLEM", 313, 325], ["culture results", "TEST", 333, 348], ["bacteremia", "OBSERVATION", 52, 62], ["MRSA bacteremia", "OBSERVATION", 121, 136], ["nosocomial", "OBSERVATION_MODIFIER", 153, 163], ["pneumonia", "OBSERVATION", 164, 173]]], ["As we reported [22] , the observed differences in pathogen etiology across institutions reflected differences in antibiotic use and local patterns of resistance, which prompted the development of a more patient specific antibiotic management.PathogensThe impact of multidrug resistant pathogens, including P. aeruginosa and MRSA, causing nosocomial infection is ever-increasing and is now recognized as a major health problem.", [["P. aeruginosa and MRSA", "DISEASE", 306, 328], ["nosocomial infection", "DISEASE", 338, 358], ["patient", "ORGANISM", 203, 210], ["P. aeruginosa", "ORGANISM", 306, 319], ["patient", "SPECIES", 203, 210], ["P. aeruginosa", "SPECIES", 306, 319], ["MRSA", "SPECIES", 324, 328], ["P. aeruginosa", "SPECIES", 306, 319], ["MRSA", "SPECIES", 324, 328], ["antibiotic use", "TREATMENT", 113, 127], ["a more patient specific antibiotic management", "TREATMENT", 196, 241], ["multidrug resistant pathogens", "PROBLEM", 265, 294], ["P. aeruginosa", "PROBLEM", 306, 319], ["MRSA", "PROBLEM", 324, 328], ["nosocomial infection", "PROBLEM", 338, 358], ["multidrug resistant pathogens", "OBSERVATION", 265, 294], ["MRSA", "OBSERVATION", 324, 328], ["nosocomial", "OBSERVATION_MODIFIER", 338, 348], ["infection", "OBSERVATION", 349, 358]]], ["Multidrug resistant pathogens have been recognized as contributing to unfavorable clinical outcome and increased resource utilization [23] .", [["Multidrug resistant pathogens", "PROBLEM", 0, 29]]], ["The greater associated hospital mortality has been attributed to the virulence of these bacteria and the increased occurrence of inadequate initial antibiotic treatment of VAP due to the presence of antibiotic resistance.", [["VAP", "DISEASE", 172, 175], ["these bacteria", "PROBLEM", 82, 96], ["inadequate initial antibiotic treatment", "TREATMENT", 129, 168], ["VAP", "PROBLEM", 172, 175], ["antibiotic resistance", "TREATMENT", 199, 220], ["greater", "OBSERVATION_MODIFIER", 4, 11], ["bacteria", "OBSERVATION", 88, 96], ["increased", "OBSERVATION_MODIFIER", 105, 114], ["antibiotic resistance", "OBSERVATION", 199, 220]]], ["However, the impact of multidrug resistance is difficult to assess because of the presence of multiple patient characteristics that may confound uniform analysis.PathogensP. aeruginosa, MRSA and A. baumannii represent the three most important microorganisms in VAP.Pseudomonas aeruginosaP. aeruginosa represents the most prevalent microorganism in VAP in different series and is associated with high mortality rates [24] .", [["VAP", "DISEASE", 261, 264], ["VAP", "DISEASE", 348, 351], ["patient", "ORGANISM", 103, 110], ["PathogensP. aeruginosa", "ORGANISM", 162, 184], ["A. baumannii", "ORGANISM", 195, 207], ["Pseudomonas aeruginosaP", "ORGANISM", 265, 288], ["aeruginosa", "ORGANISM", 290, 300], ["patient", "SPECIES", 103, 110], ["PathogensP. aeruginosa", "SPECIES", 162, 184], ["MRSA", "SPECIES", 186, 190], ["A. baumannii", "SPECIES", 195, 207], ["Pseudomonas aeruginosaP", "SPECIES", 265, 288], ["aeruginosa", "SPECIES", 290, 300], ["PathogensP. aeruginosa", "SPECIES", 162, 184], ["MRSA", "SPECIES", 186, 190], ["A. baumannii", "SPECIES", 195, 207], ["Pseudomonas aeruginosaP", "SPECIES", 265, 288], ["aeruginosa", "SPECIES", 290, 300], ["multidrug resistance", "PROBLEM", 23, 43], ["PathogensP", "PROBLEM", 162, 172], ["aeruginosa", "PROBLEM", 174, 184], ["MRSA", "PROBLEM", 186, 190], ["A. baumannii", "PROBLEM", 195, 207], ["VAP", "PROBLEM", 261, 264], ["Pseudomonas aeruginosaP", "PROBLEM", 265, 288], ["aeruginosa", "PROBLEM", 290, 300], ["VAP", "PROBLEM", 348, 351], ["high mortality rates", "PROBLEM", 395, 415], ["multidrug resistance", "OBSERVATION", 23, 43], ["aeruginosa", "OBSERVATION", 174, 184], ["MRSA", "OBSERVATION", 186, 190], ["VAP", "OBSERVATION", 261, 264], ["most prevalent", "OBSERVATION_MODIFIER", 316, 330], ["microorganism", "OBSERVATION", 331, 344], ["VAP", "OBSERVATION", 348, 351]]], ["Some surface factors, by either injecting cytotoxin to damaged epithelial cells or by rupturing epithelial integrity or by mechanisms like the type III secretion system, increase P. aeruginosa's virulence, particularly exoU.", [["surface", "ANATOMY", 5, 12], ["epithelial cells", "ANATOMY", 63, 79], ["epithelial", "ANATOMY", 96, 106], ["epithelial cells", "CELL", 63, 79], ["epithelial", "TISSUE", 96, 106], ["type III secretion", "GENE_OR_GENE_PRODUCT", 143, 161], ["P. aeruginosa", "ORGANISM", 179, 192], ["surface factors", "PROTEIN", 5, 20], ["cytotoxin", "PROTEIN", 42, 51], ["damaged epithelial cells", "CELL_TYPE", 55, 79], ["P. aeruginosa", "SPECIES", 179, 192], ["P. aeruginosa", "SPECIES", 179, 192], ["Some surface factors", "PROBLEM", 0, 20], ["damaged epithelial cells", "PROBLEM", 55, 79], ["rupturing epithelial integrity", "PROBLEM", 86, 116], ["the type III secretion system", "PROBLEM", 139, 168], ["P. aeruginosa's virulence", "PROBLEM", 179, 204], ["surface", "OBSERVATION_MODIFIER", 5, 12], ["factors", "OBSERVATION", 13, 20], ["epithelial cells", "OBSERVATION", 63, 79], ["rupturing epithelial integrity", "OBSERVATION", 86, 116]]], ["The type III secretion system induces the translocation of toxins from the bacterial cytoplasm into the cytosol of host cells directly.", [["cytoplasm", "ANATOMY", 85, 94], ["cytosol", "ANATOMY", 104, 111], ["cells", "ANATOMY", 120, 125], ["type III secretion", "GENE_OR_GENE_PRODUCT", 4, 22], ["cytoplasm", "ORGANISM_SUBSTANCE", 85, 94], ["cytosol", "CELLULAR_COMPONENT", 104, 111], ["cells", "CELL", 120, 125], ["host cells", "CELL_TYPE", 115, 125], ["The type III secretion system", "PROBLEM", 0, 29], ["toxins", "PROBLEM", 59, 65], ["the bacterial cytoplasm", "PROBLEM", 71, 94], ["type III", "OBSERVATION_MODIFIER", 4, 12], ["secretion system", "OBSERVATION", 13, 29], ["bacterial cytoplasm", "OBSERVATION", 75, 94], ["host cells", "OBSERVATION", 115, 125]]], ["P. aeruginosa strains producing type III secreted proteins are linked with worse outcome [25] .Pseudomonas aeruginosaZhuo et al. [26] reported that patients with large burdens of P. aeruginosa had an increased risk of death and possessed more virulent strains.", [["P. aeruginosa", "DISEASE", 179, 192], ["death", "DISEASE", 218, 223], ["P. aeruginosa strains", "ORGANISM", 0, 21], ["type III secreted proteins", "GENE_OR_GENE_PRODUCT", 32, 58], ["patients", "ORGANISM", 148, 156], ["P. aeruginosa", "ORGANISM", 179, 192], ["type III secreted proteins", "PROTEIN", 32, 58], ["P. aeruginosa", "SPECIES", 0, 13], ["Pseudomonas aeruginosaZhuo", "SPECIES", 95, 121], ["patients", "SPECIES", 148, 156], ["P. aeruginosa", "SPECIES", 179, 192], ["P. aeruginosa", "SPECIES", 0, 13], ["P. aeruginosa", "SPECIES", 179, 192], ["P. aeruginosa strains", "PROBLEM", 0, 21], ["type III secreted proteins", "PROBLEM", 32, 58], ["Pseudomonas aeruginosaZhuo", "PROBLEM", 95, 121], ["P. aeruginosa", "PROBLEM", 179, 192], ["death", "PROBLEM", 218, 223], ["virulent strains", "PROBLEM", 243, 259], ["large", "OBSERVATION_MODIFIER", 162, 167]]], ["Therefore, a high burden of P. aeruginosa may be a marker of inadequate host defense and its presence may also further compromise target host immune cells, for example, macrophages and neutrophils, allowing organisms to evade the immune response and often reducing the number of viable host defense cells.Staphylococcus aureusS. aureus is the most important Gram-positive pathogen in VAP.", [["immune cells", "ANATOMY", 142, 154], ["macrophages", "ANATOMY", 169, 180], ["neutrophils", "ANATOMY", 185, 196], ["cells", "ANATOMY", 299, 304], ["P. aeruginosa", "DISEASE", 28, 41], ["VAP", "DISEASE", 384, 387], ["P. aeruginosa", "ORGANISM", 28, 41], ["host immune cells", "CELL", 137, 154], ["macrophages", "CELL", 169, 180], ["neutrophils", "CELL", 185, 196], ["host defense cells", "CELL", 286, 304], ["Staphylococcus aureusS", "ORGANISM", 305, 327], ["aureus", "ORGANISM", 329, 335], ["Gram-", "GENE_OR_GENE_PRODUCT", 358, 363], ["immune cells", "CELL_TYPE", 142, 154], ["macrophages", "CELL_TYPE", 169, 180], ["neutrophils", "CELL_TYPE", 185, 196], ["host defense cells", "CELL_TYPE", 286, 304], ["P. aeruginosa", "SPECIES", 28, 41], ["Staphylococcus aureusS", "SPECIES", 305, 327], ["aureus", "SPECIES", 329, 335], ["P. aeruginosa", "SPECIES", 28, 41], ["Staphylococcus aureusS", "SPECIES", 305, 327], ["aureus", "SPECIES", 329, 335], ["a high burden of P. aeruginosa", "PROBLEM", 11, 41], ["inadequate host defense", "PROBLEM", 61, 84], ["macrophages", "PROBLEM", 169, 180], ["neutrophils", "PROBLEM", 185, 196], ["organisms", "PROBLEM", 207, 216], ["Staphylococcus aureusS", "PROBLEM", 305, 327], ["aureus", "PROBLEM", 329, 335], ["VAP", "PROBLEM", 384, 387], ["host immune cells", "OBSERVATION", 137, 154], ["viable host defense cells", "OBSERVATION", 279, 304], ["most important", "OBSERVATION_MODIFIER", 343, 357], ["positive", "OBSERVATION_MODIFIER", 363, 371], ["pathogen", "OBSERVATION", 372, 380], ["VAP", "OBSERVATION", 384, 387]]], ["In the recent European multicenter study [27] , EUVAP, the most common isolate was S. aureus in 32.3 % of cases; 16.3 % were MSSA and 16.0 % MRSA.", [["S. aureus", "DISEASE", 83, 92], ["MSSA", "CHEMICAL", 125, 129], ["MRSA", "DISEASE", 141, 145], ["S. aureus", "ORGANISM", 83, 92], ["S. aureus", "SPECIES", 83, 92], ["MRSA", "SPECIES", 141, 145], ["S. aureus", "SPECIES", 83, 92], ["MSSA", "SPECIES", 125, 129], ["EUVAP", "TEST", 48, 53], ["S. aureus", "TEST", 83, 92], ["cases", "TEST", 106, 111], ["MSSA", "TEST", 125, 129], ["MRSA", "PROBLEM", 141, 145], ["aureus", "OBSERVATION", 86, 92]]], ["Virulence and therapyrelated factors, such as inappropriate antibiotic prescription, have been consistently associated with increased mortality.", [["therapyrelated factors", "PROTEIN", 14, 36], ["Virulence", "PROBLEM", 0, 9], ["therapyrelated factors", "TREATMENT", 14, 36], ["inappropriate antibiotic prescription", "TREATMENT", 46, 83], ["increased mortality", "PROBLEM", 124, 143], ["increased", "OBSERVATION_MODIFIER", 124, 133], ["mortality", "OBSERVATION", 134, 143]]], ["There are several factors linked with MRSA isolation in VAP episodes: Administration of antibiotics before the development of VAP [28] and length of hospital stay, rather than the period of mechanical ventilation, were strongly associated with MRSA isolation [29] .", [["MRSA", "DISEASE", 38, 42], ["VAP", "DISEASE", 56, 59], ["VAP", "DISEASE", 126, 129], ["MRSA", "SPECIES", 38, 42], ["MRSA", "SPECIES", 244, 248], ["MRSA", "SPECIES", 38, 42], ["MRSA isolation", "TREATMENT", 38, 52], ["VAP episodes", "PROBLEM", 56, 68], ["antibiotics", "TREATMENT", 88, 99], ["VAP", "PROBLEM", 126, 129], ["mechanical ventilation", "TREATMENT", 190, 212], ["MRSA isolation", "PROBLEM", 244, 258], ["MRSA", "OBSERVATION", 38, 42], ["VAP", "OBSERVATION", 126, 129], ["mechanical ventilation", "OBSERVATION", 190, 212]]], ["Vidaur et al. [30] found that MRSA VAP treated with appropriate therapy resolved more slowly than VAP due to Haemophilus influenzae, MSSA, and P. aeruginosa treated with appropriate therapy.", [["MRSA", "CHEMICAL", 30, 34], ["VAP", "DISEASE", 35, 38], ["VAP", "DISEASE", 98, 101], ["Haemophilus influenzae, MSSA, and P. aeruginosa", "DISEASE", 109, 156], ["Haemophilus influenzae", "ORGANISM", 109, 131], ["MSSA", "CANCER", 133, 137], ["P. aeruginosa", "ORGANISM", 143, 156], ["MRSA", "SPECIES", 30, 34], ["Haemophilus influenzae", "SPECIES", 109, 131], ["P. aeruginosa", "SPECIES", 143, 156], ["Haemophilus influenzae", "SPECIES", 109, 131], ["P. aeruginosa", "SPECIES", 143, 156], ["MRSA VAP", "PROBLEM", 30, 38], ["appropriate therapy", "TREATMENT", 52, 71], ["VAP", "PROBLEM", 98, 101], ["Haemophilus influenzae", "PROBLEM", 109, 131], ["MSSA", "PROBLEM", 133, 137], ["P. aeruginosa", "PROBLEM", 143, 156], ["appropriate therapy", "TREATMENT", 170, 189], ["MRSA", "OBSERVATION", 30, 34]]], ["The risk of death in MRSA episodes is 20 times higher than in episodes caused by MSSA strains treated with beta-lactams [31] and a recent report showed that MRSA-VAP episodes were independently associated with prolonged hospitalization and higher costs than MSSA VAP episodes, even when therapy was appropriate [32] .Acinetobacter baumanniiSeveral studies have investigated the attributable mortality of A. baumannii and found controversial results.", [["death", "DISEASE", 12, 17], ["MRSA", "DISEASE", 21, 25], ["MSSA", "CHEMICAL", 81, 85], ["beta-lactams", "CHEMICAL", 107, 119], ["MRSA", "CHEMICAL", 157, 161], ["VAP", "DISEASE", 162, 165], ["MSSA", "CHEMICAL", 258, 262], ["VAP", "DISEASE", 263, 266], ["beta-lactams", "CHEMICAL", 107, 119], ["A. baumannii", "ORGANISM", 404, 416], ["MRSA", "SPECIES", 21, 25], ["MRSA", "SPECIES", 157, 161], ["A. baumannii", "SPECIES", 404, 416], ["MSSA", "SPECIES", 81, 85], ["A. baumannii", "SPECIES", 404, 416], ["death", "PROBLEM", 12, 17], ["MRSA episodes", "PROBLEM", 21, 34], ["MSSA strains", "PROBLEM", 81, 93], ["beta-lactams", "TREATMENT", 107, 119], ["MRSA", "PROBLEM", 157, 161], ["VAP episodes", "PROBLEM", 162, 174], ["MSSA VAP episodes", "PROBLEM", 258, 275], ["Acinetobacter baumanniiSeveral studies", "TEST", 317, 355], ["A. baumannii", "PROBLEM", 404, 416], ["MRSA", "OBSERVATION", 21, 25], ["MRSA", "OBSERVATION", 157, 161], ["VAP", "OBSERVATION", 162, 165]]], ["Fagon et al. [33] reported higher mortality in cases with VAP caused by A. baumannii and P. aeruginosa than in controls with bronchial colonization.", [["bronchial", "ANATOMY", 125, 134], ["VAP", "DISEASE", 58, 61], ["A. baumannii", "ORGANISM", 72, 84], ["P. aeruginosa", "ORGANISM", 89, 102], ["bronchial", "MULTI-TISSUE_STRUCTURE", 125, 134], ["A. baumannii", "SPECIES", 72, 84], ["P. aeruginosa", "SPECIES", 89, 102], ["A. baumannii", "SPECIES", 72, 84], ["P. aeruginosa", "SPECIES", 89, 102], ["VAP", "PROBLEM", 58, 61], ["A. baumannii", "PROBLEM", 72, 84], ["P. aeruginosa", "PROBLEM", 89, 102], ["bronchial colonization", "PROBLEM", 125, 147], ["bronchial", "ANATOMY", 125, 134], ["colonization", "OBSERVATION", 135, 147]]], ["In contrast, Garnacho-Montero et al. [34] , found that VAP due to A. baumannii was not associated with worse outcomes than other causes of VAP in a matched case-control study.", [["VAP", "DISEASE", 55, 58], ["VAP", "DISEASE", 139, 142], ["A. baumannii", "ORGANISM", 66, 78], ["A. baumannii", "SPECIES", 66, 78], ["A. baumannii", "SPECIES", 66, 78], ["VAP", "PROBLEM", 55, 58], ["A. baumannii", "PROBLEM", 66, 78], ["VAP", "PROBLEM", 139, 142], ["control study", "TEST", 161, 174], ["VAP", "OBSERVATION", 55, 58], ["baumannii", "OBSERVATION", 69, 78]]], ["A. baumannii exhibits intrinsic resistance to multiple antimicrobial agents and generates continuing controversy about whether VAP caused by this microorganism increases morbidity and mortality independently of the effects of other confounding factors in ICU setting.Candida speciesIn immunocompetent mechanically ventilated patients, isolation of Candida spp. from the respiratory tract is relatively common.", [["respiratory tract", "ANATOMY", 370, 387], ["VAP", "DISEASE", 127, 130], ["Candida spp", "DISEASE", 348, 359], ["A. baumannii", "ORGANISM", 0, 12], ["Candida species", "ORGANISM", 267, 282], ["patients", "ORGANISM", 325, 333], ["Candida spp", "ORGANISM", 348, 359], ["respiratory tract", "ORGANISM_SUBDIVISION", 370, 387], ["A. baumannii", "SPECIES", 0, 12], ["patients", "SPECIES", 325, 333], ["A. baumannii", "SPECIES", 0, 12], ["baumannii", "PROBLEM", 3, 12], ["multiple antimicrobial agents", "TREATMENT", 46, 75], ["VAP", "PROBLEM", 127, 130], ["this microorganism", "PROBLEM", 141, 159], ["Candida species", "PROBLEM", 267, 282], ["Candida spp", "PROBLEM", 348, 359], ["baumannii", "OBSERVATION", 3, 12], ["intrinsic resistance", "OBSERVATION", 22, 42], ["multiple", "OBSERVATION_MODIFIER", 46, 54], ["antimicrobial agents", "OBSERVATION", 55, 75], ["immunocompetent", "OBSERVATION_MODIFIER", 285, 300], ["mechanically ventilated", "OBSERVATION", 301, 324], ["Candida spp", "OBSERVATION", 348, 359], ["respiratory tract", "ANATOMY", 370, 387], ["relatively", "OBSERVATION_MODIFIER", 391, 401], ["common", "OBSERVATION", 402, 408]]], ["Olaechea et al. [35] found an association with Candida spp. isolation and longer ICU and hospital stays and resource utilization.", [["Candida spp", "DISEASE", 47, 58], ["Candida spp", "ORGANISM", 47, 58], ["Candida spp", "PROBLEM", 47, 58], ["resource utilization", "TREATMENT", 108, 128], ["Candida spp", "OBSERVATION", 47, 58]]], ["Azoulay et al. [36] reported that Candida spp. colonization was associated with an increased risk of P. aeruginosa VAP.", [["Candida spp", "DISEASE", 34, 45], ["P. aeruginosa VAP", "DISEASE", 101, 118], ["Candida spp", "ORGANISM", 34, 45], ["P. aeruginosa", "ORGANISM", 101, 114], ["P. aeruginosa", "SPECIES", 101, 114], ["P. aeruginosa", "SPECIES", 101, 114], ["Candida spp", "PROBLEM", 34, 45], ["colonization", "PROBLEM", 47, 59], ["P. aeruginosa VAP", "PROBLEM", 101, 118], ["increased", "OBSERVATION_MODIFIER", 83, 92], ["aeruginosa VAP", "OBSERVATION", 104, 118]]], ["Candida spp. and P. aeruginosa were among the most common microorganisms retrieved from endotracheal tube biofilm and tracheal secretions in patients with VAP.", [["endotracheal tube biofilm", "ANATOMY", 88, 113], ["tracheal secretions", "ANATOMY", 118, 137], ["VAP", "DISEASE", 155, 158], ["Candida spp.", "ORGANISM", 0, 12], ["P. aeruginosa", "ORGANISM", 17, 30], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 88, 105], ["tracheal secretions", "ORGANISM_SUBSTANCE", 118, 137], ["patients", "ORGANISM", 141, 149], ["Candida spp.", "SPECIES", 0, 12], ["P. aeruginosa", "SPECIES", 17, 30], ["patients", "SPECIES", 141, 149], ["Candida spp.", "SPECIES", 0, 12], ["P. aeruginosa", "SPECIES", 17, 30], ["Candida spp.", "TEST", 0, 12], ["P. aeruginosa", "PROBLEM", 17, 30], ["endotracheal tube biofilm", "TREATMENT", 88, 113], ["tracheal secretions", "PROBLEM", 118, 137], ["VAP", "PROBLEM", 155, 158], ["endotracheal tube", "OBSERVATION", 88, 105], ["biofilm", "OBSERVATION_MODIFIER", 106, 113], ["tracheal", "ANATOMY", 118, 126], ["secretions", "OBSERVATION", 127, 137]]], ["This can be explained because both microorganisms have identical functional enzymes, such as 2' phosphotransferase, acting in concert with ligase to splice transfer RNA molecules.", [["2' phosphotransferase", "GENE_OR_GENE_PRODUCT", 93, 114], ["functional enzymes", "PROTEIN", 65, 83], ["2' phosphotransferase", "PROTEIN", 93, 114], ["ligase", "PROTEIN", 139, 145], ["splice transfer RNA molecules", "PROTEIN", 149, 178], ["both microorganisms", "PROBLEM", 30, 49], ["functional enzymes", "TEST", 65, 83], ["2' phosphotransferase", "TREATMENT", 93, 114]]], ["Preemptive treatment with local or systemic therapy has been proposed in order to reduce the incidence of P. aeruginosa VAP [37] .VAT might represent an intermediate process between colonization and VAP [38] and probably is a continuum between bronchitis and pneumonia in mechanicallyA New Approach to Ventilator-associated Pneumonia Based on the PIRO System 485 ventilated patients.", [["P. aeruginosa VAP", "DISEASE", 106, 123], ["VAP", "DISEASE", 199, 202], ["bronchitis", "DISEASE", 244, 254], ["pneumonia", "DISEASE", 259, 268], ["Pneumonia", "DISEASE", 324, 333], ["P. aeruginosa", "ORGANISM", 106, 119], ["VAT", "TISSUE", 130, 133], ["patients", "ORGANISM", 374, 382], ["P. aeruginosa", "SPECIES", 106, 119], ["patients", "SPECIES", 374, 382], ["P. aeruginosa", "SPECIES", 106, 119], ["Preemptive treatment", "TREATMENT", 0, 20], ["local or systemic therapy", "TREATMENT", 26, 51], ["P. aeruginosa VAP", "PROBLEM", 106, 123], ["VAT", "PROBLEM", 130, 133], ["an intermediate process", "PROBLEM", 150, 173], ["VAP", "PROBLEM", 199, 202], ["a continuum between bronchitis", "PROBLEM", 224, 254], ["pneumonia", "PROBLEM", 259, 268], ["Pneumonia", "PROBLEM", 324, 333], ["intermediate", "OBSERVATION_MODIFIER", 153, 165], ["process", "OBSERVATION", 166, 173], ["colonization", "OBSERVATION_MODIFIER", 182, 194], ["bronchitis", "OBSERVATION", 244, 254], ["pneumonia", "OBSERVATION", 259, 268], ["New", "OBSERVATION_MODIFIER", 286, 289], ["Pneumonia", "OBSERVATION", 324, 333]]], ["Host defenses can be overwhelmed by a large aspirated inoculum or an inherently virulent organism and the main reason for developing infection in the upper airways is the imbalance between host defenses and excess of mucus.", [["upper airways", "ANATOMY", 150, 163], ["mucus", "ANATOMY", 217, 222], ["infection", "DISEASE", 133, 142], ["upper airways", "MULTI-TISSUE_STRUCTURE", 150, 163], ["mucus", "ORGANISM_SUBSTANCE", 217, 222], ["a large aspirated inoculum", "PROBLEM", 36, 62], ["an inherently virulent organism", "PROBLEM", 66, 97], ["developing infection in the upper airways", "PROBLEM", 122, 163], ["mucus", "PROBLEM", 217, 222], ["large", "OBSERVATION_MODIFIER", 38, 43], ["aspirated inoculum", "OBSERVATION", 44, 62], ["inherently", "OBSERVATION_MODIFIER", 69, 79], ["virulent", "OBSERVATION_MODIFIER", 80, 88], ["organism", "OBSERVATION", 89, 97], ["main reason for", "UNCERTAINTY", 106, 121], ["infection", "OBSERVATION", 133, 142], ["upper", "ANATOMY_MODIFIER", 150, 155], ["airways", "ANATOMY", 156, 163], ["host defenses", "OBSERVATION", 189, 202], ["mucus", "OBSERVATION", 217, 222]]], ["Recent studies have shown that bronchial/tracheal epithelial cells are functionally different and represent a first step of injury [39] .", [["bronchial", "ANATOMY", 31, 40], ["tracheal epithelial cells", "ANATOMY", 41, 66], ["tracheal epithelial cells", "CELL", 41, 66], ["bronchial/tracheal epithelial cells", "CELL_TYPE", 31, 66], ["Recent studies", "TEST", 0, 14], ["bronchial/tracheal epithelial cells", "PROBLEM", 31, 66], ["injury", "PROBLEM", 124, 130], ["bronchial", "ANATOMY", 31, 40], ["tracheal", "ANATOMY", 41, 49], ["epithelial cells", "OBSERVATION", 50, 66], ["different", "OBSERVATION_MODIFIER", 84, 93], ["injury", "OBSERVATION", 124, 130]]], ["VAT represents an interesting target for treatment since it may prevent the progression to VAP, shorten the use of antibiotics that reduce cost and minimize the selective pressure on ICU ecology [40] .Blood TransfusionThe majority of critically ill patients require a transfusion of packed red blood cells (RBCs) at some point during their ICU stay.", [["Blood", "ANATOMY", 201, 206], ["red blood cells", "ANATOMY", 290, 305], ["RBCs", "ANATOMY", 307, 311], ["VAP", "DISEASE", 91, 94], ["critically ill", "DISEASE", 234, 248], ["VAT", "TISSUE", 0, 3], ["Blood", "ORGANISM_SUBSTANCE", 201, 206], ["patients", "ORGANISM", 249, 257], ["red blood cells", "CELL", 290, 305], ["RBCs", "CELL", 307, 311], ["packed red blood cells", "CELL_TYPE", 283, 305], ["RBCs", "CELL_TYPE", 307, 311], ["patients", "SPECIES", 249, 257], ["treatment", "TREATMENT", 41, 50], ["VAP", "PROBLEM", 91, 94], ["antibiotics", "TREATMENT", 115, 126], ["Blood Transfusion", "TREATMENT", 201, 218], ["a transfusion of packed red blood cells (RBCs", "TREATMENT", 266, 311], ["majority", "OBSERVATION_MODIFIER", 222, 230], ["critically", "OBSERVATION_MODIFIER", 234, 244], ["ill", "OBSERVATION_MODIFIER", 245, 248]]], ["The incidence of blood transfusion during the ICU stay has been reported to be as frequent as 37.0 % [42] .", [["blood", "ANATOMY", 17, 22], ["blood", "ORGANISM_SUBSTANCE", 17, 22], ["blood transfusion", "TREATMENT", 17, 34]]], ["Nevertheless, transfusion of packed RBCs is not without risk since it represents an insult to the host's immune system with enhancement of cytokine response.", [["RBCs", "ANATOMY", 36, 40], ["immune system", "ANATOMY", 105, 118], ["RBCs", "CELL", 36, 40], ["immune system", "ANATOMICAL_SYSTEM", 105, 118], ["packed RBCs", "CELL_TYPE", 29, 40], ["cytokine", "PROTEIN", 139, 147], ["transfusion of packed RBCs", "TREATMENT", 14, 40], ["an insult", "PROBLEM", 81, 90], ["cytokine response", "PROBLEM", 139, 156], ["packed RBCs", "OBSERVATION_MODIFIER", 29, 40], ["not without", "UNCERTAINTY", 44, 55], ["insult", "OBSERVATION", 84, 90], ["cytokine response", "OBSERVATION", 139, 156]]], ["Antiinflamatory (interleukin [IL]-10) and pleiotropic (IL-6) cytokines are increased during transfusion of packed RBCs.", [["RBCs", "ANATOMY", 114, 118], ["interleukin [IL]-10", "GENE_OR_GENE_PRODUCT", 17, 36], ["IL-6", "GENE_OR_GENE_PRODUCT", 55, 59], ["RBCs", "CELL", 114, 118], ["Antiinflamatory (interleukin [IL]-10", "PROTEIN", 0, 36], ["pleiotropic (IL-6) cytokines", "PROTEIN", 42, 70], ["packed RBCs", "CELL_TYPE", 107, 118], ["Antiinflamatory (interleukin [IL]", "TREATMENT", 0, 33], ["pleiotropic (IL-6) cytokines", "TREATMENT", 42, 70], ["transfusion of packed RBCs", "TREATMENT", 92, 118], ["packed RBCs", "OBSERVATION", 107, 118]]], ["Blood transfusion has been associated with nosocomial infection-like surgical site infections and potentiates the risk for catheter-related blood stream infection but also increases the risk of developing VAP.Blood TransfusionShorr et al. [42] reported that transfusion was independently associated with an increased risk for VAP, the effect of transfusion on late-onset VAP being more pronounced and dose-response dependent.", [["Blood", "ANATOMY", 0, 5], ["site", "ANATOMY", 78, 82], ["blood", "ANATOMY", 140, 145], ["Blood", "ANATOMY", 209, 214], ["infection", "DISEASE", 54, 63], ["infections", "DISEASE", 83, 93], ["blood stream infection", "DISEASE", 140, 162], ["VAP", "DISEASE", 205, 208], ["VAP", "DISEASE", 326, 329], ["VAP", "DISEASE", 371, 374], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["blood", "ORGANISM_SUBSTANCE", 140, 145], ["Blood", "ORGANISM_SUBSTANCE", 209, 214], ["Blood transfusion", "TREATMENT", 0, 17], ["nosocomial infection", "PROBLEM", 43, 63], ["surgical site infections", "PROBLEM", 69, 93], ["catheter", "TREATMENT", 123, 131], ["blood stream infection", "PROBLEM", 140, 162], ["developing VAP", "PROBLEM", 194, 208], ["Blood Transfusion", "TREATMENT", 209, 226], ["transfusion", "TREATMENT", 258, 269], ["VAP", "PROBLEM", 326, 329], ["transfusion", "TREATMENT", 345, 356], ["VAP", "PROBLEM", 371, 374], ["response dependent", "PROBLEM", 406, 424], ["associated with", "UNCERTAINTY", 27, 42], ["nosocomial", "OBSERVATION_MODIFIER", 43, 53], ["infection", "OBSERVATION", 54, 63], ["surgical site", "OBSERVATION_MODIFIER", 69, 82], ["infections", "OBSERVATION", 83, 93], ["catheter", "OBSERVATION", 123, 131], ["stream", "OBSERVATION_MODIFIER", 146, 152], ["infection", "OBSERVATION", 153, 162], ["VAP", "OBSERVATION", 205, 208], ["VAP", "OBSERVATION", 326, 329], ["more pronounced", "OBSERVATION_MODIFIER", 381, 396]]], ["Therefore, blood transfusion needs to be considered cautiously in critical care patients in order to evaluate potential adverse events and to acknowledge that the burden of proof is shifting to suggest that transfusion avoidance may be the safer paradigm [43] .Components of the VAP-PIRO Score: Response Clinical ResolutionEarly clinical recognition of therapeutic failure is of paramount importance if corrective measures are to be taken.", [["blood", "ANATOMY", 11, 16], ["VAP", "DISEASE", 279, 282], ["blood", "ORGANISM_SUBSTANCE", 11, 16], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["blood transfusion", "TREATMENT", 11, 28], ["potential adverse events", "PROBLEM", 110, 134], ["transfusion avoidance", "TREATMENT", 207, 228], ["therapeutic failure", "PROBLEM", 353, 372], ["corrective measures", "TREATMENT", 403, 422], ["VAP", "OBSERVATION", 279, 282]]], ["Several studies have suggested that improvement in oxygenation is the most reliable criteria to distinguish patients who are responding to antibiotic treatment from those who are not.", [["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116], ["Several studies", "TEST", 0, 15], ["antibiotic treatment", "TREATMENT", 139, 159], ["improvement", "OBSERVATION_MODIFIER", 36, 47]]], ["Luna et al. [44] evaluated the performance of the Clinical Pulmonary Infection Score (CPIS) in identifying which patients with VAP respond to therapy.", [["Pulmonary", "ANATOMY", 59, 68], ["Pulmonary Infection", "DISEASE", 59, 78], ["VAP", "DISEASE", 127, 130], ["Pulmonary", "ORGAN", 59, 68], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["the Clinical Pulmonary Infection Score", "PROBLEM", 46, 84], ["CPIS", "TEST", 86, 90], ["VAP", "PROBLEM", 127, 130], ["therapy", "TREATMENT", 142, 149], ["Pulmonary", "ANATOMY", 59, 68], ["Infection", "OBSERVATION", 69, 78]]], ["These authors discovered that only the PaO 2 /FiO 2 ratio could distinguish survivors from non-survivors, as early as day 3 of therapy for VAP.", [["VAP", "DISEASE", 139, 142], ["FiO 2", "CHEMICAL", 46, 51], ["PaO 2", "GENE_OR_GENE_PRODUCT", 39, 44], ["FiO 2", "GENE_OR_GENE_PRODUCT", 46, 51], ["the PaO", "TEST", 35, 42], ["therapy", "TREATMENT", 127, 134], ["VAP", "PROBLEM", 139, 142]]], ["Moreover they reported that the PaO 2 /FiO 2 ratio improved above 250 mmHg in survivors, and this improvement happened before improvement in the other components of the score (white blood cell count, fever, secretions, and radiographic abnormalities).", [["white blood cell", "ANATOMY", 176, 192], ["secretions", "ANATOMY", 207, 217], ["fever", "DISEASE", 200, 205], ["FiO 2", "CHEMICAL", 39, 44], ["PaO 2", "GENE_OR_GENE_PRODUCT", 32, 37], ["FiO 2", "GENE_OR_GENE_PRODUCT", 39, 44], ["blood cell", "CELL", 182, 192], ["the PaO", "TEST", 28, 35], ["FiO 2 ratio", "TEST", 39, 50], ["the score", "TEST", 165, 174], ["white blood cell count", "TEST", 176, 198], ["fever", "PROBLEM", 200, 205], ["secretions", "PROBLEM", 207, 217], ["radiographic abnormalities", "PROBLEM", 223, 249]]], ["Thus, the PaO 2 /FiO 2 ratio may represent a very accurate and rapid measure of the patient's response to therapy and can help tailor appropriate duration of therapy.", [["FiO 2", "CHEMICAL", 17, 22], ["PaO 2", "GENE_OR_GENE_PRODUCT", 10, 15], ["FiO 2", "GENE_OR_GENE_PRODUCT", 17, 22], ["patient", "ORGANISM", 84, 91], ["patient", "SPECIES", 84, 91], ["the PaO 2 /FiO 2 ratio", "TEST", 6, 28], ["therapy", "TREATMENT", 106, 113], ["therapy", "TREATMENT", 158, 165], ["may represent", "UNCERTAINTY", 29, 42]]], ["However, Vidaur et al. [45] reported that improvement in oxygenation was unreliable in patients with the acute respiratory distress syndrome (ARDS), and only fever was delayed compared with non-ARDS patients.", [["respiratory", "ANATOMY", 111, 122], ["acute respiratory distress syndrome", "DISEASE", 105, 140], ["ARDS", "DISEASE", 142, 146], ["fever", "DISEASE", 158, 163], ["non-ARDS", "DISEASE", 190, 198], ["patients", "ORGANISM", 87, 95], ["patients", "ORGANISM", 199, 207], ["patients", "SPECIES", 87, 95], ["patients", "SPECIES", 199, 207], ["the acute respiratory distress syndrome", "PROBLEM", 101, 140], ["ARDS", "PROBLEM", 142, 146], ["fever", "PROBLEM", 158, 163], ["acute", "OBSERVATION_MODIFIER", 105, 110], ["respiratory", "ANATOMY", 111, 122], ["distress", "OBSERVATION", 123, 131]]], ["At days 7 -8 of treatment, when antibiotics for VAP are commonly discontinued [46] , Chastre et al. reported that more than 35 % of ARDS patients with VAP remain febrile.XIIClinical patterns, such as fever and hypoxemia, are clinical variables that can be easily followed at the bedside of the patient simply by physical examination to monitor clinical response and to individualize and shorten the duration of antibiotic therapy.Use of Biomarkers to Quantify the Response to VAPSeveral biomarkers have been proposed as the most promising candidates, such as leukocyte count, C-reactive protein (CRP) and procalcitonin (PCT), for correlating with the prognosis of VAP [47] .", [["leukocyte", "ANATOMY", 559, 568], ["VAP", "DISEASE", 48, 51], ["ARDS", "DISEASE", 132, 136], ["VAP", "DISEASE", 151, 154], ["febrile", "DISEASE", 162, 169], ["fever", "DISEASE", 200, 205], ["hypoxemia", "DISEASE", 210, 219], ["VAP", "DISEASE", 664, 667], ["patients", "ORGANISM", 137, 145], ["patient", "ORGANISM", 294, 301], ["leukocyte", "CELL", 559, 568], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 576, 594], ["CRP", "GENE_OR_GENE_PRODUCT", 596, 599], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 605, 618], ["C-reactive protein", "PROTEIN", 576, 594], ["CRP", "PROTEIN", 596, 599], ["procalcitonin", "PROTEIN", 605, 618], ["PCT", "PROTEIN", 620, 623], ["patients", "SPECIES", 137, 145], ["patient", "SPECIES", 294, 301], ["treatment", "TREATMENT", 16, 25], ["antibiotics", "TREATMENT", 32, 43], ["VAP", "PROBLEM", 48, 51], ["ARDS", "PROBLEM", 132, 136], ["VAP", "PROBLEM", 151, 154], ["febrile", "PROBLEM", 162, 169], ["fever", "PROBLEM", 200, 205], ["hypoxemia", "PROBLEM", 210, 219], ["physical examination", "TEST", 312, 332], ["antibiotic therapy", "TREATMENT", 411, 429], ["Biomarkers", "TREATMENT", 437, 447], ["VAPSeveral biomarkers", "TEST", 476, 497], ["leukocyte count", "TEST", 559, 574], ["C", "TEST", 576, 577], ["CRP", "TEST", 596, 599], ["procalcitonin", "TEST", 605, 618], ["PCT", "TEST", 620, 623], ["VAP", "PROBLEM", 664, 667], ["ARDS", "OBSERVATION", 132, 136], ["febrile", "OBSERVATION", 162, 169], ["hypoxemia", "OBSERVATION", 210, 219]]], ["Seligman et al. [48] reported that decreases in either serum PCT or CRP levels between onset and the fourth day of treatment could predict survival of VAP patients.", [["serum", "ANATOMY", 55, 60], ["VAP", "DISEASE", 151, 154], ["serum", "ORGANISM_SUBSTANCE", 55, 60], ["PCT", "GENE_OR_GENE_PRODUCT", 61, 64], ["CRP", "GENE_OR_GENE_PRODUCT", 68, 71], ["patients", "ORGANISM", 155, 163], ["serum PCT", "PROTEIN", 55, 64], ["CRP", "PROTEIN", 68, 71], ["patients", "SPECIES", 155, 163], ["serum PCT", "TEST", 55, 64], ["CRP levels", "TEST", 68, 78], ["treatment", "TREATMENT", 115, 124], ["VAP patients", "TREATMENT", 151, 163], ["decreases", "OBSERVATION_MODIFIER", 35, 44]]], ["Similarly, Luyt et al. [49] reported different procalcitonin levels as strong predictors of unfavorable outcome (death, recurrent VAP or development of extrapulmonary infection) by a point-of-care test at days 1, 3 and 7 in patients with VAP.", [["extrapulmonary", "ANATOMY", 152, 166], ["death", "DISEASE", 113, 118], ["VAP", "DISEASE", 130, 133], ["extrapulmonary infection", "DISEASE", 152, 176], ["VAP", "DISEASE", 238, 241], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 47, 60], ["patients", "ORGANISM", 224, 232], ["procalcitonin", "PROTEIN", 47, 60], ["patients", "SPECIES", 224, 232], ["different procalcitonin levels", "TEST", 37, 67], ["unfavorable outcome (death", "PROBLEM", 92, 118], ["recurrent VAP", "PROBLEM", 120, 133], ["extrapulmonary infection", "PROBLEM", 152, 176], ["VAP", "PROBLEM", 238, 241], ["extrapulmonary", "ANATOMY", 152, 166], ["infection", "OBSERVATION", 167, 176], ["VAP", "OBSERVATION", 238, 241]]], ["However, neither PCT nor CRP threshold values nor their kinetics could predict the development of septic shock in VAP patients [50] .Use of Biomarkers to Quantify the Response to VAPRecently, other biomarkers such us midregional pro-atrial natriuretic peptide (MR-proANP) and copeptin have been suggested and tested as prognostic markers, but their function in VAP resolution is still unproven [51, 52] .CompartmentalizationThe response to VAP may vary from compartmentalized forms that account for a local response with minor systemic compromise to systemic spillover or escape of inflammation leading to septic shock and uninfected multiorgan failure.CompartmentalizationCytokines are the key factors in the pathogenesis of pneumonia and add complexity of signaling during VAP development.", [["multiorgan", "ANATOMY", 634, 644], ["septic shock", "DISEASE", 98, 110], ["VAP", "DISEASE", 114, 117], ["VAP", "DISEASE", 361, 364], ["VAP", "DISEASE", 440, 443], ["inflammation", "DISEASE", 582, 594], ["septic shock", "DISEASE", 606, 618], ["multiorgan failure", "DISEASE", 634, 652], ["pneumonia", "DISEASE", 726, 735], ["VAP", "DISEASE", 775, 778], ["CRP", "GENE_OR_GENE_PRODUCT", 25, 28], ["patients", "ORGANISM", 118, 126], ["pro-atrial natriuretic peptide", "GENE_OR_GENE_PRODUCT", 229, 259], ["MR-proANP", "GENE_OR_GENE_PRODUCT", 261, 270], ["copeptin", "GENE_OR_GENE_PRODUCT", 276, 284], ["multiorgan", "ORGAN", 634, 644], ["PCT", "PROTEIN", 17, 20], ["CRP", "PROTEIN", 25, 28], ["MR", "PROTEIN", 261, 263], ["copeptin", "PROTEIN", 276, 284], ["patients", "SPECIES", 118, 126], ["PCT", "TEST", 17, 20], ["CRP threshold values", "TEST", 25, 45], ["septic shock", "PROBLEM", 98, 110], ["Biomarkers", "TREATMENT", 140, 150], ["other biomarkers", "TEST", 192, 208], ["midregional pro-atrial natriuretic peptide", "TREATMENT", 217, 259], ["MR", "TEST", 261, 263], ["copeptin", "TREATMENT", 276, 284], ["prognostic markers", "TEST", 319, 337], ["VAP resolution", "TEST", 361, 375], ["VAP", "PROBLEM", 440, 443], ["minor systemic compromise", "PROBLEM", 521, 546], ["systemic spillover", "PROBLEM", 550, 568], ["inflammation", "PROBLEM", 582, 594], ["septic shock", "PROBLEM", 606, 618], ["uninfected multiorgan failure", "PROBLEM", 623, 652], ["pneumonia", "PROBLEM", 726, 735], ["signaling during VAP development", "PROBLEM", 758, 790], ["septic shock", "OBSERVATION", 98, 110], ["VAP", "OBSERVATION", 440, 443], ["systemic spillover", "OBSERVATION", 550, 568], ["inflammation", "OBSERVATION", 582, 594], ["septic shock", "OBSERVATION", 606, 618], ["uninfected", "OBSERVATION_MODIFIER", 623, 633], ["multiorgan failure", "OBSERVATION", 634, 652], ["pneumonia", "OBSERVATION", 726, 735]]], ["Millo et al. [53] reported that the production of cytokines and cytokine inhibitors was compartmentalized within the lungs in patients who developed VAP.", [["lungs", "ANATOMY", 117, 122], ["VAP", "DISEASE", 149, 152], ["lungs", "ORGAN", 117, 122], ["patients", "ORGANISM", 126, 134], ["cytokines", "PROTEIN", 50, 59], ["cytokine", "PROTEIN", 64, 72], ["patients", "SPECIES", 126, 134], ["cytokines and cytokine inhibitors", "TREATMENT", 50, 83], ["VAP", "PROBLEM", 149, 152], ["lungs", "ANATOMY", 117, 122], ["VAP", "OBSERVATION", 149, 152]]], ["They reported a significant increase in concentration of tumor necrosis factor (TNF)-\u03b1, soluble TNF-\u03b1 receptors [sTNFaRI], IL-1\u03b1, and IL-1\u03b2 in non-directed bronchoalveolar lavage (BAL) fluid.CompartmentalizationSimilarly, VAP is characterized by a shift in the local hemostatic balance to the procoagulant side, which precedes the clinical diagnosis of VAP.", [["bronchoalveolar lavage (BAL) fluid", "ANATOMY", 156, 190], ["procoagulant", "ANATOMY", 293, 305], ["tumor", "DISEASE", 57, 62], ["necrosis", "DISEASE", 63, 71], ["VAP", "DISEASE", 222, 225], ["VAP", "DISEASE", 353, 356], ["tumor necrosis factor (TNF)-\u03b1", "GENE_OR_GENE_PRODUCT", 57, 86], ["TNF-\u03b1 receptors", "GENE_OR_GENE_PRODUCT", 96, 111], ["TNFaRI", "GENE_OR_GENE_PRODUCT", 114, 120], ["IL-1\u03b1", "GENE_OR_GENE_PRODUCT", 123, 128], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 134, 139], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 156, 178], ["BAL", "MULTI-TISSUE_STRUCTURE", 180, 183], ["tumor necrosis factor (TNF)-\u03b1", "PROTEIN", 57, 86], ["TNF-\u03b1 receptors", "PROTEIN", 96, 111], ["TNFaRI", "PROTEIN", 114, 120], ["IL-1\u03b1", "PROTEIN", 123, 128], ["IL-1\u03b2", "PROTEIN", 134, 139], ["tumor necrosis factor", "PROBLEM", 57, 78], ["TNF", "TEST", 80, 83], ["soluble TNF", "TEST", 88, 99], ["receptors", "TEST", 102, 111], ["TNFaRI", "TEST", 114, 120], ["IL", "TEST", 123, 125], ["IL", "TREATMENT", 134, 136], ["non-directed bronchoalveolar lavage", "TEST", 143, 178], ["VAP", "PROBLEM", 222, 225], ["a shift", "PROBLEM", 246, 253], ["VAP", "PROBLEM", 353, 356], ["significant", "OBSERVATION_MODIFIER", 16, 27], ["increase", "OBSERVATION_MODIFIER", 28, 36], ["concentration", "OBSERVATION_MODIFIER", 40, 53], ["tumor", "OBSERVATION_MODIFIER", 57, 62], ["necrosis", "OBSERVATION", 63, 71], ["bronchoalveolar lavage", "OBSERVATION", 156, 178], ["VAP", "OBSERVATION", 222, 225], ["VAP", "OBSERVATION", 353, 356]]], ["Fibrin deposits enhance inflammatory responses by increasing vascular permeability, activating endothelial cells to produce pro-inflammatory mediators, and eliciting recruitment and activation of neutrophils; eventually, these effects will disrupt normal gas exchange by creating intrapulmonary shunts and ventilation-perfusion mismatches.CompartmentalizationAs has been reported by Schultz et al. [54] , patients with VAP, before the clinical manifestation, had a dramatic increase in procoagulant activity, increased BAL levels of thrombin-antithrombin III complex (TAT), and decreased fibrinolysis, as reflected by a gradual fall in BAL levels of plasminogen activator activity.ShockThe inflammatory response of the host to an infection is associated with increased circulating levels of pro-inflammatory cytokines, such as IL-6 and IL-8.", [["vascular", "ANATOMY", 61, 69], ["endothelial cells", "ANATOMY", 95, 112], ["neutrophils", "ANATOMY", 196, 207], ["intrapulmonary", "ANATOMY", 280, 294], ["BAL", "ANATOMY", 636, 639], ["VAP", "DISEASE", 419, 422], ["infection", "DISEASE", 730, 739], ["Fibrin", "GENE_OR_GENE_PRODUCT", 0, 6], ["vascular", "MULTI-TISSUE_STRUCTURE", 61, 69], ["endothelial cells", "CELL", 95, 112], ["neutrophils", "CELL", 196, 207], ["intrapulmonary", "MULTI-TISSUE_STRUCTURE", 280, 294], ["patients", "ORGANISM", 405, 413], ["thrombin-antithrombin III complex", "GENE_OR_GENE_PRODUCT", 533, 566], ["TAT", "GENE_OR_GENE_PRODUCT", 568, 571], ["BAL", "ORGANISM_SUBSTANCE", 636, 639], ["plasminogen activator", "GENE_OR_GENE_PRODUCT", 650, 671], ["IL-6", "GENE_OR_GENE_PRODUCT", 827, 831], ["IL-8", "GENE_OR_GENE_PRODUCT", 836, 840], ["endothelial cells", "CELL_TYPE", 95, 112], ["pro-inflammatory mediators", "PROTEIN", 124, 150], ["neutrophils", "CELL_TYPE", 196, 207], ["thrombin", "PROTEIN", 533, 541], ["antithrombin III complex", "PROTEIN", 542, 566], ["TAT", "PROTEIN", 568, 571], ["plasminogen", "PROTEIN", 650, 661], ["pro-inflammatory cytokines", "PROTEIN", 791, 817], ["IL-6", "PROTEIN", 827, 831], ["IL-8", "PROTEIN", 836, 840], ["patients", "SPECIES", 405, 413], ["Fibrin deposits", "PROBLEM", 0, 15], ["inflammatory responses", "PROBLEM", 24, 46], ["increasing vascular permeability", "PROBLEM", 50, 82], ["activating endothelial cells", "PROBLEM", 84, 112], ["pro-inflammatory mediators", "PROBLEM", 124, 150], ["activation of neutrophils", "PROBLEM", 182, 207], ["intrapulmonary shunts", "TREATMENT", 280, 301], ["VAP", "PROBLEM", 419, 422], ["a dramatic increase in procoagulant activity", "PROBLEM", 463, 507], ["increased BAL levels of thrombin", "PROBLEM", 509, 541], ["antithrombin III complex", "PROBLEM", 542, 566], ["decreased fibrinolysis", "PROBLEM", 578, 600], ["a gradual fall in BAL levels of plasminogen activator activity", "PROBLEM", 618, 680], ["Shock", "PROBLEM", 681, 686], ["an infection", "PROBLEM", 727, 739], ["increased circulating levels of pro-inflammatory cytokines", "PROBLEM", 759, 817], ["IL", "TEST", 827, 829], ["deposits", "OBSERVATION", 7, 15], ["inflammatory", "OBSERVATION_MODIFIER", 24, 36], ["increasing", "OBSERVATION_MODIFIER", 50, 60], ["vascular permeability", "OBSERVATION", 61, 82], ["endothelial cells", "OBSERVATION", 95, 112], ["pro-inflammatory", "OBSERVATION_MODIFIER", 124, 140], ["recruitment", "OBSERVATION_MODIFIER", 166, 177], ["gas exchange", "OBSERVATION", 255, 267], ["intrapulmonary", "ANATOMY", 280, 294], ["shunts", "OBSERVATION", 295, 301], ["perfusion mismatches", "OBSERVATION", 318, 338], ["dramatic", "OBSERVATION_MODIFIER", 465, 473], ["increase", "OBSERVATION_MODIFIER", 474, 482], ["procoagulant activity", "OBSERVATION", 486, 507], ["decreased", "OBSERVATION_MODIFIER", 578, 587], ["fibrinolysis", "OBSERVATION", 588, 600], ["gradual", "OBSERVATION_MODIFIER", 620, 627], ["fall", "OBSERVATION", 628, 632], ["inflammatory", "OBSERVATION_MODIFIER", 690, 702], ["infection", "OBSERVATION", 730, 739], ["associated with", "UNCERTAINTY", 743, 758], ["increased", "OBSERVATION_MODIFIER", 759, 768], ["circulating levels", "OBSERVATION", 769, 787], ["pro-inflammatory cytokines", "OBSERVATION", 791, 817]]], ["The clinical presentation of VAP varies widely, from a relatively benign illness to A New Approach to Ventilator-associated Pneumonia Based on the PIRO System 487 XII a devastating illness resulting in septic shock.", [["VAP", "DISEASE", 29, 32], ["Ventilator", "DISEASE", 102, 112], ["Pneumonia", "DISEASE", 124, 133], ["illness", "DISEASE", 181, 188], ["septic shock", "DISEASE", 202, 214], ["VAP", "PROBLEM", 29, 32], ["a relatively benign illness", "PROBLEM", 53, 80], ["A New Approach", "TREATMENT", 84, 98], ["Pneumonia", "PROBLEM", 124, 133], ["a devastating illness", "PROBLEM", 167, 188], ["septic shock", "PROBLEM", 202, 214], ["VAP", "OBSERVATION", 29, 32], ["benign", "OBSERVATION_MODIFIER", 66, 72], ["Pneumonia", "OBSERVATION", 124, 133], ["devastating", "OBSERVATION_MODIFIER", 169, 180], ["septic shock", "OBSERVATION", 202, 214]]], ["The incidence of septic shock among VAP patients can be as high as 50 % in reported series [48] .", [["septic shock", "DISEASE", 17, 29], ["VAP", "DISEASE", 36, 39], ["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["septic shock", "PROBLEM", 17, 29], ["VAP", "PROBLEM", 36, 39], ["septic", "OBSERVATION_MODIFIER", 17, 23], ["shock", "OBSERVATION", 24, 29]]], ["Bonten et al. [55] reported that high circulating levels of IL-6 and IL-8 were associated with higher mortality rates and with a clinical presentation of severe sepsis or septic shock.", [["sepsis", "DISEASE", 161, 167], ["septic shock", "DISEASE", 171, 183], ["IL-6", "GENE_OR_GENE_PRODUCT", 60, 64], ["IL-8", "GENE_OR_GENE_PRODUCT", 69, 73], ["IL-6", "PROTEIN", 60, 64], ["IL-8", "PROTEIN", 69, 73], ["IL", "TEST", 60, 62], ["IL", "TEST", 69, 71], ["higher mortality rates", "PROBLEM", 95, 117], ["severe sepsis", "PROBLEM", 154, 167], ["septic shock", "PROBLEM", 171, 183], ["severe", "OBSERVATION_MODIFIER", 154, 160], ["sepsis", "OBSERVATION", 161, 167], ["septic shock", "OBSERVATION", 171, 183]]], ["Moreover soluble triggering receptor expressed on myeloid cells (sTREM)-1 is particularly increased on evolution from sepsis or severe sepsis to septic shock in patients with VAP.", [["myeloid cells", "ANATOMY", 50, 63], ["sepsis", "DISEASE", 118, 124], ["sepsis", "DISEASE", 135, 141], ["septic shock", "DISEASE", 145, 157], ["VAP", "DISEASE", 175, 178], ["myeloid cells", "CELL", 50, 63], ["TREM)-1", "GENE_OR_GENE_PRODUCT", 66, 73], ["patients", "ORGANISM", 161, 169], ["soluble triggering receptor", "PROTEIN", 9, 36], ["myeloid cells", "CELL_TYPE", 50, 63], ["patients", "SPECIES", 161, 169], ["myeloid cells", "PROBLEM", 50, 63], ["sTREM", "TEST", 65, 70], ["sepsis", "PROBLEM", 118, 124], ["severe sepsis", "PROBLEM", 128, 141], ["septic shock", "PROBLEM", 145, 157], ["VAP", "PROBLEM", 175, 178], ["myeloid cells", "OBSERVATION", 50, 63], ["increased", "OBSERVATION_MODIFIER", 90, 99], ["sepsis", "OBSERVATION", 118, 124], ["severe", "OBSERVATION_MODIFIER", 128, 134], ["sepsis", "OBSERVATION", 135, 141], ["septic shock", "OBSERVATION", 145, 157]]], ["Its sustained increase might be an indicator for poor outcome [56] .ShockOur group reported that septic shock was an independent variable associated with ICU mortality (OR 4.40 CI 2.71 -7.15) [3] .", [["septic shock", "DISEASE", 97, 109], ["septic shock", "PROBLEM", 97, 109], ["ICU mortality", "PROBLEM", 154, 167], ["CI", "TEST", 177, 179], ["sustained", "OBSERVATION_MODIFIER", 4, 13], ["increase", "OBSERVATION_MODIFIER", 14, 22], ["septic shock", "OBSERVATION", 97, 109]]], ["The early stages of VAP may be accompanied by circulatory insufficiency resulting from hypovolemia, myocardial depression, increased metabolic rate, and vasoregulatory perfusion abnormalities.", [["myocardial", "ANATOMY", 100, 110], ["VAP", "DISEASE", 20, 23], ["circulatory insufficiency", "DISEASE", 46, 71], ["hypovolemia", "DISEASE", 87, 98], ["myocardial depression", "DISEASE", 100, 121], ["myocardial", "MULTI-TISSUE_STRUCTURE", 100, 110], ["VAP", "PROBLEM", 20, 23], ["circulatory insufficiency", "PROBLEM", 46, 71], ["hypovolemia", "PROBLEM", 87, 98], ["myocardial depression", "PROBLEM", 100, 121], ["increased metabolic rate", "PROBLEM", 123, 147], ["vasoregulatory perfusion abnormalities", "PROBLEM", 153, 191], ["early stages", "OBSERVATION_MODIFIER", 4, 16], ["VAP", "OBSERVATION", 20, 23], ["circulatory insufficiency", "OBSERVATION", 46, 71], ["hypovolemia", "OBSERVATION", 87, 98], ["myocardial", "ANATOMY", 100, 110], ["depression", "OBSERVATION", 111, 121], ["increased", "OBSERVATION_MODIFIER", 123, 132], ["metabolic rate", "OBSERVATION", 133, 147], ["perfusion abnormalities", "OBSERVATION", 168, 191]]], ["As a consequence, a variety of hemodynamic combinations create a systemic imbalance between tissue oxygen supply and demand, leading to global tissue hypoxia and shock.", [["tissue", "ANATOMY", 92, 98], ["tissue", "ANATOMY", 143, 149], ["oxygen", "CHEMICAL", 99, 105], ["hypoxia", "DISEASE", 150, 157], ["shock", "DISEASE", 162, 167], ["oxygen", "CHEMICAL", 99, 105], ["tissue", "TISSUE", 92, 98], ["oxygen", "SIMPLE_CHEMICAL", 99, 105], ["tissue", "TISSUE", 143, 149], ["a systemic imbalance", "PROBLEM", 63, 83], ["tissue oxygen supply", "TREATMENT", 92, 112], ["global tissue hypoxia", "PROBLEM", 136, 157], ["shock", "PROBLEM", 162, 167], ["systemic", "OBSERVATION_MODIFIER", 65, 73], ["imbalance", "OBSERVATION", 74, 83], ["oxygen supply", "OBSERVATION", 99, 112], ["global tissue", "OBSERVATION", 136, 149], ["hypoxia", "OBSERVATION", 150, 157], ["shock", "OBSERVATION", 162, 167]]], ["Early correction of septic shock is crucial for patient outcomes, for which reason consensus guidelines now recommend early goaldirected therapy [57] for the first six hours of sepsis resuscitation.ImmunoparalysisIn the past, immodulatory therapies in sepsis were driven by the assumption that the adverse outcomes were related to an overly exuberant inflammatory response.", [["septic shock", "DISEASE", 20, 32], ["sepsis", "DISEASE", 177, 183], ["sepsis", "DISEASE", 252, 258], ["patient", "ORGANISM", 48, 55], ["patient", "SPECIES", 48, 55], ["septic shock", "PROBLEM", 20, 32], ["early goaldirected therapy", "TREATMENT", 118, 144], ["sepsis resuscitation", "TREATMENT", 177, 197], ["immodulatory therapies", "TREATMENT", 226, 248], ["sepsis", "PROBLEM", 252, 258], ["the adverse outcomes", "PROBLEM", 294, 314], ["an overly exuberant inflammatory response", "PROBLEM", 331, 372], ["septic shock", "OBSERVATION", 20, 32], ["sepsis", "OBSERVATION", 177, 183], ["sepsis", "OBSERVATION", 252, 258], ["exuberant", "OBSERVATION_MODIFIER", 341, 350], ["inflammatory", "OBSERVATION", 351, 363]]], ["However, over the last few years, new evidence on cytokine production in response to bacterial antigens, lymphocyte proliferation in response to recall antigens, or new antigen presentation as a marker of immune function has been released.", [["lymphocyte", "ANATOMY", 105, 115], ["lymphocyte", "CELL", 105, 115], ["cytokine", "PROTEIN", 50, 58], ["bacterial antigens", "PROTEIN", 85, 103], ["cytokine production", "PROBLEM", 50, 69], ["bacterial antigens", "PROBLEM", 85, 103], ["lymphocyte proliferation", "PROBLEM", 105, 129], ["new antigen presentation", "PROBLEM", 165, 189], ["cytokine production", "OBSERVATION", 50, 69], ["bacterial antigens", "OBSERVATION", 85, 103], ["lymphocyte proliferation", "OBSERVATION", 105, 129], ["new", "OBSERVATION_MODIFIER", 165, 168]]], ["For example, low HLA-DR expression has been correlated with the development of nosocomial infections, and persistence of abnormally low levels of HLA-DR in the late phase of septic shock (day 5-7) has been linked to death [58] .", [["nosocomial infections", "DISEASE", 79, 100], ["septic shock", "DISEASE", 174, 186], ["death", "DISEASE", 216, 221], ["HLA-DR", "GENE_OR_GENE_PRODUCT", 17, 23], ["HLA-DR", "GENE_OR_GENE_PRODUCT", 146, 152], ["DR", "PROTEIN", 21, 23], ["HLA-DR", "PROTEIN", 146, 152], ["nosocomial infections", "PROBLEM", 79, 100], ["abnormally low levels of HLA", "PROBLEM", 121, 149], ["septic shock", "PROBLEM", 174, 186], ["low HLA", "OBSERVATION_MODIFIER", 13, 20], ["nosocomial", "OBSERVATION_MODIFIER", 79, 89], ["infections", "OBSERVATION", 90, 100], ["abnormally", "OBSERVATION_MODIFIER", 121, 131], ["low levels", "OBSERVATION_MODIFIER", 132, 142], ["late phase", "OBSERVATION_MODIFIER", 160, 170], ["septic shock", "OBSERVATION", 174, 186]]], ["New studies based on HLA-DR modulation in patients with VAP might improve the understanding of the response to VAP.Immunomodulatory Effects of MacrolidesCompelling evidence has shown that appropriate antibiotic therapy is the cornerstone of success in the treatment of patients with VAP [59] .", [["VAP", "DISEASE", 56, 59], ["VAP", "DISEASE", 111, 114], ["Macrolides", "CHEMICAL", 143, 153], ["VAP", "DISEASE", 283, 286], ["Macrolides", "CHEMICAL", 143, 153], ["HLA-DR", "GENE_OR_GENE_PRODUCT", 21, 27], ["patients", "ORGANISM", 42, 50], ["Macrolides", "SIMPLE_CHEMICAL", 143, 153], ["patients", "ORGANISM", 269, 277], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 269, 277], ["New studies", "TEST", 0, 11], ["HLA", "TEST", 21, 24], ["VAP", "PROBLEM", 56, 59], ["VAP", "PROBLEM", 111, 114], ["Macrolides", "TREATMENT", 143, 153], ["appropriate antibiotic therapy", "TREATMENT", 188, 218], ["VAP", "PROBLEM", 283, 286], ["Macrolides", "OBSERVATION", 143, 153]]], ["However, despite early diagnosis and prompt initiation of antibiotics, mortality remains high in severe sepsis [60] .", [["sepsis", "DISEASE", 104, 110], ["antibiotics", "TREATMENT", 58, 69], ["mortality", "TEST", 71, 80], ["severe sepsis", "PROBLEM", 97, 110], ["severe", "OBSERVATION_MODIFIER", 97, 103], ["sepsis", "OBSERVATION", 104, 110]]], ["Recent studies suggest that macrolides may have beneficial effects for patients at risk of certain infections due to their immunomodulatory effects rather than their antimicrobial properties [61] .", [["macrolides", "CHEMICAL", 28, 38], ["infections", "DISEASE", 99, 109], ["macrolides", "CHEMICAL", 28, 38], ["macrolides", "SIMPLE_CHEMICAL", 28, 38], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["Recent studies", "TEST", 0, 14], ["macrolides", "TREATMENT", 28, 38], ["certain infections", "PROBLEM", 91, 109], ["their immunomodulatory effects", "PROBLEM", 117, 147], ["macrolides", "OBSERVATION", 28, 38], ["infections", "OBSERVATION", 99, 109]]], ["Based on favorable results in experimental models of sepsis caused by Gram-negative organisms, Giamarellos-Bourboulis et al. [62] conducted a randomized controlled trial (RCT) in 200 patients with VAP who were randomly assigned to receive either placebo or clarithromycin.", [["sepsis", "DISEASE", 53, 59], ["VAP", "DISEASE", 197, 200], ["clarithromycin", "CHEMICAL", 257, 271], ["clarithromycin", "CHEMICAL", 257, 271], ["patients", "ORGANISM", 183, 191], ["clarithromycin", "SIMPLE_CHEMICAL", 257, 271], ["patients", "SPECIES", 183, 191], ["sepsis", "PROBLEM", 53, 59], ["Gram-negative organisms", "PROBLEM", 70, 93], ["a randomized controlled trial (RCT)", "TREATMENT", 140, 175], ["VAP", "PROBLEM", 197, 200], ["placebo", "TREATMENT", 246, 253], ["clarithromycin", "TREATMENT", 257, 271], ["sepsis", "OBSERVATION", 53, 59]]], ["They showed that despite no differences in 28-day mortality rates between the two groups, clarithromycin accelerated the resolution of VAP and weaning from mechanical ventilation in surviving patients and delayed death in those who died of sepsis.", [["clarithromycin", "CHEMICAL", 90, 104], ["VAP", "DISEASE", 135, 138], ["death", "DISEASE", 213, 218], ["sepsis", "DISEASE", 240, 246], ["clarithromycin", "CHEMICAL", 90, 104], ["clarithromycin", "SIMPLE_CHEMICAL", 90, 104], ["patients", "ORGANISM", 192, 200], ["patients", "SPECIES", 192, 200], ["clarithromycin", "TREATMENT", 90, 104], ["VAP", "PROBLEM", 135, 138], ["mechanical ventilation", "TREATMENT", 156, 178], ["delayed death", "PROBLEM", 205, 218], ["sepsis", "PROBLEM", 240, 246], ["VAP", "OBSERVATION", 135, 138], ["sepsis", "OBSERVATION", 240, 246]]], ["The explanation can be based on the regulation of leukocyte function and production of inflammatory mediators, control of mucus hypersecretion, resolution of inflammation, and modulation of host defense mechanisms or on bacterial quorum sensing in P. aeruginosa infections.", [["leukocyte", "ANATOMY", 50, 59], ["mucus", "ANATOMY", 122, 127], ["inflammation", "DISEASE", 158, 170], ["P. aeruginosa infections", "DISEASE", 248, 272], ["leukocyte", "CELL", 50, 59], ["mucus", "MULTI-TISSUE_STRUCTURE", 122, 127], ["P. aeruginosa", "ORGANISM", 248, 261], ["inflammatory mediators", "PROTEIN", 87, 109], ["P. aeruginosa", "SPECIES", 248, 261], ["P. aeruginosa", "SPECIES", 248, 261], ["leukocyte function", "TEST", 50, 68], ["inflammatory mediators", "PROBLEM", 87, 109], ["mucus hypersecretion", "PROBLEM", 122, 142], ["inflammation", "PROBLEM", 158, 170], ["host defense mechanisms", "PROBLEM", 190, 213], ["bacterial quorum sensing", "PROBLEM", 220, 244], ["P. aeruginosa infections", "PROBLEM", 248, 272], ["inflammatory", "OBSERVATION_MODIFIER", 87, 99], ["mucus hypersecretion", "OBSERVATION", 122, 142], ["inflammation", "OBSERVATION", 158, 170], ["host defense", "OBSERVATION", 190, 202]]], ["Moreover, some evidence suggests that macrolides might facilitate the killing of micro-organisms in acute respiratory infections through the stimulation of neutrophil activation, whereas blood monocytes release lower amounts of TNF-\u03b1 without any change in tissue bacterial load [63] .Components of the VAP-PIRO Score: Organ DysfunctionRenal Failure VAP is a risk factor for the development of acute renal failure.", [["respiratory", "ANATOMY", 106, 117], ["neutrophil", "ANATOMY", 156, 166], ["blood monocytes", "ANATOMY", 187, 202], ["tissue", "ANATOMY", 256, 262], ["Renal", "ANATOMY", 335, 340], ["renal", "ANATOMY", 399, 404], ["macrolides", "CHEMICAL", 38, 48], ["respiratory infections", "DISEASE", 106, 128], ["VAP", "DISEASE", 302, 305], ["Organ Dysfunction", "DISEASE", 318, 335], ["VAP", "DISEASE", 349, 352], ["acute renal failure", "DISEASE", 393, 412], ["macrolides", "CHEMICAL", 38, 48], ["macrolides", "SIMPLE_CHEMICAL", 38, 48], ["neutrophil", "CELL", 156, 166], ["blood", "ORGANISM_SUBSTANCE", 187, 192], ["monocytes", "CELL", 193, 202], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 228, 233], ["tissue", "TISSUE", 256, 262], ["Renal", "ORGAN", 335, 340], ["renal", "ORGAN", 399, 404], ["blood monocytes", "CELL_TYPE", 187, 202], ["TNF", "PROTEIN", 228, 231], ["macrolides", "TREATMENT", 38, 48], ["micro-organisms", "PROBLEM", 81, 96], ["acute respiratory infections", "PROBLEM", 100, 128], ["neutrophil activation", "PROBLEM", 156, 177], ["blood monocytes", "TEST", 187, 202], ["TNF", "TEST", 228, 231], ["any change in tissue bacterial load", "PROBLEM", 242, 277], ["the VAP", "PROBLEM", 298, 305], ["Organ Dysfunction", "PROBLEM", 318, 335], ["Renal Failure VAP", "PROBLEM", 335, 352], ["a risk factor", "PROBLEM", 356, 369], ["acute renal failure", "PROBLEM", 393, 412], ["macrolides", "OBSERVATION", 38, 48], ["acute", "OBSERVATION_MODIFIER", 100, 105], ["respiratory infections", "OBSERVATION", 106, 128], ["neutrophil activation", "OBSERVATION", 156, 177], ["bacterial load", "OBSERVATION", 263, 277], ["VAP", "OBSERVATION", 302, 305], ["Organ", "ANATOMY", 318, 323], ["Dysfunction", "OBSERVATION", 324, 335], ["Failure", "OBSERVATION", 341, 348], ["VAP", "OBSERVATION", 349, 352], ["acute", "OBSERVATION_MODIFIER", 393, 398], ["renal", "ANATOMY", 399, 404], ["failure", "OBSERVATION", 405, 412]]], ["The incidence of acute renal failure for the population at risk has been reported to be around 38 % [64] .", [["renal", "ANATOMY", 23, 28], ["acute renal failure", "DISEASE", 17, 36], ["renal", "ORGAN", 23, 28], ["acute renal failure", "PROBLEM", 17, 36], ["acute", "OBSERVATION_MODIFIER", 17, 22], ["renal", "ANATOMY", 23, 28], ["failure", "OBSERVATION", 29, 36]]], ["In this study, VAP caused by multidrug resistant pathogens and sepsis were independent risk factors for the development of acute renal failure.", [["renal", "ANATOMY", 129, 134], ["VAP", "DISEASE", 15, 18], ["sepsis", "DISEASE", 63, 69], ["acute renal failure", "DISEASE", 123, 142], ["renal", "ORGAN", 129, 134], ["this study", "TEST", 3, 13], ["VAP", "PROBLEM", 15, 18], ["multidrug resistant pathogens", "PROBLEM", 29, 58], ["sepsis", "PROBLEM", 63, 69], ["independent risk factors", "PROBLEM", 75, 99], ["acute renal failure", "PROBLEM", 123, 142], ["sepsis", "OBSERVATION", 63, 69], ["acute", "OBSERVATION_MODIFIER", 123, 128], ["renal", "ANATOMY", 129, 134], ["failure", "OBSERVATION", 135, 142]]], ["However, there is not yet enough evidence in the published data to explain the relationship between multidrug resistant infections and the development of acute renal failure.Acute Respiratory Distress SyndromeNosocomial pneumonia is a frequent complication of ARDS and vice versa.", [["renal", "ANATOMY", 160, 165], ["infections", "DISEASE", 120, 130], ["acute renal failure", "DISEASE", 154, 173], ["Respiratory Distress SyndromeNosocomial pneumonia", "DISEASE", 180, 229], ["ARDS", "DISEASE", 260, 264], ["renal", "ORGAN", 160, 165], ["multidrug resistant infections", "PROBLEM", 100, 130], ["acute renal failure", "PROBLEM", 154, 173], ["Acute Respiratory Distress SyndromeNosocomial pneumonia", "PROBLEM", 174, 229], ["ARDS", "PROBLEM", 260, 264], ["vice versa", "PROBLEM", 269, 279], ["resistant", "OBSERVATION_MODIFIER", 110, 119], ["infections", "OBSERVATION", 120, 130], ["acute", "OBSERVATION_MODIFIER", 154, 159], ["renal", "ANATOMY", 160, 165], ["failure", "OBSERVATION", 166, 173], ["Respiratory", "ANATOMY", 180, 191], ["Distress", "OBSERVATION", 192, 200], ["pneumonia", "OBSERVATION", 220, 229], ["ARDS", "OBSERVATION", 260, 264]]], ["Epidemiologic studies have reported that VAP was present in 20 -75 % of patients dying of ARDS [65] .", [["VAP", "DISEASE", 41, 44], ["ARDS", "DISEASE", 90, 94], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["Epidemiologic studies", "TEST", 0, 21], ["VAP", "PROBLEM", 41, 44], ["ARDS", "PROBLEM", 90, 94], ["VAP", "OBSERVATION", 41, 44], ["ARDS", "OBSERVATION", 90, 94]]], ["Fibrin deposition within the air space is one of the hallmarks of ARDS.", [["air space", "ANATOMY", 29, 38], ["ARDS", "DISEASE", 66, 70], ["Fibrin", "GENE_OR_GENE_PRODUCT", 0, 6], ["air", "MULTI-TISSUE_STRUCTURE", 29, 32], ["Fibrin deposition within the air space", "PROBLEM", 0, 38], ["ARDS", "PROBLEM", 66, 70], ["deposition", "OBSERVATION", 7, 17], ["air space", "OBSERVATION", 29, 38], ["one", "OBSERVATION_MODIFIER", 42, 45], ["hallmarks", "OBSERVATION_MODIFIER", 53, 62], ["ARDS", "OBSERVATION", 66, 70]]], ["Alveolar fibrin deposits appear to contribute to the magnitude of the inflammatory response by virtue of the ability of their cleavage and degradation products to promote chemotaxis, to increase vascular permeability, and to exert modulatory effects on various immune cells.", [["Alveolar fibrin", "ANATOMY", 0, 15], ["vascular", "ANATOMY", 195, 203], ["immune cells", "ANATOMY", 261, 273], ["Alveolar", "MULTI-TISSUE_STRUCTURE", 0, 8], ["fibrin", "GENE_OR_GENE_PRODUCT", 9, 15], ["vascular", "MULTI-TISSUE_STRUCTURE", 195, 203], ["immune cells", "CELL", 261, 273], ["immune cells", "CELL_TYPE", 261, 273], ["Alveolar fibrin deposits", "PROBLEM", 0, 24], ["the inflammatory response", "PROBLEM", 66, 91], ["their cleavage", "TREATMENT", 120, 134], ["degradation products", "TREATMENT", 139, 159], ["various immune cells", "TREATMENT", 253, 273], ["fibrin deposits", "OBSERVATION", 9, 24], ["magnitude", "OBSERVATION_MODIFIER", 53, 62], ["inflammatory", "OBSERVATION", 70, 82], ["vascular", "ANATOMY", 195, 203], ["immune cells", "OBSERVATION", 261, 273]]], ["In addition, fibrin may participate in the resolution phase of ARDS, possibly contributing to lung fibrosis by providing a matrix for macrophage migration and by promoting angiogenesis and collagen deposition [66] .ConclusionDespite recent advances in VAP management, VAP cannot yet be prevented.", [["lung", "ANATOMY", 94, 98], ["matrix", "ANATOMY", 123, 129], ["macrophage", "ANATOMY", 134, 144], ["ARDS", "DISEASE", 63, 67], ["fibrosis", "DISEASE", 99, 107], ["VAP", "DISEASE", 252, 255], ["VAP", "DISEASE", 268, 271], ["fibrin", "GENE_OR_GENE_PRODUCT", 13, 19], ["lung", "ORGAN", 94, 98], ["matrix", "CELLULAR_COMPONENT", 123, 129], ["macrophage", "CELL", 134, 144], ["collagen", "GENE_OR_GENE_PRODUCT", 189, 197], ["fibrin", "PROTEIN", 13, 19], ["collagen", "PROTEIN", 189, 197], ["fibrin", "TREATMENT", 13, 19], ["ARDS", "PROBLEM", 63, 67], ["lung fibrosis", "PROBLEM", 94, 107], ["a matrix for macrophage migration", "TREATMENT", 121, 154], ["VAP management", "TREATMENT", 252, 266], ["VAP", "PROBLEM", 268, 271], ["fibrin", "OBSERVATION", 13, 19], ["ARDS", "OBSERVATION", 63, 67], ["possibly contributing to", "UNCERTAINTY", 69, 93], ["lung", "ANATOMY", 94, 98], ["fibrosis", "OBSERVATION", 99, 107]]], ["Some risk factors for developing VAP are not modifiable and the etiology of each episode varies markedly according to the time to pneumonia onset and underlying diseases in the host.", [["VAP", "DISEASE", 33, 36], ["pneumonia", "DISEASE", 130, 139], ["Some risk factors", "PROBLEM", 0, 17], ["developing VAP", "PROBLEM", 22, 36], ["each episode", "PROBLEM", 76, 88], ["pneumonia onset", "PROBLEM", 130, 145], ["underlying diseases in the host", "PROBLEM", 150, 181], ["VAP", "OBSERVATION", 33, 36], ["pneumonia", "OBSERVATION", 130, 139], ["diseases", "OBSERVATION", 161, 169]]], ["The VAP-PIRO approach takes into account these risk factors and the consideration of predisposing conditions, the nature and extent of insult, the nature and magnitude of the host response; in addition, the degree of concomitant organ dysfunction provides a useful and novel approach to VAP.", [["organ", "ANATOMY", 229, 234], ["organ dysfunction", "DISEASE", 229, 246], ["VAP", "DISEASE", 287, 290], ["organ", "ORGAN", 229, 234], ["The VAP-PIRO approach", "TREATMENT", 0, 21], ["these risk factors", "PROBLEM", 41, 59], ["predisposing conditions", "PROBLEM", 85, 108], ["insult", "PROBLEM", 135, 141], ["concomitant organ dysfunction", "PROBLEM", 217, 246], ["VAP", "PROBLEM", 287, 290], ["VAP", "OBSERVATION", 4, 7], ["insult", "OBSERVATION", 135, 141], ["host response", "OBSERVATION", 175, 188], ["concomitant organ dysfunction", "OBSERVATION", 217, 246]]], ["The VAP-PIRO approach may improve the understanding of the natural history and the stratification of patients according to severity of each VAP episode.", [["VAP", "DISEASE", 140, 143], ["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["The VAP-PIRO approach", "TREATMENT", 0, 21], ["each VAP episode", "PROBLEM", 135, 151], ["VAP", "OBSERVATION", 4, 7]]], ["VAP-PIRO could be useful both for benchmarking and for balancing sickness severity in future randomized clinical trials.", [["VAP", "DISEASE", 0, 3], ["VAP", "PROBLEM", 0, 3], ["PIRO", "TREATMENT", 4, 8], ["balancing sickness severity", "PROBLEM", 55, 82]]]]}